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ABSTRACT
Introduction: Pancreatic cancer is a challenging solid organ malignancy, which despite 
advancements in surgery and oncology carries a dismal outcome. It is characterised by a 
dense desmoplastic stroma accounting for its bulky fibrotic nature. Recent years have seen 
the focus shift from the tumour cells as direct drivers of carcinogenesis to the wider tumour 
microenvironment. The distinct molecular ‘cross-talk5 between cancer cells and the 
surrounding desmoplastic stroma has emerged as a key mediator of carcinogenesis, affecting 
angiogenesis, invasion, metastasis and evasion of the host defences. It has been previously 
demonstrated through 2-DE analysis of laser capture microdissected malignant and stromal 
components of pancreatic tumours that high levels of S100A8 and S100A9 are expressed in 
tumour-associated stroma but not in malignant epithelial cells. It has also been demonstrated 
that SMAD4-negative pancreatic tumours contain fewer stromal S100A8-positive cells than 
their SMAD4-positive counterparts. The aims of this project were to unravel the association 
of S100A8 and S100A9 with tumour cells and elucidate their role in pancreatic cancer 
tumorigenesis.
Methodology: Protein expression (S100A8 and S100A9) was validated using a pancreatic 
cancer tissue microarray by immunohistochemistry and co-immunofluorescence methods, 
identifying the presence of these proteins in CD14+/CD68" monocytes/macrophages. The 
effects of conditioned media from pancreatic cancer cells on the expression of S100A8 and 
S100A9 was also evaluated using western blotting. Recombinant GST-tagged S100A8 and 
S100A9 proteins were generated in E. Coli and purified using a glutathione-sepharose 
column. The effects of these proteins on the motility and proliferation of pancreatic and 
colorectal cancer cell lines, including SMAD4 negative cell lines in which SMAD4 has been 
re-expressed was accessed using modified Boyden Chamber Assays and MTT assays. The 
presence of TGF-{3 and CD68+ macrophages was evaluated in the pancreatic cancer 
microenvironment and associations with SI00A8/A9-expressingmonocytes determined.
Results: The treatment of cultured monocytes (primary and cell lines) with conditioned 
medium from pancreatic cancer cell lines induced the expression of S100A8 and S100A9 
proteins in them. Possible mediators of this effect included TGF-p and VEGF-A, the presence 
of which was identified in the conditioned media collected from pancreatic cancer cell lines 
and in tissue specimens (for TGF-J3). Low levels of TGF-|3 expression in the tumours
XI
significantly correlated with reduced number of S100A8-positive monocytes (p~0.04) and 
moreover high levels of tumour nuclear TGF-p expression coiTelated to a poor 2-year 
survival (p = 0.039). Incubation with GST-S100A8 and GST-S100A9 on their own or in 
combination significantly increased pancreatic and colorectal cancer cell motility by up to 10- 
fold compared to the GST protein control which varied based on the type of cell line used. 
Proliferation of the colorectal cancer cells was significantly increased in a dose-dependent 
manner with GST-S100A8 and GST-S100A9, with the highest increase in proliferation 
occurring between 36 and 48 hours of incubation. Treatment of SMAD4 positive and 
negative re-expressing colorectal cancer cells did not demonstrate any differential chemotaxis 
or growth.
Conclusion: These experiments have unravelled a relationship between cancer cells and 
S100A8 and S100A9 proteins in the pancreatic cancer microenvironment. There is a direct 
effect of pancreatic cancer cells on the expression of S100A8 and S100A9 in monocytes in 
vitro. These proteins significantly increase pancreatic and colorectal cancer cell motility and 
proliferation. Certainly further studies to evaluate the mechanisms of S100A8/A9 signalling 
in the tumour microenvironment will shed light on how these proteins influence the processes 
of tumour development and spread providing opportunities for targeted intervention.
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PART ONE: INTRODUCTION
CHAPTER ONE
BIOLOGY OF PANCREATIC CANCER
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1.1 Pancreatic Cancer
Incidence
Pancreatic ductal adenocarcinoma (PDAC) (referred in the text also as pancreatic cancer) 
is amongst the most challenging of solid organ malignancies, being the 5th leading cause 
of cancer related deaths in the developed world owing to its propensity for late 
presentation and chemo resistant tumour biology (Chua and Cunningham, 2006; Siegel et 
al., 2012; Vincent et ah, 2011). In the UK, pancreatic cancer is ranked 11th accounting for 
over 7000 newly diagnosed cases per annum (Cancer Research, 2009; Neoptolemos, 
2011), with a worldwide incidence of nearly a quarter of a million newly diagnosed cases 
(Ghaneh et ah, 2007; Vincent et ah, 2011). The American Cancer Society estimates, ovei 
40000 newly diagnosed pancreatic cancer cases in the USA alone (Siegel et ah, 2012) 
(Society, 2010) with Europe having over 60,000 new cases per year (Ghaneh et ah, 
2007). The International Agency for Cancer Research (IARC) estimates that there will 
be over 230,000 new cases of pancreatic cancer and about 227,000 deaths worldwide due 
to this devastating disease (IARC, 2008). Moreover, European cancer mortality 
prediction figures for 2012, indicate that pancreatic cancer mortality rates are likely to 
increase by 2-3% this year with all other tumours, except lung cancer, demonstrating a 
decrease in cancer related mortality (Malvezzi et ah, 2012).
Despite improvements in the field of patient management and a better comprehension of 
the cytogenetics of this disease, the overall 5-year survival is still dismal at less than 5% 
(Buchholz and Gress, 2009; Vincent et ah, 2011). Without treatment, metastatic
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pancreatic cancer carries a grave prognosis, with median survival between 3-5 months 
(Wray et ah, 2005). This is not significantly better for locally advanced disease, which is 
6-10 months (Buchholz and Gress, 2009) (Ghaneh et ah, 2007). Surgery remains the main 
stay of treatment, however owing to the late presentation and aggressive nature of this 
cancer only 10-15% of patients are deemed operable at the time of presentation 
(Neoptolemos, 2011; Tuveson and Neoptolemos, 2012; Wray et ah, 2005). Data from 
clinical trials indicate that chemotherapy enhances survival in both patients undergoing 
surgery and in those with advanced disease (Cunningham et ah, 2009; Neoptolemos et al., 
2004; Neoptolemos et al., 2009). Those patients undergoing resections and adjuvant 
chemotherapy have a median survival of approximately 23 months with a 5-year survival 
ranging between 10-20% (Ghaneh et al., 2007; Neoptolemos, 2011; Thomas et al.,
2010).
Advancement in the field of molecular research allowing for a better understanding of 
pancreatic cancer tumour biology have made way for novel therapeutic taigets which 
work in conjunction with current therapies enhancing their efficiency (Matsuo et al., 
2012; Moore et al, 2007; Vincent et al, 2011). In addition, research into predictive 
biomarkers of response to standard therapies have also led to improved outcomes in 
patient cohorts (Costantino et al, 2009; Richards et al, 2010) with the ultimate aim being 
to provide tailored therapeutic regimes for patient with pancreatic cancer based on theii 
tumour cytogenetics. Improvement in clinical services, particularly centralisation of 
care and a multidisciplinary team approach to perioperative management have also
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contributed towards improved survival in the last two decades with in hospital mortality 
decreasing by up to 6 fold in some reports (Alexakis et al., 2004; Lemmens et al., 2011). 
There is substantial geographical variation in the incidence of this disease with the 
highest incidence seen in northern countries such as Iceland, Finland and the USA along 
with countries closer to the equator such as Egypt, Tunisia, Zimbabwe and India 
(Agbunag C and Bar-Sagi D, 2004; Raimondi et ah, 2009). This incidence in these areas 
has remained constant over the last 3 decades in contrast to that in Western Europe, 
which has seen a steady rise (de Braud et al., 2004; Ghadirian et al., 2003). There exists a 
tenfold difference in both incidence and mortality rates when comparisons are made 
between countries with the highest and lowest risks for pancreatic cancer (Raimondi et 
al., 2009). The incidence is generally lower in women, although it is almost equal to that 
of men in groups that are exposed to additional risk factors such as alcohol consumption 
and smoking (Silverman DT et al., 2003; Wahi et al., 2009). One possible hypothesis for 
a lower incidence in females is the protective effect oestrogen is thought to have on 
pancreatic cancer (Wahi et al., 2009). The lowest prevalence of pancreatic cancer is 
observed in Africa and South Asia, although Japan is an exception with a high incidence 
reported (Ghadirian et al., 2003; Kinoshita et al., 2007). Populations in several Polynesian 
groups including Maoris and native Hawaiians are known to have a high incidence 
(Ghadirian et al., 2003) with Nigerians demonstrating a very low incidence of the disease.
Environmental risk factors primarily cigarette smoking (Lee and Hamling, 2009a; Lee 
and Hamling, 2009b; Porta et al., 2009) have been attributed towards the high incidence 
of this disease making it equal in both sexes. A significant difference is seen in age-
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adjusted incidence of pancreatic cancer in global cancer registries (Raimondi et al., 
2009). This variance is probably caused by different exposures to lifestyle and 
environmental factors or both, since careful genetic studies in twins predict that about 
two-thirds of pancreatic cancer is related to environmental factors (Lichtenstein et al., 
2000). Similarly, epidemiological studies comparing the incidence of disease amongst 
Japanese migrants to the USA found it to be far higher than in theii native Japanese 
family members (Ghadirian et al., 2003).
The disease has preponderance for age with an increasing incidence after 75 years, 
affecting 2 per 100,000 / year between 40-44 years compared to 67 per 100000/year in 
patients over 75 years of age. The 5—10% of patients who develop pancreatic cancel 
before the age of 50 years, are likely to include patients with underlying predisposing 
genetic disorders or those who have undergone previous treatments for cancer, such as 
radiotherapy (Raimondi et al., 2007). Certain race and ethnic groups, e.g. Jews in Europe 
and African Americans are at an appreciably higher risk for developing pancreatic cancer 
compared to white or Asian populations. The reasons for this are unclear, although 
various nongenetic risk factors, such as smoking, diabetes, body mass index, and vitamin 
D insufficiency have been suggested (Raimondi et al, 2009; Silverman DT et al., 2003) 
(Ghadirian et al., 2003).
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Aetiology and Risk Factors
Pancreatic cancer like other malignancies is multi-factorial in aetiology and 
heterogeneous in its development arising from a multitude of genetic and epigenetic 
defects. A better comprehension of the aetiology and molecular events over the last two 
decades has been instrumental in further understanding, management and screening of 
this devastating disease. Environmental and genetic risk factors for pancreatic cancer are 
further detailed in the sections below.
Smoking
Smoking is one of the primary risk factors for developing pancreatic cancer confeuing a 
70-100% increased risk (lodice et al, 2008). This risk does gradually diminish, after 
cessation of smoking but does not return to baseline before at least 10 years (lodice et al., 
2008; Lowenfels and Maisonneuve, 2006). Tobacco products such as cigars and chewing 
tobacco exert a moderate increase in risk of pancreatic cancer with borderline 
significance (Alguacil and Silverman, 2004; Lowenfels and Maisonneuve, 2006). Though 
the exact mechanisms of the risk incurred by smoking is not yet clear, it is thought to be 
as a result of nitrosamines contained in nicotine. These are considered to be genotoxic in 
their effects, causing the induction of mutations in genes such as KRAS (Porta et al., 
2009; Schuller HM, 2002). Crous-Bou et al. analysed mutations in codon 12 of the 
KRAS oncogene have challenged this hypothesis and lifetime consumption of tobacco in 
patients with pancreatic cancer, to conclude that smoking does not play a major part in 
the acquisition of KRAS mutations in the pancreatic epithelium (Crous-Bou et al., 2007). 
More recently, a meta-analysis of clinical and epidemiological studies concluded that a
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lifetime history of tobacco consumption was not significantly associated with the 
frequency of KRAS mutations in pancreatic cancer (Porta et ah, 2009).
Diet
Dietary factors seem to influence the development of pancreatic cancel and account foi a 
several fold increase in the incidence of this disease in various countries (Lowenfels and 
Maisonneuve, 2006). There is some data to suggest that a diet high in vegetables and fruit 
is protective with a few of case control studies reporting a positive association with 
increased meat and cholesterol intake and pancreatic cancer development (Vincent et ah, 
2011) (Jiao et ah, 2009) (Howe GR and Burch JD, 1996). However, no strong link 
between the development of pancreatic cancer and diet has yet been established. A laige 
cohort study involving over half a million subjects in 10 European countries failed to find 
any protective benefit from fruit and vegetable consumption (Vrieling et ah, 2009). 
Folates confer a lower risk, but data on this is inconsistent (Skinner HG et ah, 2004) as is 
that on Vitamin D which in some studies is shown to have a protective effect on the 
development of pancreatic cancer (Giovannucci, 2009). Moreover, prospective and 
experimental studies have shown that obesity itself confers an increase risk of pancreatic 
cancer (Khasawneh et ah, 2009) (Calle et ah, 2003). The mechanism may be by direct 
tumour promotion or indirectly via obesity related dampening of inflammatory and 
protective responses (Khasawneh et ah, 2009).
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Alcohol and Coffee consumption
The role of alcohol in the aetiology of pancreatic cancer has been supported by 
retrospective, ecologic and cohort investigations (Ghadirian et al, 2003), however studies 
to the contrary have shown that moderate alcohol consumption does not increase the risk 
of developing the disease (Lowenfels and Maisonneuve, 2006; Rohrmann et al., 2009). 
Only high lifetime ethanol intake from spirits and liquor tended to be associated with a 
higher risk of developing PD AC (Rohrmann et al, 2009). The proposed mechanism of 
how alcohol increases the risk of PDAC is thought to be by induction of mutation in the 
KRAS gene which has been reported to be three times higher in both smokers and alcohol 
drinkers compared to non consumers with pancreatic cancer (Malats et al., 1997). Crous- 
Bou et al analysed the lifetime history of alcohol consumption and KRAS mutations to 
conclude that alcohol consumption is only weakly associated with an increased risk of 
having a KRAS mutated PDAC. Furthermore, to confirm or refute the hypothesis that 
alcohol might influence the acquisition or persistence of KRAS mutations in the 
pancreatic ductal cells large and unselected studies are warranted (Crous-Bou et al., 
2009). High alcohol intake itself leads to chronic pancreatitis which is a risk for 
developing pancreatic cancer (Ghaneh et al., 2007). The concept that coffee is a risk 
factor for pancreatic cancer has been challenged with recent data failing to demonstrate a 
significant association (Maitra and Hruban, 2008).
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Diabetes Mellitus
Even though diabetes exists in approximately 10% of the population, the role of diabetes 
in pancreatic cancer has been investigated with conflicting results (Chari et ah, 2008, 
Pandey et ah, 2011; Raimondi et ah, 2009). Everhart et al undertook one of the initial 
meta-analysis examining 20 epidemiological studies and revealed a causal link between 
diabetes and the risk of developing pancreatic cancer (Everhart and Wright, 1995). A 
further analysis (Huxley et ah, 2005) showed a more modest iclationship between long 
standing diabetes of greater than 5 years and pancreatic cancer (odds ratio 1.5) with the 
risk being higher for patients who had diabetes mellitus for less than 5 yeais (odds latio 
2.0). Other case control and prospective studies have also demonstrated an increased risk 
of pancreatic cancer in diabetics (Luo et ah, 2007). One of the majoi concerns in all of 
these studies is the fact that diabetes mellitus was diagnosed shortly before or 
concomitantly with the cancer and therefore whether diabetes mellitus causes pancreatic 
cancer or arises secondary to cancer is a controversial issue (Lowenfels and 
Maisonneuve, 2006) (Raimondi et ah, 2009). Both experimental and epidemiological 
evidence to support the argument on both sides exit. Islet cell dysfunction has been 
implicated as one of the underlying factors behind diabetes seen with pancreatic cancer 
(Same M and Pour PM, 2003). This dysfunction is a result of a primary alteration by a 
carcinogen, or secondary damage caused by the cancer cells themselves. A further theory 
proposes the production of diabetogenic substances by the cancer cells themselves, which 
early studies have revealed to be low molecular weight peptides detected in the serum of 
patients with pancreatic cancer (Basso D et ah, 2002). Islet amyloid polypeptide (amylin) 
has been investigated by several groups and is thought to have a similar function (Same
10
M and Pour PM, 2003). The impact of therapy for diabetes on pancreatic cancer risk has 
been examined with Metformin, an oral antidiabetic agent, being associated with a 
decreased risk of pancreatic cancer (Currie et al., 2009). Studies have also identified the 
relationship of obesity which not only affects peripheral insulin resistance resulting in 
cancer related diabetes, but is also seen to significantly increase the risk of pancreatic 
cancer (Calle EE and Kaaks R, 2004; Luo et ah, 2007). The jury is out as to whether 
diabetes is an actual risk factor for pancreatic cancer or is diabetes in pancreatic cancer a 
result of the disease itself.
Other medical associations
Previous gastrointestinal surgery in particular cholecystectomy is a risk factor with 
reports from clinical studies suggesting a relative risk of developing pancreatic cancer in 
the range of 1.2-2 (Lin Y et ah, 2002). To the contrary a larger prospectively designed 
study by Schernhammer et al involving over 100,000 patients indicated the actual risk 
of pancreatic cancer due to cholecystectomy to be very low (Schernhammer ES et ah, 
2002). A recent meta-analysis of 18 studies has concluded that individuals with a history 
of a cholecystectomy are at an increased risk of developing pancreatic cancer (Lin et ah, 
2012). Previous partial gastrectomy for benign peptic ulcer disease has also been reported 
to carry an increased risk of pancreatic cancer, the mechanisms of which are unclear, but 
an increased production of nitrosamines is one of the proposed mechanisms (Tascilai M
et ah, 2002).
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Helicobacter pylori (H. pylori) infection as a possible risk factor for pancreatic cancer has 
also met with conflicting results with some studies quoting an odds ratio ranging from 
1.87-2.1 (Lowenfels and Maisonneuve, 2006). A large population based study from 
Sweden concluded no association between H. pylori infection and the risk for pancreatic 
cancer in the total cohort, however in a subset of subjects who were non-smokers and low 
alcohol consumers a positive H. pylori serology was associated with an incieased lisk foi 
pancreatic cancer (Lindkvist et ah, 2008). A recent cumulative meta-analysis has 
concluded that there is no increased risk of pancreatic cancer with Helicobacter pylon (H. 
pylori) infection (Trikudanathan et ah, 2012).
Other viral infective agents that are known to cause acute pancreatitis e.g. coxsackie, 
mumps, HIV are not known to cause pancreatic cancer (Lowenfels and Maisonneuve, 
2006), however studies have detected a link between Hepatitis B / Hepatitis C virus 
infections and pancreatic cancer (El-Serag et ah, 2009).
Industrial and Environmental Risk Factors
Studies have linked pancreatic cancer to several occupational groups; workers in mines, 
metal works, sawmills, chemical plants, rubber factories and the petrochemical industry 
are at an increased risk (Andreotti and Silverman, 2012). Exposure to chlorinated 
hydrocarbon compounds, pesticides, polycyclic aromatic hydrocarbons (PAHs), metals, 
nitrosamines, radiation, naphthylamine, and benzidine have been reported to be linked to 
pancreatic cancer with the strongest evidence being associated with chlorinated 
hydrocarbons and PAHs (de Brand et ah, 2004) (Andreotti and Silverman, 2012).
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1.2 Pancreatitis and its role in Pancreatic Cancer development
Chronic pancreatitis
There is a well-established link between inflammation and cancer such as gastritis in the 
cases of stomach cancer or hepatitis causing hepatocellular carcinoma. Chronic 
pancreatitis is recognised to confer a 15-25 fold risk for pancreatic cancer in some studies 
(Olson, 2011) (Malka et al, 2002) (Howes and Neoptolemos, 2002). Patients with 
chronic pancreatitis usually have disease for a duration greater than 20 years and as a 
result of this tend to have calcification, increasing the risk of complications (pseudo cysts, 
diabetes) (Howes et al., 2004). Exocrine organ dysfunction and pancreatitis are thought to 
promote carcinogenesis in part by promoting the local release of giowth factois, 
cytokines and reactive oxygen species resulting in cell proliferation, disruption of cell 
differentiation and enhancing oncogene mutations (Carriere et al., 2011; DiMagno and 
DiMagno, 2009; Zavoral et al., 2011).
Analysis of specimens resected for chronic pancreatitis have revealed that over a third of 
patients have KRAS mutations in the pancreatic tissue, moreover the presence of 
pancreatic cancer precursor lesions PanlN (pancreatic intraepithelial neoplasia) were 
detectable in 63% of specimens. This further supports the association of pancreatitis as a 
risk factor for pancreatic cancer (Andea et al., 2003; Guerra et al., 2007). Mouse model 
experimentation has also shown that induction of pancreatitis in a 2 month old mouse 
causes rapid PanlN progression and PD AC development by the age of 4 months (Carriere
et al., 2011).
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The developmentally regulated family of Hedgehog genes also has a role in chronic 
pancreatitis and pancreatic cancer (Hidalgo and Maitra, 2009; Jones et ah, 2008). The 
Hedgehog pathway is one of the core signalling pathways that undergoes alteration in 
pancreatic cancer (Hidalgo and Maitra, 2009). Likewise this pathway is also seen as 
unregulated in chronic pancreatitis (Kayed et ah, 2004), reflecting its contribution 
towards pathogenesis. Mouse model experimentation has also shown upregulation of the 
Hedgehog pathway in rats with chronic pancreatitis (Wei-Guo et ah, 2010).
Local factors produced in chronic pancreatitis in the way of proinflammatory cytokines 
(interleukins) and growth factors (epidermal and platelet derived) can cause activation of 
the NF-kB pathway (nuclear factor kappa-light-chain-enhancer of activated B ceils) 
(Zavoral et ah, 2011). The pathway is known to regulate cancer relevant processes 
including immune modulation, angiogenesis, and apoptosis (Zavoral et ah, 2011). Normal 
pancreatic tissue does not demonstrate any NF-kB activity, however inflamed acinar cells 
and local stromal cells (such as macrophages) through autocrine and paracrine channels 
result in activation of this pathway modulating early pancreatic cancer pathogenesis 
(Chandler NM et ah, 2004). Another downstream mediator of inflammation is the 
cyclooxygenase-2 (COX-2) which is a key enzyme in the production of prostaglandins 
and is seen to be up-regulated in pancreatitis and overexpressed in pancreatic cancer 
(Albazaz et ah, 2005) (Zavoral et ah, 2011). The association of a chronic inflammatory 
response in the pancreatitis microenvironment leads to tissue damage and fibrosis, which 
can also promote tumorigenesis by release of cytokines and growth factors, as well as 
release of reactive oxygen species (ROS) (Farrow and Evers, 2002). An increase in
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intracellular reactive oxygen species can cause DNA damage, contribute to telomere 
shortening and mutation of proto-oncogenes, resulting in pancreatitis having a role 
pancreatic cancer tumorigenesis (Farrow et ah, 2008) (Masamune et ah, 2009b).
Hereditary pancreatitis
Hereditary pancreatitis confers a 70-100 fold-increased risk of developing pancreatic 
cancer (Haddad et ah, 2011
; Howes N et ah, 2004). Hereditary pancreatitis is an autosomal dominant disorder with 
an estimated penetrance of 80% (Ghadirian et ah, 2003) and equal gender incidence, 
presenting in children and younger adults (Ghaneh et ah, 2007) (Greer et ah, 2009). 
EUROPAC, which is the European data registry for hereditary pancreatitis and familial 
pancreatic cancer, defines hereditary pancreatitis as two or more first degree relatives or 
three or more second degree relatives in two or more generations with recurrent acute 
pancreatitis and or chronic pancreatitis in the absences of gallstones, tropical pancreatitis 
or excess alcohol (Howes et ah, 2004). It is characterised by recurrent attacks of acute 
pancreatitis that begin in childhood resulting in chronic pancreatitis by the age of 25 
years.
A vital genetic mutation in hereditary pancreatitis was first described by Whitcomb et al 
in 1996, who discovered a specific mutation on the cationic trypsinogen gene (PRSS1) in 
affected individuals from five kindred (Whitcomb DC et ah, 1996). Up to 25 further 
mutations of the PRSS1 gene were subsequently described (Howes N et ah, 2004) with
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the R122H and N291 making 70% of those mutations (Greer et al., 2009). Mutated 
PRSS1 causes premature cationic trypsinogen gene activation resulting in excessive 
intracellular activation of trypsinogen to trypsin; the gain of function leading to chronic 
pancreatitis. The risk of developing pancreatic cancer is linked to the duration of chronic 
pancreatitis with cancer occurring 30 years after the onset of chronic pancreatitis, the 
incidence showing a very significant increase in smokers (Greer et al., 2009). Mutation in 
the pancreatic secretory trypsin inhibitor gene, SP1NK1, has been associated with 
“tropical pancreatitis” which is seen in Asia and Africa conferring a risk of 100 fold with 
onset of cancer being about 14 years earlier than in sporadic cases (Whitcomb, 2004). 
Finally, there is a link between chronic pancreatitis and pancreatic cancer in patients with 
cystic fibrosis. Mutation in the CFTR gene causes impairment of enzyme secretion of 
pancreatic digestive enzymes resulting in ductal obstruction with pancieatitis leading to 
chronic fibrosis and ultimately cancer (Haddad et al., 2011 
; Noone PG et al., 2001).
Inherited Genetics of Pancreatic Cancer
The inherited predisposition attributable to genetic factors accounts for 5-10% of 
observed cases of pancreatic cancer (Haddad et al., 2011
; Klein AP et al., 2004; Vincent et al., 2011). Germline mutation have been linked to 
familial pancreatic ductal adenocarcinoma including those targeting tumour suppressor 
genes: INK4A, BRCA2 and LKB1, MLH1 (Jaffee et al., 2002), however penetrance of 
these is low and they are seen to impact tumour progression rather than initiation (Hezel
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et al., 2006). In certain families this has an associated autosomal dominant pattern of 
inheritance with the risk of developing pancreatic cancer amongst first degree relatives of 
an affected individual estimated to be 18 fold in kindreds’ with two, and as high as 57 
fold in kindreds’ with three or more affected family members (Jorgensen et al, 2008). An 
inherited predisposition to pancreatic cancer has been suggested with some authors 
grouping them in syndromic and non-syndromic groups (Jorgensen et al., 2008). 
Commonly they care divided into three groups:
(1) As an adjunct to a familial cancer syndrome
(2) As an inherited predisposition to pancreatic cancer linked to another condition for 
example, hereditary pancreatitis
(3) As part of familial pancreatic cancer group where there is a predisposition to 
pancreatic cancer without a causative agent.
Familial pancreatic cancer
Familial pancreatic cancer (FPC) is rare in occurrence, being characterised by at least two 
first degree relatives or two or more second degree relatives (one of whom had an early 
onset below the age of 50 years) with histologically confirmed pancreatic cancer that 
does not fulfil the criteria of another hereditary cancer syndrome (Lynch et al., 1989) 
(Maitra and Hruban, 2008). Data from a prospective study suggested that the relative risk 
of developing pancreatic cancer among relatives of a pancreatic cancer patient was 
calculated to be 4.6 fold in kindred with one, 6.4-fold in kindred with two, and as high as
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32-fold in kindred with three or more first degree family members (Jorgensen et ah, 
2008; Klein AP et ah, 2004). The gender distribution for FPC is 43% men and 57% 
women, with a mean age of pancreatic cancer being 65 years (Lynch HT et ah, 1990). 
The principle causative gene mutation has not been identified however up to 20% of 
families with familial pancreatic cancer have a BRCA2 germline mutation(Hahn et ah, 
2003). Palladdin, a gene encoding for cytoskeleton proteins has recently been suggested 
as a candidate gene being identified in the susceptibility locus of 4q32-34 (Pogue-Geile et 
ah, 2006) however these have not been seen in other large familial pancreatic cancer 
kindred (Earl et ah, 2006).
Pancreatic cancer in a familial cancer syndrome
As described in the above, pancreatic cancer can occur as part of a defined genetic 
syndrome (Vitone et ah, 2006) (Maitra and Hruban, 2008) (Greer et ah, 2009). Peutz- 
Jeghers syndrome, which is a rare autosomal dominant condition, and poses the highest 
overall risk for pancreatic cancer with a 120-fold lifetime risk and cumulative lifetime 
risk of 36% (Giardiello FM et ah, 2000). It consists of oral mucosal naevi associated with 
intestinal hamartomas due to serine / threonine kinase 11 (STKl 1) mutations (Grutzmann 
et ah, 2004). In addition, it is associated with the development of cancer at multiple sites 
e.g. colonic cancer. Hereditary non-polyposis colorectal cancer (HNPCC) has an 
autosomal dominant pattern caused by mutations in hMLHl and hMLH2 genes 
accounting for 90% of mutations (Peltomaki and Vasen, 2004). Aarnio et al studied over 
290 carriers in 40 families identifying 6 cases of pancreatic cancer making the overall
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risk low (Aarnio et al., 1995; Jorgensen et al, 2008). Familial ovarian and breast 
cancer is caused by germline mutation in BRCA1 or BRCA2 genes, exhibiting a lifetime 
risk for developing pancreatic cancer in the order of 5% (Vitone et ah, 2006). The BRCA2 
protein product interacts with proteins involved in cell cycle regulation, transcriptional 
regulation and DNA repair. Hereditary breast cancer is mainly caused by germline 
mutations in the BRCA1 or BRCA2 genes (Daniel DC, 2002). In a large multicenter study, 
Thompson et al. demonstrated that the relative risk for pancreatic cancer in BRCA1 
carriers was increased by 2.26 fold which was statistically significant (Thompson D and 
Easton DF, 2002). This relative risk in BRCA1 carriers is lower than that in BRCA2 
carriers which has been estimated to range from 3.5 to 8 fold (Ozcelik H et al., 1997). 
Familial adenomatous polyposis is an autosomal dominant inherited diseases caused by 
germline mutation of ARC (Adenomatous polyposis coli) resulting in thousands of 
colonic polyps appearing at an early age resulting in colonic cancer, however the leported 
incidence of pancreatic cancer in these patients is too small establish a definitive link 
(Offerhaus et al., 1992).
Pancreatic cancer is the second most common cancer that occurs in the familial atypical 
multiple mole melanoma syndrome and is particularly significant in patients and 
families with pl6 mutations (Vasen et al., 2000). In all the families with FAMM 
described so far the causative germline mutation has been found to be INK4A. 
Melanoma-pancreatic cancer syndrome: the joint occurrence of melanoma and 
pancreatic cancer in combination with a CDKN2A Germline mutation appears to be a 
distinct tumour predisposition syndrome, which has been termed melanoma-pancreatic
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cancer syndrome (Bartsch DK et al., 2002). Ataxia Telangiectasia is an autosomal 
recessive syndrome that is associated with inactivation of the ataxia telangiectasia 
mutated ATM gQ\\Q. The protein product has an important role in the cellular response to 
genetic stress inducing cell cycle arrest or apoptosis, by a p53 independent pathway 
(Yang J et al., 2003). Carriers of the mutated gene have a relative risk of pancreatic 
cancer of approximately three-fold (Geoffroy-Perez B et al., 2001). The syndromes and 
associated genetic mutations, which are known to occur in them aie summaiised in Table 
1.1.
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Syndrome Inheritance Mechanism Gene
involved
Risk
Peutz-Jeghers
Syndrome
Autosomal
dominant
Serine /
threonine kinase
11 mutations
STK11/LK
Bl
4.5 fold (Latchford
et al., 2006)
Familial Breast 
and Ovarian
Cancer
Germline
mutation
Disruption of
cell cycle and
transcriptional
regulation
BRCA1
and
BRCA2
2.26
fold(Thompson D 
and Easton DF,
2002)
Familial Atypical 
Multiple Mole 
Melanoma
Autosomal
dominant
PI6 inactivation CDKN2 13 fold
(Bezel et al., 2006)
Flereditary Non­
polyposis Colon 
Cancer
Autosomal
dominant
by mutations in
DNA repair 
genes
MLH1,
MSH2,
MSH6,
PMS1,
PMS2
5 fold (Brentnall,
2000)
Ataxia-
Telangiectasia
Autosomal
recessive
Induction of cell
cycle arrest
ATM 3 fold (Geoffroy-
Perez B et al.,
2001)
Fanconi Anaemia Autosomal
recessive
Repair of DNA
damage
FANCA
genes
5 fold (van der 
Heijden et al.,
2004)
Li-Fraumeni
Syndrome
Autosomal
dominant
Germline
mutations in p53
p53 2 fold (Ruijs et al.,
2010)
Familial
Adenomatous
Polyposis
Autosomal
dominant
APC Low risk- 4.5 fold
(Giardiello FM et 
al., 1993;
Offerhaus et al., 
1992)
Table 1.1: Table detailing familial cancer syndromes and associated genetic mutations
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1.3 Molecular genetics of pancreatic cancer
The understanding of pancreatic cancer genetics and linkage of key moleculai events to 
histopathologic stages is a rapidly evolving field, which has seen numerous developments 
recently (Vincent et ah, 2011) (lacobuzio-Donahue, 2011). Pancreatic cancer is a 
heterogeneous disease of inherited and somatic mutations however, the moleculai 
mechanisms linking these genetic changes to the aggressive nature of this disease remains 
to be fully understood. Recent publications using advanced sequencing methods for 
mutational analysis of tumours and corresponding metastasis have given an in-depth 
insight into the genetic evolution of pancreatic cancer (Jones et ah, 2008) (Campbell et 
ah, 2010; Yachida et ah, 2010). Moreover, studies mapping timeframes of tumours 
initiation, progression and kinetics of metastasis have revealed that these processes are 
considerably longer than previously thought to be (Haeno et ah, 2012; Yachida et ah, 
2010).
Pancreatic cancer exhibits all the hallmarks of malignant cancer cells, including autociine 
growth signalling, insensitivity to growth inhibition, evasion of lysis, angiogenesis, 
invasion and metastasis (Hanahan and Weinberg, 2011; lacobuzio-Donahue, 2011). 
These occur through complex biological pathways related to mutations, activation of 
proto-oncogenes and inactivation of tumour suppressor genes, abnormalities in growth 
factors and their receptors, gene amplifications, chromosomal losses and telomere 
shortening (Buchholz and Gress, 2009) (Mihaljevic et ah, 2010
) (Haeno et ah, 2012). This subsequently has a knock-on effect on downstream signal 
transduction pathways involved in the control of growth and differentiation.
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Pancreatic cancer cells have certain signature molecular aberrations, which distinguish 
them from normal pancreatic ductal cells and are vital in maintaining the transformed 
phenotype of tumour cells. Jones et al. (Jones et ah, 2008) in 2008 published a landmark 
paper delineating discovered aberrations to core signalling pathways in pancreatic cancer. 
The authors analysed 24 pancreatic tumours to a large-scale genomic analysis of 20,661 
protein-coding genes, uncovering 1562 somatic mutations, 198 homozygous deletions 
and 144 amplifications. Thirty-one gene sets were identified as altered in a majority of 
the 24 pancreatic tumours analysed; these could be linked to 12 cores signalling pathways 
some of which have been studied in detail, whereas others have not previously been 
implicated in pancreatic cancer.
Molecular evolution of pancreatic cancer in terms of a temporal sequence of genetic 
alterations has revealed that a majority of genetic alterations occur early in the neoplastic 
process and are present in the primary tumour and metastases arising from it (Campbell et 
ah, 2010). Using somatic mutations as molecular clocks, Yachida et al were able to 
determine that an initial precursor neoplastic clone will take about 10 years to evolve into 
a malignant clone and several years for metastatic subclones to emerge from within the 
primary cancer (Yachida et ah, 2010). This timeline is certainly longer than previously 
perceived and has improved prospects for therapeutic treatment and screening. The same 
group, using mathematical and computational analysis of primary pancreatic tumours and 
associated metastasis has more recently suggested that targeting tumour cells using 
chemotherapy whilst they were rapidly growing was crucial and surgery prior to
23
chemotherapy may reduce survival. This has challenged current piactices tiiggeiing the 
need for further research, in particular novel clinical trials (Haeno et al., 2012).
Oncogenes
Oncogenes are dominant genes, which induce or maintain cellular transformation, which 
when mutated or expressed at high levels, help convert a normal cell into a tumour cell. 
Proto-oncogenes are present normally in cells and are involved in regulating cellular 
growth or differentiation (Vinay Kumar, 2007). Abnormal cells normally undeigo a 
programmed form of death called apoptosis, however activated oncogenes can cause 
those cells to survive and proliferate instead. Mutations in proto-oncogenes result in 
unrestricted cell growth and this may be a result of (1) Point mutations (2) Chromosomal 
translocation (3) Gene amplification (4) Environmental factors (5) Viral infections 
(Vinay Kumar, 2007).
KRAS mutations
One of the fundamental oncogenetic mutations in pancreatic cancer is KRAS (V-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog), which is reported to be mutated in 75 A to 
90 % of cases (Buchholz and Gress, 2009; Hruban et al., 1993) (lacobuzio-Donahue, 
2011). KRAS is 21 kDa protein (Ghaneh et al., 2007) and member of the RAS family of 
GTP-binding (Guanosine-5'-triphosphate) proteins that mediate a wide variety of cellulai 
functions including proliferation, differentiation, cell survival and cytoskeletal 
remodelling amongst a few (Campbell et al., 1998; Hingorani and Tuveson, 2003;
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lacobuzio-Donahue, 2011). The active form of the protein is bound to GTP and 
inactivation occurs through guanosine triphosphate activating proteins (GTPase 
activating proteins), which promote hydrolysis to the diphosphate foim (GDP). These 
activating mutations impair the intrinsic GTPase activity on the KRAS gene product, 
resulting in a protein that is constitutively active in intracellular signal transmission 
(Hingorani and Tuveson, 2003) leading to uncontrolled cell growth (Hruban et ah, 2008). 
Activating KRAS point mutations occur at codon 12 resulting in the substitution of 
glycine with aspartate, valine, or arginine (Hruban et ah, 1993). KRAS mutations are also 
demonstrable in the pancreatic cancer progression model, being present in up to 87% of 
cancer associated PanIN-2/3 lesions (Matthaios et ah, 2011).The high frequency of KRAS 
mutation detected in PanINs support its function as an initiating event in the development 
of invasive disease (Hingorani et ah, 2003j Hruban and Adsay, 2009, Matthaios et ah, 
2011). The other members of the RAS family {HRAS and NRAS) are not affected in 
pancreatic cancer (Rodenhuis, 1992). KRAS activation seem to be essential foi panel eatic 
cancer maintenance as has been demonstrated by non-viability of dominant negative 
mutants cancer models and the use of interference siRNA knockdown studies (Fleming et 
ah, 2005). Mice model experimentation has shown that the KRAS protein is required not 
only for initiation of pancreatic cancer but also for its maintenance suggesting a potential 
therapeutic target (Collins et ah, 2012 1957). Posttranslational modification of RAS 
protein by C-terminus farnesylation through fernesyl transferase is a major therapeutic 
target using inhibitors of farnesyl transferase, however phase III trials have been 
unsuccessful (Rocha-Lima, 2008).
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Activated KRAS is involved in three main effector pathways which are (1) RAF activated 
kinase (MAPK: Mitogen-activated protein kinase), (2) phosphoinositide-3-kinase (PI3K) 
and (3) RalGDS (guanine nucleotide dissociation stimulator) pathways.
The RAF family of serine / threonine kinase binds to activated KRAS, resulting in 
MAPK/ERK kinase activation through a series of phosphorylation culminating in 
proliferation and enhancement of a variety of intracellular systems (Hezel et ah, 2006). 
Hirano et al has demonstrated that inhibition of MAPK/ERK using pharmacological 
agents results in decreased proliferation and cell cycle arrest indicating the potential role 
of this pathway as a therapeutic target (Hirano et ah, 2002; Neel et ah, 2011). The 
inhibitor of RAF-1 kinase, Sorafenib (Kane et ah, 2006) has been used successfully in 
practice to treat renal cell carcinoma. Sorafenib has limited activity in advanced 
pancreatic cancer (Matthaios et ah, 2011). Isolated B-RAF mutations are present in about 
a third of pancreatic carcinomas, with a wild-type KRAS resulting in activation of RAF- 
MAPK signalling in the absence of KRAS mutation (Calhoun et ah, 2003), indicating a 
KRAS independent pathway.
The PBK signalling pathway, which can be activated by KRAS, regulates cell survival, 
size, and proliferation via several downstream effectors including AKT (serine/threonine 
protein kinase), p70-S6K, and the small GTPase (Cantley, 2002, Rodiiguez-Viciana et 
ah, 1996). The PI3K-AKT pathway is activated in most pancreatic cancers via KRAS 
however there are genomic events which allow this to be activated independently namely 
via activation of AKT2 gene on chromosome 19q (Mihaljevic et ah, 2010
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). This gene has been demonstrated to be amplified and activated in up to 60% of 
pancreatic cancers (Altomare et ah, 2003). The protein mTOR (mammalian target of 
rapamycin) a downstream regulator of PI3K and AKT pathway has emerged to have a 
role in KRAS mediated cell proliferation, which has been inhibited using CCI-779, 
causing growth inhibition, but is still under investigation as a form of therapy for 
pancreatic cancer (Javle et al., 2010).
Mutations of KRAS also affect downstream regulation of the RalGDS pathways through 
RalA, which has recently emerged as an important molecule in the regulation of KRAS 
mediated functions (Lim et al., 2006). Experimental work analysing the functioning of 
RalA and RalB discovered the former critical to tumour initiation, with the latter being 
important in tumour metastasis when tested in cancer cell lines (Neel et al., 2011). The 
potential of these proteins as future therapeutic targets in halting pancreatic cancer 
progression is yet to be identified (Neel et al., 2011).
The nuclear factor kappa B transcription factor (NF-kB) is another important downstream 
mediator of mutated KRAS signalling in pancreatic ductal adenocarcinoma being 
activated via the PIS / AKT pathway. This pathway is activated in response to cell 
stresses by stimulation of proinflammatory cytokines such as tumour necrosis factor 
alpha (TNF-a) and growth factors having a role therefore in regulating immune response, 
apoptosis, and angiogenesis (Hayden and Ghosh, 2004). TNF-a is produced by a variety 
of cell including, macrophages as well as pancreatic acinar cells having a paracrine and 
autocrine effect on cancer cells. A majority of pancreatic cancer and cancer cell lines
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demonstrate NFkB activity in the presence of KRAS activation as dominant negative 
KRAS alleles show no activity of NFkB (Liptay et ah, 2003). The Figure 1.1 below 
demonstrates a simplified schematic representation of KRAS signalling in pancreatic 
cancer.
Cell mobility and 
cytoskeletal modelling
NFkB
MEK/ERK
RAS-GDP
Other mediators
RAS-GTP
Active RAS
Cell proliferationCell cycle progression Cell survival and growth
Figure 1.1: The RAS signalling pathway in pancreatic cancer. (Abbreviations of text in 
above section)
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Tumour Suppressor Genes
Pancreatic cancer is associated with a high rate of inactivation of three tumour suppressor 
genes: INK4A, p53 and MADH/DPC4 (SMAD4) (Tuveson and Neoptolemos, 2012). 
Tumour suppressor genes normally function in order to stop signals for cell division, with 
their activity going unchecked in carcinogenesis resulting in unregulated cell proliferation 
and growth. Unlike oncogenes, tumour suppressor genes generally follow the 'two-hit 
hypothesis', as the presence of one functional copy in most cases is sufficient to maintain 
the function of the gene (Knudson A, 1978). These tumour suppressor genes can be 
inactivated by a number of mechanism including homozygous deletion, intragenic 
mutations, or promoter hypermethylation (Hruban et al., 2008). Oncogene mutations, in 
contrast, generally involve a mutation to single allele, resulting in a single point mutation. 
There are notable exceptions to the 'two-hit' rule for tumour suppressors, such as certain 
mutations in the p53 gene. Mutations of p53 gene can function as a 'dominant negative', 
meaning that a mutated p53 protein can prevent the function of normal protein from the 
un-mutated allele occurs (Baker et al., 1990).
INK4A
The gene P16/CDKN2A (Cycl in-dependent kinase inhibitor-2A) also known as INK4A 
suffers a loss of function, which is brought about by mutation, deletion, or promoter 
hypermethylation and occurs in about 80%—95% of sporadic pancreatic ductal 
adenocarcinomas (Rozenblum et al,, 1997; Vincent et al., 2011). In 40% of cancers 
homozygous deletion of both alleles of the gene (Hruban et al., 2008).
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As a result, of either environmental carcinogens or instability of DNA, cell cycle fail safe 
mechanisms are activated to ensure the accuracy of each step of DNA synthesis is 
maintained. Depending on the phase in which damage is detected, non-transformed cells 
arrest in the Gi (growth-1 phase), S (synthesis phase) or G2 phase, (growth 2 phase) of 
the cell cycle allowing repair or apoptosis if repair is not possible to occur (Vinay Kumar, 
2007). Loss of one or more of these cell cycle fail safe mechanisms results in 
uncontrolled proliferation of the cancer cells (Liu et al., 2010). Cyclin dependant kinase 
(CDKs) which form complexes with respective cyclin subunits (e.g. Cyclin-D and 
Cyclin-E) are at the heart of the cell cycle enabling phosphorylation of specific 
substrates and hence proliferation (Liu et al., 2010).
The CDKN2A locus {9q21) encodes two overlapping tumour suppressors INK4A and 
ARF, and their respective protein products pl6INK4A and pl9ARF via distinct first exons 
and alternative reading frames in shared downstream exons (Sherr, 2004). The close 
genetic proximity of both genes is the reason why genetic alteration affects both the 
tumour suppressor genes together on most occasions (Mihaljevic et al., 2010 
). The function of the product of the CDKN2A (INK4A) gene, p!61NK4A is to bind cyclin- 
dependant kinases CDK4/CDK6 thereby preventing the formation of active cyclinD- 
CDK4/CDK6 complex. The cyclinD-CDK4/CDK6 complex inhibits phosphorylation of 
Rb (retinoblastoma protein) which is a tumour suppressor protein (Sherr, 2004) (Liu et 
al., 2010). This in turn will block entry into the S phase of the cell cycle, which is the 
DNA synthesis phase (Maitra and Hruban, 2008). In pancreatic cancer, the Rb/INK4A 
tumour suppressor pathway is disrupted due to INK4A mutation resulting in uncontrolled
30
cell growth. The other tumours suppressor gene at the CDKN2A locus (9q21), ART 
encodes for a product pl9ARF that also inhibits cell proliferation being involved in the 
p53/MDM2 pathway. The protein p!9ARF inhibits MDM2-dependent proteolysis of p53 
resulting in activation of p53 hence Rb dependent cell cycle arrest (Sherr, 2006) (Hezel et 
ah, 2006). Furthermore, ARF seems to have a p53 independent tumour suppressor 
function by inhibiting NF-kB function and its anti-apoptotic activity (Rocha et ah, 2003). 
Both mutation of INK4A and ARF gene occur simultaneously in around 40% of 
pancreatic cancers however, mutation targeting INK4A alone are commonly (Bardeesy 
and DePinho, 2002) observed as a major event in the development of pancreatic cancer. 
Bardeesy et al. has proven using mouse model experiments that 1NK4A mutation in co­
operation with KRAS is paramount for the progression of pancreatic cancer producing 
tumours with notably less differentiation and a higher malignant and invasive potential 
(Bardeesy et ah, 2006). Furthermore, INK4A abolition can accelerate tumour progression 
in the setting of concurrent mutation of p53 (Bardeesy et ah, 2006).
p53 Mutation and cell cycle regulation
The p53 tumour suppressor gene is present at chromosome 17p being inactivated in over 
50%-75% of pancreatic ductal adenocarcinomas, most commonly due to missence 
alterations of the DNA-binding domain (lacobuzio-Donahue, 2011; Redston MS et ah, 
1994). This tumour suppressor gene plays an essential role in regulating cell growth and 
inactivation is seen to occur in the later-stages in PanINs (pancreatic intraepithelial 
neoplasia) and adenocarcinoma when the tumour is seen to have attained significant
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dysplasia (Hruban and Adsay, 2009; Maitra et al., 2003) (lacobuzio-Donahue, 2011). It 
is proposed that in more advanced PanINs genetic damage is more pronounced because 
of telomerase erosion and radical oxygen species hence allowing for p53 elimination. 
This allow for cells harbouring genetic aberrations to grow in an uncontrolled manner 
(Maitra et al., 2006). Mutations in p53 are crucial affecting the very core of the cell cycle. 
The p53 protein regulates the G1 to S phase of the cell cycle checkpoint and maintains 
the G2 to M arrest point (Maitra and Hruban, 2008). Loss of p53 function therefore 
serves to enable the growth and survival of cells harbouring procarcinogenic 
chromosomal aberrations. The p53 protein is also involved in the apoptotic pathway, the 
potential loss of these two important functions by inactivation or mutation of p53 may be 
a critical event in pancreatic cancer (Berrozpe G et al., 1994). As described previously in 
the INK4A section, the relationship between ARF and p53 is important as ARF inhibits 
MDM2 mediated targeting of the p53 protein from degradation (Bardeesy and DePinho, 
2002; Rozenblum et al., 1997). An ARF deficiency would result in marked reduction of 
p53 protein levels (Sherr, 2006) however in pancreatic adenocarcinoma p53 mutations 
and ARF deletion coexists suggesting the non-overlapping function of these proteins 
(Maitra et al., 2003). ARF also has p53 independent functioning such as inhibition of 
RNA processing resulting in apoptosis (Paliwal et al., 2006). A detailed explanation of 
regulation of the cell cycle is beyond the scope of this thesis, a brief account is described 
in the following paragraph and demonstrated in figure 1.2.
The cell cycle consists of four stages mitotic (M) phase, growth 1 phase (Gl), synthesis 
phase (S) and growth 2 phase (G2) with cell division occurring the in M phase and DNA
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synthesis occurring in the S phase(Vinay Kumar, 2007). The G1 and G2 phase provides 
additional checkpoints in which damaged DNA replication and cellular division errors are 
repaired (Bharadwaj and Yu, 2004). In the normal cell cycle the primary regulators are 
cyclin dependent kinase (CDKs) which attain an active kinase activity following binding 
with cyclin subunits which direct them (CDKs) towards phosphorylation of stage 
appropriate proteins (Liu et al., 2010; Maitra and Hruban, 2008). The CDK-cyclin 
complexes can be inactivated by removing the cyclin subunit, dephosphorylation, or by 
inhibition from a specific group of proteins called the cyclin dependant kinase inhibitors 
(CKI) which can potentially act as tumour suppressors (Liu et al., 2010). Many subsets of 
the CDK family have been identified in different phases of the cell cycle forming unique 
combinations of cyclins and CDKs at different stages of the cell cycle (Malumbres and 
Barbacid, 2005). Three different CDKs participate in the G phase (CDK2, CDK4, CDK6) 
whereas CDK1 is active in mitosis (M phase). The CDK4 and CDK6 are driven by the 
three D-type cyclins Dl, D2 and D3 and cyclin-E, which specifically activates CDK2 
(Malumbres and Barbacid, 2005). The primary target of the D-cyclin and to a lesser 
extent the E-cyclin is the retinoblastoma (pRb) gene product, a crucial regulator of 
cellular proliferation (Classon M and Harlow E, 2002). Phosphorylation of the pRb 
inactivates it, which results in it dissociation of Rb from transcription factors (E2F), 
leading to the generation of protein and DNA polymerases that are essential for DNA 
transcription at the Gl/S phase transition (Hochegger et al., 2008). Mutation of the Rb 
gene is one of the first genetic alterations described in human cancers that leads to 
increased activation of E2F, unregulated transcriptional activation and uncontrolled cell 
growth (Johnson DG, 2000). It has also been seen in pancreatic cancer that mutation of
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pRb expression and over-expression of E2F correlate with tumour grade (Hochegger et 
al., 2008).
The cyclin-CDK complex is inhibited by two classes of cyclin dependant kinase 
inhibitors in humans, the Cip/Kip family and the INK4A family (Liu et al., ; Sherr and 
Roberts, 1999). The Cip/Kip family is composed of three members: p21WAF/CIP1, p27KIP1 
and p57KIP2, which have a broad spectrum of activity, binding to cyclin-CDK complexes 
and inhibiting their activity. Besides regulating the cell cycle, Cip/Kip proteins play 
important roles in apoptosis, transcriptional regulation, cell fate determination, cell 
migration and cytoskeletal dynamics (Besson et al., 2008). The INK4A family is 
composed of pi5, pi6, pi8 and pi9, which more specifically disrupt CDK4 and CDK6 
binding to it D-type cyclins in the G1 phase, therefore preventing phosphorylation of Rb 
protein as described previously.
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Cell Cycle Regulation
Cyrlins
D1.D2.D3
Figure 1.2: Schematic representation of Cell cycle with cyclin regulatory checkpoints
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Developmental and signalling pathways
The understanding of the association of hedgehog and notch signalling pathways in 
pancreatic carcinoma has been established over the last decade shedding light on the 
embryologic development of the pancreas and pancreatic cancer (Maitra and Hruban, 
2008). The section below briefly highlights the pathways involved, both biochemical and 
molecular which link pancreatic development to cancer.
Hedgehog
The hedgehog signalling pathway is important in pancreatic cancer growth and 
development which in the adult pancreatic tissue is turned off but reactivated in 
pancreatic cancer tumorigenesis (Hidalgo and Maitra, 2009). The mammalian family of 
hedgehog signalling pathway consists of three members: Sonic, Indian and Desert. 
Hedgehog works together with its transmembrane receptors partners ‘patched’ and 
smoothened allowing for signal transmission. Hedgehog pathway has a critical role in 
pancreatic cancer tumorigenesis as it is often mutated (Jones et al., 2008) and inhibition 
of this pathway with cyclopamine enhances survival in genetic mouse models (Feldmann 
et al, 2008) which occurs through direct interactions with Smoothened. The Sonic 
hedgehog signalling seems to be involved in pancreatic cancer stem cell viability (Jimeno 
et al., 2009) the existence of which is based on the hypothesis that cancers grow and 
propagate from a small proportion of cells which have properties similar to normal stems 
cell such as differentiation and renewal. Smoothened inhibitor IPI-926 has proven 
beneficial to survival when applied in conjunction with gemcitabine in a pancreatic 
cancer mouse model (Olive et al., 2009). This drug was able to achieve efficacy by
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reducing fibrosis facilitating the distribution of gemcitabine. The hedgehog signalling 
pathway therefore seems linked not only to cancer and stem cell progression, but also to 
the microenvironment. There is evidence to suggest the hedgehog pathway is involved in 
pancreatic cancer initiation as the hedgehog ligand is over expressed in precursor lesion 
like PanINs and IMPN (Intraductal papillary mucinous neoplasm), along with chronic 
pancreatitis (Hidalgo and Maitra, 2009). Moreover it has been proposed in the literature 
that pancreatic cancer cell secrete hedgehog ligands activating the hedgehog pathway in 
the stroma promoting the dense desmoplastic response seen in pancreatic cancer (Hidalgo 
and Maitra, 2009).
Notch
The notch pathway has an important function in directing the processes by which 
precursor cells develop in the pancreas and in pancreatic cancer, initiation and invasion 
occurs (Ranganathan et al., 2011; Wang et al., 2011
). The Notch signalling pathway is activated by the binding of Notch ligands (delta-like 
and jagged) to one of the four Notch receptors (Notches 1-4)(Ranganathan et al., 2011). 
The interactions result in the proteolytic degradation of the Notch receptors, subsequent 
translocation and activation of target genes. Notch pathway is activated in PanIN lesions 
and invasive cancer where it is seen to promote vascularisation (Rehman and Wang, 
2006). This pathway is also involved in mediating communication between adjacent cells 
expressing similar receptors and ligands being of importance in process of apoptosis 
differentiation and proliferation.
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There is also evidence to suggest that Notch interacts with KRAS to initiate and maintain 
pancreatic ductal adenocarcinoma with the notch target gene Hesl seen to be elevated in 
precursor lesions in mouse models (Sundaram, 2005). Plentz et al. has shown that 
pharmacological blockage of the downstream Notch signalling pathway in pancreatic 
cancer cell lines results in decreased growth, and prevents pancreatic cancer formation in 
the mouse model (Plentz et al., 2009).
Telomere length abnormalities
The telomere is hexameric TTAGGG repeats at the end of chromosome arms, which 
allows for stability during cell division. Loss of telomeres results in chromosome 
breakage during anaphase (Meeker and De Marzo, 2004). This results in areas on the 
chromosomes that can develop regional amplification and deletions (O'Hagan et al., 
2002). Telomere abnormalities are one of the commonest aberrations occurring in 
pancreatic cancer with over >90% of low grade PanIN lesions demonstrating shortening 
(Haeno et al., 2012; van Heek NT et al., 2002). As a result of telomere erosion in PanINs 
an environment is created which allows for acquisition of chromosomal rearrangement, 
however telomerase reactivation in invasive cancer allows for stability to invasive cancer 
cells (Sato et al., 2002). Chronologically it is known that telomere shortening precedes 
the loss of p53 function and it is likely that telomere activates p53 mediated suppressor 
pathways (Hruban et al., 2000; Vincent et al., 2011).
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1.4 Pathogenesis of Pancreatic Cancer and Genetic Evolution 
Morphology
Pancreatic ductal adenocarcinoma is seen to arise from the ductal epithelium accounting 
for over 90% of all pancreatic cancers. It arises most commonly (70%) in the head of the 
pancreas with infiltration into surrounding tissues including lymphatics, spleen, and the 
peritoneal cavity. Macroscopically, pancreatic cancers are firm, poorly defined tissue 
sclerotic masses with tongues of the cancer extending beyond the main tumour (Maitra 
and Hruban, 2008) (Vincent et ah, 2011). It is characterised histologically by a dense 
stroma of fibroblasts and inflammatory cells, called desmoplasia which form a majority 
of the tumour mass with only a small number of cells being from the neoplastic ductal 
elements. The cancer primarily exhibits a glandular pattern with ductal structures 
demonstrating varying degrees of cellular atypia and differentiation. Vascular and 
perineural invasion is present in a majority of resected specimens along with metastasis to 
regional lymph nodes (Hruban, 2006; Vincent et al., 2011).
There are a number of histological variations of pancreatic cancer, which are less 
common, and have been enumerated in Table 1.2. It is important to differentiate these 
carcinoma owing to their better prognosis (colloid and medullary) in comparison to 
infiltrating ductal cancer (Hruban, 2006; Maitra and Hruban, 2008). The majority of 
pancreatic cancers express numerous immunohistochemically detectable pioteins 
common amongst them being the carcinoembryonic antigen (CEA), carbohydrate antigen 
CA19-9, and CA-125. More recently members of the SI00 family of calcium binding 
proteins S100A4, S100A6 and S100P have been identified and are now being utilised in
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histological reporting of pancreatic cancer as they have prognostic value (Cmogorac- 
Jurcevic et al., 2003; Vimalachandran et al., 2005).
Malignant Tumours of the Exocrine Pancreas
1) Ductal adenocarcinoma (most common)
2) Mucinous noncystic carcinoma
3) Signet ring cell carcinoma
4) Adenosquamous carcinoma
5) Undifferentiated (anaplastic) adenocarcinoma
6) Undifferentiated carcinoma with osteoclast-like giant cells
7) Mixed ductal-endocrine carcinoma
8) Serous cyst adenocarcinoma
9) Mucinous cyst adenocarcinoma
1) non-invasive
2) invasive
10) Intraductal papillary mucinous carcinoma
1) non-invasive
2) invasive (papillary mucinous carcinoma)
11) Acinar cell carcinoma
1) Acinar cell cyst adenocarcinoma
2) Mixed acinar-endocrine carcinoma
12) Pancreatoblastoma
13) Solid-pseudopapillary carcinoma
Table 1.2: Malignant tumours of the pancreas
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Pancreatic cancer precursor lesions
Clinical and histological studies have linked precursor lesions to pancreatic cancer. The 
most common and extensively studied lesion is pancreatic intraepithelial neoplasia, 
PanIN which is found in the smaller calibre pancreatic ducts (<5mm) (Hruban and Adsay, 
2009; Hruban et ah, 2001; lacobuzio-Donahue, 2011). PanINs can be either papillary or 
flat being composed of cubodial cells with varying amount of mucin. Other precursor 
lesions analysed are mucinous cystic neoplasm (MCN) and Intraductal papillary 
mucinous neoplasm (IPMN) (Matthaei et ah, 2011). IPMNs are similar to PanINs in their 
architectural structure however grow into large cystic lesions. MCNs are large mucin 
producing epithelial lesions with a cystic architecture harbouring a distinctive ovarian- 
type stroma. They arise in the main pancreatic duct or one of its ductal structures 
(Matthaei et ah, 2011). Autopsy findings and analysis of resected pancreatic cancer 
specimens show the occurrence of PanINs alongside pancreatic adenocarcinoma, 
suggesting a biologic and developmental relationship (Hruban et ah, 2001; Hruban et ah, 
2000).
PanINs lesions show a spectrum of varying morphology compared to ductal elements and 
are therefore graded from stages I to III (Hruban et ah, 2000) (Hruban et ah, 2008). The 
earliest stage is characterized by the appearance of a columnar, mucinous epithelium, 
with increasing architectural disorganization and nuclear atypia appearing through stages 
II and III. Invasion beyond the basement membrane signifies the transformation to frank 
pancreatic ductal adenocarcinoma (Hruban et ah, 2001). Studies for molecular profiling 
have over the last two decades reinforced the PanIN to PDAC progression model through
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documentation of an increasing number of gene alterations (Campbell et al., 2010; 
Hruban and Adsay, 2009; lacobuzio-Donahue, 2011; Rhim et al.3 2012). A standard 
classification system has been put forward by the National Cancer Institute (NCI) Cancer 
Think-tank in 2000 (Hruban et al., 2001) and is now used as standard both in research 
and for histological reporting worldwide.
Pancreatic Cancer Progression Model
The standard classification system put forward in 2000 (Hruban et al, 2001) was based 
on the fact that genetic mutations occurring in pancreatic cancer appear to be in a 
temporal, ordered sequence rather than a random fashion. This confirms the theory that 
neoplastic progression is a result of a combination of growth promoters and inhibitors. A 
pancreatic cancer progression model show below has been taken from Hezel et al 2006, 
indicating the pancreatic cancer progression and critical genetic mutation (Figure 1.3).
KRAS mutations and telomere shortening are seen as early events, being demonstrable in 
the pancreatic cancer progression model and present in up to 87% of cancer associated 
Pan IN 2/3 lesions (Scarlett et al, 2011) (Maitra et al, 2005). The high frequency of 
KRAS mutation detected in PanINs support its role as an initiating event in the 
development of invasive disease (Hingorani et al, 2003; Hruban and Adsay, 2009). 
Inactivation of p!6INK4A gene has been detected in PanIN-1 lesions, however is more 
commonly seen in intermediate lesions (PanIN 2/3) with inactivation found to increase up
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to 85% in invasive cancers (Scarlett et al., 2011). Late occurring genetic aberrations in 
the pancreatic cancer progression model are overexpression of p53 and loss of SMAD4 
which are seen to occur in later stages in PanINs and adenocarcinoma, when the tumour 
has attained significant dysplasia (Maitra et al., 2003) (Luttges et al., 2001). Occurring in 
less than 50% of PanIN-3 lesions (Schwarte-Waldhoff et al., 2000) loss of SMAD4 
expression is predominately seen in invasive cancers.
The role of PanINs as preinvasive lesions which share many histological and molecular 
features with advanced carcinomas excepting breachment of the basement membrane has 
recently been challenged by Rhim et al (Rliim et al, 2012). Contrary to prevailing 
concepts, the authors showed that low-grade PanINs that harbour KRAS mutations have 
migrated into the surrounding tissue in genetically engineered mice. Additionally, they 
showed that the preneoplastic cells which had migrated into the stroma exhibited features 
of mesenchymal cells. These features highlighted the long standing debate of epithelial to 
mesenchymal cell transition, changing fundamentally our concept of pancreatic cancer 
development and progression, in that very early precursor cells, until now thought to lack 
invasive properties, were capable of invasion and seeding distant sites (Rhim et al, 
2012).
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Figure 1.3: Pathological and molecular progression model of pancreatic cancer. Taken 
from Hezel, et al., Genetics and biology of pancreatic ductal adenocarcinoma (Hezel et 
al., 2006)
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CHAPTER TWO
THE CANCER MICROENVIRONMENT
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2.1 The Tumour Microenvironment
The tumour microenvironment is composed of an ecosystem of tumours cells, resident 
and infiltrating non-tumour cells termed the ‘stroma’ along with molecules, which serve 
as chemomediators (Joyce and Pollard, 2009; Neesse et ah, 2011; Shields et ah, 2012b; 
Witz, 2008). A distinct molecular ‘cross talk’ between the host and its surrounding cells 
is seen to occur and is currently the subject of study in a variety of cancer settings 
(Polyak et ah, 2009). The complex interplay, between parenchymal cells and their 
microenvironments is aimed at maintaining a homeostatic balance however, disruption of 
the interplay can induce aberrant cell proliferation, adhesion, function and migration. 
This process is considered to promote the initiation of malignancy with studies indicating 
that changes in stromal behaviour can promote epithelial transformation (Polyak et ah, 
2009).
Locally activated cellular and extracellular elements of the host microenvironment 
secrete molecules that can also influence the malignant phenotype and modify the 
proliferative and invasive behaviour of the tumour (Whiteside, 2008). This has been 
proposed to occur via increasing the genetic instability of tumour cells, inducing 
signalling cascades in tumour cells through tumour-associated receptors and by exerting 
selective pressures on tumour cells (Shapiro et ah) (Liotta and Kohn, 2001). A better 
understanding of stromal epithelial paracrine interaction pathway has brought forward 
many new concepts in tumour initiation, proliferation and opened the ways for new 
therapeutic targets (Polyak et ah, 2009). The hedgehog signalling pathway in pancreatic 
cancer is one such example where cancer associated fibroblasts and not epithelial cells as
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previously thought) are responsible for enhanced epithelial cell proliferation providing 
therapeutic targets (Yauch et ah, 2008).
Epithelial to mesenchymal transition (EMT) is a process in which epithelial cells can 
convert to mesenchymal cells, being essential for organogenesis however, in cancer it can 
contribute to tumour cell heterogeneity and metastatic progression. Stromal and epithelial 
interactions in tumour microenvironment have an important role in the EMT process and 
the concepts of co-evolution of tumour cells and their microenvironment has met with 
some controversy (Sipos and Galamb, 2012) (Hill et ah, 2005). Different putative 
models are proposed, some suggesting it is the stromal cells such as genetically altered 
fibroblast that can initiate tumourogensis in epithelial cells (Kuperwasser et ah, 2004). In 
pancreatic cancer Rliim et ah recently published a paper suggesting that inflammation 
enhances cancer progression in part by facilitating EMT and treatment with the 
immunosuppressive agent dexamethasone abolished dissemination (Rhim et ah, 2012). 
Stromal and tumour interaction are widely studied in breast and prostate cancers, with 
fibroblasts and inflammatory cells being at the centre of attention. Stromal fibroblasts in 
prostate cancer contribute towards the tumour’s formation, with a similar effect exerted 
by fibroblasts in breast cancer progression. Macrophages similarly have a role in 
promotion of extravasation, seeding and persistent growth of breast cancer cells (Qian et 
ah, 2011; Yates, 2011).
In contrast, the tumours seem to have a greater impact on its host stroma in terms of 
signalling and recruitments of cells. It is well established that the malignant tumour cells
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recruit vasculature and stroma cells through secretion and production of stimulatory 
growth factors and chemokines (He et aL, 2011) (Friedl and Alexander, 2011). This 
signalling can result in modification of the microenvironment by the tumour cells 
themselves, in order to facilitate tumour invasion and progression. Moreover, it has been 
revealed that stromal cells are also recruited to the microenvironment from the circulation 
and bone marrow to allowing growth of the primary cancer to facilitate metastatic 
dissemination (Gil-Bernabe et al., 2012; Hiratsuka et al., 2006; Joyce and Pollard, 2009). 
It is now recognised that the complicated interactions between tumour cells and 
surrounding stromal host cells is a vital regulator for conferring the metastatic potential of 
cancer cells.
The concept of the tumour and microenvironmental interactions is not new. In fact 
Stephen Paget put forward the concept of the ‘seed and soil’ about 100 years ago. He 
postulated that the microenvironmental components (the ‘soil’) exert a selective pressure 
on the tumour cells (the ‘seed’) which determines the cancer cell’s malignant phenotype 
driving tumour progression and metastases (Witz and Levy-Nissenbaum, 2006). In 
addition, specific stromal components have also emerged as markers of poor survival in 
cancer patients (Bingle et al., 2002; Koukourakis et al., 2003; Neesse et al., 2011).
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2.2 Pancreatic Cancer Microenvironment
There has been an extensive focus in genomic research to further elucidate our 
understanding of genetic alterations in pancreatic cancer cells (Jones et al., 2008), with 
attention now increasingly expanding towards the microenvironment, in particular the 
stromal cellular compartment (Lonardo et al., 2012) (Neesse et al., 2011). Pancreatic 
cancer, besides consisting of a collection of homogenous cancer cells, demonstrates a 
characteristically intense desmoplastic stroma which can account for up to 75% of the 
pancreatic tumour volume(Seymour et al., 1994). The stroma consists of an extracellular 
matrix maintained by diffusible paracrine growth factors and cytokines, a cellular tissue 
framework of tumour associated vascular, inflammatory and fibroblastic cells (Friedl and 
Alexander, 2011). These components of the stroma are either locally derived or recruited 
from the circulation and surrounding interacting with the cancer cells (Chu et al., 2007; 
Farrow et al, 2008). lacobuzio-Donahue et al subdivided the pancreatic host stromal 
compartments into two distinct regions, juxtatumoral stroma and panstroma (lacobuzio- 
Donahue et al., 2002b). The term ‘juxtatumoral stroma’ refers to stromal cells, which are 
in direct contact with the tumour, while ‘panstroma’ refers to all stromal cells within the 
desmoplastic response to the infiltrating tumour (Figure 1.4). The pattern of gene 
expression in these stromal sub-compartments was found to be distinct (lacobuzio- 
Donahue et al., 2002b) potentially reflecting specific functions for each sub­
compartment.
Pancreatic cancer cells have been shown to modify the extracellular matrix components 
through paracrine effects (Koninger et al., 2004). In healthy tissue, complex
49
communications between host cells maintains a healthy tissue homeostasis, inhibiting 
inappropriate mixing of cells from differing tissue types. Malignant cells, in contrast, 
ignore these signals and dominate the local host cell populations through the production 
of stimulatory growth factors and cytokines. Desmoplasia containing extracellular matrix 
proteins and cells can therefore modulate the growth of pancreatic cancer cells providing 
a scaffolding for cancer growth (Pandol et ah, 2009). Histologically PDAC tumour 
consists of cancer cells and a stromal compartment which can vary significantly from 
tumour to tumour suggesting that stroma formation depends on a complex set of 
interactions between cancer cells, non-malignant cells and extracellular matrix (ECM) in 
a particular tissue(Chu et ah, 2007). More recently, pancreatic cancer subtypes have been 
described following transcriptional profiles of cancer samples and cell lines. Further gene 
signatures for these subtypes have also been defined, which may have utility in stratifying 
patients for their response to different therapeutic agents (Collisson et ah, 2011).
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Figure 1.4: Histological section of pancreatic cancer showing stroma and malignant 
ductal epithelial cells
PanIN stroma formation
PanlNs which represent precursor lesions which arise in the normal pancreatic tissue 
(Hruban et al., 2001). Being an in-situ neoplasm it has been described as confined to the 
basement membrane, however recent publications have challenged this concept 
suggesting that early preinvasive precursors were seen to invade and spread beyond the 
basement membrane (Rhim et al., 2012). The stroma surrounding the PanIN lesions
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shows a variable response based on the aggressiveness of the lesion. PanIN associated 
stroma is characterised by neovascularisation and increased inflammatory cell count and 
it is therefore suggested that the stroma surrounding PanINs promote tumour growth, 
angiogenesis, ECM remodelling aiding tumour invasion converting an insitu lesion to an 
invasive one (Detlefsen et al., 2005) (Scarlett et ah, 2011).
2.3 Components of pancreatic cancer stroma
The extensive stromal response seen in pancreatic cancer is a complex structure 
characterised by activation of pancreatic stellate cells (which have myofibroblastic 
properties), vascular proliferation, infiltration of inflammatory cells and extensive 
extracellular matrix formation (Farrow et ah, 2008) (Neesse et ah, 2011). The above 
responses can be divided into 3 broad areas, which have been discussed in subsequent 
sections in further detail. They are:
(1) Extracellular matrix components (the framework interacting with the cellular 
components exerting signalling properties)
(2) Stromal cellular components
(3) Cell mediators (including growth factors and cytokines)
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Extracellular matrix components
The extracellular matrix (ECM) is part of the dense stromal response seen in pancreatic 
cancer and it is an integral part of the functional network of cell to cell interactions 
contributing to shaping the metastatic character of pancreatic cancer (Kresse and 
Schonherr, 2001). There is a multiplicity of matrix proteins present in pancreatic cancer 
primarily formed by collagens types I and IV (Shields et ah, 2012b). Additionally, 
adhesive glycoprotein such as laminin, fibronectin, vitronectin and tenascin are present in 
the pancreatic cancer microenvironment (Bachem et ah, 2005) which exert signalling 
properties either through interactions with growth factors or directly (Schonherr et ah, 
2001). Koninger et al. have shown that small leucine rich proteoglycans (SLRPs), decorin 
and lumican are present in abundance in the pancreatic cancer microenvironment and are 
now known to be produced primarily by the stellate cells rather than the primary 
pancreatic carcinoma itself (Koninger et ah, 2004).
The fibrotic matrix was initially regarded as a host barrier against cancer invasion 
however, it is now evident that it can modulate and initiate carcinogenesis by influencing 
growth, differentiation and motility of cancer (Bissell and Radisky, 2001). The 
extracellular matrix undergoes a constant remodelling process primarily by proteases, 
most notably the metalloproteinases which aid in the regulation of a wide variety of 
cellular processes from proliferation to cell death therefore inducing tumour progression 
(Stamenkovic I, 2003) (Munshi and Stack, 2006; Pupa SM et ah, 2002). The fibrillary 
collagens, fibronectin and laminin increase cancer cell growth and promote resistance to 
chemotherapeutic agents in a variety of pancreatic cancer cell lines. Type I collagen can
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regulate cellular proliferation modulating intracellular signal transduction affecting cell- 
cycle regulatory proteins cyclins and CDKs (Van Hoorde et al.5 2000).
Cell migration is an essential part of tumour invasion with the loss of cellular adhesions 
being a key event in tumour invasion and progression. There are a number of 
glycoprotein adhesion receptors that mediate cellular adhesion, an important one being 
integrin. These transmembrane proteins combine with the extracellular matrix 
components and to the intracellular actin cytoskeleton. The integrins are also known for 
activation of intracellular signal transduction pathways (Danen EHJ and Sonnenberg A, 
2003). Specific integrins act as receptors for structural ECM proteins such as laminin and 
fibronectin allowing for signalling and adhesion (Heino J, 1996). Increased expression of 
laminin-binding integrins or decreased expression of fibronectin integrins has been 
associated with aggressive growth and metastatic capacity in pancreatic cancer (Arao S et 
ah, 2000). Fibrinogen has been shown to be induce the production of interleukin 6 (IL6), 
interleukin 8 (IL8), monocyte chemoattractant protein-1, vascular endothelial growth 
factor, and type I collagen in pancreatic stellate cells with integrins working as counter 
receptors for fibrinogen in these cells demonstrating molecular interactions in the 
pancreatic cancer stroma (Masamune et ah, 2009a).
Matrix Metalloproteinase
During the invasive process cancer cells rely on activation of the surrounding stroma, 
resulting in disruption of the periglandular basement membrane and hemi-desmosome
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structure (Shields et al., 2012b). Stromal and tumour cell interactions produce 
modifications to the adjacent ECM allowing for favourable grounds to allow for 
microinvasion (Hwang et ah, 2008). Enzymes that degrade the ECM and its associated 
proteins are tightly regulated and are produced both by tumour cells and host stromal 
cells. These enzymes can be classified into two categories (1) Matrix metalloproteinase 
(MMPs) and (2) Tissue serine proteases
The Matrix metalloproteinase family have an important regulatory function in 
maintaining the extracellular environment aiding in the remodelling and hence invasion 
of pancreatic cancer cells. MMPs are expressed in pancreatic cancer cells, fibroblasts, 
activated pancreatic stellate cells and immunocytes, with MMP 1,2,3,7,9,11,13 been 
described in pancreatic ductal cancer cells (Duner et ah, 2010; Kordes et ah, 2005). The 
MMPs are a family of highly conserved zinc dependant endopeptidases, which 
collectively are capable of degradation of the basement membrane, in particular collagen 
type IV (Phillips PA et ah, 2003). MMPs, can be subdivided into four groups: the 
collagenases, the stromelysins, the gelatinases and the membrane type MMPs (MT- 
MMPs) (Munshi and Stack, 2006). Several of the MMPs have been localised to the same 
chromosomal location, llq23, a region which is amplified in several solid organ human 
tumours (Rooney PH et ah, 1999).
Of note in pancreatic cancer are MMP-2 and MMP-9, with the latter having the ability to 
mobilise VEGF hence playing a vital part in angiogenesis (Bergers G et ah, 2000; Harvey 
SH et ah, 2003). Pancreatic stellate cells and macrophages predominantly secrete
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gelatinases (MMP2, MMP9), which degrade the basement membrane collagen (type IV) 
and are associated with inflammation, fibrosis, angiogenesis, and cancer invasion (Duner 
et ah, 2010; Phillips et ah, 2003). MMP-7 is present in most PDACs, in particular in the 
epithelial cells at the invasive tumour front and is significantly correlated with advanced 
pathologic stages, and poor prognosis (Yamamoto et ah, 2001). MMP11 is expressed in 
pancreatic cancer stromal cells in a juxtatumoural distribution and may indicate a direct 
communication between tumour and stromal cells (lacobuzio-Donahue et ah, 2002b).
The activities of MMPs can be blocked by non-specific inhibitors such as a2- 
macroglobulin and a 1-antiprotease, the main physiological inhibitors are the tissue 
inhibitors of metalloproteinase (TIMPs) (Curran S and Murray GI, 1999). Several 
different TIMPs have been identified (TIMP 1-4) and studies have found an inverse 
relationship between TIMP-1 expression and metastatic potential (Bloomston M et ah, 
2002) (Alexander CM and Werb Z, 1992). Activation of pro-MMP2 to MMP2 by 
membrane bound MT-MMP is a critical step in pancreatic cancer (Bramhall SR et ah, 
1997) with pro-MMP2 being produced by stromal cells and activated by pancreatic 
cancer cell membrane bound MT-MMP. Similarly, MT1-MMP is overexpressed in 
pancreatic cancer cells at sites of PDAC invasion (lacobuzio-Donahue et ah, 2002b) with 
genetic studies indicating MT1-MMP to be a primary regulator of collagenolysis (Shields 
et ah, 2012a). It has also recently been shown to have a role in generation of collagen rich 
stromal reaction with mouse models demonstrating that high MT1-MMP presence is 
associated with large stromal dense pancreatic cancers having increased TGF-pl
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signalling. This suggests that MMPs are vital mediators at the cross roads of pancreatic 
cancer and stromal interactions having a role in cancer progression (Krantz et al, 2011).
Serine proteases
The urokinase-type plasminogen activation (uPA) system is a family of serine proteases, 
primarily focused at proteolytic degradation involved in thrombolysis and extracellular 
matrix degradation (Berger DH, 2002). Invading tumour cells have proteolytic activity 
on their cell surface mediated through receptors for the serine proteases. uPA released 
from either the tumour or stromal cells, bind to these tumour cell receptors (uPA-R) 
which focuses the enzymatic proteolytic activity to the tumour cell surface. Urokinase 
Plasminogen activator (uPA) converts inactive plasminogen to plasmin, which acts both 
directly and indirectly (through the activation of MMPs) to degrade extracellular matrix 
proteins and thereby facilitate cell proliferation, invasion and metastasis (Andreasen PA 
et al., 1997).
Binding of uPA to its receptor also initiates intracellular transduction eliciting a variety of 
cellular functions such as migration of endothelial cells, chemotaxis of neutrophils and 
tyrosine phosphorylation (Nguyen DHD et al., 2000). Experimental models have 
indicated an association of uPA in the development of metastases with high levels of uPA 
appearing to predict a poor prognosis in human cancers (Kim SJ et al., 1998). In 
pancreatic cancer specifically, activation of the uPA system mediates the invasiveness of
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pancreatic cancer cell lines, and tumour cell motility can be inhibited by uPA inhibitors 
(Diaz VMetal, 2002).
Stromal cellular component
The stroma is composed of a number of different host cell types, which are both locally 
derived and/ or recruited from the circulation (Joyce and Pollard, 2009). Even though 
there is structural heterogeneity, tumour stroma can be broken down into constituent 
parts.
Mesenchymal cells
These cells represent a population of spindle shaped cells comprising mainly of 
traditional fibroblasts, which normally form the bulk of the connective tissues support. 
These fibroblasts are present around the ducts, interlobar spaces and blood vessels 
forming an essential part of the microenvironment exhibiting proliferation in pancreatic 
injury such as pancreatitis and PDAC (Hwang et ah, 2008). Other mesenchymal cells 
include pericytes that are derived from bone marrow (lacobuzio-Donahue et ah, 2002a). 
The mesenchymal cell population is composed of a variety of cell types, which are 
constantly believed to be interacting with the surrounding tumour. Molecular analysis of 
pancreatic cancer tissue has suggested patterns of stromal heterogeneity with invasion 
associated genes found to be expressed differentially in the 2 stromal compartments, the 
juxtastroma and the panstroma (lacobuzio-Donahue et ah, 2002b).
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Fibroblasts upon stimulation may proliferate to produce an extracellular matrix rich in 
collagen. Embedded within the extracellular matrix niche they characteristically express 
vimentin and fibroblast specific protein-1 (FSP1) (Kalluri and Zeisberg, 2006). Important 
functions, other than production of extracellular matrix, include epithelial differentiation, 
regulation of inflammation and involvement in wound healing by synthesising collagen 
type I, II and IV (Chu et al., 2007; Neesse et ah, 2011). Basement membrane production 
and remodelling through protease metalloproteinases (MMPs) are crucial functions of 
fibroblasts in maintaining the ECM homeostasis (Neesse et ah, 2011). In the cancer 
setting fibroblasts can acquire an activated phenotype, triggered by growth factors such as 
transforming growth factor beta (TGF-(3), epidermal growth factors (EDGF), platelet 
derived growth factor (PDGF), and fibroblast derived growth factors (FGF) which are 
released from cancer epithelial cells, infiltrating mononuclear cells and macrophages 
(Mahadevan and Von Hoff, 2007). Fibroblasts can also be activated by direct cell-to-cell 
communication via intercellular adhesion molecules (ICAM) or vascular adhesion 
molecules (VCAM1) (Clayton et ah, 1998).
Activated fibroblasts express smooth muscle actin (a-SMA) converting them into 
myofibroblasts (Bachem MG et ah, 1998) which allow them to develop contractile 
characteristics, often being termed “carcinoma induced f^broblasts,, (Chu et ah, 2007). 
These cells have the capacity to express growth factors such as vascular endothelial 
growth factor, insulin like growth factor and hepatocyte growth factor (Neesse et ah, 
2011). Furthermore, they also express ECM degrading metalloproteinases MMP2, MMP7 
and MMP9 which facilitate ECM turnover (Hwang et ah, 2008). In pancreatic cancer
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there is accumulating evidence to suggest that cancer-associated stromal fibroblasts 
(CAP) contribute to tumour growth and the desmoplastic reaction by actively 
communicating with cancer cells, myofibroblasts and pancreatic stellate cells (Lonardo et 
ah, 2012; Walter et ah, 2010). In other cancers, i.e. breast adenocarcinoma, CAFs have 
been demonstrated to aid angiogenesis (Kitamura et ah, 2007). Gene expression profiling 
of human pancreatic CAFs and nonneoplastic pancreatic fibroblasts have identified the 
hedgehog receptor smoothened (SMO) to be upregulated in CAFs relative to control 
fibroblasts suggesting that stromal cells may be a therapeutic target for smoothened 
antagonists in pancreatic cancer (Walter et ah, 2010).
The activated cancer associated fibroblasts are not a homogenous entity but are a 
collection of cells with a varying genotype reflected in their differing cellular functioning 
cytokine and ECM production and paracrine effects (Kalluri and Zeisberg, 2006). They 
remain an area of active interest amongst scientist owing to their ever complex role and 
interactions.
Pancreatic stellate cells (PSC)
Pancreatic stellate cells are a group of quiescent state cells, which comprise 
approximately 4% of the pancreatic cell population and are a major contributor towards 
stromal formation in both cancer and the pancreatitis setting (Masamune et ah, 2009b) 
(Duner et ah, 2010; Lonardo et ah, 2012). Their origins are uncertain and they may be 
derived from circulating progenitor cells being identified by their spindle shaped
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appearance as they lie in the periacinar area. They express desmin and glial fibrillary 
acidic protein (Farrow et ah, 2008). They also have the ability to store vitamin A which 
makes them similar to hepatic stellate cell (Duner et ah, 2010). Upon stresses due to 
pancreatic injury or inflammation, stellate cells become active in a similar fashion to 
myofibroblasts like cells, expressing a-SMA (Bachem MG et ah, 1998; Kleeff et ah, 
2007). Studies reveal that soluble cytokines (interleukin IL-1, IL-6), tumour necrosis 
factor alpha (TNF-a) and growth factors e.g. platelet derived growth factor (PDGF), 
TGF-pl, and fibroblast growth factor-2 are regulators of PSC activation (Masamune and 
Shimosegawa, 2009) (Bachem et ah, 2005) (Duner et ah, 2010). These are produced by a 
host of cells in the microenvironment, such as acinar cells, inflammatory cells, ductal 
cells, endothelial cells and cancer cells.
Myofibroblasts and pancreatic stellate cells have a wide range of functions, including 
organogenesis (Simon-Assmann P et ah, 1995), wound healing (Moore R et ah, 1998), 
angiogenesis, production of cytokines, growth factors (IL-1 [3, IL-6, TNF-a, TGF-pi) 
ECM proteins and metalloproteinases (MMP-2, MMP-9, MMP-13) , as well as inhibitors 
of MMPs (Masamune et ah, 2009a; Vonlaufen et ah, 2008) (Kleeff et ah, 2007) (Hwang 
et ah, 2008). Stellate cells also produce chemokines such as monocytes chemoattractants 
and IL-8, which aid recruitment of inflammatory cells to the pancreatic cancer 
microenvironment (Andoh et ah, 2000). These cytokines produced by stellate cells have a 
proliferative effects on pancreatic cancer cells in experimental models with these cells 
exhibiting increased Notch signalling (Fujita et ah, 2009).
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More recently, PSCs have been identified to express toll-like receptors which are 
involved in activation of innate immunity (Masamune et ah, 2008b). They also have a 
role in phagocytosis displaying a “macrophage” like function comparable to Kupffer cells 
in the liver, playing a pail in maintaining homeostasis of the pancreas (Masamune et ah, 
2009b). PSCs are proangiogenic, expressing vascular endothelial growth factor as well as 
for VEGF and angiopoietin-1 receptors. In vitro conditioned media from stellate cells is 
seen to induce angiogenesis (Masamune et ah, 2008a).
Pancreatic stellate cells have emerged as one of the major mediators of the increased 
integrins mediated cell-to-cell adhesion, and migration of pancreatic cancer cells (Fujita 
et ah, 2009). Lonardo et al have also very recently demonstrated that PSCs are 
important in forming a paracrine niche for pancreatic cancer stem cells promoting their 
invasiveness and highlighting a target for therapeutic intervention (Lonardo et ah, 2012). 
Similarly, SPARC (secreted protein acidic and rich in cysteine) is also expressed in high 
quantities in pancreatic stellate cells promoting PDAC cell invasiveness and poor 
prognosis (Chen et ah, 2010). Strikingly PSCs have also been demonstrated in metastatic 
foci of nude mice suggesting a co-migration to produce favourable microenvironment 
conditions at distant sites of metastases (Vonlaufen et ah, 2008).
Immune cells
Immune cells comprise of a variety of different cells (lymphocytes, dendritic cells, 
neutrophils, macrophages, monocytes, mast cells, natural killer cells and eosinophils).
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Together they make up the adaptive and innate immunity of the body. Their 
morphological appearance is similar to granulation tissue and desmoplasia (Coussens and 
Werb, 2002), though their role in pancreatic cancer progression is a matter of 
investigation (Ang et al., 2010). There tends to be less immune cell infiltrate around the 
tumour glands with clustering of immune cell around the invasive tumour front (Pandol et 
al., 2009). Stroma in pancreatic cancer is seen to have an increased numbers of T-cells, 
mast cells and macrophages as well as monocytes (Emmrich et al., 1998) (Sheikh et al., 
2007; Wachsmann et al., 2012) and these may participate in cancer cell growth either 
directly or indirectly by altering the tumour microenvironment (Ang et al., 2010; 
Whiteside, 2008).
Pancreatic cancer cells in contrast to other cancers express a variety of cancer associated 
antigens that can potentially be recognized by T-cells and publications have demonstrated 
that there is a surge in functionally competent CD4+ and CD8+ T cells in the bone marrow 
and peripheral circulation of these patients (Kubuschok et al., 2004) (Schmitz- 
Winnenthal et al., 2005). T-cells rely on dendritic cells for antigen presentation and hence 
stimulation. Dendritic cells once stimulated allow for activation of tissue and bone 
marrow based T-cells. Dendritic cell stimulation is modulated by a variety of signals such 
as heat shock proteins, ECM degradation products and suppressed by cytokines such as 
interleukin-10 (IL-10), TGF-pl with the latter (suppressive cytokines) being produced in 
abundance by pancreatic stellate cells and infiltrating macrophages (Esposito et al., 
2004). As a result of this, pancreatic cancer, through stromal activation can induce an 
immune suppressive microenvironment. In the tumour mass itself, pancreatic cancer is
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characterized by the presence of few tumour-specific CD8+ T cells, B-cells, and tumour- 
reactive antibody-producing plasma cells. Moreover, when evaluated the presence of 
both CD4+ and CD8+T-cells in malignant PDAC tissue correlates with a better prognosis 
(Fukunaga et ah, 2004). Pancreatic cancer can has been shown to successfully employ 
various mechanisms to evade immune surveillance. These involve down regulation of 
major histocompatibility complex molecules, rendering neoplastic cells more resistant to 
recognition by T-cells (Wachsmann et al., 2012), secretion of inhibitory cytokines such 
as IL-10 and TGF-pl which further reduce local T-cell activity (Wachsmann et al., 2012).
Natural killer cells are a subset of cytotoxic lymphocytes that only recently received 
attention for their role in tumour development and progression (Wachsmann et al., 2012). 
Natural killer cells do not express unique antigen-specific receptors, but they play an 
important role in innate immunity and antitumor immunity (Raulet and Guerra, 2009). In 
PDAC, two phenotypically and functionally distinct subsets of NK cells are present based 
on the levels of CD56 expression and cytokine secretion. Natural killer cells in PDAC 
have been reported to mediate tumour cell lysis with the presence of high levels of these 
cells conferring a better prognosis (Degrate et al., 2009).
There are few studies involving the role of mast cells in PDAC, however studies on mast 
cells and macrophages have indicated that these cells express angiogenic factors (VEGF) 
aiding in tumour neovascularisation (Esposito et al., 2004). Strouch et al has 
demonstrated that mast cell infiltration was significantly increased in pancreatic cancer
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compared with normal controls and correlated with higher-grade tumours, decreased 
recurrence-free and disease-specific survival (Strouch et ah, 2010).
Vascular tissue
Angiogenesis is essential for tumour growth and progression, which is why not only 
pancreatic cancer but all solid tumours undergo a process of dynamic neovascularisation 
and vascular remodelling (Chu et ah, 2007). Vascular tissue formation is to a greater 
extent controlled by the balance of pro- and anti-angiogenic factors produced by a variety 
of cancer cells and stromal cells with vascular endothelial growth factor-A (VEGF-A) at 
the centre of this function. This initiation of new vessel formation, the so called 
“angiogenic switch”, occurs very early on in tumour development and is essential for 
tumour development (Ribatti et ah, 2007; Ruoslahti E, 2002). Early tumour angiogenesis 
may be due to the hypoxic environment. Pericytes, which are mesenchymal cells, defined 
by their close association with endothelial cells have been implicated as vital regulators 
of angiogenesis including vascular development, stabilization, and remodelling (Armulik 
et ah, 2005). Pericytes are fairly plastic cells and can differentiate into vascular smooth 
muscles as well as stromal cells (Armulik et ah, 2005). Pancreatic cancer angiogenesis is 
not controlled by the expression of VEGF-A in the tumour and stromal cells alone, but is 
a complex balance of other signalling molecules such as metalloproteinases and platelet 
derived growth factors (PDGF) which are present in the microenvironment (Korc, 2003; 
Song et ah, 2005). The immune cells, which contribute towards the inflammatory 
response in the tumour microenvironment, also have a crucial role in vascular tissue
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development. Infiltrating immune cells mainly neutrophils and macrophages are 
proangiogenic conferring a worse prognosis (Imhof and Aurrand-Lions, 2006) (Tartour et 
ah, 2011). Although PD AC is not a vascular tumour, it has areas of enhanced endothelial 
cell proliferation with significant correlations between blood vessel density and disease 
progression, suggesting that antiangiogenic therapy many have a role as a therapeutic 
target. Moreover, although antiangiogenic strategies that target VEGF alone have not yet 
shown efficacy for the treatment of pancreatic cancer, some antiangiogenic molecules 
reduce the immunosuppression associated with cancer (Tartour et ah, 2011 
) by decreasing immunosuppressive cells (T-cells) and immunosuppressive cytokines (IL- 
10 and TGF-p). This suggests the links in the pancreatic cancer microenvironment 
between cells of immune system and vascular tissue engaged in cross-talk.
Cytokines expression in the pancreatic cancer microenvironment
Cytokine production into the local microenvironment of the pancreas plays a important 
role in the basis of molecular cross-talk between epithelial derived tumour cells and its 
surrounding mesenchymal stromal cells (Farrow and Evers, 2002; Kleeff et ah, 2007) 
(Bellone et ah, 2006; Farrow et ah, 2008). These soluble messengers act in a paracrine 
and / or autocrine fashion, and are responsible for a variety of biological processes 
including cell proliferation, modulation of host immune response, tumour growth, cell 
signalling, cell trafficking, neovascularisation and metastasis. Cytokines have a varying 
function most importantly working in combination with others mediators maintaining a
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homeostatic balance. Using serum from pancreatic cancers patients and pancreatic cancer 
cell lines, Bellone et aL evaluated the cytokine profile in the tumour microenvironment 
(Bellone et al., 2006).
Roles of cytokines in tumour biology vary, some have been termed as “protective” with 
moderate expression, appearing to confer some survival advantage whereas elevated 
levels of expression of others correlate to poor survival. Sources of cytokines once again 
vary and are produced by the pancreatic cancer cells or being expressed by the stromal 
cells (Ang et al.,; Sheikh et al., 2007). Salient cytokines present in the microenvironment 
of pancreatic cancer are detailed below.
Vascular Endothelial Growth Factor
Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) is a major 
inducer of tumour vascularisation which is essential for tumour sustainability (Ferrara N 
and Davis-Smyth T, 1997). In situ hybridisation studies have confirmed that VEGF 
mRNA is up regulated in many human tumours (Ferrara N and Keyt B, 1997). Studies in 
pancreatic cancer have revealed that overexpression of VEGF correlates with 
microvascular density, tumour progression and poor prognosis (Wachsmann et al., 2012) 
(Kuwahara K et al., 2003).
Soluble VEGF binds to receptors of VEGF (VEGFR1/ VEGFR2) which are also 
overexpressed in pancreatic cancer (Itakura et al., 2000). VEGF/VEGFR-2 complexes on
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endothelial cells can result in several downstream events that promote angiogenesis. Both 
VEGF and VEGFR signalling is essential for growth of pancreatic tumours as 
demonstrated by inhibition leading to profound reduction in local and metastatic growth 
(Fukasawa and Korc, 2004; Ribatti et ah, 2007). Trials using monoclonal antibodies to 
VEGF (bevacizumab) however did not yield a survival advantage compared to patients 
having standard chemotherapy (Van Cutsem et ah, 2009).
Interestingly, angiogenic receptors may not only be expressed on endothelium but are 
also present on functional pancreatic cells. There is mounting evidence to suggest that 
high expression of VEGF is associated with poor prognosis and liver metastasis (Seo et 
al., 2000). It is therefore conceivable that agents targeting VEGF or its receptors may 
have a dual inhibitory effect on pancreatic cancer growth suppressing both angiogenesis 
and cancer cell function (Kleeff et al., 2007). Phase II trials utilising axitinib which is a 
VEGFR-1-3 and gemcitabine have also met with a discouraging result (Spano et al., 
2008).
Hypoxia is seen to activate HIF-1 induction that can induce VEGF expression (Buchler P 
et al., 2003; Masamune et al., 2008a). In order to confirm that hypoxia activates HIF-1 
induced VEGF expression, Buchler et al analysed the mRNA expression of HIF-1 and 
VEGF in vivo. Low oxygen tension induced both HIF-1 and VEGF production in human 
pancreatic tissue and in cancer cell lines (Buchler P et al., 2003).
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VEGF is not only expressed in the pancreatic cancer cell but is also shed into the 
microenvironment as a significant regulatory cytokine. Its production is also seen to 
occur in the stromal inflammatory infiltrate (mast cells and macrophages), which are 
recruited from the blood stream (Dineen et ah, 2008). Angiogenesis is an important 
process in carcinogenesis originating from pre-existing venules within the tumour mass 
or the host tissue (Shannon AM et ah, 2003). Tumour vessels, unlike normal vessels, are 
not arranged in a hierarchical fashion but haphazardly and are structurally heterogeneous 
and are hyper-permeable to plasma and proteins, as they are lined by actively dividing 
endothelial cells (Dvorak HF, 2003). Hyper-permeability is primarily a result of VEGF, 
which is 50,000 times more potent than histamine and hence important in the 
development of both tumour vasculature and tumour stromal elements (Dvorak HF, 
2003). The mechanisms by which it does this is essentially the same as wound healing. 
As a result of vascular hyperpermeability and leakage of plasma, extravasated fibrin 
deposition in the tissue occurs which leads to formation of a fibrin gel, which is degraded 
and replaced by desmoplasia in the case of tumours or scar tissue in the case of wounds. 
VEGF is an essential modulator of this process and hence an anti-angiogenic approach to 
tumour treatment remains an important target for treatment particularly of advanced 
pancreatic cancer (Kleeff et al., 2007).
Interleukins
Interleukins are a group of communicatory cytokines first observed to be expressed in 
leukocytes (Sims et al., 1988) and since found to be produced by a wide variety of cells
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including cancer cells. The majority of interleukins are synthesized by lymphocytes, as 
well as monocytes, macrophages, and endothelial cells.
Pancreatic cancer secretes and expresses a host of both pro inflammatory (IL-1, IL-2, IL- 
6, IL-8, 1L-12, and IL-18) and anti-inflammatory interleukins (IL-10, IL-11, IL-13) 
(Bellone et ah, 2006). These interleukins are involved in a variety of cellular processes, 
both involving the stromal cell as well as the tumour cells, which include cellular 
proliferation, migration, metastasis, dampening and upregulating of immune response and 
angiogenesis (Feurino et ah, 2006). IL-8 is a proinflammatory interleukin upregulated 
significantly in the pancreatic cancer microenvironment,(Farrow et ah, 2008) with over 
60% of resected cancer specimens displaying positive receptor expression (Kuwada et ah, 
2003). IL-8 also interacts closely with nitric oxide molecule, which is a regulator of 
vasodilation and angiogenesis in pancreatic cancer. High levels of nitric oxide results in 
the higher levels of IL-8 production and vice versa (Xiong, 2004).
Interleukins also serve as growth modulators with some increasing and others exerting a 
negative growth effect. IL-8 and IL-4 act as growth factors for pancreatic cancer as when 
inhibited in experimental conditions a reduction in cancer cell growth is demonstrated 
(Prokopchuk et ah, 2005). Moreover, levels of IL-8 correlate with the metastatic potential 
of pancreatic cancer cell lines (Matsuo et ah, 2004) as cells when cultured with IL-8 show 
an increase in cell growth and motility that is decreased when monoclonal antibodies to 
IL-8 are used (Matsuo et ah, 2004). The presence of certain interleukins in the pancreatic 
cancer (IL-6 and IL-10) are a poor prognostic indicator and directly associated with poor
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survival and recovery from surgery (Friess et al., 1999). Interleukins are important 
mediators of cellrto-cell interactions contributing towards the aggressive nature of 
pancreatic cancer.
Interleukins form communication channels between pancreatic cancer cells and host 
immune cells, which allow them to evade natural immune defence mechanisms 
(Ebrahimi et al., 2004). IL-10 is known to suppress T-cell activity in the pancreatic 
cancer microenvironment hence hindering anti-cancer response (Ebrahimi et al., 2004). 
Antigen presenting cells (Dendritic cells) in experimental conditions are inhibited by IL-6 
produced by BxPC-3 pancreatic cancer cell lines (Feurino et al., 2006). IL-4 has a 
growth promoter effect on experimental cancer cell lines and mouse models alike 
(Kimura et al., 1999) with IL-12 in the other hand showed cancer growth inhibition in 
nude mice (Motoi et al., 2000). More recently, IL-6 and IL-8 have been shown in 
experimental conditions to induce and maintain EMT in pancreatic cancer cells when 
exposed to these soluble factor interleukins. IL-8 also has also shown to have an essential 
role for the acquisition and/or maintenance of the mesenchymal and invasive features in 
different cancer cells (Fernando et al, 2011; Huang et al, 2011).
Tumour necrosis factor
Tumour necrosis factor (TNFa and TNFj3) are monocytes/macrophage derived cytokines 
which are involved in tumour carcinogenesis, septic shock and systemic inflammatory 
response (Baran et al, 2009). Their primary role is regulation of immune cells with
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dysregulation of production seen in a variety of human cancers (Locksley et al.5 2001). 
In the pancreatic cancer setting, TNFa induces an increase in cell proliferation, which 
contrasts to the cytokine’s inherent ability for tumour suppression. This is because TNFa 
has two receptors, RI that activates apoptosis, and RII which acts to increase levels of 
other growth factors such as epithelial derived growth factor and transforming growth 
factor alpha (TGF-a), resulting in enhanced cell growth (Schmiegel et al., 1993). 
Experimental evidence indicates that TNF-a interacts with other cytokines such as IL-8 
affecting its induction in PANC-1, MIA PaCa-2 and BxPC-3 cancer cell lines(Takaya et 
al., 2000). TNF-a also aids the induction of monocyte chemotactic protein (MCP-1) 
which is a mediator for attracting monocytes, T-cells and other leukocytes (Takaya et al., 
2000). This can possibly explain high levels of monocytic infiltration at varying degrees 
of maturation seen in the pancreatic cancer stroma (Sheikh et al., 2007).
One of TNF-a key functions is induction of apoptosis in cancer cells and recruitment of 
inflammatory cells in acute inflammatory conditions such as acinar injury (Farrow and 
Evers, 2002). In pancreatic cancer, TNF-a inhibits apoptosis thorough a mechanism 
centering on the NF-kB pathway. More recently its has been demonstrated that 
exogenous TNFa induced pancreatic cancer cell motility as well as epithelial- 
mesenchymal transition (EMT) (Baran et al., 2009). Functionally, however, TNF-a may 
cause greater tumour necrosis by increasing local thrombosis within the tumour 
vasculature leading to tumour shrinkage. It is this feature that can potentially be 
exploited for therapeutic benefit particularly in delivering radiation therapy (Feurino et 
al., 2006).
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Growth Factors
Over expression of growth factors and their receptors is vital in the pathogenesis of 
pancreatic cancer. Growth factors act on nuclear transcription factors altering the 
expression of genes responsible for cell proliferation. They can also trigger cell death by 
activating specific cell surface receptors involved in cellular processes such as apoptosis. 
Some of these growth factors are produced by the cells of the tumour microenvironment 
highlighting the critical position tumour-host interactions occupy in carcinogenesis 
(DranoffG, 2004).
Fibroblast growth factor (FGF)
The fibroblast growth factor family are a family of heparin binding polypeptide growth 
factors that are involved in mitogenesis, cell differentiation and angiogenesis (Ozawa et 
al., 2001). The FGF system has been implicated in the regulation of E-cadherin, an 
important adhesion molecule that is often altered in pancreatic cancer (El-Hariry I et al., 
2001). Expression of FGF in pancreatic cancer is evident in both tumour as well as 
stroma cells, with signalling mediated by a dual receptor system comprising four high 
affinity transmembrane tyrosine-kinase FGF receptors (FGFR). This is mediated by a 
number of different intracellular pathways. Pancreatic stellate cells are known to produce 
FGF in response to different stimuli and have a role in maintaining homeostasis in the 
pancreatic cancer microenvironment (Duner et al., 2010). In pancreatic cancer, 
overexpression of FGF-1, FGF-2, FGF-5 and FGF-7 has been demonstrated (Kornmann 
M et al., 1998) with FGF-7 expression appearing to occur predominantly in the tumour
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cells, as opposed to FGF-5 which localises predominantly to the stromal fibroblasts 
(Kornmann M et ah, 1997). FGF-1, FGF-2 and FGF-5 enhance the growth of pancreatic 
cancer cells (Kornmann M et al., 1998) (Kleef J et al., 1998; Kornmann M et ah, 1997). 
Over expression of FGFRs have also been demonstrated in pancreatic cancer (Ishiwata et 
ah, 1998) (Kobrin MS et ah, 1993), and may occur independently of FGF expression 
(Leung HY et ah, 1994) suggesting they have an independent role involved in other 
pathways. Experimental evidence has suggested that conditioned media from pancreatic 
cancer cells stimulate pancreatic stellate cell activation via FGFs, the effects being 
neutralised by antibodies (Bachem et ah, 2005) indicating their role in tumour cross talk. 
Furthermore, FGFRs signalling may contribute towards the desmoplasia as increased 
expression is seen in tumours with high levels of expression (Hezel et ah, 2006).
Epidermal growth factor (EGF)
Epidermal growth factor (EGF) primarily functions in induction of cellular proliferation. 
Other members of its family include transforming growth factor alpha (TGF-a), and 
heparin binding EGF (HB-EGF). Its receptor is known as human EGF receptor-1 
(HER1) and is closely related to several other similar receptors, including, HER-2 (c- 
erbB2), HER-3 (c-erbB3) and HER-4 (c-erbB4) (Ozawa et ah, 2001).
Ligand binding results in phosphorylation of the receptors and through a series of 
intracellular signalling mechanisms involving tyrosine kinase, biological response ensues. 
These pathways culminate in an activation cascade involving RAF and MAP kinase 
which is a cellular process involved in cellular proliferation (Ozawa et ah, 2001) (Seger
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and Krebs, 1995; Tjomsland et al., 2011). Epidermal growth factor receptor 
overexpression may be detected in up to 90% of pancreatic tumours with high levels of 
EGF expression being associated with decreased survival and metastasis (Troiani et al., 
2012). EGF has important paracrine interactions in the pancreatic cancer 
microenvironment as high levels are expressed in stromal cells with pancreatic cancer 
cells expressing receptors (Farrow et al., 2008; Tjomsland et al., 2011). EGF and its 
associated ligands have a part in the development of pancreatic cancer in transgenic 
mouse models with the transformed cells displaying an increased expression of EGF 
receptors and of the EGF itself. Two pharmacological agents, neutralizing monoclonal 
antibodies and small molecule tyrosine inhibitors have been employed to inhibit 
epidermal growth factor receptor function in pancreatic cancer treatment, however they 
have not been successful.
Crosstalk in the pancreatic microenvironment
Crosstalk between PDAC tumour cells and stromal components are complex interactions. 
Knowledge on this subject is still limited with some of these intricate pathways yet to be 
unravelled(Shields et al., 2012b). Cancer cells secret numerous growth factors such as 
TGF, VEGF, as well as ECM modifying matrix metalloproteinase, which all work 
towards stimulating angiogenesis, fibroblastic proliferation and recruitment of 
inflammatory cells (Matsuo et al., 2012; Neesse et al., 2011; Shields et al., 2012b). In a 
paracrine feedback loop, the affected cells stimulate proliferation of not only stromal 
compartment cells but also aid in the growth and proliferation of tumour cells.
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CHAPTER THREE
SMAD4 AND TGF-P SIGNALLING IN PANCREATIC 
CANCER
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3.1 SMAD4
A signature genetic mutation occurring frequently in PD AC is loss of the SMAD4 (DPC4) 
transcriptional regulator (Matthaios et al., 2011; Mihaljevic et ah, 2010 
) (Lowery and O'Reilly, 2011). This is a key downstream regulator of the transforming 
growth factor beta (TGF-(3) signalling cascade (Massague J et al., 2000), hence loss of 
SMAD4 renders cells resistant to the growth inhibitory effects of TGF-(3 (Singh et al., 
2011). Mutation of SMAD4 also occurs in colorectal cancer, and small bowel tumours. 
The SMAD family of proteins signals through serine threonine kinase receptor complexes 
that propagate signalling in response to TGF-P (Massague J et al., 2000) (Singh et al., 
2011).
The SMAD4 gene maps to chromosome 18q21 and is lost in over 50% of pancreatic 
carcinomas (Hahn et al., 1996). The locus coding for SMAD4 undergoes loss of 
herterozygosity in >90% of pancreatic cancers and in half the cases biallelic inactivation 
by homozygous deletion or by missense or nonsense mutations occurs (Hahn et al., 
1996). Loss of SMAD4, as implicated in earlier studies has been shown to confer a worse 
prognosis (Tascilar et al., 2001). Tasilar et al. analysed 249 resected PDAC specimens 
and showed that patients retaining SMAD4 expression had a significant survival benefit 
of about 5 months (Tascilar et al., 2001). This is contrary to Biankin et al, who have 
published an increase in postoperative survival in for patients whose tumours lacked 
expression of SMAD4 (Biankin et al., 2002). More recently, the association between 
SMAD4 expression in tumours and patterns of disease spread has been examined (Crane 
et al., 2011) (lacobuzio-Donahue et al., 2009). Metastasis was seen in 71% of patients
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who lost SMAD4 expression compared to 27% in patients who retained expression of this 
gene (Crane et al., 2011). Moreover, these findings concur with autopsy data from 
patients with advanced pancreatic cancer which showed that in metastatic cases 75% of 
patients had a loss of SMAD4 compared to 22% of patients who had no metastasis but 
only localised spread (lacobuzio-Donahue et al., 2009). This data suggest that SMAD4 
loss predicts for local pattern of disease progression and therefore may allow for selection 
who would benefit from local therapies (lacobuzio-Donahue et al., 2009). SMAD4 has 
been designated a ‘progression allele’ as it is necessary for the maintenance of PDAC 
occurring later in PanIN lesions (Wilentz et al., 2000). Loss of SMAD4 is present in 
metastastic cancer indicating the possible role in this process both directly and indirectly 
(Hruban and Adsay, 2009).
SMAD family of proteins
The SMAD family compromises three subcategories: receptor regulated SMADs (R- 
SMAD), common partner SMADs (Co-SMADs) and inhibitory SMADs (i-SMADs) 
(Massague et al., 2000; Truty and Urrutia, 2007b). The R-SMADs are SMAD2 and 
SMAD3, which are directly phosphorylated by TGF-|3 receptors upon activation by TGF- 
P cytokine. Upon activiation, the phosphorylated R-SMADs then associate forming 
hetero-oligomeric complexes with Co-SMADs. There is only one member of the Co- 
SMAD group which is SMAD4. Complex of R-SMADs (SMAD2 and SMADS) and Co- 
SMAD (SMAD4) are then able to translocate to the nucleus where they enable regulation 
of both positive and negative transcriptional complex formation for differentiation,
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growth suppression and apoptosis (Kitamura et ah, 2007; Singh et al., 2011). Inhibitory 
SMAD (SMAD-7) is normally present in the nucleus at basal levels and is thought to 
inhibit signalling by inhibiting phosphorylation of TGF-(3 receptors by binding to them 
(Schmierer and Hill, 2007). This is thought to be activated through a negative feedback 
loop with continual stimulation of TGF-p leading to transcription of SMAD7 thereby 
ensuring a negative feedback.
SMAD4 as an independent functioning molecule
SMAD4 is characterised as a transmitter of signal for the TGF-|3 superfamily of 
cytokines, whose widely expressed member TGF-pi, is a potent growth inhibitor. It was 
therefore assumed on discovery of SMAD4 that loss of TGF-(3 growth inhibitory 
response was a result of mutation in SMAD4 expression (Stuhler et al., 2006)which has 
been challenged with multiple reports in the literature to suggest that these are 
independent processes (Lowery and O'Reilly, 2011; Singh et al., 2011; Volmer et al., 
2004). Evidence from various groups suggest that SMAD4 has a wider independent 
function in carcinogenesis supporting a broad array of transcription factors controlling 
important tumour biological processes, for example apoptosis, epithelial mesenchymal 
transition and cell migration (Kitamura et al., 2007) (Schwarte-Waldhoff et al., 1999) 
(Zapatka et al., 2007). These not only have a bearing on the cancer cell protein expression 
but also interconnect SMAD4 signalling with other signalling mechanisms in the 
crosstalk process with the surronding stroma (Kitamura et al., 2007; Sheikh et al., 2007).
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In experiments utilizing human pancreatic cell lines, restoration of SMAD4 in negative 
cells lines, demonstrates that SMAD4 can control the angiogenic switch (Schwarte- 
Waldhoff et al., 2000). SMAD4 restoration in cells produced an inhibition of 
angiogenesis by decreasing expression of VEGF and increasing expression of 
thrombospondin-1, as well as reducing invasion and possibly ECM remodelling through 
downregulation of MMP-2 and MMP-9 (Schwarte-Waldhoff et al., 2000). In colonic 
cancer cell lines SW480 re-expression of SMAD4 resulted in morphological reversion in 
the cell from mesenchymal like spindle shaped cells to an epithelial phenotype (Muller et 
al., 2002). In addition to this, the invasion suppressor gene E-cadherin was also induced 
in these cells, indicating that SMAD4 has tumour suppressor functions. A more recent 
study has indicated that SMAD4 also targets genes, involved in the extracellular matrix 
generation. Breachment of the basement membrane is usually brought about by epithelial 
and stromal cells and is a hallmark of invasive carcinomas (Zapatka et al, 2007). 
Laminin-5 is a one such heterodimeric epithelial-derived basement membrane 
component, commonly lost in carcinomas but not in insitu tumours. In human colon and 
pancreatic tumour cells, SMAD4 functions as a positive transcriptional regulator of all 
three genes encoding laminin-5. This transcriptional activity was lost in SMAD4 negative 
cell lines and re-expression of the three laminin-5 chains was induced by reconstitution of 
SMAD4 (Zapatka et al, 2007).
Proteomic analysis of conditioned media and cell lysate from SMAD4 re-expressing 
colorectal and pancreatic cancer cell lines has shown differentially expressed proteins in 
both groups compared to their respective SMAD4 negative counterpart. Furthermore, up-
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and downregulation of certain proteins has also been demonstrated (Volmer et al., 2004) 
(Volmer et ah, 2005) (Stabler et al, 2006). Analysing the secretomes of SW-480 colonic 
cancer cell lines demonstrated that expression of SMAD4 in the cancer cell lines was 
suppressed by the expression SPRAC which is a secreted matricellular macromolecule 
exhibiting a host of biological functions ranging from cell adhesion, tissue remodelling, 
proliferation and motility (Volmer et al., 2004). Proteomic analysis of SW-480 colonic 
cancer cell lines using two dimensional gel electrophoresis, has determined over 47 
proteins, which have a SMAD4 dependent expression (Stuhler et al., 2006).
Cytokine profiling of pancreatic cancer cells and specimens has been undertaken by 
Bellone et al analysing their prognostic relevance, however differential cytokine 
expression based on their SMAD4 status was not demonstrated (Bellone et al., 2006). 
Kitamura and colleagues have also used a mouse model to investigate the role SMAD4 
has on influencing the surrounding cellular microenvironment. Experiments with mutant 
mouse models in which the SMAD4 gene has been knocked out, accumulated CD34 
positive myeloid cells which express matrix metalloproteinases MMP9 and MMP2 
promoting the invasive front (Kitamura et al., 2007). SMAD4 forms a key regulator of 
tumour progression and cellular cross talk; its role however is not fully understood and is 
a matter of investigation. Additionally, the influence other mediators have on affecting 
SMAD4 mutation and loss in tumours cell is also a subject of great interest.
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3.2 TGF-P
TGF-|3 is an important cytokine that is involved in a wide range of biological processes. It 
was discovered in 1983 and named after its ability to ‘transform’ rat fibroblasts (Anzano 
et al., 1983). It is primarily known for its capacity as a potent inhibitor of cellular 
proliferation in normal cells (Bierie and Moses, 2006; Singh et ah, 2011). In addition, the 
TGF-p signalling pathway is responsible for numerous other cellular responsibilities 
including differentiation, apoptosis, angiogenesis, immunosuppression, and wound 
healing. The pathogenesis and progression of numerous cancers such as pancreas, colon, 
breast, melanoma, prostate, gastric, neuroendocrine, gynaecologic, skin, and nervous 
system malignancies, are reliant on the disruption of normal TGF-p signalling (Truty and 
Urrutia, 2007a) (Massague et ah, 2000). This is essentially a result of the loss of the 
normal growth inhibitory response of TGF-p.
In humans, there are three expressed ligand isoforms (TGF-P 1, TGF-p2, and TGF-P3) 
encoded by different genes, expressed in a tissue specific manner. They all function 
through the same receptor signalling systems (Massague, 1998). These isoforms are 
expressed in epithelial, endothelial, hematopoietic, and mesenchymal cells with TGF-P 1 
being the most widely expressed. Pancreatic tissue normally expresses TGF-p in both 
acinar and ductal cells (Yamanaka et ah, 1993) and it is found as a secreted molecule in 
the extracellular matrix (Massague, 1998). TGF-P isoforms signal through a family of 
receptors (Massague, 1998) which are characterised as type-I TGF-p receptor (TGFRI), 
type II TGF-p receptor (TGFRII), and the type III TGF-receptor (TGFRIII) with the latter 
having no intrinsic signalling function by itself (Huang and Huang, 2005). The final
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target of TGF-J3 signalling involves interaction with DNA and subsequent transcriptional 
control of numerous genes with SMAD mediators transmitting these membranes bound 
signals to the nucleus.
TGF-P in pancreatic cancer
Important events associated with pancreatic malignant transformation are the activation 
of oncogenes, inactivation of tumour suppressors and loss of sensitivity to the inhibitory 
effects of TGF-p. In pancreatic cancer the cancer cells have lost their ability to respond 
to the growth suppressive effects of TGF-p (Ozawa et ah, 2001). Immunohistochemical 
analysis of pancreatic cancer tissue shows the overexpression of all three isoforms of 
TGF-P (Friess et ah, 1993) with overexpression being associated with advanced stage and 
poor survival (Friess et ah, 1993). Serum levels of TGF-isoforms are elevated in patients 
with pancreatic cancer compared to matched controls and low circulating levels of TGF 
have been associated with prolonged survival (Bellone et ah, 2006).
Mutations of the TGF-P transduction pathway have been characterised in pancreatic 
cancer accounting for loss of its tumour suppressive effects. The mutation or deletion of 
SMAD4 a downstream mediator of this pathway is the most common mutation (Hahn 
SA and et al, 1996). Inactivating mutations in the SMAD4 gene and upregulation of the 
inhibitory SMAD6 and SMAD7 genes are therefore thought to contribute towards 
unresponsiveness to TGF-p signalling (Singh et ah, 2011). Furthermore, studies have 
shown that loss of SMAD4 signalling in T-lymphocytes leads to spontaneous epithelial
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tumours throughout the gastrointestinal tract including pancreatic tumours, whereas 
epithelial specific deletions did not thus suggesting that SMAD4 signalling plays a 
critical role in the immunologic suppression of gastrointestinal cancer (Kim et ah, 2006).
The reports regarding the TGF-P receptors are slightly more conflicting with over­
expression being reported in some studies (Friess et ah, 1993; Lu et ah, 1997) in 
pancreatic cancer cell lines while other studies reporting under expression (Nicholas FJ 
and Hills CS, 2003). The genes encoding the human TGF receptors have also been found 
to be inactivated by mutations. Mutations in the TGFRII gene are found in pancreatic as 
well as in colon, gastric, liver, and breast tumours (Massague et ah, 2000). Most of these 
are a result of frameshift and result in truncated proteins that lack both the 
transmembrane and intracellular domains (Markowitz SD and Roberts AB, 1996). 
Epigenetic regulation of expression control of TGFRII is another way receptor function is 
lost. Epigenetic mechanisms are changes in gene expression without associated DNA 
alterations. This is done primarily through defects in transcriptional regulation at the 
promoter and histone level leading to repression and gene silencing (Truty and Urrutia, 
2007a).
The role of TGF p in tumour suppression
The most critical role of TGF-p is its role as a tumour suppressor agent. The inhibition of 
cellular proliferation is central to TGF-p responses in epithelial, endothelial, 
hematopoietic, neural and certain types of mesenchymal cells (Massague et ah, 2000). 
TGF-p primarily induces inhibition of cell cycle progression during G1 phase [3]. This is
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brought about by inducing the expression of the cyclin kinase inhibitors such as pi 5, p21, 
and p27 (Truty and Urrutia, 2007a). These inhibitors block cyclins and CDKs complexes 
from phosphorylating Rb and thereby inhibiting Gl/S progression. In addition, TGF-p 
also directly suppresses mitogenic c-myc expression (Pietenpol et al., 1990), which is a 
promoter of cell growth and proliferation. Pancreatic cancer cells and other cancer cells 
are also susceptible to apoptosis which is induced by TGF-|3 (Truty and Urrutia, 2007a).
The role of TGF-p in tumour progression
One of the unique aspects of TGF-p lies within its apparent dichotomy of functions. In 
normal cells, TGF-P 1 functions as a potent tumour suppressor however conversely in 
malignant cells it behaves as a tumour promoter being indicative of a more aggressive 
phenotype (Glynne-Jones et al., 1994). In addition, high levels of this cytokine can be 
produced in the tumour stroma and microenvironment (Sieweke and Bissell, 1994). The 
tumour promoter activity is due to the overexpression of TGF-P 1 itself directly affecting 
the cancer cells, however it is also attributed to several other causes. These are altered 
expression of ECM components, the stimulation of angiogenesis, and the 
immunosuppressive effects (Massague et al., 2000). Current evidence suggests that this 
cancer mediated immune evasion is due to the potent immunosuppressive effects of 
overexpressed TGF-P 1 (Wojtowicz-Praga, 2003). Tumour associated TGF-P 1 down 
regulates the host immune system and contributes to the generation of T-suppressor cells 
with impaired cytotoxic function and inability to mount an anti-tumour response in 
vivo(Bellone et al., 1999). These cells then act to suppress other lymphocyte populations
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leading to an overall dampened response against tumours. TGF-|31 can also inactivate 
natural killer (NK) and lymphokine-activated killer (LAK) cells. It is also a potent 
regulator of the ECM and induces the expression of many of its components such as 
fibrosis (Truty and Urrutia, 2007a). Overexpression of TGF-pl induces epithelial to 
mesenchymal transition (EMT) of normal and transformed epithelial cells thus enhancing 
their migratory ability. This is demonstrated in myofibroblasts and stellate cells in 
pancreatic cancer (Bachem et ah, 2005). Cells losing epxression of SMAD4 show 
enhanced TGF- |3 mediated epithelial -mesenchymal tranisition (EMT). This has been 
explained by the hypothesis that loss of SMAD4 lead to activation of STAT-3 ( signal 
transducter and activator of transcription 3) which contributes towards switiching TGF-|3 
from a tumour supressor to a tumour promoter (Matthaios et ah, 2011) (Gaspar et ah, 
2007). TGF-pl overexpression by tumour cells causes an increase in the production of 
other mitogenic growth signals, including PDGF, and FGF in addition to activating 
SMAD independent proliferative pathways, such as the RAS/MAPK (Elliott and Blobe, 
2005) making it a key crosstalk molecule in the tumour microenvironment.
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CHAPTER FOUR
MONOCYTES AND MACROPHAGES
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4.1 Monocytes and macrophages
Monocytes and macrophages are haematopoietic cells, which are derived from CD34 
positive progenitor cells being produced in the bone marrow (Kurahara et al., 2009; 
Murdoch et al., 2008). Monocytes mature from precursor myelomonocytic stem cells 
forming pro-monocytes and then monocytes in the bone marrow. This process is brought 
about by Interleukin (IL-4) and granulocyte and macrophage colony stimulating factor 
(GM-CSF) (Murdoch et al., 2008; Valenti et al., 2006). Monocytes and macrophages 
form an essential part of the innate immunity defending the body against microbes. They 
are recruited to sites of infection and are present as resident cells in some tissue e.g. 
Kuffer cells in the liver. In addition to this, these cells are also known to participate in the 
inflammatory process producing a host of cytokines, which possess both pro- and anti­
inflammatory roles (Ruffell et al., 2012).
In cancer these cells have a major role in several aspects of tumour biology, including 
invasion, recruitment of leukocytes, activation of T-cells, angiogenesis, growth and 
metastasis hence making them an essential regulator in the tumour microenvironment 
(Coffelt et al., 2009; Joyce and Pollard, 2009; Lamagna et al., 2006; Ruffell et al., 2012; 
Schmid and Varner, 2007) (Dirkx et al., 2006). Monocytes are continually shed into the 
circulation from the bone marrow (Lewis and Pollard, 2006) from where they extravasate 
into tissue and undergo a phenotypic transformation to form ‘Tissue associated 
macrophages” (TAMs) (Kurahara et al., 2012a; Lewis and Pollard, 2006; Ruffell et al., 
2012). Macrophages recruited to tissues, are distinct from the classical monocytic 
population which are involved in inflammatory processes hence have been called
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“resident monocytes” by some authors to differentiate them from TAMs (Gordon and 
Taylor, 2005). Monocytes/ macrophages in some cases are seen to constitute a large 
proportion of the tumour mass up to 80% in some cancers(Ruffell et al., 2012) (Pollard, 
2004). They also carry a prognostic value as a high infiltrate of tumour associated 
macrophages correlate with poor prognosis in over 80% of studies published in a variety 
of tumour including pancreatic cancer (Single et al., 2002; Kurahara et al., 2012b). In 
colorectal cancers, macrophages have been linked with an improved prognostic benefit 
with macrophages found at the invasive tumour front (Forssell et al., 2007). In human 
breast cancers, there is a positive correlation between poor prognosis and the density of 
tumour-associated macrophages (Lin et al., 2002; Ruffell et al., 2012). More recently, a 
bone marrow derived subset of monocytes, which are recruited to tumour sites has been 
described, known as Tie2 expressing monocytes (TEM) (De Palma et al., 2005). Tie2 is 
Tyrosine kinase with immunoglobulin-like and EGF-like domains. It is an angiopoietin 
receptor resulting in cell signalling and angiogenesis promotion.
TAMs and TEMs
TEMs are a subpopulation of tumour infiltrating monocytes originally described in mice, 
with an affinity towards highly vascularised stromal regions. TEMs can make up to 30% 
of macrophages in the tumour environment in highly vascular tumours and are virtually 
absent in necrotic tumours (De Palma et al., 2003). The origins of TEMs are unclear with 
various school of thought in place. Some believe they are derived from specialised 
monocyte precursors distinct from those which generate TAMs (De Palma and Naldini, 
2009 1765), whereas others believe there are microenvironmental factors in play which
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can induce the TEM phenotype in extravasated monocytes or even in TAMs. Studies 
have shown that TEMs in humans express CD 14, CD 16 and CD11c surface markers that 
are similar to the so-called “resident monocytes” indicating the link between TAMs and 
TEM cells (Gordon and Taylor, 2005). It is clear that TEMs are involved in the 
angiogenesis process however their exact role is still under review.
Macrophages and in particular TAMs are highly versatile and multifunctional 
components of the innate immune system and have therefore gained significant 
importance in the carcinogenesis process of a variety of cancers (Ruffell et ah, 2012; 
Solinas et ah, 2009). Macrophages exhibit a variety of phenotypes and functions 
depending on the physiological and pathological conditions they are recruited to, with 
ability to secret growth factors, cytokines, proteases and complement components 
(Lamagna et ah, 2006). Macrophages are characterised into 2 broad categories as type I 
(Ml) and Type II (M2), on the basis of their activation states, receptor expression and 
cytokine production (Joyce and Pollard, 2009; Kurahara et ah, 2009; Ruffell et ah, 2012; 
Sica et ah, 2006). Type I macrophages are cells which are capable of producing large 
quantities of proinflammatory cytokines, expressing high levels of MHC molecules and 
implicated in killing pathogens and tumour cells. Type II (M2) macrophages exhibit a 
moderate inflammatory response with their function mainly focused at eliminating cell 
waste, promoting angiogenesis and tissue remodelling (Sica et ah, 2006). TAMs belong 
primarily to the M2 population of macrophages (Kurahara et ah, 2009) (Lamagna et ah, 
2006). The macrophage subpopulation (Ml and M2) have different types of receptor 
expression and cytokine profile. Ml macrophages express high levels of IL-12 and IL-23
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and low levels of IL-10, in contrast to M2 macrophages whose expression of interleukins 
is entirely opposite the former (Ruffell et al., 2012; Sica et ah, 2006). Tissue 
macrophages express a variety of surface markers with CD68 being the most well known 
to be expressed in TAMs. As TAMs exhibit the M2 phenotype, they also express CD 163 
and CD204 (Kurahara et ah, 2012b; Pollard, 2004). In pancreatic cancer Kurahara et ah 
have shown that the M2 type TAMs, which express CD 163 and CD204, conferred a 
worse prognosis exhibiting increase lymphatic metastasis. This was not demonstrated 
when correlations of metastasis and survival were made with CD68 expression in 
pancreatic cancer (Kurahara et al., 2009). The same author has very recently 
demonstrated the presence of folate receptor expressing TAMs in pancreatic cancer, 
which confer a high incidence of haematogenous metastasis and poor survival (Kurahara 
et al., 2012b). This indicates that heterogeneity is seen in infiltrating tissue macrophages 
which has been suggested in the recent literature (Ruffell et al., 2012).
A variety of subpopulation of TAMs exist in a tumour, being placid, they have the ability 
to adapt and undergo transition based on the location and requirements from these cells 
(Joyce and Pollard, 2009 1674). The ability of macrophages to assume varying roles and 
phenotypes seems to be influenced by tumours through the process of cellular crosstalk. 
When monocytes are exposed to anti-inflammatory molecules IL-4, IL-10, glucocorticoid 
and TGF-p they develop into M2 type macrophages (Siveen and Kuttan, 2009; Solinas et 
al, 2009).
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Macrophages normally provide support for developing tissues through their matrix 
remodelling capacities, synthesis of growth and angiogenesis factors. They have the 
ability to engulf debris and apoptosis. A detailed role of monocytes and macrophages in 
cancer is described in the sections to follow.
Recruitment of monocytes / macrophages to tumour
Chemotactic products produced by stromal and tumour cells drive monocytic and 
macrophage recruitment. These primarily include the chemokines (CC), CCL2 also 
known as MCP-1 (monocyte chemotactic protein-1) and CCL5 (RANTES) which are key 
regulators (Coussens and Werb, 2002). In addition increased levels of CCL3 
(macrophage inflammatory protein-alpha MIP-1A), CCL4 (MIP-1B), CCL8 (MCP-2), 
placental growth factor (PIGF) , TNF-a, TGF-P, colony stimulating factor (CSF), 
vascular derived growth factor (YEFG) are also found in the tumour microenvironment 
serving as chemoattractants (Coffelt et al., 2009; Fischer et al., 2007; Scotton et al., 2001; 
Siveen and Kuttan, 2009; Wu et al., 2008). Moreover, monocytes could be attracted by 
fibronectin, fibrinogen and other factors produced during the cleavage of ECM proteins 
induced by macrophage and/or tumour cell-derived proteases (Coffelt et al., 2009). 
Monocytes once recruited to the tumour environment can be grouped into different 
subsets based on their receptor expression and can be either inflammatory or resident 
monocytes, which will go on to form Ml macrophages and M2 macrophages 
respectively. This is an important process, as the type of macrophage developed will have 
a bearing on the tumours growth and invasive potential. It has been shown that low levels
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of CCL2 production by the tumour corresponds to a modest infiltration of monocytes 
leading to tumour growth due to selection of M2 TAMs. On the other hand, high levels 
correspond to increased Ml TAM development leading to destruction of the tumour. This 
would suggest the biological effect of CCL2 is biphasic depending on the levels of 
secretion of the chemokine (Nesbit et al., 2001). Interestingly TEMs do not express 
receptors for CCL2 and therefore do not respond to this chemokine suggesting their 
recruitment is guided by different chemokines. Monocytic recruitment is achieved 
thorough chemokines CCL3, CCL5 and CCLB ,through chemokines receptors CCR1 and 
CCR5 (Murdoch et al., 2008) present on the monocytes. More recent studies indicate that 
TEMs are recruited by the Tie2 ligand angiopoietin-2 which is produced by hypoxic 
tumours and endothelial cells (Gu et al., 2006).
CCL5 is produced by T-cells, however it is also produced by certain tumour cells such as 
breast carcinoma cells, contributing to monocytic migration and also TEMs recruitment. 
It also induces the monocytes to express CCL2, CCL3 and CCL4 allowing for an 
autocrine effect (Locati et al., 2002). Similarly CSF-1 is produced by macrophages and 
monocytes and is involved in their recruitment being a key regulator of this function as 
experiments with transgenic mouse models show that the CSF-1 null mutant have a 
marked reduction in monocytic infiltration(Lin et al., 2001). VEGF expressed in 
macrophages serves as a chemoattractant for monocytes via activation of VEGF receptors 
VEGF-R1, as evidenced by data showing that neutralizing antibodies against VEGF 
reduce migration of monocytes (Single et al., 2002). VEGF is mainly expressed in areas
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of hypoxia and as TAMs express high levels of VEGF they tend to accumulate in necrotic 
and poorly vascularised tissue (Ruffell et ah, 2012).
A group of molecules known as alarmins has also been under the spotlight regarding their 
role in monocytes recruitment (Ehrchen et ah, 2009). High mobility group box protein-1 
is one such protein which is seen to attract monocytes and macrophages alike, being 
released in areas of necrosis and by dying tumour cells (Schlueter et al., 2005).
4.2 Role of macrophages and monocytes in the tumour 
microenvironment
Role in Tumour proliferation and metastasis
It is now clear that stromal cells are drivers of variety of functions, which aid in tumour 
growth, spread and invasion. Tumour infiltrating myeloid cells (macrophages and 
monocytes) have a multi-faceted role in this process. Primarily myeloid cells have 
important and well-studied roles in tumour proliferation, metastasis and angiogenesis. 
Mouse model experimentation has confirmed their prometastatic role, as neutralizing 
antibodies to chemoattractants leads to a lack of monocytic / macrophages recruitment 
into tumours, resulting in impaired metastasis (Lin et al., 2001). In vivo mouse model 
experiments, it has been observed that monocytes when coengrafted with human tumour 
cells, tumour growth enhanced, with lesser growth seen when a low ratio of human 
monocytes was co-grafted. Also repeated contact of monocytes with tumour cells leads to 
decreased production of cytotoxic molecules (TNF-a, reactive oxygen intermediates, and
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IL-12) and increased production of immunosuppressive cytokine (IL-10) (Baj- 
Krzyworzeka et al., 2004). Experimental and histological evidence has indicated the 
presence of monocytes in areas of basement-membrane breaches and also at the invasive 
front in more advanced tumours (Lin and Pollard, 2004).
Experiments utilizing mammary tumour cells by Condeelis et al. indicate that TAMs and 
tumour cells closely interact, with TAMs producing epidermal growth factor (EGF) and 
tumour cells producing CSF-1 to simulate migration of each other (Condeelis and 
Pollard, 2006; lyWyckoff et al., 2007). This reciprocal crosstalk can be blocked resulting 
in decreased migration and invasion of both cell types (Wyckoff et ah, 2004). The group 
has also shown, using multiphoton imaging, that there is a presence of macrophages at 
the tumours invasive front. It has also been determined that macrophages aid in the 
invasion of epithelial cells at the tumour front (Pollard, 2004). Macrophage derived 
tumour necrosis factor TNF-a increases the invasiveness and motility of breast and 
ovarian cell lines inducing the production of matrix metalloproteinases in them 
(Schoppmann et ah, 2002; Solinas et ah, 2009). This has a paracrine effect on 
macrophages, stimulating them to produce MMP-2 and MMP-9 that aids in metastasis 
(Solinas et ah, 2009). In pancreatic cancer cell lines motility is increased by the presence 
of TNF-a acting either directly or through the paracrine mechanisms that is described 
above (Baran et ah, 2009). MMP-7 is also upregulated in macrophages in areas of tumour 
hypoxia, which controls downstream regulation of prometastatic factors aiding tumour 
progression (Coffelt et ah, 2009; Lynch et ah, 2005). Hiratsuka et al have illustrated that
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macrophages produce MMP-9 in response to tumour VEGF at sites of distant metastasis, 
hence aiding tumour spread (Hiratsuka et ah, 2006).
Macrophages are a major producer of proteases, allowing tumour cells to invade bloods 
vessels and breach the basement membrane. These include specific metalloproteinases, 
cathepsins and serine proteases (Egeblad and Werb, 2002; Mohamed and Sloane, 2006). 
These proteases enable tumour cell mobility by cleaving cell surfaces proteins such as E- 
cadherin, degradation of ECM proteins and activation of growth factors and cytokines 
through cleavage of active domains. Monocytes secrete MMP-19 and urokinase 
plasminogen activator (uPA) which allows tumour cells to detach and disseminate 
leading to distant metastasis (Robinson et al., 2002). Protease-enhanced invasion is not an 
individual phenomenon but is regulated through a cascade of interactions working 
together. Being potent effectors of tumour invasion and growth, macrophages hold a 
central position and are the subject of future therapeutic modalities.
Role in Angiogenesis
Promotion of angiogenesis leading to cancer growth and metastases is a well established 
role of monocytes and macrophages having been studied in a variety of tumours. Clinical 
evidence show a correlation between local macrophage density and areas of intense 
angiogenesis defined by the presence of microvessels, leading to poor prognosis 
(Murdoch et al., 2008; Solinas et al., 2009; Valkovic et al., 2002). In the mouse breast 
cancer model, macrophages (TAMs) were expressed in high numbers even in
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premalignant lesions and seen to initiate the “angiogenic switch” (Lin et al.5 2006). This 
is identified as the formation of a high-density vessel network and is closely associated 
with the transition to malignancy. The angiogenic switch was delayed if inhibition of 
macrophage infiltration occurred. This study shows that TAMs play a key role in 
promoting tumour angiogenesis, an essential step in tumour progression from insitu to 
invasive malignancy (Lin et al., 2006).
TAMs release a host of proangiogenic growth factors such as VEGF, TNF-a, PDGF, 
TGF-p, members of the FGF family, cyclooxygenase-2, plasminogen activator, urokinase 
and metalloproteinases MMP7, MMP9, and MMP12 (Murdoch et al., 2008; Solinas et al., 
2009),(De Palma and Naldini, 2009). Macrophages also produce the angiogenic factor 
thymidine phosphorylase, which in vitro promotes endothelial cell migration (Solinas et 
al., 2009). Macrophages tend to accumulate in areas of hypoxia or necrosis in numerous 
tumours such as breast, colon, ovary, bladder (Murdoch et al., 2008). Hypoxia promotes 
HIF-1 and HIF-2 transcription factors in macrophages whose targets include genes of 
proangiogenic factors such as VEGF, endothelins and those of proliferation, and 
metabolism (Lewis and Murdoch, 2005). Macrophages also produce a potent 
proangiogenic enzyme MMP9 which is responsible for degradation of ECM and 
promotion of angiogenic factors; inhibition of the which blocks the release of VEGF and 
thereby inhibiting angiogenesis (Coussens et al., 2000) (Condeelis and Pollard, 2006). 
Similarly microarray studies on pancreatic carcinoma sections have shown an increased 
infiltrate of mast cells and macrophages which were not only indicative of a poor 
prognosis but resulted in high levels of tumour stromal cellular expression of VEGF-A,
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VEGF-C and FGF (Esposito et al., 2004). Direct blockage of VEGF in a process to 
control tumour growth and angiogenesis has met with varying levels of success with 
Bevacizumab being successful in treatment of colorectal cancer but has no role in 
pancreatic cancer (Dineen et ah, 2008). Dineen et al. have demonstrated that 2C3, a 
monoclonal antibody to VEGF prevents it from binding to VEGFR-2, has been effective 
in reducing the number of tumour-associated macrophages in pancreatic cancer treatment 
resulting in decreased macrophage population and subsequent angiogenesis (Dineen et 
ah, 2008).
It is interesting to note that MCP-1 expression correlates significantly with levels of 
VEGF, TNF-cx, and IL-8, suggesting a possible role for MCP-1 as an angiogenesis 
regulator as well (Dirkx et ah, 2006). The expression of chemokines involved in 
angiogenic processes is also regulated by chemokines such as CCL2, CXCL8, CXCL1, 
CXCL13, and CCL5. Levels of CXCL5 and CXCL8 were associated with increased 
neovascularisation and correlated inversely with survival (Balkwill, 2004; Luster, 1998; 
Mantovani et ah, 2004; Stricter et ah, 2004). Thus, TAMs have the capacity to affect 
each phase of the angiogenic process including degradation of extracellular matrix, 
endothelial cell proliferation, and endotheital cell migration. Transgenic mouse model 
experimentation in which Tie2 expressing cells were killed using the drug ganciclovir, 
showed a profound reduction in angiogenesis and growth in tumours (De Palma et ah, 
2005). Ablation of TEMs from these tumours did not affect the population of TAMs, 
which would suggest that rather than giving rise to them TEMs are a distinct 
subpopulation cells. The roles of how TEMs effect angiogenesis in human tumours is still
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under investigation however in murine models TEMs produce bFGF and proteolytic 
factors such as MMP9, however by and large their exact functioning is still a matter of 
investigation(De Palma and Naldini, 2009) (De Palma et al., 2005)
Summary of the role of macrophages and monocytes
The Figure 1.5 demonstrates a schematic representation of the role of macrophages and 
monocytes in tumour biology and the relationship they have with, stromal and tumour 
cells.
Metastasis
Survival
Angiogenesis
Recruitment Differentiation
Matrix remodelling
Tumour and cell 
proliferation
Macrophages / Monocytes
Tumour Cells and Stromal cells
Figure 1.5: Schematic presentation of monocytes and macrophages involvement in 
cancer progression and cell and complex crosstalk between cells.
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CHAPTER FIVE
CALCIUM BINDING PROTEINS
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5.1 S100 Family of Calcium binding proteins
Calcium ions form an important intracellular mediator to a variety of secondary 
messengers, which either can enter the cell through calcium channels in cell membranes 
or be mobilised from internally sequestered stores. Calcium ions form parts of a variety 
of cellular functions which include cell-cycle progression, differentiation, muscle 
contraction, enzyme activation and apoptosis (Kim E. Barrett et ah, 2010). Calcium ions 
often couple with a variety of proteins, affecting their architecture, resulting in activation 
of their function, in turn affecting their cellular response (Ikura M et ah, 2002).
The commonest protein from this family is that with the EF-hand motif. First described 
by Kretsinger and Nockolds in 1973 (Kretsinger RH and Nockolds CE, 1973), the EF 
hand motif is a calcium binding motif comprised to two helices (E and F) which are 
joined by a loop. It is within this loop region that calcium ion binds (Zimmer DB et ah, 
1995) resulting in the EF-hand proteins to undergoing a conformational change.
The SI00 protein family is a multigene calcium binding protein family which constitute 
the largest subgroup of EF hand proteins. The family consists of over 20 known members 
in humans each coded by a separate gene (Schafer BW and Heizmann CW, 1996). First 
described by Moore et al. in 1965 these proteins are small acidic proteins between 10-12 
KDa and were termed SI00 as they dissolved in 100% saturated ammonium sulphate at 
neutral pH (Moore BW, 1965; Zimmer DB et al., 1995). Many of the S100 proteins 
demonstrate tissue and cell specific expression patterns. In addition to this they are 
unusual in that they also occur in the extracellular space, where they are thought to act
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like cytokines (Marenholz et al., 2004). In the recent years they have been linked with 
various human pathologies including inflammatory and neoplastic disorders (Ghavami et 
al., 2008b{Gebhardt, 2006 #1084; Salama et al, 2008). They also have critical roles in 
signal transduction pathways including the RAGE pathway (receptor for advanced 
glycation pathway) (Ghavami et al.,; Ghavami et al., 2008b; Nacken et al., 2003).
In addition to calcium, many of the SI 00 proteins also display high affinity for zinc and 
copper ions and this may influence their activity in the extracellular space (Heizmann 
CW and Cox JA, 1998). Further evidence and indication of their involvements in 
inflammatory and neoplastic disorders is that most SI00 genes are found near the 
breakpoint region of chromosome lq21 which when affected results in a number of 
genetic abnormalities related to autoimmune pathologies or cancer (Mischke et al., 1996).
The SI00 proteins have the ability to form homodimers and heterodimers (Barger SW et 
al., 1992). The S100 proteins (Figure 1.6) have two distinct EF hands, one common to all 
EF proteins in the C-terminus and one specific to this family on the N-terminus. In 
addition, beyond the C-terminus in EF hand region is a stretch of amino acids referred to 
as the C-terminal extension, which is variable in different SI00 proteins accounting for 
varying properties and biological function (Nacken et al., 2003) (Salama et al., 2008).
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Figure 1.6: Schematic depiction of the secondary structure of an SI00 protein. The 
monomeric structure consists of a repetitive EF-hand motif. The N-terminal and the C- 
terminal EF hands are connected by a linker region (hinge region). The hinge region and 
the C-terminal extension (boxed in red) display the least amount of sequence homology 
among SI00 paralogs.
Function of S100 Proteins
The SI 00 proteins are involved in a broad range of cellular processes, including cell cycle 
regulation, cell growth, cell differentiation and motility. Intracellular functions include 
protein phosphorylation, enzyme activation, calcium homeostasis, regulation of 
cytoskeletal components and regulation of transcriptional factors (Santamaria-Kisiel et 
al., 2006). A number of SI00 proteins interact with p53 with both S100B and S100A4 
being the most relevant (Grigorian et al., 2001). Both of these proteins have been shown
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to inhibit p53 phosphorylation leading to inhibition of transcriptional activity inducing 
p53 related cell growth arrest (Scotto C et al., 1998) (Grigorian et ah, 2001). In contrast, 
S100A2 promotes p53 transcriptional activity thus allowing for a balance of actions, 
which are regulated by different members of the SI00 family within a single cell 
(Mueller et ah, 2005). S100A4 has been shown to have a role in cytoskeletal modulation 
because of interactions with tubulins, actin and myosin filaments producing cell motility 
and in the cancer setting modulating metastasis (Grigorian et ah, 2001). Primarily 
S100A1, but also to lesser degree S100B, stimulate calcium release in skeletal muscle 
cells producing cell contractility (Fano G et ah, 1989). S100A10 forms a natural ligand of 
annexin II and binding with the protein induces co-localisation of annexin II (Thiel C et 
al., 1992) and inhibits its phosphorylation regulating annexin II activity and interaction 
with cytoskeleton constituents. In pancreatic cancer, Nedaji et at reported co-localisation 
of annexin II and S100A6 in the plasma membrane and a direct association of levels of 
membranous annexin II expressions and cytoplasmic S100A6 expression (Nedjadi et ah, 
2009).
Extracellular effects have been described for S100B, S100A1, S100A2, S100A4, 
S100A7, S100A10 and S100A12 with secretion noted to occur for S100B, SI00A8 and 
S100A9 (Donato, 2003). The S100A8/A9 complex is secreted by neutrophils and 
monocytes by a novel secretion pathway relying on an intact microtubule network 
(Ryckman et ah, 2003) acting as a potent chemotactic agent for other macrophages and 
inflammatory cells (Yogi et al., 2004). In addition, these complexes are also detected at 
sites of acute and chronic inflammation, where it may have a role in leukocyte trafficking
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(Ryckman et al., 2003). S100A10 binds tissue type plasminogen activator (tPA), 
plasminogen and plasmin, and stimulates the tPA dependant conversion of plasminogen 
to plasmin, and thus may play an essential role in the inhibition of fibrin clot lysis (Kang 
HM et ah, 1998).
S100 Protein expression in Cancer
Several members of the SI00 family are differentially expressed in a variety of human 
cancers conferring a prognostic benefit. S100B, S100A2, S100A4, S100A6, S100A7 and 
SI0011 (Salama et ah, 2008) have been studied in detail with S100A4 having attracted 
the most attention, particularly in colorectal cancer where it has been associated 
significantly with survival (Gongoll S et al., 2002). Their role in carcinogenesis is 
variable and at times not fully understood however, primarily they are involved in 
regulation of cellular processes of cell cycle progression and differentiation (Donato, 
2003). The SI00 family gene cluster is at chromosome lq21 and is frequently disrupted 
in different tumour types, resulting in differential expression of these proteins, hence 
providing a link between S100 protein and neoplasia (Schafer BW and Heizmann CW, 
1996).
S100B protein is overexpressed in melanoma with high levels being associated with 
metastasis. Increased serum levels corelate to poor survival reflecting tumour load, stage 
and prognosis (Harpio and Einarsson, 2004) is being used as a valuable marker to assess
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patients response to treatment. To a lesser extent this protein is also detected in thyroid 
and renal cell carcinomas (Ghavami et ah, 2009),
Elevated levels of tumour expression of S100A4 of both protein and mRNA are seen in 
bladder (Salama et ah, 2008), colorectal (Gongoll S et ah, 2002), breast (Rudland et ah, 
2000), thyroid (Helfman et ah, 2005), pancreas (Rosty et ah, 2002)and prostate cancer 
(Gupta et ah, 2003). The expression of S100A4 has been related to an aggressive tumour 
phenotype yielding a poor prognosis particularly in colorectal and gastric cancers 
(Gongoll S et ah, 2002). Overexpression of S100A4 in mouse model experiments has 
shown S100A4 to promote metastasis by affecting metalloproteinase activity and cell 
motility (Mathisen et ah, 2003). S100A4 and S100B are thought to inhibit p53 
transcriptional activity by inhibition of its phosphorylation and therefore affecting its 
tumour suppressor activity (Grigorian et ah, 2001). Kim et al. have demonstrated 
S100A4 to have a prognostic benefit in predicting relapse of gastric cancer following 
curative resection (Kim et ah, 2008).
Unlike the rest of the SI 00 family of proteins which show an up regulation in malignancy 
S100A2 is down regulated in many cancers including melanoma (Maelandsmo et ah, 
1997), lung (Smith et ah, 2004) oral and breast (Liu et ah, 2000) cancers. This however is 
not always the case as this protein is overexpressed in oesophageal and non small cell 
lung carcinoma (Salama et ah, 2008) and the mechanism of how the protein serves as a 
tumour suppressor and a tumour promoter is not fully understood. The down regulation 
of S100A2 protein in lung cancer occur early in lung carcinogenesis and therefore has a
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potential place as a biomarker of early change in this process (Feng et ah, 2001). Another 
significant SI00 proteins which is expressed in cancer is S100A7. High levels of 
expression were seen in psoriatic keratinocytes (Emberley ED et ah, 2003). It is also 
overexpressed in ductal breast cancer cell lines as well as invasive ductal breast cancer 
and ductal carcinoma insitu; its presence bearing a poor prognosis (Emberley ED et al., 
2003). The precise mechanism through which this protein affects breast cancer is not 
known, however, there is evidence linking this protein to BRCA1 gene mutation, which 
is very important in breast carcinoma tumorigenesis (Kennedy et al, 2005).
S100 proteins in pancreatic cancer
There are a number of SI00 proteins which are overexpressed in pancreatic cancer 
including S100A2, S100A4, S100A6, S100A11 and S100P (Vimalachandran et al, 2005) 
(Cross et al, 2005; Ohuchida et al, 2005) with S100A6 carrying a poor survival benefit. 
Crnogorac-Jurcevic et al. (Crnogorac-Jurcevic et al, 2003) carried out cDNA array 
analysis of pancreatic cancer tissue and cancer cell lines publishing a detailed account of 
several SI00 genes which are regulated in pancreatic cancer tumorigenesis. The group 
found that the genes for S100A2, S100A4, S100A6 and SI OOP were upregulated in 
pancreatic cancer, whereas the expression of S100A1, S100A7, S100A8, S100A10, 
S100A11, S100A12 and S100A13 were low. Of the most importance were the S100A6 
and SI OOP genes, which had the highest differential gene expression.
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S100A6 protein is overexpressed not only in ductal pancreatic cancer but also in PanIN 
lesions (Vimalachandran et al., 2005) and intraductal papillary mucinous neoplasms 
(Ohuchida et al., 2007b) with high level expression linked to poor outcome 
(Vimalachandran et ah, 2005). Depletion of S100A6 in pancreatic cancer cells has proven 
to decrease invasive potential by decreasing pancreatic cancer cell motility in 
experimental conditions (Nedjadi et al., 2009). Additionally Nedjadi et al. have also 
shown that knockdown of S100A6 in pancreatic cancer cells is accompanied with a 
reduction in cells expressing membranous Annexin A2 which is known to effect cell 
motility.
S100A6 is also upregulated in a variety of tumours other than pancreatic cancer including 
gastric (Yang et al., 2007) thyroid (Brown et al., 2006) breast (Cross et al., 2005) and 
colorectal cancers (Stulik et al, 2000) (Komatsu et al., 2000). In colorectal cancer, there 
is increased S100A6 expression at the cancer invasive front suggesting the role of this 
protein in invasion and metastasis (Komatsu et al., 2000). Similarly, in cutaneous 
melanoma cell line experimentation in nude mice, elevated S100A6 cancer expression 
correlated with high metastatic ability (Weterman et al., 1992).
S100A4 is frequently overexpressed in ductal pancreatic cancer (Rosty et al., 2002) and 
malignant intraductal papillary mucinous neoplasm of the pancreas (IPMN) (Jang et al., 
2009)however pancreatic intraepithelial neoplasia (PanINs) do not shown any expression 
of this protein (Rosty et al., 2002). In experimental conditions knocking down S100A4 
expression using interference RNA strongly suppressed cell growth, induced G2 arrest
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leading to eventual apoptosis and additionally decreased cell migration (Tabata et al.5 
2009). In pancreatic cancer, S100A2 is overexpressed in ductal adenocarcinomas, 
compared to IPMNs (Ohuchida et al., 2007a). Amongst the pancreatic cancers, ductal 
carcinomas with poor differentiation show high level of expression of S100A2. Bainken 
et al. have shown that patients having S100A2-negative tumours had a significant 
survival benefit from pancreatectomy even in the presence of involved surgical margins 
or lymph node metastases compared to those who expressed S100A2 (Biankin et al., 
2009). Recent microarray analyses revealed that expression of S100A11 is upregulated in 
pancreatic cancer, which is interesting since it is tumour suppressive gene. Analysis by a 
Japanese group has shown that S100A11 expression is increased in the early stages of 
pancreatic carcinogenesis and decreased during subsequent progression to invasive 
cancer (Ohuchida et al., 2006). Similarly, S100P which is a 10.4kDa secreted protein is 
also expressed in most PDACs and its upregulation correlates to increasing PanIN grade 
(Dowen et al., 2005). More recently a SI OOP binding protein has been demonstrated in 
pancreatic cancer cell lines with downregulation of this protein leading to decreased 
PDAC adhesion over expression (Lines et al., 2012).
5.2 S100A8 AND S100A9
S100A8 (MRP8, Calgranulin A) and S100A9 (MRP 14, Calgranulin B) are calcium 
binding proteins which have been implicated in a variety of inflammatory pathologies, 
being predominantly expressed in cells of myeloid lineage (Ehrchen et al., 2009; 
Ghavami et al., 2009; Srikrishna, 2012). Both S100A8 and S100A9 proteins have low 
molecular weight, weighting 10 kDa and 14 kDa respectively (Roth et al., 2001).
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Expression of S100A8 and S100A9
These proteins are classically expressed in circulating neutrophils, monocytes and 
immature macrophages and therefore are implicated in a number of inflammatory 
diseases (Nacken et al, 2003; Odink et al., 1987) (Goebeler et ak, 1994; Nacken et ah, 
2003). Zwadlo et al demonstrated the presence of both SI00 proteins in monocytes 
which were expressed specifically at early stages of monocyte differentiation and 
downregulated during maturation to macrophages (Cheng et ah, 2008) (Zwadlo et ah, 
1988). The expression of S100A8 and S100A9 changes as monocytes recruited from the 
blood stream to sites of inflammation, differentiate to mature macrophages (Zwadlo et ah, 
1988). They initially express both S100A8 and S100A9 and as they mature S100A8 
expression ceases leaving only S100A9 which is also subsequently lost as the cell 
matures further (Zwadlo et ah, 1988)(Figure 1.7). Furthermore, these proteins are not 
expressed in resting tissue macrophages and lymphocytes (Frosch et ah, 2004; Nacken et 
ah, 2003; Roth et ah, 2003).
Similarly, S100A8 and S100A9 are expressed in mucosal epithelium and epidermis under 
inflammatory conditions such as psoriasis and malignant disorders (Zucchini et ah, 
2001). These proteins have also been detected in a variety of tumours being upregulated 
in breast, gastric, lung, colorectal (Stulik J et ah, 1999) and prostate cancers and 
downregulated in squamous oesophageal cancers (Cross et ah, 2005; Gebhardt et ah, 
2006). More importantly, these proteins form part of the cancer microenvironment 
having a role in mediating metastatic spread (Hiratsuka et ah, 2006) and regulating
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tumour cell growth (Ghavami et ah, 2009) which is discussed in further detail in the next
section.
Mature
Macrophage
S100A8+/A9+/ ______ S100A87A9+ ---------- ► S100A87A9'
Figure 1.7: Diagram showing the maturation process of monocytes to macrophages and 
changes in protein expression
S100A8/S100A9 Complex formation and secretion
Although S100A8 and S100A9 exist as homodimers similar to many other SI00 proteins, 
they preferentially form functional anti-parallel heterodimers of S100A8/A9, also known 
as calprotectin (Ehrchen et ah, 2009). In monocytes S100A8 and S100A9 are 
predominantly found in the cytoplasm being transferred from the cytosol to the
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cytoskeleton and then to the plasma membrane on elevation of cytosolic calcium levels 
(Ehrchen et ai.5 2009; Roth J et al., 1993). They have a strong tendency to form stable 
heterodimer complexes on the plasma membrane at sites of inflammation(Nacken et al., 
2003) (Striz and Trebichavsky, 2004) and these complexes are thought to contribute to 
the host inflammatory responses (Nacken et al., 2003; Ryckman et al., 2004; Ryckman et 
al, 2003). Following their migration to the plasma membrane, they appear as non- 
covalently associated S100A8/A9 heterodimers on the cell surface. The mechanism by 
which the heterodimer penetrates the plasma membrane and remains anchored in the 
plasma membrane is still unclear (Cheng et al, 2008; Roth et al, 2003). Both proteins 
can be simultaneously induced in monocytes and monocytic cell line HL-60 by several 
mediators, including LPS, TNF-a, ILla , TGF-(31, IL-lp , IL-10 or IL-22 (Goyette and 
Geczy, 2010). Upon stimulation, calprotectin is secreted by a novel secretion pathway 
dependant on a intact microtubule network (Rammes et al, 1997).
Role of S100A8 and S100A9 in Inflammation
S100A8 and S100A9 are primarily expressed in the leukocytes of the inflammatory tissue 
and in addition to being present in tissue, elevated levels of these protein are also detected 
in the plasma (Nacken et al, 2003) and can be useful in monitoring the inflammatory 
response in such diseases (Roth et al, 2001). In rheumatoid arthritis S100A8/A9 are used 
as clinical markers of disease remission (Berntzen et al, 1989). Compared to C-reactive 
protein, S100A8 and S100A9 have been shown to have higher sensitivity and specificity 
in detecting disease remission and response to therapy. Levels of these proteins are
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detected in body fluids and histological specimens alike (Kane et ah, 2003). In 
inflammatory bowel disease (Ulcerative Colitis and Crohn’s disease) 
immunohistochemistry of colonic tissue confirms the presence of elevated infiltrating 
monocytes and neutrophils expressing S100A8 and S100A9 with faecal calprotectin 
levels being a useful monitor of disease activity (Tibbie et al.5 2000).
The presence of calprotectin at sites of inflammation (Nacken et al, 2003) (Striz and 
Trebichavsky, 2004) contributes to the host inflammatory response by mediating 
leukocyte trafficking, adhesion and migration (Nacken et al., 2003; Ryckman et ah, 2004; 
Ryckman et al., 2003). These proteins also promote monocytic and phagocyte migration 
(Manitz et al., 2003; Yogi et al., 2004) and the S100A8/S100A9 heterodimer is believed 
to recruit further monocytes to sites of inflammation (Eue et al., 2000). S100A9 and 
S100A8/A9 act as regulatory molecules for transendothelial migration of monocytes by 
enhancing ICAM-1 ligand binding to monocytes and in turn effecting Mac-1 activity 
(Eue et al., 2000). Secreted S100A8/A9 also has potent antimicrobial properties and 
works by depriving the microbes of zinc and manganese ions (Corbin et al., 2008). Due 
to these proinflammatory properties, S100A8/A9 targeting by antibodies is a novel way 
to treat these conditions. The proteins, particularly S100A8, are susceptible to oxidation 
by peroxide, hypochlorite and nitric oxide. This susceptibility, combined with expression 
in monocytes and immature macrophages produces abundant reactive oxygen species 
during inflammation and indicates that S100A8 and S100A9 may protect tissues against 
oxidative damage (Goyette and Geczy, 2010).
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Role of S100A8 and S100A9 in Cancer
Expression of S100A8 and S100A9 in cancer cells
Recent clinical and experimental data has shown a strong S100A8 and S100A9 up- 
regulation in breast, lung, gastric, colorectal, and prostate cancer (Gebhardt et al., 2006) 
whereas a down-regulation is detected for squamous oesophageal carcinomas (Kong et 
al., 2004). Furthermore, altered S100A9 expression in carcinomas of glandular cell 
origin, e.g. breast, lung, and thyroid gland, corresponded to poor tumour differentiation 
(Gebhardt et al., 2006; Kong et al, 2004). Expression of both S100A8 and S100A9 has 
been observed by immunohistochemistry in invasive squamous cell carcinoma of the 
uterine cervix and prostate cancer (Cross et al, 2005; Hermani et al, 2005). In case of the 
latter (Hermani et al, 2005) S100A9 levels were significantly elevated in serum from 
prostate cancer patients compared to healthy controls and patients with benign prostatic 
hyperplasia (Hermani et al, 2006). Moreover, both proteins were detected in the cystic 
fluid and serum of patients with ovarian carcinomas (Ott et al, 2003). S100A9 expression 
is induced in hepatocellular carcinoma through activation of the NF-kB signalling 
pathway (Nemeth et al, 2009). Some studies have attempted to correlate S100A8 and 
S100A9 expression to the degree of invasive and non-invasive potential of the tumour in 
experimental conditions but have met with conflicting results.
114
Role of S100A8 and S100A9 in tumour suppression
The S100A8/A9 protein complex also has a role in apoptosis and has cytotoxic effects 
against various cancer cell lines in experimental conditions (Ghavami et ah, 2009). 
Ghavami et al. has shown this occurs through a mitochondrial pathway involving 
modulation of the balance of pro and anti-apoptotic family of cell regulators e.g. BCL-2 
(Ghavami et ah, 2008a). In addition to this, the S100A8/A9 protein complex 
(Calprotectin) also induces apoptosis by exclusion of zinc from tumour cells (Ghavami et 
ah, 2009). These studies indicate that S100A8 and S100A9 elicit anti-tumour responses, 
and that the cell death pathway mediated by these proteins therefore might provide targets 
for developing novel therapeutic tools against cancers. However like many other cellular 
molecules these proteins have a dual role both in cancer suppression and progression and 
further understanding of the complex relations these proteins have in the carcinogenesis 
process still remains to be unravelled.
Role of S100A8 and S100A9 in tumour progression
The role of S100A8/A9 has recently received a lot of attention in the literature for its role 
in tumour progression. Calprotectin, has been shown to induce proliferation of human 
breast cell lines (MCF-7 and MDA-MB231) and neuroblastoma cancer cell lines (SHEP 
and Kelly) via the RAGE (receptor of advanced glycation product) pathway (Ghavami et 
ah, 2008b). Activation of RAGE resulted in downstream activation of the PI3K and RAS 
related NF-kB pathway, which induced growth factors and cytokines leading to cell 
proliferation. S100A8/A9, increase migration of benign prostate PNT1A cells in a scratch
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wound healing assay (Hermani et ah, 2006) and similarly promote migration of Lewis 
lung carcinoma cells and B16 melanoma cells in Boyden chambeis expeiiments 
(Hiratsuka et ah, 2006). They have also been shown (described in more detail in the 
results section) to increase motility and proliferation of pancreatic and colorectal cancer 
cell lines (Ang et ah, 2010). In breast cancer, induction of S100A8/A9 converts tumour 
cells into a migratory phenotype, accompanied by increased expression of matrix 
metalloproteinases that promote tumour invasion (Moon et ah, 2008). Furtheimoie, 
siRNA-targeted knockdown of S100A8/A9 expression reduces H-RAS induced invasion.
Binding of S100A8/A9 to tumour cells activates the RAGE mediated pathway and in 
colon tumour cells, enhances expression of Cxcll, Ccl5 and CWZgenes, The products of 
these genes promote leukocyte recruitment, angiogenesis, tumoiu migiation, and 
formation of premetastatic niches (described below) in distal metastatic organs (Ichikawa 
etah, 2011).
Studies by Roth’s group in Germany using a mouse model have defined the presence of a 
myeloid-derived suppressor cells (MDSCs) which accumulate in tumours and in sites of 
inflammation leading to suppression of anti-tumour immune responses (Cheng et ah, 
2008). The molecular mechanism behind this is unclear however; up-regulation of the 
myeloid-related protein S100A9 enhances MDSC production in cancer. Moreover, mice 
that were deficient in S100A9 protein mounted a potent antitumor response and rejected 
implanted tumours indicating a key role of S100A9 protein in MDSC accumulation and 
tumour growth. This study demonstrates that tumour-induced upregulation of S100A9
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protein is critically important for accumulation of MDSCs and reveals a novel molecular 
mechanism in cancer.
S100A8 and S100A9 have been associated with a sentinel role in cancer metastasis 
(Hiratsuka et al., 2006) particularly in the development of the “pre-metastatic niche” 
(Figure 1.8). Using a mouse model, it has been demonstrated that S100A8 and S100A9 
expression was induced in myeloid and endothelial cells in the lungs of mice by secreted 
soluble factors such as TGF-p, TGF-a and VEGF-A. These soluble factors were derived 
from the distant primary cancer cells (B16 melanoma or Lewis Lung carcinoma) and 
form part of the premetastatic phase which enables priming of the distant metastatic 
microenvironment. This priming of the distant metastatic site allowed for 
microenvironmental changes, enabling migration and implantation of the tumour cells. 
Additionally, these proteins also increase motility of circulating cancer cells by activation 
of pseudopodia which accelerate assembly at metastatic focus (Rafii and Lyden, 2006). 
Systematic inhibition of S100A8 and S100A9 proteins using blocking antibodies 
inhibited metastatic disease making these proteins an attractive target for drug therapy. 
Increased numbers of cells bearing the classical markers of murine MDSC have also been 
identified in premetastatic lungs and liver in tumour-bearing mice (Yan et al., 2010). 
S100A9-deficient mice show reduced accumulation of these cells in premetastatic sites 
further substantiating the role for S100A8/A9 in formation of premetastatic 
niches and accumulation of MDSC.
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Recently Ichikawa et al. have, in colon cancer mice models, demonstrated elevated levels 
of S100A8/A9 in sera of tumour-bearing wild-type mice, prior to any evidence of 
metastasis. This suggests that these proteins are early makers for metastatic disease 
having potential to amplify pro-tumour responses (Ichikawa et al., 2011). In addition 
mice lacking S100A9 showed a significantly reduced incidence of colon tumours, tumour 
growth and metastasis, reduced chemokine levels, and reduced infiltration of myeloid 
cells. These findings reveal a novel role for S100A8/A9 in activating specific 
downstream genes associated with carcinogenesis that promote tumour growth and 
metastasis identifying them as important players in the molecular crosstalk (Ichikawa et 
al., 2011),
Figure 1.8: Figure adapted from Hiratsuka et al. demonstrating the premetastic metastatic 
phase. TGF-p and VEGF produced by the tumour cells induced the production of 
S100A8 and S100A9 in lung tissue aiding migration of further myeloid cells to the lung 
hence preparing the lung tissue for metastatic tumour cell to deposit.
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Receptors for S100A8 and S100A9
As eluded in the earlier sections S100A8/A9 signalling is through interactions with cell 
surface pattern recognition receptors such as Toll-like receptors (TLRs) and RAGE 
(Srikrishna, 2012). Yogi et al. was the first to provide evidence that purified S100A8 bind 
to TLRs (Yogi et al.} 2007). The group also showed that S100A8/A9 amplified 
endotoxin-mediated inflammatory responses through TLRs. Subsequently, using a mouse 
autoimmune model, Loser et al (Loser et ah, 2010) showed that S100A8/A9 locally 
present in extracellular medium in tissues of a mouse autoimmune model interacted with 
TLRs. This interaction increased expression of IL-17, which promoted induction of 
autoreactive CD8+ T cells, and the development of systemic autoimmunity. In 
premetastatic lungs of tumour-bearing mice, Hiratsuka et al. identified SAA3 as a 
important downstream effectors of S100A8 and S100A9 ligand for TLR. Therefore, 
although signalling mediated by a direct interaction of S100A8/A9 with TLR is not 
implicated, a paracrine cascade consisting of S100A8/ A9, SAAB and TLR appears of 
critical importance (Hiratsuka et ah, 2006).
RAGE is a transmembrane protein, being a signalling receptor of the immunoglobulin 
super family. Although originally identified as a receptor for advanced glycation end 
products, it is known to bind many structurally unrelated ligands. RAGE and S100A8/A9 
are co-expressed in tumours and linked to downstream signalling in tumour cells 
(Ghavami et ah, 2009; Ghavami et ah, 2008a). Extracellular S100A8/A9 promote the 
growth of tumour cells, an effect blocked by RAGE gene silencing or by treatment with 
anti-RAGE (Ghavami et ah, 2008b). Although both TLR4 and RAGE are implicated in
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S100A8/A9-mediated pathological effects, which receptor and signalling pathways are 
preferentially employed may depend on the pathological settings, cell types involved 
and is still a matter of active investigation.
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CHAPTER SIX
BACKGROUND RESULTS
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6.1 Results leading towards the project
My projects evolved from findings based on the 2-DE proteomic analysis undertaken by 
Mr Dale Vimalachandran (MD student under Dr E Costello), comparing similar 
quantities of microdissected tumour-associated stroma to benign or malignant ductal 
pancreatic cancer cells (Vimalachandran et ah, 2005). He identified two spots with higher 
intensities in gels containing stromal derived proteins compared to the gels containing 
proteins from benign or malignant ductal cells. Both of these spots were undetectable in 
all the benign ductal epithelial cells (n^S) and malignant cells (n=3) cases he examined.
In order to independently confirm the proteomic findings, an immunohistochemical 
analysis of archival paraffin embedded tissue sections from patients with pancreatic 
cancer was undertaken. This clearly demonstrated positive immunoexpression in stromal 
cells rather than malignant ductal cells. These finding were then followed up by staining 
of a tissue microarray, which held information on 71 patients, which was undertaken by 
Dr. E Costello.
S100A9 and S100A8 expression in stromal cells
Immunohistochemical staining of a pancreatic cancer tissue microarray for S100A8 and 
S100A9 resulted in no specific immunostaining of either benign or malignant epithelial 
cells (Figure 1.9) as mentioned above. In contrast, strong immunostaining was readily 
detected in the inflammatory cells in the tumour associated stroma (Figure 1.9). Some 
tumours contained a limited number of S100A8- and S100A9- positive inflammatory
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cells while others displayed a high density of positive cells infiltrating the tumour. 
Positive immunostaining was detected in the stromal component of all tumours (71/71).
Figure 1.9: Photomicrographs showing sections of malignant tissue, from a pancreatic 
cancer microarray immunohistochemically stained for S100A8 (left panel) (i) and 
S100A9 (right panel) (ii) demonstrating their presence in inflammatory cells.
Quantification of S100A8 and S100A9 staining
To evaluate the extent of S100A8 and S100A9 expression in pancreatic tumour- 
associated stroma Dr E Costello counted the number of positively stained cells in each 
tumour core of the immunostained cancer microarray. The mean number of positive cells 
per duplicate patient core is shown in the box plot below (Figure 1.10). Tumours 
contained significantly fewer numbers of S100A8- positive cells than S100A9-positive 
cells (Sheikh et al., 2007). The median number of S100A8-positive cells was 15.0 (inter­
quartile range 5.2 - 43.7) compared to a median number of 35 (inter-quartile range 20- 
74.5) S100A9-positive cells (p<0.0001, Wilcoxon Signed Rank Test). A strong positive 
correlation was observed between the number of S100A8- and S100A9- positive cells 
(Fisher’s exact test, P = 0.0001)
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Figure 1.10: Median S100A8 and S100A9 positive cell counts in pancreatic cancer cores 
on the TMA from 71 patients shown as box plots.
Association of S100A8 and S100A9 expression with patient parameters
Based on the information held in the pancreatic cancer database the number of S100A8 
and S100A9 positive cells were correlated with patient parameters. Survival data for all 
71 patients was available with no correlation to patient survival (Spearman Rank 
correlation, Rho = -0.08 and -0.02 for S100A8 and S100A9 respectively; P= 0.48 and 
0.85 respectively) was demonstrable. For the purposes of examining associations 
between the number of S100A8 or S100A9 immunopositive cells and other patient
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parameters, patients were categorized into two groups, i.e. those having positive cell 
numbers less or equal to the median or greater than the median for the two respective 
proteins. Data was available on gender, age at surgery, nodal metastases, tumour size and 
grade, for all 71 patients. Resection margin status, vascular invasion and perineural 
invasion data was available for 63, 65 and 68 patients respectively. No associations were 
observed between the numbers of stromal associated S100A8- or S100A9-positive cells 
and these clinicopathological parameters (Table 1.3).
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Parameters All
Cases
n=71
(%)
Low
S100A8+
(<; median) 
n=36 (%)
High
S100A8+
(> median) 
n=35 (%)
Sign if. Low
S100A9+
(< median) 
n=39 (%)
High 
S100A9+ 
(>median) 
N=32 (%)
Signif.
Gender
Male 43 (61) 25 (69) 18(51) ns' 23 (59) 20 (63) ns1
Female 28 (39) 11(31) 17(49) 16(41) 12(37)
Age at surgery
<60 yrs 20 (28) 7(19) 13(37) ns1 7(18) 13(40) ns1
>60 yrs 51(72) 29 (81) 22(63) 32 (82) 19(60)
Tumour size
<20mm 22 (31) 13(36) 9(26) ns1 13(33) 9(28) ns1
>20mm 49 (69) 23 (64) 26 (74) 26 (67) 23(72)
Tumour grade
Poorly dif. 25 (35) 13(36) 12(34) 15(38) 10(31)
Moderate dif. 36 (51) 15(42) 21 (60) 17(44) 19(59) ns2
Well dif. 10(14) 8(22) 2(6) 7(18) 3(10)
Nodal metastases
Present 57 (80) 28 (78) 29 (83) ns1 37 (79) 26(81) ns1
Not present 14(20) 8(22) 6(17) 8(21) 6(19)
Involved resection 
margin (n=63)
Yes 42 (59) 22 (61) 20 (57) 24 (67) 18(56) ns1
No 21 (30) 9(25) 12(34) 10(26) 17(34)
Not recorded (n=8) 8(11) 5(14) 3(9) 5(13) 3(10)
Vascular invasion 
(n=65)
Present 54 (76) 28 (78) 26 (74) 32 (82) 22 (69)
Not present 11 (16) 5(14) 6(17) ns1 4(10) 7(22) ns1
Not recorded (n=6) 6(8) 3(8) 3(9) 3(8) 3(9)
Neural invasion 
(n=68)
Present 65 (92) 33 (92) 32 (91) 37 (95) 28 (88)
Not present 3(4) 1(3) 2(6) ns1 0(0) 3(9) ns1
Not recorded (n=3) 3(4) 2(5) 1(3) 2(5) 1 (3)
Fishers two sided exact test (significance set at p<0.05); ns = not significant
Table 1.3: The association of the mean number of S100A8- and S100A9- expression 
with clinicopathological parameters, showing no significant correlation.
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Association of S100A8 and S100A9 expression with SMAD4 status of 
the pancreatic cancer cells
SMAD4 expression data was available for 64 patients (array stained and scored by Mr D 
Vimalachandran) of which 29 patients (45%) were SMAD4 negative and the rest were 
positive. The number of S100A9-positive cells was independent of the SMAD4 status of 
tumours (Table 1.4) (p = 0.21; Fisher's Exact Test), however the SMAD4 negative 
tumours significantly correlated with the numbers of S100A8-positive cells (p = 0.023; 
Fisher’s Exact Test, Table 1.4).
5MAD4
EXPRESSION
ALL
CASES
LOW
S100A8+
CELLS
HIGH
S100A8+
CELLS
SIGNIFICANCE LOW
S100A9+
CELLS
HIGH
S100A9+
CELLS
SIGNIFICANCE
Pancreatic n=71 n=36 n=35 n=39 n=32
Cancer(n=64)
Positive 35 19 10 0.023' 18 19 0.211
Negative 29 12 23 16 11
Mot Recorded
--------------rrr
7 5 2 5 2
Fishers two sided exact test (significance set at p<0.05)
Table 1.4: SMAD4 expression and its association with S100A8 and S100A9 expression 
in the pancreatic cancer stroma.
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Interestingly when the median number of S100A8 positive cells per tumour core was 
examined relative to SMAD4 status, SMAD4-negative tumours had significantly fewer 
S100A8 positive cells (median 8, IQR 3.0 — 20) compared to SMAD4-positive tumours 
(median 20.5, IQR 9 - 49; p = 0.01, Mann-Whitney U test). Such a relationship was not 
established for S100A9-positive cells and SMAD4 status (Figure 1.11). The median 
number of S100A9-positive cells in SMAD4-negative tumours was 28 (IQR 18.7 - 60), 
compared to a median of 40 (IQR 23.5 - 98.2, p = 0.21, Mann-Whitney U test) in 
SMAD4-positive tumours.
Figure 1.11: The median numbers of S100A8- (A) or S100A9- positive (B) cells per 
patient were plotted tor SMAD4-negative and SMAD4-positive tumours. The p-value 
shown is for comparison (using the Mann-Whitney U-test) of the median number of 
S100A8- or S100A9- positive cells for SMAD4 negative and SMAD4 positive tumours.
Moreover, when the ratio of S100A9 to S100A8 cells in SMAD4-positive and SMAD4- 
negative tumours was examined, a striking difference between the two groups was
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noticed. A median of 1.67 fold (1QR 1.21 to 2.4) greater S100A9 to S100A8 positive 
cells in SMAD4-expressing tumours was observed compared with a median of 3.16 (IQR 
1.89 to 6.54) fold greater S100A9 to S100A8 positive cells in SMAD4-negative tumours 
(p=0.004, Mann-Whitney U test)(Figure 1.12). Thus, a strongly negative relationship 
between the expression of SMAD4 in tumours cells and the expression of S100A8 in 
stromal inflammatory cells was established.
Smad4‘ Smad4+
Figure 1.12: Box plot showing the ratio of S100A9 / S100A8 positive cells plotted for 
SMAD4-negative and SMAD4-positive tumours.
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CHAPTER SEVEN
AIMS OF MY RESEARCH
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7.1 Aims and objectives of my research
The background results described above demonstrated the presence of S100A8- and 
S100A9- positive cells in the pancreatic cancer stroma. A relationship between the 
phenotype of these cells and the tumours SMAD4 status was also uncovered. This 
indicated the possibility of cellular crosstalk in the pancreatic tumour microenvironment. 
There has been overwhelming evidence implicating the role of the tumour 
microenvironment in cancer progression, however there is still an incomplete 
understanding of the composition and function of the desmoplastic response seen 
particularly in pancreatic cancer. Furthermore, although it is hypothesised that the cancer 
progression involves epithelial stromal interactions, the signalling pathways that these 
interactions employ have yet to be defined. The presence of S100A8 and S100A9 
expression in the pancreatic cancer stromal cells and its association with the cancer 
SMAD4 status allowed for the development of my MD project.
Statement of Aim
To understand the role S100A8 and S100A9 proteins played in the pancreatic 
cancer microenvironment.
Objectives of my MD project
1. To determine which inflammatory cells in the pancreatic cancer stroma expressed 
the presence of S100A8 and S100A9 proteins using immunohistochemical and 
co-immunoflorescence technology.
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2. To determine the effects pancreatic cancer cells had on the expression of S100A8 
and S100A9 in these stromal cells. This would be undertaken using cancer cell 
lines and primary human cells in cell culture experiments. Protein expression 
would be measured using western blotting analysis.
3. To determine the effects SMAD4 positive and negative cancer cells have on the 
expression of S100A8 and S100A9, using cell culture methodology and proteomic 
analysis with western blotting.
4. To determine potential cellular mediators of S100A8 and S100A9 induction in the 
pancreatic cancer microenvironment, using cell culture methodology and 
proteomic analysis with western blotting.
5. To produce recombinant GST tagged S100A8 and S100A9 protein and study their 
effects on pancreatic and colorectal cancer cell characteristics such as motility and 
proliferation. This would be undertaken using Boyden chamber experiments and 
MTT proliferation assay.
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PART 2: METHODS, RESULTS 
AND DISCUSSION
133
CHAPTER EIGHT
IMMUNOHISTOCHEMISTRY METHODOLOGY 
AND ANALYSIS OF TISSUE MICRO ARRAY
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8.1 Pancreatic Cancer Tissue Microarray
Pancreatic cancer tissue microarrays (TMAs) were generated at the Cancer Tissue Bank 
Research Centre, University of Liverpool, UK using the method described by Kononen et 
al. (Kononen J et ah, 1998). Full ethical approval from the local research ethics 
committee along with patient’s written consent for storage of tissue and use in research 
was obtained prior to construction of the microarray. The TMA contained matched sets of 
tumour and non-neoplastic pancreatic tissue samples from 71 pancreatic cancer patients 
treated at the Royal Liverpool University Hospital between 1994 and 2003.
The TMAs used contained pancreatic ductal adenocarcinoma tissue cores in duplicates 
from 71 patients along with matched normal tissue from 53 patients also in duplicates (a 
total of 248 cores). In addition, the array also contained 8 cores each of normal colonic, 
liver and kidney tissue samples for control purposes.
The TMAs were used to analyse the expression of S100A8, S100A9, CD68 and TGF-pl 
in pancreatic cancer tissue. The proteins of interest were visualized on the TMAs with 
immunohistochemistry (IHC) and diaminobenzidine (DAB)-based detection (details 
given in 2.1.2). A consultant histopathologist, Dr Fiona Campbell and my supervisor Dr 
E Costello performed SI00A8 and S100A9 expression analysis and scoring of the TMAs. 
All other staining and scoring (CD68 and TGF-(31) was undertaken by me under the
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supervision of Dr Fiona Campbell and Mr Andrew Dodson (Department of Pathology, 
Royal Liverpool University Hospital).
The information recorded included the cell type stained (Tumour or Stroma), and the 
subcellular location of tissue staining (i.e. nuclear, cytoplasmic, both) [recorded for TGF- 
pl]. Intensity of staining (graded on a scale from 0 to 3, where 0 was no stain to blush 
and 3 was maximal brown staining) and the percentage of cells demonstrating positive 
immunoreactivity (0-100% of cells) was also recorded [recorded for TGF-pi]. In the 
case of CD68 (undertaken by me), S100A8 and S100A9 (undertaken by Dr E Costello), 
the exact number of positive cells per core were counted. For TGF-pl staining the total 
score for each subcellular compartment was obtained as a product of the intensity and 
extent (percentage of cells stained) of staining.
Details of histopathological data for each case on the TMA were obtained from 
pathological reports. The data recorded included patient age, sex, tumour size and grade, 
lymph node and resection margin status and the presence or absence of perineural or 
vascular invasion. Survival status, and where applicable, the dates of death were 
obtained from a clinical database held by the pancreatic nurse specialist, general 
practitioners, cancer tissue bank registry and individual health authorities. The majority 
of the above-mentioned information was already present on the TMA database and any 
deficiencies were obtained and completed by myself.
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8.2 Immunohistochemical staining (IHC)
Immunohistochemical staining was performed with the help of Mr Andrew Dodson for 
S100A8, S100A9 proteins (performed by Mr D Vimalachandran and myself), CD68 and 
TGF p-1 (performed by myself).
Stages used in Immunohistochemical staining
Slide preparation
Paraffin embedded pancreatic cancer tissue sections, five-micron in thickness were 
deparaffinised in xylene for 3 minutes and then rehydrated through decreasing alcohol 
concentrations (100%, 90%, 70%, 50%, 30%). Slides were placed in varying 
concentrations of alcohol for 15 seconds each and finally washed twice in distilled water. 
Peroxidises were blocked on the slides with a peroxidase block provided in the Dako 
Cytomation kit K4010 (Dako Systems), by incubation for 5 minutes. The slides were 
subsequently washed in tap and deionised water for 3 minutes each.
Antigen retrieval
Antigen retrieval was necessary for all primary antibodies (S100A8, S100A9, CD68, 
TGF-pi) used. This was performed by pressure-cooking the slides in a solution 
containing 10 mM EDTA (pH 7.4) for 3 minutes, followed by rapid cooling in tap water.
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Staining with Primary antibodies
Immunohistochemical (IHC) staining was performed using either an automatic staining 
system (Autostainer, DAKO Cytomation) or manually. Primary antibody diluted up to 
200f.iL in Chemomate, (protein buffered solution and detergent, DAKO Systems) was 
placed on each slide and incubated either 1 hour at room temperature or overnight at 4° C 
depending on when the experiment was conducted in the day.
Slides were incubated with either polyclonal goat anti-S100A8 antibody (Santa Cruz 
Biotechnology 1:200) or polyclonal rabbit anti-S100A9 antibody (Santa Cruz 
Biotechnology) 1:400) or polyclonal rabbit anti-TGF-|31 antibody (pre diluted, Abeam) or 
monoclonal mouse anti-CD68 antibody (1:400 Santa Cruz Biotechnology). Following 
incubation with primary antibody, the slides were washed thrice with Tris buffered saline 
(50 mM Tris, 150 mM NaCl, Adjusted to pH 7.6 with HC1) for 3 minutes on each 
occasion. Negative controls were incubated with the labelled secondary antibodies only.
Staining with Secondary Antibodies and Substrate for IHC
Antibody localisation was visualised by incubating sections with a horse radish 
peroxidase conjugated secondary antibody for 1 hour followed by 3 washes with tris 
buffered saline each lasting for 3 minutes. This step was followed by incubation with 
diaminobenzidine (DAB) (Dako systems) for 10 min. 20 pL of liquid DAB + Chromogen 
from DakoCytomation kit K4010 were mixed gently with 1 mL of buffer provided in the
138
kit to produce the substrate diaminobenzidine. Following incubation, the slides were 
washed thrice in Tris-buffered saline for 3 minutes each.
Haematoxylin staining
The slides were then counterstained with haematoxylin for 30 seconds, followed by a 
wash in Scott’s water (1L tap water, 23mM sodium bicarbonate, 83mM MgS04) and then 
under normal tap water for 30 seconds each. The slides were dehydrated in varying 
concentration of ethanol (30%, 70%, and 100%) for 3 seconds each and then in 100% 
xylene for 3 seconds also. The slides were then air-dried and cover slips mounted with 
DPX mountant media (BDH compounds).
8.3 Immunofluorescence (IF) Staining
Immunofluorescent staining was performed under the supervision of Mr Andrew Dodson 
(Department of Pathology, Royal Liverpool University Hospital), in a similar manner to 
immunohistochemistry on paraffin embedded pancreatic cancer tissue slides. Stages of 
slide preparation and antigen retrieval were exactly the same for Immunofluorescence 
staining as they were for Immunohistochemical staining. Co-immunofluorescence was 
undertaken to determine whether S100A8 and S100A9 co-localised with other cellular 
markers. Slides were incubated with a variety of primary antibodies listed in Table 2.1, 
either singly or concurrently in pairs. Slides were then incubated in a dark room for 1 
hour. Following incubation with primary antibodies the sections were washed in Tris- 
buffered saline.
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Primary Antibody Dilution
Polyclonal goat anti-S100A8 Santa Cruz Biotechnology diluted 1:200
Polyclonal rabbit anti-S100A9 Santa Cruz Biotechnology diluted 1:400
Polyclonal rabbit anti-TGF-|31 pre diluted, Abeam
Monoclonal mouse anti-CD68 Santa Cruz Biotechnology diluted 1:400
Monoclonal mouse anti-smooth muscle 
actin
(smooth muscle / myofibroblast marker)
Santa Cruz Biotechnology diluted 1:50
Monoclonal mouse anti-desmin 
(smooth muscle / myofibroblast marker)
Santa Cruz Biotechnology diluted 1:40
Polyclonal goat anti-vimentin Santa Cruz Biotechnology diluted 1:200
Monoclonal mouse anti-CD20 
(B lymphocyte marker)
Santa Cruz Biotechnology diluted 1;4000
Monoclonal mouse anti-CD34 
(endothelial marker)
Santa Cruz Biotechnology diluted 1:50
Monoclonal mouse anti-CD38 
(plasma cell marker)
Santa Cruz Biotechnology diluted 1:100
Monoclonal mouse anti-CD3 
(T-cell marker)
Santa Cruz Biotechnology diluted 1:100
Monoclonal mouse anti-CD79A 
(B-cell marker)
Santa Cruz Biotechnology diluted 1:500
Monoclonal mouse anti-mast cell trypsin 
(mast cell marker)
Santa Cruz Biotechnology diluted 1:400
Table 2.1: Table enumerating various primary antibodies and their concentration used.
140
Staining with Secondary Antibodies for Immunofluorescence
Detection of bound antibody was achieved by manual staining with FITC-labelled 
donkey anti-goat IgG (SOgg/mL, Santa Cruz Biotechnology), TRITC-labelled swine anti­
rabbit IgG (25}.ig/mL DakoCytomation), FITC- labelled conjugated horse anti-mouse IgG 
(Vector Laboratories, 1:50) fluorescently labelled secondary antibodies on a flat-bed 
incubation tray in a dark room. Incubation was undertaken for 60 minutes with a mixture 
of either one or two antibodies.
Mounting
Sections were washed in Tris-buffered saline thrice for 3 minute each and mounted in 
aqueous mounting medium containing DAPI 4, 6-diamidino-2-phenylindole (Vector 
Laboratories, H-1500).
Microscopy and photography
Microscopy and photography of co-immunofluorescence stained sections was undertaken 
immediately, once mounting was complete, on a fluorescence microscope to achieve 
sharp image quality free of background noise.
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8.4 Co- immunofluorescence analysis
In order to identify the cells expressing S100A8 and S100A9, co-immunofluorescent 
analysis was undertaken. To analyse whether S100A8 and S100A9 are co-expressed, 
immunofluorescent double staining experiments were performed (n=5) on independent 
pancreatic cancer cases. Serial sections were incubated separately or concurrently with 
polyclonal goat anti-SlOOAS and / or polyclonal rabbit anti-S100A9 antibody. In all 
cases, this was followed by the application of two fluorescently labelled secondary 
antibodies: FITC-labelled donkey anti-goat IgG for the detection of the S100A8 antibody 
and the TRITC-labelled swine anti-rabbit IgG for the detection of S100A9 antibody. As 
demonstrated in Figure 2.1(1) and 2.1(11), under conditions of single labelling S100A8 
immunoreactive cells are green and S100A9 immunoreactive cells are red. Cross­
reactivity between primary goat and secondary rabbit or primary rabbit and secondary 
goat antibodies was not detected and the tumour cells remained unstained for either 
S100A8 or S100A9 protein as demonstrated by their blue colour.
Dual staining (Figure 2.1(111) and (IV)) revealed the presence of S100A8 and S100A9 in 
the same cells presenting as yellow. Under the same conditions (of dual staining) a 
number of cells showed expression of S100A9 only (red), (photographed more clearly in 
Figure 2.1 (III)) whereas no cells expressed S100A8 only (green). Therefore, S100A8 
was detected in a subset of S100A9-positive cells contained within the stromal 
compartment of pancreatic cancer sections.
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Morphologically S100A8- and S100A9-positive cells resembled cells of myeloid linage, 
possibly monocytes/ immature macrophages. To further evaluate the nature of the 
S100A8 and S100A9 expressing cells, immunofluorescent double staining experiments 
on pancreatic cancer specimens were undertaken with a variety of cellular markers. These 
experiments showed no co-localisation with CD68, a marker for mature macrophages 
(Figure 2.2 (I)), and positive co-localisation of S100A9 with monocytic marker CD 14 
(Figure 2.2 (II)).
The co-expression of S100A9 was also evaluated with other cell types, which form part 
of the pancreatic cancer’s dense stroma. This was undertaken using immunofluorescent 
double staining with a variety of cellular markers, including markers for T-cell (Figure 
2.3(1)), fibroblasts (Figure 2.3(H)), B-lymphocytes (Figure 2.3 (III), myofibroblasts 
(Figure 2.3 (IV)), plasma cells (Figure 2.3 (V)), endothelial cells (Figure 2.3 (VI)), mast 
cells (Figure 2.3 (VII)), and B-cell marker (Figure 2.3 (VIII)). Co-expression of S100A9 
was not detected with any of these cellular markers as seen in the Figure 2.3.
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Figure 2.1: Pancreatic cancer sections were stained for (I) immunofluorescence analysis with 
anti-S100A8-FITC (green), (II) anti-S100A9-TRITC (red), (III) co-stained with anti-S100A8- 
FITC and anti-S100A9-TRITC at low magnification X20 (IV) co-stained with anti-S100A8- 
FITC and anti-S100A9-TRITC at high magnification X40.
Figure 2.2: Pancreatic cancer sections showing co-staining of anti-S100A9-TRITC (red) 
with (I) anti-CD68-FITC (green), (II) anti-CD 14-FITC (yellow)
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Figure 2.3: Pancreatic cancer sections showing co-staining of anti-S100A9-TRITC (red) 
with (I) Anti-CD3-FITC (green), (II) Anti-vimentin-FITC (green), (III) Anti-CD20 - 
FITC (green), (IV) Anti-smooth muscle actin-FITC (green), (V) Anti-CD38-FITC 
(green), (VI) Anti-CD34-FITC (green), (VII) Anti-mast cell trypsin--FITC (green), (VIII) 
Anti-CD79A—FITC (green)
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8.5 Association of stromal S100A8 and S100A9 expression with 
TGF-pl and CD68 expression in pancreatic cancer tissue
Findings of mouse model experiments by Hiratsuka et ah suggested the role of S100A8 
and S100A9 in cancer metastasis (Hiratsuka et al.5 2006). They showed that secreted 
factors from the primary tumours (i.e. TGF-[3, TGF-a and VEGF-A) induced expression 
of S100A8 and S100A9 in myeloid cells in lung tissue, in turn aiding metastases of 
primary tumour cells to the lung. Therefore, the expression of TGF-pl in the pancreatic 
cancer tissue (ductal and stromal elements) and its association with stromal S100A8 and 
S100A9 expression was examined. The lack of overlap in expression between 
S100A8/S100A9 and CD68 on the co-immunoflorescence, prompted me to examine the 
relationship between S100A8/S100A9 expressing cells and CD68 expressing cells in 
pancreatic cancer tissue.
TGF-pl expression in the pancreatic cancer tissue and its association 
with stromal S100A8 and S100A9 expression
Immunohistochemical analysis of pancreatic cancer TMAs, revealed differential levels 
of TGF-piexpression in the nucleus (nuclear TGF-pl, nTGF-p) and cytoplasm 
(cytoplasmic TGF-pl, cTGF-P) of pancreatic cancer cells and its surrounding stroma 
(stromal TGF-pl, sTGF-P) (Figure 2.4). Differential expression of TGF-pl in stromal 
cytoplasm and nucleus was not possible owing to uniform staining in terms of intensity 
and pattern in both these compartments.
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Figure 2.4: Immunohistochemical staining showing expression of TGF-(31 observed in 
the nucleus (nTGF-pl) and cytoplasm (cTGF-pl) of pancreatic cancer cells and 
surrounding stroma (sTGF-(31).
For the purpose of examining associations between tumour (nuclear and cytoplasmic) and 
stromal TGF-pi expression the patients were categorised into two groups, i.e. those 
having low levels of expression with immunohistochemical scores of less than or equal to 
the median and those with high levels of expression i.e. having a score greater than the 
median score. All patients (n=69) expressed the presence of TGF-pl in the tumour 
(nucleus and cytoplasm) and in stromal cells. The median immunohistochemical score for 
the 3 compartments was nTGF-pl: 80 (IQR: 25-147.8), cTGF-pi: 200 (IQR 140-200), 
and sTGF-pi: 90 (IQR: 50-140) (Table 2.2).
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COMPARTMENT 
EXPRESSING TGF-pl
TOTAL
PATIENTS
LOW LEVELS OF 
EXPRESSION n (%)
HIGH LEVELS OF 
EXPRESSION n (%)
Nuclear TGF-pi 
(nTGF-pi)
69 38 (55.1%) 31 (44.9%)
Cytoplasmic TGF-pl 
(cTGF-pl)
69 16(13.2%) 53 (76.8%)
Stromal TGF-pl 
(sTGF-pl)
69 25 (36.2%) 44 (63.8%)
Table 2.2: Tables demonstrating numbers of patients expressing high and low levels of 
TGF-pi expression in various compartments.
High levels of tumour nuclear TGF-pl expression were significantly associated with high 
stromal TGF-|31 expression (p = 0.04; Mann Whitney test). Interestingly, tumour nuclear 
nTGF-pi expression was not associated with tumour cytoplasmic TGF-pl levels (p=0.09; 
Mann Whitney test). In addition, tumour cytoplasmic expression of TGF-pl showed no 
correlation to stromal TGF-pl expression either (p=0.068; Mann Whitney test).
Based on the information held in the pancreatic cancer database nuclear, cytoplasmic and 
stromal TGF-pi expression in pancreatic cancer tissue was correlated to patient clinco- 
pathological parameters. Expression in these compartments was correlated to patient age, 
gender, size of tumour, differentiation grade, vascular invasion, perineural invasion and 
nodal metastasis, however no significant associations (Fishers exact test) were established 
(Table 2.3).
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PATIENT NUCLEAR TGF-pl CYTOPLASMIC TGF-B1 STROMAL TGF-pl
PARAMETERS EXPRESSION EXPRESSION EXPRESSION
(n=69) (n=69) (n=69j
High Low P- High Low P- High Low 1^
(n) (n) Value (n) (n) Value (n) (n) Value
Age
<60yrs 9 11 0.9 15 5 0.9 14 6 0.6
>60yrs 22 27 (ns) 37 12 (ns) 30 19 (ns)
Sex
Male 19 22 0.8 30 12 0.6 23 18 0.2
Female 12 16 (ns) 21 6 (ns) 20 8 (ns)
Size of tumor
< 20mm 7 14 0.3 15 6 0.9 14 7 0.8
> 20mm 24 24 (ns) 36 12 (ns) 29 19 (ns)
Differentiation
grade
Well-moderate 17 28 0.1 32 11 0.8 32 12 0.4
Poor 11 13 (ns) 19 7 (ns) 11 14 (ns)
Vascular invasion
Yes 26 28 0.5 39 14 0.9 32 21 0.3
No 3 6 (ns) 8 2 (ns) 8 2 (ns)
Unrecorded 3 3 2 4 4 2
Perineural
invasion
Yes 28 35 0.9 44 16 0.6 39 24 0.3
No 1 2 (ns) 5 1 (ns) 3 0 (ns)
Unrecorded 1 2 0 3 0 3
Nodal metastasis
Yes 26 30 0.8 41 13 0.9 33 22 0.3
No 5 8 (ns) 11 4 (ns) 11 3 (ns)
Table 2.3: Pancreatic cancer TGF-pl expression in tumour nuclear, tumour cytoplasm 
and stromal compartments and its association to clinicopathological parameters.
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The correlation between TGF-|31 expression in pancreatic cancer (tumour nuclear, tumour 
cytoplasm and stroma) and the number of S100A8 and S100A9 expressing cells was also 
determined as established previously. Tumour nuclear TGF-J31 expression significantly 
correlated to the number of stromal S100A8 expressing cells (p = 0,0488; Mann Whitney 
test) as well as the number of S100A9 expressing cells (p = 0.0138; Mann Whitney test) 
(Figure 2.5). On the other hand, tumour cytoplasmic TGF-fH significantly correlated with 
the number of cells expressing S100A8 (p = 0.0374; Mann Whitney test) only and not 
S100A9 (p = 0.115; Mann Whitney test) (Figure 2.5). Stromal TGF-pl showed no 
significant correlation with the number of cells expressing both S100A8 (p = 0.1377; 
Mann Whitney test) and S100A9 (p = 0.1377; Mann Whitney test) (Figure 2.5).
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Figure 2.5: Figure demonstrating the association of (A) tumour nuclear (nTGF-pl), (B) 
tumour cytoplasmic (cTGF-pi) and (C) stromal (sTGF-pi) and mean numbers of 
S100A8- and S100A9- positive stromal cells.
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Survival analysis using a Kaplan Meier curve (Figure 2,6) assessing the impact of nTGF- 
pi, cTGF-pi and sTGF-|31 expression on patient survival found patients with high nTGF- 
pi expression in the pancreatic cancer had a significantly poorer 2-year survival 
compared to those with lower levels of expression (p = 0.04). Univariate and multivariate 
Cox proportional hazards regression analyses was used to predict survival for all clinico- 
pathologic parameters (patient age, gender, size of tumour, differentiation grade, vascular 
invasion, perineural invasion and nodal metastasis) and nTGF-pi expression, however 
none were significant (Table 2.4). Only nTGF-pl expression remained an independent 
predictor of survival in the multivariate analysis with hazard ratio of 0.5 (0.3 - 0.9, p = 
0.03).
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Variables Categories Cases
(n
69)
Univariate analysis Multivariate analysis
HR (95% Cl) P-value HR (95% P- value
Cl)
Age <60yrs 20 0.6 (0.3- 1.3) 0.2 0.6 (0.3 - 0.1
>60yrs 49 1.2)
Gender Female 28 0.9 (0.5-1.6) 0.8
Male 41
Nodal metastasis No 13 0.6 (0.3- 1.4 0.3 0.8 (0.3 - 0.3
Yes 56 1.5)
Differentiation Well-
grade moderate 45 0.8 (0.4-1.4) 0.3
Poor 24
Size of tumour < 20mm 21 0.6 (0.3- 1.1) 0.09 0.6 (0.3- 0.2
> 20mm 48 1.3)
Vascular invasion No 9 0.8 (0.4-1.8) 0.6
Yes 54
unrecorded 6
Perineural No 3 0.7 (0.2-2.9) 0.6
invasion Yes 63
unrecorded 3
Mean Stromal - 69 1 (0.9-1) 0.2 1(1-1.1) 0.6
S100A8 cells
Mean Stromal - 69 1(0.9- 1) 0.2 1 d-l.l) 0.9
S100A9 cells
Nuclear TGF-pi Low 38 0.6(0.4-l) 0.04 0.5 (0.3 - 0.028
High 31 0.9)
Table 2.4: Univariate and multivariate Cox proportional hazards regression analyses to 
derive risk estimates related to survival for all clinicopathological parameters and nTGF- 
pl expression.
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Figure 2.6: Kaplan Meier curve showing the difference in 2-year survival for nTGF-pl 
expression.
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Pancreatic cancer stromal CD68 expression and its association with 
S100A8 and S100A9 protein expression
The presence of CD68 expressing macrophages (marker for tissue macrophages) was also 
found to be present in the pancreatic cancer associated stroma as previously been reported 
in the literature (Figure 2.7).
CD68
expressing
macrophages
Figure 2.7: Figure demonstrating the presence of CD68 positive macrophages in the 
pancreatic cancer stroma.
For the purpose of examining associations between the number of CD68 immunopositive 
cells and other patient parameters, patients were categorized into two groups, i.e. those 
having CD68-positive cell numbers less than or equal to the median (low levels of CD68 
expression) or those having CD68-positive cells greater than the median (high levels of 
CD68 expression). Similarly, for examining associations for S100A8- or S100A9- 
immunopositive cells the patients were categorised in a similar manner i.e. into two 
groups, those having positive cell numbers less than or equal to the median or greater 
than the median for the two respective SI00 proteins.
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The number of positively immunostained cells in each tumour core of the pancreatic 
cancer TMA were counted for the presence of CD68 positive cells. All patients (n=71) 
expressed the presence of CD68 positive cells in the tumour stoma. The mean number of 
cells per duplicate core was 96.7 (range 24-275 cells) with the median being 83.5 (IQR 
63.5). Thirty-five patients (49.2%) had low levels of CD68 positive cells, compared to 36 
(50.8%) patients who demonstrated high levels of CD68 positive cell expression in the 
pancreatic cancer stroma. Tumours containing low numbers of CD68-positive cells 
correlated significantly with the tumours which had low numbers of S100A8- positive 
cells (p=0.001; Fisher’s exact test) and S100A9-positive (p=0.0001; Fisher’s exact test) 
cells (Figure 2.8).
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Figure 2.8: Box plots demonstrating the association of CD68 positive cells and S100A8 
positive (A) and S100A9 positive (B) cells in the pancreatic cancer stroma.
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Using the information held in the pancreatic cancer database the number of CD68- 
positive cells in the pancreatic cancer stroma was correlated to patients clinico- 
pathological parameters, which included age, gender, size of tumour, differentiation 
grade, vascular invasion, perineural invasion and nodal metastasis. No significant 
association (Fishers exact test) was established between the number of CD68 positive 
cells and these patient parameters (Table 2.5). Moreover, the number of CD68- positive 
cells did not confer any survival benefit (Survival analysis using a Kaplan Meier: p=0.4) 
(Figure 2.9).
High levels of CD68 positive 
Cells
Low levels of CD68 positive 
Cells
P= 0.41
Time in months
Figure 2.9: Kaplan Meier curve showing the difference in survival for low and high 
levels of CD68 positive cells in the pancreatic cancer stroma.
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Parameter All
Cases
n=71
Low
CD68+
(< median) 
n=35
High
CD68+
(> median) 
n=36
P-value
Age
<60yrs 21 5 16 0.1
>60yrs 50 29 21
Sex
Male 43 20 23 0.8
Female 28 14 14
Size of tumor 
< 20mm 22 13 9 0.2
> 20mm 49 21 28
Differentiation grade
Well-moderate 46 20 26 0.2
Poor 25 14 11
Vascular invasion
Yes 54 27 27 0.5
No 11 4 7
Unrecorded 6 4 2
Perineural invasion
Yes 65 31 34 0.9
No 3 1 2
Unrecorded 6 3 3
Nodal metastasis
Yes 57 26 31 0.6
No 14 8 6
Table 2.5: Pancreatic cancer stromal CD68 expression and its association to 
clinicopathological parameters
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8.6 Discussion
Based on the proteomic analysis of microdissected stromal and ductal elements of 
pancreatic cancer tissue undertaken by Mr D Vimalachandran it was determined that 
S100A8 and S100A9 proteins are expressed in the stromal cellular compartment. 
Moreover, the immunohistochemical analysis undertaken by Dr Costello confirmed the 
presence of cells expressing both S100A8 and S100A9 in the stroma and not in the 
malignant epithelial elements.
I undertook a detailed review of the literature to understand the relationship these proteins 
had in the in the tumour microenvironment. The literature indicated the presence of 
S100A8 and S100A9 to be linked to monocytes and immature macrophages (Nacken et 
ah, 2003; Odink et ah, 1987) being implicated in a number of inflammatory disorders 
(Goebeler et ah, 1994); (Gebhardt et ah, 2006; Nacken et ah, 2003; Srikrishna, 2012).
Immunofluorescent co-localisation experiments on pancreatic cancer specimens showed 
co-localisation of S100A9 with CD 14, a monocyte/ immature macrophage marker, 
confirming the expression of these proteins in monocytes as indicated in the literature 
(Nacken et ah, 2003). Additionally, expression of S100A8 was detectable in a subset of 
S100A9-positive cells. Neither of the SI 00 proteins co-expressed with CD68, a marker of 
mature tissue macrophages (Lewis and Pollard, 2006; Ruffell et ah, 2012). Moreover, the 
cellular markers of smooth muscle, myofibroblasts, lymphocytes, T- and B-cells, 
endothelial cells, mast cells and plasma cells also failed to co-localise with S100A9. The 
presence of Tie2 was not assessed on the TMA as TEMs in humans express CD 14, CD 16
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and CD 11c surface markers and are similar to the so-called “resident monocytes” in 
morphological appearances (Gordon and Taylor, 2005; Kurahara et al., 2009). There is no 
association in the literature linking expression of S100A8 and S100A9 to TEMs, with 
TEMs involvement in carcinogenesis not fully understood. Immunofluorescent co­
localisation findings confirmed the presence of these proteins to be in monocytes which 
was consistent with the reported abundant expression of these proteins in cells of the 
myeloid lineage (Nacken et al., 2003; Srikrishna, 2012) . Zwadlo et al. demonstrated the 
presence of both SI00 proteins in monocytes which were expressed specifically at early 
stages of monocyte differentiation being down regulated during maturation to 
macrophages (Zwadlo et al., 1988). This is believed to change as monocytes, recruited 
from the blood stream to sites of inflammation differentiate to mature macrophages. They 
initially express both S100A8 and S100A9 and as they mature S100A8 expression ceases 
leaving only S100A9 which is also subsequently lost as the cell matures further (Zwadlo 
et al., 1988). The co-immunofluorescence data is consistent with the presence of S100A8 
in a subset of S100A9-positive pancreatic cancer stromal cells. Our findings of the 
immunohistochemical analysis of the TMA, SMAD4 negative tumours demonstrated 
significantly fewer number of S100A8-postive cells in the stroma compared to S100A9, 
moreover the ratio of S100A9/S100A8 was significantly higher in SMAD4 negative 
tumour compared to SMAD4 positive tumours (Sheikh et al., 2007). Thus, a strongly 
negative relationship between the expression of SMAD4 in tumours cells and the 
expression of S100A8 in stromal inflammatory cells was established. It is thus possible 
that the maturation process of monocytes to macrophages in the pancreatic cancer tumour 
microenvironment is influenced by the SMAD4 status of tumour. The precise function of
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S100A8 and S100A9 in the pancreatic cancer tumour microenvironment was unclear, 
although their expression and secretion are likely to contribute to the host inflammatory 
response to the tumour.
Monocytes and macrophages are both haematopoietic cells, which are derived from 
common CD34-positive progenitor cells, being produced in the bone marrow (Kurahara 
et ah, 2009; Murdoch et ah, 2008). In cancer these cells have a major role being involved 
in all aspects of tumour biology, namely invasion recruitment of leukocytes, activation of 
T-cells, angiogenesis, growth and metastasis hence making them an essential regulator in 
the tumour microenvironment (Coffelt et ah, 2009; Joyce and Pollard, 2009; Lamagna et 
ah, 2006; Schmid and Varner, 2007). Tissue associated macrophages (TAMs) have 
gained significant importance for their role in carcinogenesis in a variety of cancers being 
highly versatile and multifunctional components of the innate immune system (Kurahara 
et ah, 2012a; Lamagna et ah, 2006; Ruffell et ah, 2012). Owing to the presence of high 
levels of monocytes in the microenvironment of pancreatic cancer, I undertook an 
immunohistochemical analysis of the pancreatic cancer TMA analysing the presence of 
CD68 positive cells in the stroma. Tissue macrophages express a variety of surface 
markers such as CD 163 and CD204 with CD68 being well established as a marker for 
TAMs (Pollard, 2004). My findings were consistent with the literature indicating the 
presence of CD68 positive macrophages in the pancreatic cancer stroma, however no 
associations between the number of CD68 immunopositive cells and patient clinco- 
pathological parameters, in particular survival was established (Kurahara et ah, 2009). 
This is consistent with the findings of Kurahara et al, who have shown that TAMs
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expressing CD 163 and CD204, conferred a worse prognosis exhibiting increase 
lymphatic metastasis in pancreatic cancer. This was not the case with CD68 expression 
(Kurahara et ah, 2009). The same author has very recently demonstrated the presence of 
folate receptor expressing TAMs in pancreatic cancers, which confer a high incidence of 
haematogenous metastasis and poor survival (Kurahara et al., 2012b). The number of 
CD68-positive cells in the tumour correlated significantly with the S100A8- positive and 
S100A9-positive cells indicating a common precursor cell, being that of myeloid linage.
S100A8 and S100A9 have been associated with a sentinel role in cancer metastasis 
(Hiratsuka et al., 2006) particularly in the development of the “pre-metastatic niche”. It 
has been demonstrated in a mouse model experiment that S100A8 and S100A9 
expression was induced in myeloid and endothelial cells in the lungs tissue of mice by 
secreted soluble factors such as TGF-p, TGF-a and VEGF-A. These were derived from 
the distant primary cancer cells. The presence of S100A8 and S100A9 in the lung tissue 
primed the microenvironment in what has been termed the premetastic phase hence 
aiding migration and implantation of the tumour cells. The study from Hiratsuka et al. 
indicated the role of S100A8 and S100A9 in the carcinogenesis process in a lung model, 
which suggested a similar process could likely be taking place in the pancreatic cancer 
microenvironment. Similar findings described in the more recent literature revolving 
around myeloid-derived suppressor cells (MDSCs) and the presence of S100A9 protein, 
show the presence of S100A9 enhances the production of MDSC in tumours (Cheng et 
al., 2008).
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The functions of monocytes / macrophages in the cancer microenvironment are numerous 
with the presence of TGF-(3 being central to a variety of functions (Matthaios et al., 2011; 
Tjomsland et al., 2011) (Srikrishna, 2012). My immunohistochemical analysis of the 
pancreatic cancer TMA findings indicated an association in the pancreatic cancer 
microenvironment between stromal and tumour nuclear TGF-(31 expression; however no 
correlation was seen with tumour cytoplasmic TGF-pi levels. More importantly, however 
tumour nuclear TGF-pi expression significantly correlated to stromal S100A8 and 
S100A9 expression with no correlation seen with stromal TGF-pl expression. This 
indicated the possible role of tumour TGF-pl in influencing expression and in turn the 
maturation of monocytes in the pancreatic cancer stroma. This is a plausible association, 
bearing in mind the findings of Hiratsuka et al. who have demonstrated the presence of 
secreted soluble factors (TGF-P, TGF-a and VEGF-A) as drivers of S100A8 and S100A9 
expression in lung tissue of mouse models (Hiratsuka et al., 2006). TGF-pl expression is 
overexpressed in pancreatic cancer tissue with increased expression of all three isoforms 
noted (Friess et al., 1993). This overexpression is associated with advanced stage and 
poor survival (Friess et al., 1993). My findings were consistent with the literature 
suggesting high TGF-P 1 overexpression being associated with a poor 2-year survival 
compared to those with lower levels of expression. This is primarily attributed in studies 
due to a loss of TGF-pi’s tumour suppressive and growth inhibitory effects (Truty and 
Urrutia, 2007b).
Based on the findings of Hiratsuka et al, as well as our observation regarding the 
association of S100A8 and S100A9 expression in pancreatic cancer and SMAD4
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expression (Sheikh et ah, 2007), I devised experimentation to future elucidate the 
influence conditioned media from pancreatic cancer had on the expression of S100A8 
and S100A9 on monocytic cell lines and human monocytes. Moreover, a significant 
association between tumour nuclear TGF-pl expression and S100A8 and S100A9 
expression in stromal monocytes suggested crosstalk in the pancreatic cancer 
m icro environment.
165
CHAPTER NINE
CELLULAR EXPERIMENTS AND PROTEOMIC 
ANALYSIS
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9.1 Cancer cell lines used in these experiments
Cell lines are invaluable tools for in-vitro investigation of tumour biology and genetics. 
There are approximately 40 different cell lines for pancreatic ductal adenocarcinoma, 
over 50 different colorectal and 7 human monocytic cell lines which are widely in use 
(the American tissue type culture collection, ATCC). Cell lines are quite heterogeneous 
as reflected by their grade of differentiation and diversity in structure and function. Data 
derived from cell lines should be interpreted in the background of their morphological 
differentiation, functional properties, growth kinetics and main genetic changes. Cell 
lines acquire additional genetic mutation during the process of their manipulation, 
therefore assessment of genes and proteins being studies should be accessed at all stages 
of the experiments.
Pancreatic cancer cell lines
Four pancreatic cancer cell lines (PANC-1, SUIT-2, BxPC3, and CFPAC-1) were utilized 
to provide conditioned media. In addition, motility and proliferation of PANC-I, SUIT-2 
and MIA PaCa-2 pancreatic cancer cell lines was also studied when they were treated in 
vitro with GST tagged recombinant S100A8 and S100A9. These cell lines were derived 
from the liquid nitrogen storage facility of the Division of Surgery and Oncology, 
University of Liverpool. Pancreatic cancer cell lines have been analysed for alteration in 
K-RAS, p53 pl6INK4A and SMAD4 genes (Moore et al., 2001; Sipos et al., 2003), which 
are summarized in the table below (Table 2.6). Based on their diverse variability in their 
molecular alterations particularly SMAD4 status, these cells were chosen. Their ability to 
express SMAD4 protein was subsequently analysed using western blotting of cell lysate.
167
Four pancreatic cancer cell lines (PANC-1, SUIT-2, BxPC3, and CFPAC-1) were utilized 
to provide conditioned media. For motility and proliferation experiments PANC-1, SUIT- 
2 and MIA PaCa-2 pancreatic cancer cell lines were studied following treatment with in 
vitro with GST-tagged recombinant S100A8 and S100A9. These cell lines were derived 
from the liquid nitrogen storage facility of the Division of Surgery and Oncology, 
University of Liverpool. These were chosen for study as Dr E Costello’s group had 
utilized these cell lines in the past for study of proliferation and motility assays 
(Thompson et al., 2007)
£ KRAS p53 pl6 SMAD4/DPC
Alteration Predicted
Product
Alteration Predicted
Product
Alteration Predicted
Product
Alteration Predicted
Product
>03-3 None Wild type 220 TAT- 
TGT
Tyr to Cys Heterozygous
deletion
Absent Heterozygous
deletion
Absent
PAC-1 12 GGT- 
GTT
Gly to Val 242 TGC- 
CGC
Cys to Arg Methylated Absent Heterozygous
deletion
Absent
VC-1 12 GGT- 
GAT
Gly to asp 273 CGT- 
CAT
Arg to His Heterozygous
deletion
Absent None Wild Type
IT-2 12 GGT- 
GAT
Gly to Asp 273 CGT- 
CAT
Arg to His 69 GAG-TAG Glu to stop None Wild Type
:a-2
12GGT-
TGT
Gly to Cys 248 CGG- 
TGG
Arg to Trp Heterozygous
deletion
Absent None Wt
Table 2.6: Table showing KRAS, p53, pl6 and SMAD4 mutation in 5 pancreatic 
cancer cell lines
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BxPC-3
This primary human pancreatic cancer cell line (Tan et ah, 1986) was established from a 
biopsy specimen of a histologically confirmed adenocarcinoma of the body of the 
pancreas in a 61 years old female in 1986. Histopathologically, the tumours grown in 
nude mice exhibited the original characteristics of the primary adenocarcinoma. These 
features included the production of traceable mucin in moderately well to poorly 
differentiated adenocarcinomas with occasional lymphocytic infiltrations at the tumour 
peripheries (Tan et al.5 1986).
CFPAC-1
This cancer cell line (Schoumacher et ah, 1990) was derived from a pancreatic ductal 
adenocarcinoma (liver metastasis) of a patient with cystic fibrosis. The cells exhibit ion 
transport deficiencies consistent with cystic fibrosis, expressing the product of the CF 
gene. These cells manifest the most common CF mutation, deletion of three nucleotides 
resulting in a phenylalanine-508 deletion. CFPAC-1 cells show epithelial morphology 
and express cytokeratin and oncofoetal antigens characteristic of pancreatic duct cells.
PANC-1
This is an epithelioid cell line (Lieber et ah, 1975), started from a human pancreatic 
carcinoma of ductal cell origin. Chromosome studies show a modal number of 63 with 
three distinct marker chromosomes and a small ring chromosome. The cells possess the 
type B phenotype for glucose-6-phosphate dehydrogenase (G6PD) and over expresses
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human epidermal growth-factor receptor-2 (HER2/neu) oncogene but are oestrogen 
receptor (ER) negative.
SUIT-2
SUIT-2 cell lines (Iwamura et ah, 1987) are derived from a metastatic liver tumour of 
human pancreatic carcinoma in 1987. These cells histopathologically closely resemble 
the original neoplasm, which was a moderately differentiated tubular adenocarcinoma. 
The SUIT-2 cell line produces and releases at least two tumour markers, 
carcinoembryonic antigen and carbohydrate antigen 19-9. It propagates well even in 
serum-free medium, and metastasizes to the regional lymph nodes in nude mice 
xenografts.
MIA PaCa-2
The MIA PaCa-2 cell line was established by A. Yunis et al. in 1975 from pancreatic 
cancer tissue procured form a 65-year-old Caucasian male. This is a hypotriploid human 
cell line with a few normal chromosomes absent. The cell line has a rapid doubling time 
of about 40 hours and a colony-forming efficiency in soft agar (Yunis et al., 1977)
Colorectal cancer cell lines
Colorectal cancer cell lines were used for motility and proliferation experiments as 
described in later section. These were adopted as similar immunohistochemical Two 
colorectal cancer cell lines (SW-480 and SW-837) were kindly sourced from Mr. Chin 
Ang in the Division of Surgery and Oncology, University of Liverpool. The motility and
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proliferation of these cells was analysed when they were treated in vitro with recombinant 
GST tagged S100A8 and S100A9. There are over 50 types of colorectal cancer cell lines 
with a varying spectrum of genetic abnormalities, adherent growth and epithelial 
morphology. As with the case of pancreatic cancer cells we were interested in those with 
aberration of the SMAD4 gene. In addition, the stable SMAD4 positive and negative 
clones were SW-480 derivatives, which is why this cell line was chosen. SW837 is a 
rectal cancer cell line, which is SMAD4 positive in addition to this it exhibits excellent 
growth and motility potential. The ability to express SMAD4 protein both in the parental 
and stable clones was analysed using western blotting of cell lysate.
SW- 480
SW480 was established from a primary Dukes B adenocarcinoma of the colon 
established from a 53 years old Caucasian male (Leibovitz et al, 1979). The cells over 
expresses p53 protein (Rodrigues et al., 1990) and have positive expression for 
expression for c-myc, K.-RAS, H-RAS, N-RAS, myb, sis and fos oncogenes(Trainer et al., 
1988).
SW-837
This cell lines was generated in the laboratory of Leibovitz, having been derived from a 
grade IV adenocarcinoma of the rectum. These cells are SMAD4 positive, colon antigen- 
3 negative and have mutation of the p53 gene (Chen et al, 1983; Nigro et al, 1989). The 
cells are positive for keratin by immunoperoxidase staining (Leibovitz et al, 1979; 
Rodrigues et al, 1990).
171
Monocytic cells lines
The effects of pancreatic cancer cell conditioned media on monocytes was analysed using 
HL-60 cells which are a promyelocytic cell line from a 36-year-old Caucasian female 
with acute promyelocytic leukaemia. These cells were purchased from ATCC USA 
HL-60 cells spontaneously differentiate and this can be stimulated by butyrate, 
hypoxanthine, phorbol myristic acid (PMA, TPA), dimethyl sulfoxide (DMS01%), 
actinomycin D, and retinoic acid. The expression of S100A8 and S100A9 appears to be 
restricted to early stages of myeloid differentiation, therefore the human promyelocytic 
leukaemia cell line HL-60 has been used to study S100A8 and S100A9 expression 
throughout the literature (Kerkhoff et al., 1998) (Gebhardt et ah, 2006) (Foell et ah, 2008) 
(Leukert et ah, 2006) (Roth et ah, 2001); (Suryono et ah, 2006). Untreated HL-60 cells 
express little or none S100A8 and S100A9 but these proteins are seen to be induced in 
HL-605s when the cells differentiate (Kerkhoff et ah, 1998). This differentiation has been 
shown to be achieved in a variety of studies using a host of conditions (Rahimi et ah, 
2005; Shibata et ah, 2004; Suryono et ah, 2006).
SMAD4 expressing clones (pancreatic and colorectal)
SMAD4 negative and SMAD4 re-expressing clones of colorectal cancer cell line (SW- 
480) and pancreatic cancer cell line (HS-766) lines were a kind gift from Dr I Schwarte- 
Waldhoff (Schwarte-Waldhoff et ah, 1999; Schwaite-Waldhoff and Schmiegel, 2002; 
Schwarte-Waldhoff et ah, 2000). These were generated using a full-length coding 
sequence of SMAD4 cloned into pBK-CMV expression vector using a standard calcium
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phosphate co-precipitation method. Clones were transfected with either SMAD4 or an 
empty vector to yield both positive and negative SW-480 and HS-766 clones. Expression 
of SMAD4 was determined using western blotting and northern blotting analysis 
(Schwarte-Waldhoff et al., 1999). The SWD20, SWD14, and SWD1 cell lines are 
SMAD4-re-expressing clonal derivative of SW480 following stable transfection of the 
full-length coding sequence of SMAD4/DPC4, SWK3 is a control clone lacking SMAD4.
These cell lines were used to provide conditioned media, which was used to treat 
monocytic cell lines to study the effects S100A8 and S100A9 expression in them based 
on varying SMAD4 production. Recombinant GST tagged S100A8 and S100A9 were 
used to analyse the varying effect in motility and proliferation of the SMAD4 positive 
and negative clones.
9.2 Human tissue used in these experiments
Colorectal cancer cell lines
Two colorectal cancer cell lines (SW-480 and SW-837) were sourced from ATCC 
(American Type Culture Collection, USA). The motility and proliferation of these cells 
was analysed when they were treated in vitro with recombinant GST tagged S100A8 and 
S100A9.
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Monocytic cells lines
The effects of conditioned media from pancreatic cancer cells on monocytes was 
analysed using HL-60 cell lines. These were purchased from ATCC (American Type 
Culture Collection, USA).
SMAD4 expressing clones (pancreatic and colorectal)
SMAD4-negative and SMAD4-positive re-expressing clones of colorectal cancer cell line 
(SW-480) and pancreatic cancer cell (HS-766) lines were kindly obtained from Dr I 
Schwarte-Waldoff (Schwarte-Waldhoff et ah, 1999; Schwarte-Waldhoff and Schmiegel, 
2002; Schwarte-Waldhoff et al., 2000). These SW-480 clones were utilised in motility 
and proliferation experiments with recombinant GST tagged S100A8 and S100A9 
proteins. Both SW-480 and HS-766 clones were also utilised in conditioned media 
experiments assessing monocytic S100A8 and S100A9 expression.
Human Monocytes isolation from human blood
Human blood monocytes were prepared from blood by density gradient centrifugation 
and differential adherence technique (Lewthwaite et al., 2002). Briefly, human blood was 
acquired from the UK Blood Bank (Mersey). Twenty millilitres of blood was transferred 
into heparinised sterile universal tubes (Sterilin) to which an equal volume of phosphate 
buffered saline (PBS, Sigma: 137mM sodium chloride, 8.1mM sodium phosphate pH 7.4) 
was added. Thirty millilitres (30 mL) of this mixture of blood and PBS was then carefully 
layered onto 15 mL Lymphoprep™ (Axis-Shield) which is a ready-prepared, sterile and
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endotoxin-tested solution for the isolation of pure leukocyte suspensions (composition: 
Sodium Diatrizoate 9.1% (w/v) and polysaccharide 5.7% (w/v)).
Separation 
Blood fluid
Blood floated on top ^fter 
of separation fluid Centrifugation
Monocytes collected 
in flask for use
Incubation at 37°C 
allows monocytes 
adherence to bottom
Figure 2.1: Method used to separate monocytes from blood. Three tubes are shown in order 
from left to right: one with lymphoprep, the second with blood floated on lymphoprep and 
the third after spinning and separation of different blood constituents. The WBCs separated 
were then suspended in media and also to incubate enable the monocytes to adhere to bottom
RPMI-1640 medium containing 2% foetal calf serum, L-glutamine 2mM (Sigma) and 
Penicillin-Streptomycin solution 5 mL (Sigma; composition SOU of penicillin and 50pg 
of streptomycin).
Monocytic density was counted using a haemocytometer and their viability was also 
assessed using trypan blue exclusion. Cells were then plated in 6 well plates at a density
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of 2xl06 cells per well. Plates were incubated for 1 hour at 37°C and the media removed 
leaving adherent cells (monocytes) behind. Adherent cells were then washed with PBS 
twice and cultured in conditioned media.
9.3 Cell culture and maintenance
Maintenance of all pancreatic and colorectal cancer cell lines used was undertaken using 
aseptic technique in a class II laminar flow tissue culture cabinet. Cells were cultured as a 
monolayer at 37°C with 5% CO2. They were routinely maintained in 75cm2 (T75) tissue 
culture flasks and were generally sub-cultured every 48 - 72 hours, when they were at a 
confluence of 80-90%.
The HL-60 cell line was grown in Dulbecco’s Modified Eagles’ Medium, supplemented 
with 20% Foetal Bovine Serum (Sigma), L-glutamine 2mM (Sigma) and Penicillin- 
Streptomycin solution 5 mL (Sigma; composition SOU of penicillin and 50pg of 
streptomycin). The HL-60 cell line did not form a monolayer. It remained suspended in 
medium at all times.
Pancreatic cancer cell lines were grown in RPMI-1640, supplemented with 10% Foetal 
Bovine Serum (Sigma), L-glutamine 2mM (Sigma) and Penicillin-Streptomycin solution 
5 mL (Sigma; composition SOU of penicillin and SOpg of streptomycin).
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The colorectal cell line SW-480 were grown in Dulbecco’s Modified Eagles’ Medium, 
supplemented with 10% Foetal Bovine Serum (Sigma), L-glutamine 2mM (Sigma) and 
Penicillin-Streptomycin solution 5 mL (Sigma; composition 50U of penicillin and 50pg 
of streptomycin). SW837 was grown in carbon dioxide free conditions using Leibovitz L- 
15 medium (Sigma) with all supplementations similar to the SW-480 cell lines.
SMAD4-positive and -negative colorectal (SW480) and pancreatic (HS766) cells were 
grown in Dulbecco’s Modified Eagles’ Medium, supplemented with 10% Foetal Bovine 
Serum (Sigma), L-glutamine 2mM (Sigma) and Penicillin-Streptomycin solution 5 mL 
(Sigma; composition SOU of penicillin and 50pg of streptomycin), however an additional 
supplementation of G418 disulphate salt solution at a concentration of 150 pg/mL was 
used. This maintained a selection pressure allowing only cells containing the pBK-CMV 
expression vector with the G418 resistance gene to grow.
All media, PBS and trypsin were warmed to 37°C prior to use. For subculturing media 
was removed and cells washed with sterile PBS twice to remove any residual media and 
cell debris. A ready-made Trypsin-EDTA solution from Sigma (composition: 0.5g 
porcine trypsin and 0.2 g EDTA in Hanks' Balanced Salt Solution with phenol red) was 
layered to cover the cells (2 mL per T75 flask used). Cells were incubated with this media 
for a few minutes until no longer adherent to the flask base. Microscopic confirmation of 
this non-adherence was undertaken by light microscopy. The subculture ratio and trypsin 
time for each cell line used is shown in the table 2.7.
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CELL LINE SPLIT RATIO TRYPSIN TIME
HL-60 1:8 Not Required
BxPC3-3 1:3 5 minutes
PANC-1 1:5 3 minutes
CFPAC-1 1:4 3 minutes
SUIT-2 1:10 3 minutes
MIA PaCa-2 1:8 2 minutes
SW480 (wild
type & clones)
1:6 3 minutes
HS766 (clones) 1:4 3 minutes
Table 2.7: Table showing the sub-culture ratio and trypsin time for various cell lines
Once the cells were free from the base of the flask the trypsin was neutralised with 10 ml 
of the serum containing medium. Cells were gently titrated to produce a single cell 
suspension and then re-plated at a density appropriate for each cell line (Table 2.7).
HL-60 cells are non-adherent and therefore once extracted from the T75 flask were 
centrifuged at 100 RCF for 8 minutes following which they were washed in PBS and 
centrifuged as before. The cell pellet was then suspended in 10 mL of DMEM and then 
spilt in a ratio of 1:8.
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Freezing and thawing cells
Cells were harvested with trypsin as outlined in the above. Cells from one T75 flask were 
then placed in a test tube and centrifuged at 100 RCF for 8 minutes. Cells were then 
washed in PBS and centrifuged again as before. The supernatant (PBS) was then 
removed, the cells were resuspended in ImL of freeze media (65% serum free media 
[RPMI/ DMEM/L-15], 25% Foetal Bovine Serum, 10% DMSO) and placed in a cryovial.
The cryovial was initially incubated on ice for about 1 hour and then placed at -80°C for 
24 hours prior to storage in liquid nitrogen. When required, cells were defrosted at 37°C 
and immediately transferred into pre-warmed PBS, washed twice and centrifuged at 100 
RCF for 8 minutes before being suspended in the appropriate culture media at a density 
of 3x106 cells per T75 flask. HL-60 cancer cell lines were frozen in exactly the same way 
as described in the above paragraph, except the freezing media was different (95% HL-60 
culture media and 5% DMSO).
9.4 Cell culturing in conditioned media
HL-60 cells and primary human monocytes were cultured, for defined time periods in 
conditioned media derived from pancreatic cancer cell lines (PANC-1, SUIT-2, BxPC3, 
and CFPAC-1) and SMAD4 re-expressing colorectal (SW-480) and pancreatic cancer 
(HS-766) clones.
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Collection of conditioned media from pancreatic cancer cell lines
Pancreatic cancer cell lines were plated in a T75 flask at the density previously described. 
After 48 hours when cells were approximately 85% confluent, spent medium was 
collected and centrifuged at 300 g for 8 minutes to remove cell debris. Then the media 
was filter sterilised using a 0.2 pm filter and warmed to 37°C. Fresh media was then 
added to the conditioned media in a ratio of 1:3 such that there was 1 part fresh media 
and 3 parts conditioned media. Conditioned media was also collected for control purposes 
from HL-60 cells or primary human monocytes or media derived from MEF (mouse 
embryo fibroblast) cell lines (obtained from Dr Boyd’s labs in the Division of Surgery 
and Oncology). Conditioned media from SMAD4-positive and negative colorectal 
(SW480 derivatives) and pancreatic (HS766 derivatives) cancer cell lines were obtained 
as mentioned above and treated in exactly the same manner.
Culturing of HL-60 cells and human monocytes in conditioned media
HL-60 or primary human monocytes were plated in six well plates at a density of 2x105 
cells per well. Two and half millilitres of conditioned media or cytokine-supplemented 
media was then added to each well. Monocytes and HL-60 cells were incubated for 24- 
and 48-hour period following which the cells were extracted from each well and pooled. 
The cells were then spun at 100 RCF for 8 minutes followed by a wash in PBS. The cells 
were then lysed using RIPA buffer for protein analysis using western blotting 
experiments.
180
9.5 Protein analysis of conditioned media
Conditioned medium from pancreatic cancer cell lines and HL-60 cancer cell lines was 
analysed for the presence of secreted cytokines (TGF-pl and VEGF-A in PDAC cell 
lines) and secreted forms of S100A8 and S100A9 (in HL-60 cell lines). Cells (PANC-1, 
BxPC3-3, CFPAC-1, SUIT-2 and HL-60) were plated at low density in T75 flasks using 
serum free media. The viability of the cells prior to collection of medium was assessed 
using trypan blue exclusion and medium was collected as described previously. The 
media was then centrifuged at 100 RCF for 8 minutes to remove cell debris the 
supernatant (conditioned media) then removed. The medium was then filter sterilized 
with a 0.2 pm filter and then aliquoted into 1 mL tubes. It was vacuum centrifuged at 
30°C for 3-4 hours until a 10 fold reduction in volume occurred. Aliquots were then 
pooled together and a protein assay preformed as described previously.
9.6 Western Blotting
Cell Lysate preparation
Cell pellets of monocytic cells (HL-60 and human monocytes) treated with conditioned 
media, pancreatic cancer cell lines (PANC-1, SUIT-2, BxPC3, and CFPAC-1) and 
SMAD4 re-expressing colorectal (SW-480) and pancreatic (HS-766) cancer cell lines 
were lysed on ice with RIPA buffer (50 mM Tris, 150mM Sodium Chloride, 0.5% 
Sodium Deoxycholate, 1% Igepal [a nonionic, non-denaturing detergent], 0.1% Sodium 
Dodecosulphate, made up to pH of 8.0). A protease inhibitor cocktail tablet (Roche) was
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added to a lOmL tube of RIPA buffer prior to use. Five hundred microlitres of RIPA 
buffer was added to each pellet and cells suspended in the solution and incubated on ice 
for 30 minutes. Cells were then disrupted using hydrodynamic shearing with a 21 gauge 
needle and incubated for a further 30 minutes. Samples were then spun in a centrifuge at 
10,000 RCF at 4°C for 10 minutes to remove any cellular debris, and the consequent 
supernatant was collected and utilised.
Bicmchoniiiic acid (BCA) Protein assay
A dilution curve of standard protein concentrations was created using bovine serum 
albumin (Sigma) made up in RIPA buffer using a BCA Protein Assay kit (Pierce). The 
BCA™ Protein Assay is a detergent-compatible formulation based on bicinchoninic acid 
(BCA) for the colorimetric detection and quantification of total protein.
Preparation of Diluted Albumin (BSA) Standards
To prepare diluted albumin standards, the content of one albumin standard ampoule at 
2000 pg/mL (provided in the assay kit) was diluted serially using RIPA cell lysis buffer 
to produce a set of diluted standards as shown in Table 2.8. The BCA™ Working 
Reagent (WR) was prepared by mixing 50 parts of Reagent A with 1 part of Reagent B 
(50:1, Reagent A: B) which were provided in the kit. Fifty microlitres of each sample and 
standards A-I were added in duplicate to each cuvette. This was followed by the addition 
of 1 mL of the working reagent to each sample and standard. This mixture was then 
covered and incubated for 2 hours at room temperature. The standards were read on the
182
spectrophotometer set to 562 rjm using the BCA function. Following standardisation, the 
samples were then read to determine the protein concentration of each sample.
Vial Volume of Diluents Volume of BSA Final BSA concentration
A 0 pL 300 pL of stock 2000 pg/mL
B 125 pL 375 pL of stock 1500 pg/mL
C 325 pL 325 pL of stock 1000 pg/mL
D 175 pL 175 pL of Vial B 750 pg/mL
E 325 pL 325 pL of Vial C 500 pg/mL
F 325 pL 325 pL of Vial E 250 pg/mL
G 325 pL 325 pL of Vial F 125 pg/mL
H 400 pL 100 pL of Vial G 25 pg/mL
I 400 pL 0 pL 0 pg/mL
Table 2.8: Table showing dilution of Albumin Standards used to make up Standards for 
BSA protein assay.
Denaturing of protein
Protein samples were diluted to a specified concentration using RIPA buffer (Lysis 
Buffer) and 5X SDS sample buffer (10% SDS, 50% glycerol, 600 mmol TRIS adjusted 
to pH 6.8, 0.05% Bromophenol blue made up in water) to give final volumes of lOOpL 
(with a final concentration of IX SDS sample buffer). This mixture was then heated at 
100°C for 15 minutes.
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Separation of protein by SDS-Page gel electrophoresis
The detection of S100A8 and S100A9 proteins was undertaken using 15% Tris-tricine 
(4.5 mL of 30% Acrylamide mix, 1.4 mL water, 2.9 mL Gel buffer [Tris 300 mM, ImM 
sodium dodecyl sulphate [SDS], made up to 100 mL at pH of 8.4], 1 mL Glycerol, 75pl 
of 10% Ammonium persulfate [APS], 7 pL TEMED) based SDS polyacrylamide gel 
electrophoresis (SDS-PAGE).
The detection of SMAD4, TGF-pl and VEGF-A was undertaken on a 12% tris-glycine 
based gels (4mL water, 3.3mL of 30% Acrylamide mix, 2.5 mL of 1.5M TRIS pH 8.8, 
0.1 mL of 10% SDS, O.lmL of APS, lOpL TEMED).
Larger proteins were analysed on lower percentage gels; therefore, for detection of 
SMAD4 a 10% polyacrylamide gel was used in comparison to a 15% polyacrylamide gel 
which was used for detection of S100A8 and S100A9. Gel glass plates (0.75 mm) were 
cleaned with 70% ethanol, air-dried and mounted on a Bio-Rad kit.
An SDS Polyacrylamide separating gel was poured between the plates to within 1.5cm of 
the top, covered with distilled water, left to set for 20 minutes following which the water 
was removed with blotting paper, and a stacking gel (For Tris-tricine gels: 0.82 mL 30% 
Acrylamide mix, 2.1 mL Gel buffer, 3.4mL Water 40 pL of 10% APS, 5pL TEMED; For 
Tris-glvcine gels: 2.7 mL water, 0.67 mL 30% Acrylamide mix, 0.5mL 1M TRIS pH 
6.8, 40pL 10% SDS, 40pL 10% APS 4pL TEMED) was added. A 10 well comb was 
placed into the stacking gel and allowed to set for 15 minutes before removal of the comb 
and washing out of the wells with water. The gel and plates were then transferred to a
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Mini Protean III electrophoresis chamber (Bio-Rad). In the case of Tris-tricine gels, a 
separate anode (TRIS 1M pH 8.9) and cathode buffer (lOOmM TRIS, lOOmM Tricine, 
3.5mM SDS) were added to the outer and central chamber respectively, whereas in Tris- 
Glycine gels the same electrophoresis buffer (30mM TRIS, 192mM Glycine, 1.3 mM 
SDS) was added to both chambers. The sample was loaded alongside similar volumes of 
Seeblue marker which is a pre-stained molecular weight marker (Invitrogen, technology, 
USA). Gels were run initially at 80-90 volts for 1 to 1.5 hours until adequate separation 
of marker was observed.
The gel apparatus was then dismantled, the stacking gel removed and transferred onto a 
Hybond ECL nitrocellulose membrane (Amersham Biosciences). The gel and membrane 
were sandwiched between 3mm Whatman chromatography paper (Sigma U.K) and 
sponges. This assembled apparatus was constructed in transfer buffer to prevent any air 
bubbles entering between the gel and membrane. The transfer apparatus was then 
returned to the chamber, along with an ice block for cooling, the chamber filled with the 
buffer ( 200mL Methanol, 30mM TRIS, 192mM, Glycine, 1.3 mM SDS) and transferred 
for 1 hour at 110V with a magnetic stirrer allowing circulation of transfer buffer.
Blocking
Once removed from the transfer chamber the nitrocellulose membrane was rinsed in PBS 
Tween (1L PBS solution with ImL Tween) and blocked (5% blotting grade non-fat dry 
milk powder, 2% Bovine serum albumin and PBS-tween) overnight at 4°C when probing
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for S100A8 and S100A9 and for 1 hour at room temperature when probing for SMAD4, 
TGF (3-1, and VEGF-A blocking.
Immunoblotting
Incubation with primary antibodies
Following blocking, membranes were agitated at room temperature with primary 
antibodies, which were diluted with 3% milk powder in PBS Tween at concentrations as 
outlined below, based on suppliers recommendations. Primary antibodies applied were 
either monoclonal mouse anti-S100A8 (Santa Cruz biotechnology, diluted 1:100) or 
polyclonal rabbit anti-S100A9 (Santa Cruz biotechnology, diluted 1:100) or monoclonal 
mouse anti-(3-Actin (Santa Cruz biotechnology, diluted 1:10000), or polyclonal 
mouse anti-TGF-(31 (Abeam, UK, diluted 1: 1000) or polyclonal mouse anti-SMAD4 
(Santa Cruz, biotechnology, diluted 1:2000). Following primary incubation for 1 hour at 
room temperature, the membranes were washed for 4 cycles each lasting 15 minutes in 
PBS Tween at 37°C. This was then followed by incubation with secondary antibodies, for 
1 hour each, at room temperature, with continuing agitation. The blot was washed in 
warm PBS-Tween for four cycles each for 15 minutes.
Incubation with Secondary antibodies
Based on the primary antibody utilized, the secondary antibodies were either anti-mouse 
IgG, Horse Radish Peroxidase linked whole antibody (HRP), (DAKO Img/mL diluted 
1:2000) or anti-rabbit IgG, HRP linked whole antibody, (DAKO Img/mL diluted 
1:1000). The secondary antibody was added to a solution containing 3% milk in PBS-
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Tween. Membranes were incubated with secondary antibodies for 1 hour at room 
temperature with continuous agitation and then washed with PBS Tween for 4 cycles 
each lasting 15 minutes.
Developing Western Blots
Protein bands on membranes were visualised by exposing them to medical x-ray film. For 
this, the membranes were first incubated in Enhanced Chemo-Luminescence (ECL) 
reagent plus for 5 minutes. Equal quantities of the Enhanced Luminal and Oxidising 
reagents were combined and applied to cover the entire membrane. The membrane was 
then blotted dry, wrapped in cling film and secured in a Kodak light safe developing 
cassette. The membrane was then exposed to medical x-ray film at a range of exposure 
lengths to optimise the imaging of the various proteins being studied. The film was 
consequently developed in Kodak developer and fixer for two minutes respectively and 
then rinsed in tap water and allowed to air dry.
Membrane stripping for p-actin probing
The membranes were then probed with p-actin, which enabled examination and 
documentation of equal protein loading for each lane of the gel. The membranes, which 
had ECL reagent on them, were first washed 2x15 minutes with PBS-Tween and then 
incubated with stripping buffer (Sigma U.K) at room temperature for 20 minutes. This 
was followed by two cycles of PBS-Tween washes before mouse monoclonal anti-p-actin 
antibody (dilution 1:10,000) was added to the membrane and incubated either overnight 
at 4°C or for 1 hour at room temperature. The subsequent steps were similar to standard
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western blotting with washing of primary antibody, application of secondary and 
developing as described previously.
9.7 Effects of conditioned pancreatic cancer cell line media on 
expression of S100A8 and S100A9 in human monocytes and 
HL-60 cell lines
Data from immunohistochemical staining of the pancreatic cancer TMAs revealed a 
significant association between the SMAD4 status of the tumours and the number of 
S100A8-positive cells (Sheikh et al., 2007). SMAD4 negative tumours significantly 
correlated to the number of SlOOAS-postive cells in the tumour stroma (p = 0.0023; 
Fisher’s Exact Test). This was not the case for S100A9-positive cells which were 
independent of the SMAD4 status of the tumours (p = 0.21; Fisher’s Exact Test). 
Moreover, when the ratio of S100A9 to S100A8 cells in SMAD4-positive and SMAD4- 
negative tumours was examined, a striking difference between the two groups was 
noticed. A median of 1.67 fold (IQR 1.21 to 2.4) greater S100A9 to S100A8 positive 
cells in SMAD4-expressing tumours was observed compared with a median of 3.16 (IQR 
1.89 to 6.54) fold greater S100A9 to S100A8 positive cells in $MAD4-negative tumours 
(p<0.004, Mann-Whitney U test). Thus, a strongly negative relationship between the 
expression of SMAD4 in tumours cells and the expression of S100A8 in stromal 
inflammatory cells was established. In addition to these finding as described in the 
previous section, I also was able to establish a correlation between pancreatic cancer 
nuclear TGF-pl expression and the number of S100A8- and S100A9- positive cells in the 
stroma indicating a link between cancer cells and stromal expression of these SI00 
proteins.
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Effects of conditioned media on human monocytes
In order to further elucidate the association pancreatic cancer has with the expression of 
S100A8 and S100A9 in stromal monocytes, incubation of human monocytes (n=3) with 
conditioned media, derived from 4 pancreatic cancer cell lines (PANC-1, SUIT-2, 
CFPAC-1 and BXPC3-3) was undertaken. Incubation of monocytes with conditioned 
medium from pancreatic cancer cells lines was associated with an increase in S100A8 
and S100A9 expression after 48 hours of incubation compared to the controls. The level 
of expression of both proteins varied based on the cell line that the condition medium was 
derived from. Additionally, an increase in one SI00 protein expression was not always 
mirrored by a similar level of increase in the other SI00 protein with medium derived 
from the same cell line as in the case of medium derived from SUIT-2 cell lines (Figure 
2.10).
S100A8
S100A9
P-Actin
Control SUIT-2 PANC-1 CFPAC BXPC3-3
Figure 2.10: Western blots demonstrating S100A8 and S100A9 expression in human 
monocytes when treated with media from different pancreatic cancer cell lines and 
controls.
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Effects of conditioned media on HL-60 cell line
The effects of conditioned media from pancreatic cells lines on the expression of S100A8 
and S100A9 in the HL-60 monocytic cell line was also evaluated (n=5). Media derived 
from all 4 pancreatic cancer cell lines (PANC-1, SUIT-2, CFPAC-1 and BXPC3-3) 
produced an increase in S100A8 and S100A9 expression at 48 hours compared to 
controls (Figure 2.11). The level of increase in expression varied depending on which cell 
line the media was derived from. The two controls used were spent media derived from 
HL-60 cell lines themselves (control) and Mouse embryonic fibroblasts (MEF) cell line, 
which is an inert non-cancer cell line.
S100A8
S100A9
Beta-
Actin
Control MEF CFPAC BxPC-3 PANC-1 SUIT-2
Figure 2.11: Western blots demonstrating S100A8 and S100A9 expression in HL-60 
cells at 48 hours after treatment with media from pancreatic cancer cell line and controls 
(control: media from HL-60 cell lines and MEF: media from mouse embryonic 
fibroblasts)
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SMAD4 status of cell lines used
Our findings on IHC analysis indicated an association between S100A8 and S100A9 
expressing cells and tumour SMAD4 status. In addition conditioned media from 
pancreatic cancer cells induced expression of these 2 proteins in human monocytes and 
cancer cell lines alike. Therefore, I proceeded to evaluate the presence of SMAD4 in the 
pancreatic cancer cell lines used in the above experiments. According to the literature 
PANC-1 and SUIT-2 cell lines were SMAD4 positive whereas CFPAC-1 and BxPC-3 
were SMAD4 negative. Independent verification by western analysis of cell lysate 
revealed loss of SMAD4 in CFPAC-1 and BxPC-3 but also in SUIT-2 cell line with 
PANC-1 being positive for SMAD4 (Figure 2.12). The loss of SMAD4 in the SUIT-2 
cell line may be a result of acquired mutation to the SMAD4 gene acquired as a result of 
multiple cell passages.
SMAD4
p-Actin
Figure 2.12: Western blots for demonstrating SMAD4 expression in four pancreatic 
cancer cell line lysate with P-Actin as control
Using conditioned media from various pancreatic cancer cell lines which were both 
SMAD4 positive (PANC-1) and negative (BxPC-3, CFPAC-1 and SUIT-2) did not reveal 
a differential induction in the expression of S100A8 and S100A9 in monocytes and HL- 
60 cell lines based on the SMAD4 status of the cancer cell from which the condition 
media was harvested. Therefore, media derived from stable SMAD4 positive and
PANC-1 SUIT-2 CFPAC-1 BxPC-3
191
negative colorectal and pancreatic clones was used to further define if differential 
expression of S100A8 and S100A9 occurred when conditioned media was derived from 
the same parental cell line which has both SMAD4 positive- and -negative clones.
Effects of conditioned media derived from stable SMAD4 positive and 
negative colorectal and pancreatic cancer cell lines
Media derived from stable (SMAD4 positive and negative clones) colorectal and 
pancreatic cancer cell lines SW480 (n=6) and HS766 (n=3) respectively was used to treat 
HL-60 cell lines in the same experimental conditions as described previously. Induction 
or suppression of S100A8 and S100A9 proteins in HL-60 cells was analysed using 
western blots and densomertic assessment of bands.
The experiments were performed using conditioned media from SW480 clones SWD20, 
SWD14 and SWD1 (SMAD4-positive clones) and SWK3 (SMAD4-negative clone). 
These cell lines have varied expression of SMAD4 which is demonstrated by Western 
blot analysis (Figure 2.13). SWD1 and SWD14 expresses less SMAD4 compared to 
SWD20 while in SWK3 a faint band was observed.
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SMAD4
p-actin
SWK3 SWD1 SWD14 SWD20
Figure 2.13: Figure showing western blot data from cell lysate of SW480 clones 
(SMAD4 -positive clones and -negative clones) after a delayed 15 minutes of exposure.
Densometric readings of S100A8 and S100A9 protein bands induced in HL-60 cells 
following treatment with conditioned media from the SMAD4-postive and -negative 
clones for each experiment are shown in the graphs below. These indicate an 
experimental variably in the expression of S100A8 and S100A9 inspite of all 
experimental conditions being consistent. The control displayed as a black bar in each of 
the figures (Figure 2.14 and 2.15) was the standard control used for these experiments as 
before which is spent media derived from HL-60 cells. Densometric readings for each 
band density plotted has been normalised to control i.e. the densometric reading of all 
protein bands has been divided by the densometric reading of the control. It can be seen 
that compared to the controls no consistent result can be deduced as in some experiments 
conditioned media caused an induction of S100A8 and S100A9 proteins, with other 
experiments showing reduced expression. Owing to lack of consistency in the 
experiments, no safe conclusion could be made. Additionally, and more importantly no 
variance in the levels of S100A8 and S100A9 expression was seen between media 
derived from SMAD4 re-expressing cells compared to the negative cell lines.
Similarly, a varied response in terms of the expression of S100A8 and S100A9 induced 
by the media derived from HS766 clones was also observed (Figure 2.15). The two
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graphs below show densometric readings from the experiments performed using media 
form HS766 clones where HSD4 and HSD8 are SMAD4 positive clones and HSK3 and 
HSK6 are SMAD4 negative clones. The readings have been normalised to actin in a 
similar manner to SW-480 cell line experiments. It can be seen that media from clones 
tended to increase the expression of S100A9 in the HL-60 cells, with S100A8 expression 
being suppressed compared to controls. These results did not achieve significance and 
were not consistent to make any conclusions about variation in expression of SI00 
protein from media sourced from SMAD4 re-expressing cells compared to the SMAD4- 
negative cells.
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S100A8 expression in HL-60 cells with media derived from SW480 clones 
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Figure 2.14: S100A8 (A) and S100A9 (B) expression in HL-60 cell lines following 
treatment with conditioned media derived from SMAD4 positive and negative clones of 
SW480. Densometric readings from western blots have been normalised to actin and 
control (media derived from HL-60 cell lines).
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S100A8 expression in HL-60 cells with media derived from HS-766
clones
1.2
Experiment 1 Experiment 2 Experiment 3
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■ HSK3
■ HSK6
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■ HSD8
A
S100A9 expression in HL-60 cells with media derived from HS-766
clones
Experiment 2 Experiment 3
■ Control
■ HSK3
■ HSK6
■ HSD4
■ HSD8
B
Figure 2.15: S100A8 (A) and S100A9(B) expression in HL-60 cell lines following 
treatment with conditioned media derived from SMAD4 positive and negative clones of 
HS766. Densometric readings from western blots have been normalised to control (media 
derived from HL-60 cell lines).
196
9.8. The expression of S100A8 and S100A9 and its association 
with TGF-pi and VEGF-A
In a mouse model experiment VEGF-A and TGF-pi produced by primary tumours were 
implicated as drivers of the pre-metastatic niche producing expression of S100A8 and 
S100A9 in tissue (Hiratsuka et al., 2006). I was able to demonstrate the presence of 
VEGF-A and TGF-|31 in pancreatic cancer cell lines and as secreted proteins in 
conditioned serum free media from these cells (Figure 2.16). The blots demonstrate the 
presence of TGF-pi and VEGF-A to be present both in the cells and also as a secreted 
factor in conditioned media. The absence of (3-actin bands in the serum free conditioned 
media indicate that both these proteins are secreted and not a result of cell lysis causing 
contamination. It is interesting to note here that in the cancer cell lysate multiple bands of 
VEGF-A are seen which represent isomers of the protein and only a single band is 
detected in the medium (secreted form)
VEGF-A
TGF-pl
v Cells Media ^ ^ Cells Media y i Cells Media 7 cells Media ,
’ V V v-----——'y'-—--------- '
SUIT‘2 PANC-1 BxPC-3 CFPAC
Figure 2.16: Western blots indicating the presence of TGF pi and VEGF-A in cell lysate 
and conditioned media concentrate derived from four pancreatic cancer cell lines (equal 
protein loading lOpg/ml for both cell lysate and media in each lane).
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9.9 Discussion
The immunohistochemical staining and analysis of the pancreatic cancer TMA 
demonstrated high levels of S100A8- and S100A9- expressing monocytes in the dense 
pancreatic stroma. Moreover, the expression of these proteins was linked to the SMAD4 
status of the tumour cells. These proteins have been studied in various setting primarily in 
cells of myeloid origin (Roth et al., 2001) and their expression profile has been detailed 
by Zwadlo et al (Zwadlo et al., 1988), The authors demonstrated the presence of both 
SI00 proteins in immature monocytes which were expressed specifically, at early stages 
of monocyte differentiation showing a gradual loss during maturation to macrophages 
(Zwadlo et al., 1988) with the acquisition of other surface markers (Nacken et al., 2003). 
They initially express both S100A8 and S100A9 and as they mature S100A8 expression 
ceases leaving only S100A9 which is also subsequently lost as the cell matures further 
(Zwadlo etal, 1988).
Based on the immunohistochemical analysis it was observed that stroma from SMAD4- 
negative tumours had significantly fewer numbers of S100A8 positive cells compared to 
SMAD4-positive tumours (Sheikh et al., 2007). Moreover, when the ratio of S100A9 to 
S100A8 cells in SMAD4-positive and SMAD4-negative tumour stroma was examined, a 
difference between the two groups was noticed. A median of 1.67 fold greater S100A9 to 
S100A8 positive cells in SMAD4-expressing tumours was observed compared with a 
median of 3.16 fold greater S100A9 to S100A8 positive cells in SMAD4-negative 
tumours. It therefore seemed possible that the phenotypical profile of the monocytes, that 
is their level of maturity was related to the SMAD4 status of the tumour (Sheikh et al.,
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2007). This led to the potential hypotheses that the status of the tumour seemed to have a 
bearing on the expression pattern of S100A8 and S100A9, which could be further 
interpreted as the tumour influencing the maturation and expression of these proteins. 
Referring back to the Hiratsuka et al paper (Hiratsuka et al., 2006) S100A8 and S100A9 
expression was induced in myeloid and endothelial cells in the lung tissue of mice by 
secreted soluble factors such as TGF-p, TGF-a and VEGF-A. These soluble factors were 
derived from the distant primary cancer cells. This presence of S100A8 and S100A9 in 
the lung tissue primed the microenvironment in what has been termed the premetastic 
phase affecting motility, aiding migration and implantation of the tumour cells. We 
postulated that the same process or a similar process could be occurring in the pancreatic 
cancer microenvironment. More recent literature not published at the time when I was 
undertaking these experiments has shown that systematic inhibition of S100A8 and 
S100A9 proteins with antibodies inhibited metastatic disease (Yan et al., 2010) and 
S100A9-deficient mice show reduced accumulation of MDSC cells in premetastatic sites 
further substantiating the role for S100A8/A9 in formation of premetastatic niches. 
Similarly, the presence of elevated levels of S100A8/A9 in sera of tumour-bearing wild- 
type mice, prior to any evidence of metastasis suggests that these proteins amplify pro­
tumour responses, eventually leading to malignancy (Ichikawa et al., 2011).
I therefore undertook experimentation assessing firstly the influence conditioned media 
from pancreatic cancer had on the expression of S100A8 and S100A9 in monocytic cell 
lines and secondly whether the SMAD4 status of the cancer cells affected this expression. 
The results indicated an increase in expression of S100A8 and S100A9 in both HL-60
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cell lines and human primary monocytes alike. The levels of expression induced in 
monocytes by the conditioned media from pancreatic cancer cell lines varied from cell 
line to cell line, which is in keeping with the differential genotype and protein expression 
they demonstrate. Moreover, negative SMAD4 state (in SUIT-2, CFPAC-1, and BxPC-3 
cell lines) did not show a differential ability to induce the expression of S100A8 and 
S100A9 proteins in comparison to the SMAD4 positive cell line (PANC-1).
The treatment of monocytes and monocytic cell lines with conditioned media from 
pancreatic cell lines failed to demonstrate differential expression of S100A8 and S100A9, 
based on the SMAD4 status of the tumour; I therefore undertook further experimentation 
with conditioned media from SMAD4 re-expressing colorectal and pancreatic cancer cell 
lines. These cell lines in other experiments have shown to have a differentially expressing 
protein profile based on their SMAD4 status (Volmer et ah, 2004) (Stuhler et al., 2006; 
Volmer et al., 2005). In experiments utilizing human pancreatic cell lines, restoration of 
SMAD4 in cell lines demonstrates that SMAD4 can control the angiogenic switch 
(Schwarte-Waldhoff et al., 2000). Analysing the secretomes and cell lysate of SW-480 
colonic cancer cell lines using two dimensional gel electrophoresis, demonstrated the 
expression of over 47 proteins, which had a SMAD4 dependent expression pattern 
(Stuhler et al., 2006). Conditioned media from both these pancreatic (HS-766) and 
colorectal (SW-480) cancer cell lines failed to produce a differential expression of 
S100A8 and S100A9 based on SMAD4 status of the tumour. This could be a result of 
clonal variation or the fact that SMAD4 expression in tumour cells did not influence the 
expression of S100A8 and S100A9 in monocytes.
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My results indicated that conditioned media from pancreatic cancer cell lines induce the 
expression of S100A8 and S100A9 in monocytes which was a result of mediators 
produced by the cancer cells and secreted into the media in which they grow. To evaluate 
this I analysed the conditioned media of pancreatic cancer cells lines for the presence of 
two important mediators TGF-pi and VEGF-A. These mediators have well established 
pathways in monocytic and macrophage cellular response inducing a variety of proteins 
in them (Coffelt et al, 2009; Hiratsuka et ah, 2006; Siveen and Kuttan, 2009). VEGF-A 
is a main driver for angiogenesis in pancreatic cancer (Korc, 2003). Pancreatic cancer 
angiogenesis is not controlled by the expression of VEGF-A alone but is a complex 
balance of other signalling molecules such as metalloproteinases and platelet derived 
growth factors (PDGF) (Korc, 2003; Song et al., 2005) which are present in the 
microenvironment. Similarly, TGF-pl has a multifaceted relationship in the pancreatic 
cancer having growth mediator and tumour suppressive effects (Truty and Urrutia, 
2007b). The pancreatic cancer cells in my studies exhibited levels of both of these 
mediators in the cell lysate and as secreted molecules into the medium alike, which are in 
keeping with what has been established in the literature (Bellone et al., 2006). Cytokine 
profiling studies indicated a host of different mediators produced by pancreatic cancer 
cells however, no study has been published detailing the cytokine profile of pancreatic 
cancer cells based on their SMAD4 status. The presence of TGF-pl and VEGF-A in 
pancreatic cancer cell lysate and in conditioned media suggested their possible role in 
inducing S100A8 and S100A9 in monocytes. Further evaluation by members of Dr. 
Costello’s group have demonstrated the induction of both SI00 proteins when monocytes
201
expressing these proteins were treated with VEGF-A an TGF-[31. Nedjadi et al. has 
presented data (not published) using cytokine antibody arrays, demonstrating the 
presence of numerous cytokines including TGF-f31 and VEGF-A in pancreatic cancer 
cells lines, which seems to be induced when pancreatic cancer cells are treated with 
recombinant S100A8-GST and S100A9-GST proteins. This would suggest a channel of 
crosstalk with the SI00 proteins affecting tumour cytokine profile.
Results from my experiments provided a further insight into the relationship between 
S100A8 and S100A9 proteins and cancer ceils providing further evidence to the data 
from the TMA analysis (Sheikh et al., 2007). Even though using conditioned media from 
pancreatic cancer cells induced expression of S100A8 and S100A9 in monocytes, the 
SMAD4 status of the cancer cells did not shown a differential expression pattern as 
determined by analysis of the TMA. In order to further unravel this relationship, 
recombinant GST tagged S100A8 and S100A9 were generated and used to evaluate the 
effects on motility and proliferation of cancer cells.
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CHAPTER 10
PRODUCTION OF RECOMBINANT 
GLUTATHIONE S-TRANSFERASE (GST) TAGGED 
S100A8 AND S100A9
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10.1 Preparation and Transformation of competent 
Escherichia coli
The Glutathione S-transferase (GST) gene fusion system was used for production and 
purification of fusion proteins produced in E. Coli. Plasmids encoding S100A8-GST and 
S100A9-GST fusion proteins in the pGEX4T-l vector were a kind gift from Professor Y. 
Maru, at the Tokyo Women’s Medical University School of Medicine, Japan (Hiratsuka 
et ah, 2006).
Competent E. coli BL21 and E. coli XL 1 blue were used for generation of S100A8-GST 
and S100A9-GST respectively. The coding sequence of S100A8 was cloned into the 
pGEX4T-l vector by EcoRJ, whereas S100A9 was cloned by directional cloning using a 
BamHI and Xho restriction site.
Competent E. coli XL 1 blue cells, acquired from Stratagene, were removed from storage 
at -80°C, and thawed on ice aliquotting 100 pi to which 1.7pl of p-mercaptoethanol was 
added. Following incubation on ice for 5 minutes, 5pi of plasmid reconstituted in water 
was added and left to incubate for a further 30 minutes. This mixture was then incubated 
for 45 seconds at 42°C and resuspended in ImL Luria-Bertani (LB) media (10 g Bacto 
tryptone, 5g Bacterial yeast extract, lOg NaCI made up to 1 litre pH corrected to 7.0) 
without ampicillin and placed for 1 hour at 37°C in an agitator at 240 RPM. The cells 
were then plated (500 pi) on LB agar plates with ampicillin (50 ug/ml) and left to 
incubate overnight at 37°C. Colonies were then picked from the plate at 12 hours and 6 
colonies were placed on a master plate (Figure 2.17). The selected clones were also
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grown in 2.5 ml of LB media containing ampicillin (50 pg/ml) using an oscillation of 240 
RPM in a bacterial incubator at 37° C.
Bacteria expressing S100A8 and S100A9 growing on agar plates
Colonies of bacteria 
growing on agar plates
Clone picked from colonies 
placed on master plate and 
numbered 1-6
Clones on agar plates
Figure 2.17: Figure showing bacteria growing on an agar plate (left) and transfer on to a 
master plate (right).
Plasmid DNA Purification
The QIAprep Miniprep system was used to purify DNA vectors from bacterial cells using 
silica membrane technology to elute high-quality plasmid DNA in a small volume of Tris 
buffer. The bacterial cells were lysed in an alkaline medium followed by adsorption of
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DNA onto silica. The kit comes ready prepared with all reagents named. The process 
consists of 3 keys steps:
1. Preparation and clearing of a bacterial lysate
2. Adsorption of DNA onto the QIAprep membrane
3. Washing and elution of plasmid DNA
The protocol is designed for purification of up to 20 pg of high-copy plasmid DNA from 
1-5 ml overnight cultures of E.coli in LB (Luria-Bertani) medium. For these purposes 
colonies were picked from the master plate which contained 6 E.coli clones harbouring 
the pGEX4T-l S100A8 vector and 6 clones with the pGEX4T-l-S100A9 vector. These 
cells were grown in LB media overnight and harvested by centrifugation at 6000 RCF for 
3 minutes at room temperature. The supernatant was then discarded and the pellet was 
suspended in 250 pi buffer provided with the kit. Reagents provided in the QIA prep 
Miniprep system kit were then added according to manufactures protocol and the eluted 
DNA plasmids collected were stored at either -20°C long term or in the fridge overnight.
Restriction analysis of DNA
As mentioned above competent E.coli BL21 and XL 1 blue were used for the generation of 
S100A8-GST and S100A9-GST respectively. The coding sequence of S100A8 and 
S100A9 was cloned into the pGEX4T-l vector using different restriction sites (for 
S100A8 it was EcoRI and S100A9 it was BamFlI and Xhol). The pGEX4T-l vector has a
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protease cleavage recognition site for thrombin. The map of the glutathione S-transferase 
fusion vectors showing the reading frames and main features is shown in Figure 2.18
Thrombine
^Leu Val Pro Arg Gly Ser 'Pro Glu Phe Pro Gly Arg Leu Glu A/g Pro His Arg Asp
CIG GI I CCG CGTjGGA ICC|CCG|GAA TTfiCCG ,CGG CCG
Figure 2.18: Map of the glutathione S-transferase fusion vectors showing the reading 
frames
Restriction analysis of DNA was undertaken by using 5pi of plasmid mini-preparation 
DNA and treating it with 0.3pL (3 units) of EcoRI (restriction enzyme) and IpL 0+ 
buffer (50 nM Tris pH 7.5, 10 mM Magnesium Chloride, 100 mM Sodium Chloride, 0.1 
mg/ml Bovine serum albumin, Fermentas) in the case of S100A8. For restriction analysis 
of DNA containing the S100A9 genetic sequence, 0.3pL (3 units) of Xhol buffer (10 mM 
Tris pH 8.5, lOmM Magnesium Chloride, 100 mM Potassium Chloride and 0.1 mg/ml
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bovine serum albumin), 0.3 (iL (3 units) of BamHI (restriction enzyme) and lp,L of 
Y+Tango buffer (33 mM Tris pH 7.9,10 mM Magnsium acetate, 66 mM Potassium 
acetate and 0.1 mg/ml bovine serum albumin Fermentas) were used in a lOpL reaction.
The mixture of enzymes and eluted DNA (6 clones each protein were tested) were 
incubated for 1 hour at 37° C. Three micro litres of 6X loading buffer (2.5 % Ficoll 400, 
11 mM EDTA, 3.3 mM Tris-HCl, 0.017 % SDS, 0.015 % Bromophenol Blue pH 8) was 
added to each sample prior to loading on a 1.8% agarose gel (3.6 grams agarose, IpL 
eithium bromide, 200 ml of TAE buffer[20mM Tris, 1 mL Acetic Acid, lOmM EDTA]) 
with a 1 kb DNA ladder and a 100 base pair ladder at either ends. Gels were 
electrophoresed at 100 volts for 40 minutes prior to being viewed and photographed 
under UV light. Colonies which did not incorporate the SI00 plasmid were discarded 
and the rest of the colonies were picked from the master plate and cultured in LB media 
to make glycerol stocks (600 pL of sample and 400 pL of glycerol), that were 
subsequently stored at -80° C.
10.2 Generation of GST, S100A8-GST and S100A9-GST 
proteins
The Glutathione S-transferase (GST) gene fusion system was used for purification of 
fusion proteins produced in E. Coli. The induction of GST fusion proteins was 
undertaken using one clone each expressing S100A8 and S100A9 protein. The GST
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control recombinant protein was a kind gift from Dr Timothy Devilling (Dr M Boyd’s 
Lab, Division of Surgery and Oncology, School of Cancer Studies). Bacterial cells 
harbouring S100A8-GST or S100A9-GSTor GST were cultured in LB media by adding 
lOOpL of cells from glycerol stocks into 1 mL culture medium and placing it at agitation 
(RMP 240) for 6 hours at 37°C. This culture was then diluted to larger volume of LB 
media (80 mL) and placed in agitation (RMP 240) overnight at 37°C. Following 
overnight culture cells were placed in 1 litre of LB media and allowed to culture as 
before. An hourly measurement of the optical density of the media was undertaken 
photometrically until it reached 0.8 at 600 pm. This was undertaken to determine the 
optimum level of growth of E. coli in culture, which can be divided into distinct phases, 
Lag phase, logarithmic (log) phase and the stationary phase. The lag phase occurs 
after dilution of the starter culture into fresh medium with cell division being slow as the 
bacteria adapt to the fresh medium. After 4-5 hours, the culture enters the logarithmic 
(log) phase, where the bacteria grow exponentially. This phase is followed by the 
stationary phase (~16 hours) when the available nutrients are used up and bacteria begin 
to lyse.
Attainment of the log phase was determined when the optical density (OD) was 0.8 at 
600 pm. At that stage Isopropyl-b-D-thiogalactopyranoside (IPTG)(VWR international, 
Lutterworth, UK) was added to a final concentration of 0.5 mM and cultures incubated 
for a further 4 hours. For the generation of S100A8 and S100A9 the optimum time for 
expression and harvesting the bacteria was 4 hours post IPTG addition.
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Purification of recombinant protein using GST fusion system
The E.coli cultures expressing the GST tagged proteins were collected in sterile 250 mL 
bottles and spun at 1000 RCF for 8 minutes at 4°C. The supernatant was discarded and 
the GST fusion proteins were extracted by lysing bacteria in SLIP buffer (50mM HEPES, 
10% v/v glycerol, 0.1% w/v TRITON and 150mM Sodium Chloride). The cells were 
sheared using sonication at 20% strength for 60 seconds. Confirmation of adequate lysis 
was obtained by microscopy. The lysate was then spun at 4°C for 5 minutes at 500g and 
the supernatant collected for purification.
Glutathione sepharose beads (GE Healthcare UK and Amersham biosciences) were used 
to isolate the GST moiety tagged protein (S100A8, S100A9 and control GST) from the 
lysate using disposable columns (Bio-Rad). Glutathione Sepharose 4B, beads were 
initially washed in cold (4 °C) PBS, twice and 1 mL of beads was mixed with 100 mL of 
bacterial sonicate and incubated for 1 hour at 4°C with gentle agitation. This mixture was 
then centrifuged at 500g at 4°C for 5 minutes to separate the beads form the lysate. 
Supernatants were stored in case of unsatisfactory extraction.
The Glutathione sepharose beads were then loaded on a column (Figure 2.19) and washed 
with ImL of ice cold PBS, 3 times. The wash from the column was collected for analysis, 
column and incubated at room temperature for 10 minutes. The outlet was then opened 
and the eluted protein collected. The cap was then placed on the column and a further 
ImL of elution buffer added repeating the process mentioned above. The elute was then 
pooled and analysed, subsequently the column outlet was capped and 1 mL of elution 
buffer was added to the or the presence of protein.
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Elution buffer
Purification
columnGlutathionesepharose
beads
Eluted Protein
Figure 2.19: Schematic diagram showing the process of protein elution and purification 
using Glutathione sepharose beads on a column
Quantification of recombinant protein using Albumin standards
The quantity of recombinant S100A8-GST and S100A9-GST protein was assessed by 
separation on a 15% Tris-tricine SDS-PAGE gel against serial dilutions of a reference 
standard of BSA for comparison (l-15|ig/lane). The gels were electrophoresed for 3 
hours at 80 volts to allow for good resolution of the protein band. Gels were then stained 
by incubation overnight at room temperature with Coomassie stain solution (2.5g 
Coomassie blue G, 450 mL Methanol, 100 mL Acetic Acid 450 mL water) with gentle
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agitation. The gels were then de-stained using a de-stain buffer (300 mL methanol, 100 
mL Acetic Acid and 600 mL water) to visualise the presence of stained bands.
Densitometric evaluation of the Coomassie-stained gels (GS-800 scanner, Biorad, UK) 
using Quantity One software Biorad, UK) was used to quantify the concentration of 
protein. Three batches of proteins were generated and used in experiments to confirm 
reproducibility of results.
10.3 Transformation of competent cells
Plasmids encoding S100A8-GST and S100A9-GST fusion proteins in the pGEX4T-l 
vector were transformed into competent E. coli BL21 and E. coli XL 1 blue for generation 
of S100A8-GST and S100A9-GST respectively. Initially the S100A9-GST vector was 
also transformed into E. coli XL 1 blue, however due to an additional GST tagged 26-kDa 
contaminant protein that was eluted along with the S100A9-GST protein, the vector was 
transformed into E. coli BL21. Subsequent to successful transformation, mini-preparation 
of the vector and restriction analysis of the DNA, on agarose gels was undertaken (Figure 
2.20 and Figure 2.21).
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Figure 2.20: Agarose gel showing restriction analysis of S100A8 DNA in clones 1-6 in E. 
coli E. coli XL blue. Of note clone 4 shows poor uptake of DNA with strong bands in 
clones 1,2,3,5 and 6
Figure 2.21: Agarose gel showing restriction analysis of S100A9 DNA in clones 1-6 in E. 
coli BL21. Of note clone 1 shows poor uptake of DNA with strong bands in clones 2-6
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Purification and quantification of recombinant protein using GST 
fusion system
Recombinant S100A8-GST and S100A-GST9 were purified and isolated using 
Glutathione sepharose beads and their presence was determined on a coomassie-stained 
gels illustrated in Figure 2.22, where S100A8-GST is a 34 kDa band and S100A9-GST is 
a 40 kDa band. Densitometric evaluation of Commassie stained gels to known 
concentration of albumin standards, were used to quantify the proteins.
WashWash
from from Supernatant Beads of £ Coli
•72
•55
•43
•34
•26
17
GST * S100A8-GST
protein protein
S100A9-GST
protein
Figure 2.22: Commassie stained gel showing the presence of GST, S100A8-GST and 
S100A9-GST recombinant proteins and wash from glutathione column.
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10.4 Generation of S100A9-GST protein using alternative 
methods
The plasmid for S100A9 was initially transfected in E. coli XL1 blue competent cells. 
Lysate from bacteria grown over a time course of 4 hours shows increasing presence of 
S100A9-GST protein being expressed over 4 hours on the ID SDS-PAGE gel 
(commassie stained) (Figure 2.23).
0 hr 1 hr 2 hr 3 hr 4 hr
•ar
S100A9-
GST
11
Figure 2.23: Commassie stained gel showing the presence of S100A9-GST in E. coli 
XL 1 blue cell lysate over 4-hour time course following initiation of induction
However, when incubated with the glutathione sepharose beads and purified on the 
purification column two proteins were eluted. The first was a 44 kDa protein (S100A9- 
GST) which was in very low quantity and a smaller 26 kDa protein, which was
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selectively eluted and present in a much higher quantity (Figure 2.24). This represented 
an incomplete translational product of S100A9-GSTor a degraded form of the protein.
S100A9-GST
Smaller 26KD 
protein
11
Figure 2.24: Commassie stained gel showing the presence of eluded S100A9-GST (44 
kDa band) and the smaller 26 kDa protein, produced in E. coli XL 1 blue cells
In order to overcome this problem different techniques were therefore employed. Firstly, 
different clones were used to generate S100A9-GST protein however, they resulted in 
exactly the same problem as described above. Secondly, elution of protein on the 
separation column was undertaken at 4°C, Room temperature and at 37 °C, however as 
shown in the Commassie stained gels of protein eluted using sepharose beads no 
difference was achieved and two bands were identified one at 44 kDa and the other at 26 
kDa. Thirdly, I grew the bacteria in special culture media, hypermedia (Sigma- 
Aldrich,UK) and powermedia (Sigma-Aldrich, UK) as opposed to standard LB media at 
room temperature and 37 °C. These adaptations did not resolve the issue and the 
contaminant protein was still present. Therefore, the S100A9 plasmid was transfected in
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the E. coli BL21 codon competent cells which alleviated the problem as shown in the 
Commassie stained gel below (Figure 2.25).
Supernatant 
of E.Coli
Wash Wash 
from from 
Beads Column
S100A9-
GST
protein
Figure 2.25: Commassie stained gel showing the expression of S100A9-GST produced 
in E. coli BL21 cells and eluted on a glutathione column.
217
10.5 Discussion
Cell culturing experimentation using conditioned media to treat primary monocytes and 
monocytic cell lines resulted in increased expression of S100A8 and S100A9 proteins in 
monocytes, suggesting a potential crosstalk channels between the 2 cells in the pancreatic 
cancer microenvironment. To further elucidate this, recombinant GST tagged proteins 
where generated in the Glutathione S-transferase (GST) gene fusion system. This gene 
fusion system is a versatile system for the expression, purification, and detection of 
fusion proteins produced in E. coll Expression in E. coli yields fusion S100A8 and 
S100A9 proteins with the GST moiety at the amino terminus and the SI00 protein at the 
carboxyl terminus. One of the potential advantages of GST fusion proteins is the control 
under the TAC promoter, which is induced by the lactose analog isopropyl b-D 
thiogalactoside (IPTG). All pGEX vectors are engineered with an internal /aclq gene. 
The /aclq gene product is a protein that binds to the TAC promoter, preventing expression 
until induction by IPTG, therefore maintaining a chemically inducible control over 
expression. Potential disadvantages of using the GST-fusion systems are the production 
of oligomers via the GST moiety and hindrance caused by the large fusion tag. In 
addition, the binding of the GST moiety can result in inadequate folding of the primary 
protein affecting its functional capacity. The GST tagged S100A8 and S100A9 which 
were produced for experimentation purposes have been used previously and were 
generated in a similar manner (Hiratsuka et ah, 2006).
The generation of S100A8-GST did not produce any significant problem with the protein 
being generated and eluted as expected. The generation of S100A9 however produced
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significant problems when the plasmid was transfected into E. coli XL 1 blue. The 
resultant 26KDa protein is likely to have been an incomplete translational product of 
S100A9-GST or a degraded form of the protein. The incomplete translational product 
produced may have been a result of a process called codon bias (Ermolaeva, 2001). A 
codon is a series of three nucleotides (triplets) that encodes a specific amino acid residue 
in a polypeptide chain or amino acids for the termination of translation (stop codons). 
Even though there are 64 different codons (61 codons encoding for amino acids plus 3 
stop codons) only 20 are translated into amino acids. In this process, the translation of the 
recombinant RNA is delayed, resulting in degraded RNA or codon substitutions and mis- 
incorporations that destroy the functional characteristics of the protein or result in a 
protein, which is not a full length sequence. Different experimental conditions applied did 
not resolve this problem and therefore, the S100A9 plasmid was transfected in the E. coli 
BL21 codon plus competent cells. The BL21-Codon Plus cells (Jerpseth et al., 1998) are 
designed with extra copies of tRNA genes that are rare in E. coli but frequently used in 
humans. These have been shown to prevent codon bias from occurring and allowing for 
high-level expression of proteins that are difficult to express in conventional E, coli hosts.
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CHAPTER 11
IN-VITRO CELL MOTILITY AND 
PROLIFERATION EXPERIMENTS USING 
RECOMBINANT GST TAGGED S100A8 AND 
S100A9
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11.1 Cell motility measurement - The modified Boyden 
chamber assay
A modified Boyden Chamber assay (Figure 2.26) was used to assess the motility of 
pancreatic and colorectal cancer cell lines (Thompson et ah, 2007). A cell culture insert 
with PET membrane transwell 8pm pores (VWR) was placed into each well of a 24-well 
plate as an upper chamber. Cells of interest were harvested and plated in SOOpl of serum- 
free medium in the upper chamber whereas the lower chamber contained 750pl of cell 
culture media with varying conditions.
Recombinant S100A8-GST and S100A9-GST at concentrations of 0.4 pg/ml and 2 pg/ml 
were prepared in culture media containing 1% FCS, and placed in the lower chamber 
either singly or in combination. Controls for this experiment were culture media 
containing 1% FCS with GST protein, 10% FCS, or 1% FCS alone. The chambers were 
incubated at 37°C for 18 hours, at which time, non-migrating cells were removed from 
the upper surface of inserts with a cotton swab. Cells which migrated through the pores to 
the under-surface of the insert membrane, were fixed and stained using Diff-Quick Stain 
Kit (Reagena). The membrane was then cut out and mounted onto glass slides and stained 
cells were counted with a microscope at 40x magnification. Duplicate or triplicate inserts 
were set up for each condition and the experiments were carried out on at least on two 
separate occasions.
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The number of cells placed in the upper chamber varied depending on the base line 
motility of the cells. Colorectal cell lines (SW-480/SWD20/SWK3/SWD14/SWD1/ and 
SW-837) were plated at a density of 5 x 104 cells whereas pancreatic cancer cells PANC-, 
Suit-2 and MIA PaCa-2 cells were plated at a density of 5 x 101 cells in the upper 
chamber.
Upper chamber 
(containing cell 
culture media)
Cancer cells 
plated in the 
upper chamber
Insert membrane 
(8 pm pore size)
Lower chamber 
(containing cell 
culture media 
and S100A8/A9)
Cell culture 
insert
24-well plate
Cancer cells 
migrating through 
the membrane
Cancer cells have 
migrated through the 
membrane and 
attached to the bottom 
of the insert
Figure 2.26: Figure showing a Boyden chamber and various components of the 
experimental setup
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11.2 Cell proliferation assay
Proliferation of colorectal and pancreatic cancer cells were assessed at 24 h, 36 h and 48 
h using a MTT assay utilizing the EZ4U non-radioactive cell proliferation assay 
(Biomedica} Vienna) according to the manufacturer’s instructions.
Cells were freshly suspended in 1% FBS culture media at a concentration of 3x104 
cells/mL. One hundred micro litres of cell suspension was added to 96-well plates 
containing lOOpL of 1% FBS media with recombinant S100A8-GST, S100A9-GST or 
GST at 0.4jig/mL and 2pg/mL concentrations. The SI00 proteins were either added 
singly or in combination. Experiments were performed three times and the number of 
wells utilised for each condition was either 12 or 6. Readings at absorbance of 450 nm 
were taken at 4h following incubation with the reagents. Experiments were performed at 
least three times and five wells utilised for each treatment.
11.3 Transient SMAD4 knockdown methodology
Pancreatic and colorectal cancer cells transiently depleted of S1VIAD4 were generated to 
assess differential effects of treatment with S100A8 and S100A9 proteins in terms of 
motility and proliferation. Transient knockdown of SMAD4 was undertaken in SWD20 
and PANC-1 cells using siRNA molecule sequences GUGUGCAGUUGGAAUGUAA 
(siRNAl, Dharmacon) and GUACAGAGUUACUACUUAG (siRNA2, Dharmacon). 
Two control siRNA’s were used:
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1) Non-targeting siRNA control (Dharmacon)
2) Scrambled siRNA control (GGACGCAUCCUUCUUAA, a gift from Dr M Boyd, 
University of Liverpool, UK).
Once transfected, the cells were harvested at 48 hrs which was deemed the optimum time 
for knockdown. This was determined by serial experiments assessing knockdown at 24h, 
48h and 72h.
Transient SMAD4 depletion/knockdown
Cells were harvested, washed, counted, and plated into 6-well plates at a density of 1x105 
cells in each well to achieve a cell density of -60-70%. Approximately 3 ml of culture 
media was added into each well and the plate was incubated at 37°C for 24 hours.
For transfection of each well, 4pL of lipofectamine 2000 (Sigma UK) was added to 
200pL of Optimem I (Sigma UK) in one 15 mL tube, and siRNA (ranging from 5-50 
nM) was added to 200pL of Optimem I in another 15mL tube. These two tubes were 
incubated for 5 minutes in the laminar flow hood before mixing their contents together 
and incubating for a further 20 min.
The 6-well plates were retrieved from the incubator, the wells washed with PBS and 2.6 
ml of antibiotic-free culture media was added into each well. The siRNA and 
lipofectamine 2000 mixture was then added to the wells in a drop-wise manner. The 
plates were returned to the incubator for 48 hours and cells harvested for further 
experiments.
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11.4. Cell motility experiments
The effects of S100A8-GST and S100A9-GST on Pancreatic cancer cell 
motility
Pancreatic cancer cells (PANC-1, SUIT-2 and MIAPaCaS) were treated with recombinant 
S100A8-GST and S100A9 -GST, which induced increased motility of these cell lines. 
All cell lines responded to both low (0.4pg/mL) and high (2pg/mL) concentrations of 
S100A8-GST and S100A9-GST when administered alone or in combination. PANC-1 
cells showed a significant increase in motility compared to GST control (n=5 experiments 
done in triplicate), when treated with a low concentration (0.4 pg/mL) of S100A8-GST 
(pO.OOl; paired t-test), S100A9-GST (p=0.0004; paired t-test) and combined S100A8- 
GST and S100A9-GST (p=0.002; paired t-test) recombinant proteins (Figure 2.27). 
Similarly a significant increase in motility was observed when these cells were treated 
with high concentration S100A8-GST (p=0.0005; paired t-test) and S100A9-GST 
(p=0.0079; paired t-test). Combined high concentration S100A8-GST and S100A9-GST 
(p= 0.0161; paired t-test) produced a dramatic increase in motility with a near doubling 
effect.
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Motility of PANC-1 cells when treated with recombinant 
S100A8-GST and S100A9-GST proteins
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Figure 2.27: Figure showing the mean counts of migrating PANC-1 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4|ig/mL or 2|ig/mL singly or in combination (n=5). * denotes significant result
SUIT-2 cells also showed a significant increase in motility compared to respective GST 
control (n=3 experiments, done in triplicate) (Figure 2.28), when treated with a low 
concentration (0.4|ig/mL) of S100A8-GST (p=0.01; paired t-test), S100A9-GST (p=0.02; 
paired t-test) and combined S100A8-GST and S100A9-GST (p=0.05; paired t-test) 
recombinant proteins. Similarly, a significant increase in motility was observed when 
these cells were treated with high concentration S100A8-GST (p<0.01; paired t-test) and 
S100A9-GST (p=0.01; paired t-test). Combined high concentration S100A8-GST 
&S100A9-GST also produced a significant increase in motility (p= 0.05; paired t-test).
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The response of SUIT-2 cancer cell lines to low and high concentration S100A8-GST 
was more pronounced than that of S100A9-GST.
Motility of SUIT-2 cells treated with recombinant S100A8- 
GST and S100A9-GST proteins
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GST 400r)g/mL
1% FBS
Mean Number of Cells
Figure 2.28: Figure showing the mean counts of migrating SUIT-2 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4pg/mL or 2|ig/mL singly or in combination (n=3). * denotes significant result
MIA PaCa-2 cell lines demonstrated a significant increase in motility compared to 
respective GST controls (n=3 experiments, done in triplicate) (Figure 2.29), when treated 
with a low concentration (0.4|ig/mL) of S100A8-GST (p=0.05; paired t-test) but not with 
high concentration of the protein (2pg/mL; paired t-test). A significant increase in
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chemotaxis was achieved when the cells were treated with low concentration S100A9- 
GST (p=0.03; paired t-test) and combined S100A8-GST & S100A9-GST (p=0.04; paired 
t-test) recombinant proteins. At high concentrations of S100A9-GST and combination 
S100A8-GST & S100A9-GST (n=2) MIA PaCa-2 cells also produced a significant 
increase in motility (p=0.01; paired t-test for S100A9-GST and p=0.019; paired t-test for 
combined S100A8-GST and S100A9-GST).
Motility of MIA PaCa-2 cells treated with recombinant 
S100A8-GST and S100A9-GST proteins
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Figure 2.29: Figure showing the mean counts of migrating MIA PaCa-2 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4pg/mL or 2pg/mL singly or in combination (n=3). * denotes significant result
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The effects of S100A8-GST and S100A9-GST on Colorectal cancer cell 
motility
Both recombinant S100A8-GST and S100A9-GST proteins induced motility of colorectal 
cell lines SW-837 and SW-480. SW-480 (Figure 2.30) (n=4 experiments, done in 
triplicate) cells demonstrated a dramatic increase in motility following incubation with 
low (0.4pg/mL) and high (2pg/mL) of concentration of S100A8-GST compared to GST 
alone (p=0.01 and p=0.001 respectively; paired t-test). A less marked affect was 
observed in response to low concentration S100A9-GST with a marginal increase in 
chemotaxis observed at a higher concentration of S100A9-GST protein (p=0.05, and p= 
0.004; paired t-test respectively). Combined S100A8-GST and S100A9-GST at a low and 
high concentration induced a significantly appreciable increase in motility (p=0.03, p< 
0.01; paired t-test) however, it was not as effective as S100A8-GST alone.
The response of SW-837 cells (n=3 experiments, done in triplicate) (Figure 2.31) was 
somewhat varied to both low (0.4pg/mL) and high (2pg/mL) concentrations of S100A8- 
GST and S100A9-GST. S100A8-GST proteins produced a significant increase in motility 
at high concentrations but not at low concentrations (p=0.04 for high concentration and 
0.09 for low concentration; paired t-test). S100A9-GST produced a more pronounced 
effect compared to S100A8-GST in terms of motility, it only reached significance at low 
concentrations (p=0.05 paired t-test) but not at the higher concentration (p=0.1; paired t- 
test). The combination of both proteins produced significant increases in motility at both 
low and high concentration respectively (p=0.01 and p=0.05 respectively paired t-test).
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Motility of SW-480 cells treated with recombinant S100A8- 
GST and S100A9-GST proteins
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Figure 2.30: Figure showing the mean counts of migrating SW-480 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4|ig/mL or 2pg/mL singly or in combination (n=4). * denotes significant result
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Motility of SW-837 cell lines when treated with 
recombinant S100A8-GST and S100A9-GST proteins
A8 & A9 2000r|g/mL 
A9 2000r|g/mL 
A8 2000r|g/mL 
GST 2000rig/mL
A8 & A9 400r|g/mL 
A9 400r|g/mL 
A8 400r|g/mL 
GST 400r|g/mL
1% FBS
Mean Number of Cells
Figure 2.31: Figure showing the mean counts of migrating SW-837 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4jig/mL or 2pg/mL singly or in combination (n=3). * denotes significant result
The effects of S100A8-GST and S100A9-GST on the motility of 
SMAD4-positive and -negative colorectal clones
In order to evaluate any differential effects the SMAD4 status of the cancer cells may 
pose on the chemotactic response to S100A8-GST and S100A9-GST recombinant 
proteins, SMAD4 re-expressing stable clones of colorectal cancer cell lines SW480 were 
used. These cell lines have varied expression of SMAD4 with SWD20, SWD14 and 
SWD1 expressing varying amounts of SMAD4 positivity and SWK3, expressing a small 
amount therefore being considered as a SMAD4 negative clone.
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The motility of the SMAD4 negative subclones SWK3 (n=3 experiments done in 
duplicate) (Figure 2.32) significantly increased compared to GST controls when treated 
with low concentration (0.4jig/mL) of S100A8-GST (p=0.05; paired t-test). S100A9-GST 
recombinant protein at low concentration was not tested in this cell line. At the higher 
concentration (2pg/mL), S100A8-GST attainted a significant increase in motility 
(S100A8-GST p= 0.05 paired t-test) but this was not the case with S100A9-GST (p= 0.5 
paired t-test). A combination of both proteins at high concentration (2pg/mL) produced 
significant chemotaxis (p=0.05 paired t-test) with a pronounced effect seen.
Motility of SWK3 cells treated with recombinant S100A8- 
GST and S100A9-GST proteins
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Figure 2.32: Figure showing the mean counts of migrating SWK3 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4}ig/mL or 2pg/mL singly or in combination (n=3). * denotes significant result
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Interestingly S100A9-GST protein did not induce motility in either SWD1 (Figure 2.33) 
and SWD14 (Figure 2.34) subclones at either a low (0.4pg/mL) (SWD1, p=0.11 and 
SWD14, p=0.2; paired t-test) or high concentrations (2p/mL) (SWD1, p=0.1 and SWD14 
p=0.2; paired t-test) of the protein (0=3 experiments done in duplicate). Both of these 
subclones however responded to recombinant S100A8-GST (0.4pg/mL) (n=2) inducing a 
significant increase in motility (SWD1, p=0.03; SWD14, p=0.03 paired t-test). Similarly 
using higher concentration of S100A8-GST (2jig/mL) induced a statically significant 
chemotactic response (SWD1 p=0.04; SWD14 p=0.001; paired t-test). When both 
proteins were applied in combination a significant increase in motility was induced both 
in SWD1 and SWD14 cell lines with 2pg/mL of protein (p= 0.05 and 0.009 respectively; 
paired t-test) as well as with a 0.4pg/mL of combined S100A8-GST and S100A9-GST 
(SWD1 p=0.03; SWD14 p=0.006; paired t-test).
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Motility of SWD1 cell lines treated with recombinant 
S100A8-GST and S100A9-GST proteins
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Figure 2.33: Figure showing the mean counts of migrating SWD1 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4|ig/mL or 2pg/mL singly or in combination (n=3). * denotes significant result
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Motility of SWD14 cell lines treated with recombinant 
S100A8-GST and S100A9-GST proteins
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Figure 2.34: Figure showing the mean counts of migrating SWD14 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4|ig/mL or 2pg/mL singly or in combination (n=3). * denotes significant result
The subclone SWD20 (Figure 2.35) (n= 4, experiments done in duplicate) which in 
comparison to the other clones expressed the highest quantity of SMAD4, showed a 
positive chemotactic response to recombinant S100A8-GST and S100A9-GST when 
treated at concentrations of 0.4pg/mL and 2pg/mL of the protein (S100A8: 0.4pg/mL, 
and 2pg/mL; p <0.001) (S100A9-GST: 0.4pg/mL and 2pg/mL, p <0.001; paired t-test). 
When a combination of both proteins was applied a significant increase in motility was 
observed at both low and high concentrations respectively (pO.OOl and p=0.02 
respectively; paired t-test).
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Motility of SWD20 cells treated with recombinant S100A8- 
GST and S100A9-GST proteins
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Figure 2.35: Figure showing the mean counts of migrating SWD20 cells 18h post 
incubation with recombinant S100A8-GST (A8) or S100A9-GST (A9) or GST at 
0.4fig/mL or 2|ig/mL singly or in combination (n=4). * denotes significant result
As demonstrated in the aforementioned results no consistent difference was observed in 
the effects S100A8-GST and S100A9-GST recombinant proteins had on the motility of 
colorectal sub-clones of SW-480 based on their SMAD4 status. As SMAD4 is a protein 
normally lost in the process of carcinogenesis it was therefore decided that producing a 
SMAD4 knockdown in SMAD4 positive cell lines could be a more viable method to 
study the effects that SMAD4 may have on the motility of the pancreatic cancer cells 
when treated with recombinant S100A8-GST and S100A9-GST proteins.
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The effects of S100A8-GST and S100A9-GST on SMAD4 knockdown 
pancreatic cancer cell lines
Transient knockdown of SMAD4 in PANC-1 cell lines was achieved in 24 hours 
however a complete knockdown was established at 48 hours after transfection as 
demonstrated in the western blot analysis which shows knockdown of SMAD4 at 48 
hours following treatment with two interference RNA (siRNAl and siRNA2) (Figure 
2.36).
SMAD4
------------y---------- - ----------- V----------- ----------- V » T
SiRNAl SiRNA2 Rise-free SiRNA SiRNA
Control Scramble 
control
Figure 2.36: Western data showing transient knockdown of PANC-1 cancer cells and 
control at 48 hours post transfection with various conditions.
The SMAD4-depleted cells demonstrated an overall decrease in baseline motility 
compared to the controls (Figure 2.37 and Figure 2.38). When treated with recombinant 
S100A8-GST and S100A9-GST (singly or combined) at low (0.4 pg/mL) and high 
(2pg/mL) concentrations (n=2 experiments done in duplicate) cells with SMAD4 
depleted by siRNAl had a more pronounced chemotactic response in comparison to cells 
which were knockdown using siRNA2. Cells which were knockdown by siRNAl (and 
not by siRNA2) also demonstrated a greater chemotactic response when treated with
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recombinant S100A8-GST and S100A9-GST (singly or combined) at low concentration 
(0.4 (ig/mL) compared to the scrambled control only and not to RISC-FREE and Control- 
1. This effect was not demonstrable when treated with higher concentrations (2pg/mL) of 
both recombinant proteins (applied singly or in combination). Owing to the experiment 
being conducted twice, no statistical calculations were possible to make a safe 
conclusion.
Motility of Panc-1 SMAD4-depleted cells and controls treated with 0.4 
pg/ml of recombinant S100A8-GST and S100A9-GST proteins
A8 & A9 400r|g/mL
A9 400r|g/mL
A8 400r|g/mL
GST 400r)g/mL
1% FBS
0 100 200 300 400 500
Mean number of cells
■■
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H siRNA 2
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control
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■ RISC-FREE
Figure 2.37: Figure showing the mean counts of migrating SMAD4-depleted PANC-1 
and control PANC-1 cells, 18h post incubation with recombinant S100A8-GST or 
S100A9-GST or GST at 0.4p/mL.
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Motility of Panc-1 SMAD4-depleted cells and controls treated with 
2pg/mL of recombinant S100A8-GST and S100A9-GST proteins
A8 & A9 2000r|g/mL
A9 2000r|g/mL
GST 2000r|g/mL
1% FBS
Mean number of cells
« siRNA 2
■ siRNA 1
w Scrambled control
■ Control 1
■ RISC-FREE
Figure 2.38: Figure showing the mean counts of migrating SMAD4-depleted PANC-1
and control PANC-1 cells, 18h post incubation with recombinant S100A8-GST or
S100A9-GST or GST at 2pg/mL.
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11.5 Cell proliferation experiments
The effects of S100A8-GST and S100A9-GST on cell proliferation
The proliferation of pancreatic and colorectal cancer cell as described in the previous 
sections was assessed following incubation with medium containing 1% FBS 
supplemented with the recombinant proteins S100A8-GST, S100A9-GST or control 
GST, generated and purified from E. coli.
The effects of S100A8-GST and S100A9-GST on Pancreatic cancer cell 
proliferation
Pancreatic cancer cells (PANC-1, SUIT-2 and MIAPACA3) were incubated with 
recombinant S100A8-GST and S100A9-GST and their proliferation at 24h, 36h and 48h 
was measured. All three of the cell lines responded to both low (0.4pg/mL) and high 
(2iag/mL) concentrations of S100A8-GST and S100A9-GST when administered alone or 
in combination.
PANC-1 cell lines showed a significant increase in proliferation at 48 hours compared to 
their respective GST control (n=3 experiments conducted in quintet). When treated with a 
low (0.4pg/mL) and high (2p.g/mL) concentration of S100A8-GST (p=0.05 for low 
concentration and p<0.001 for high concentration; paired t-test). Similarly at 48hrs when 
treated with S100A9-GST a significant increase in proliferation was seen (p=0.02 for low 
concentration and p=0.03 for high concentration; paired t-test) (Figure 2.39). Treatment 
of PANC-1 cells with combined S100A8-GST and S100A9-GST proteins produced a
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significant increase in proliferation at both low and high concentrations (p—0.02 for low 
and p=0.03 for high concentration; paired t-test). At 24h only low concentrations 
(0.4pg/mL) of S100A8-GST and S100A9-GST managed to induce significant growth in 
PANC-1 cells. At 36h no significant growth induction by the recombinant proteins was 
measured compared to the GST controls.
Proliferation of PANC-1 cancer cells when treated with 
recombinant S100A8-GST and S100A9-GST proteins
■ 24hours
■ 36hours 
h 48hours
Figure 2.39: MTT proliferation assay for PANC-1 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GS1 (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05)
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SUIT-2 cells showed a significant increase in proliferation compared to respective GST 
control after 36h of incubation (n=3, conducted in quintet) (Figure 2.40), when treated 
with a high concentration (2pg/mL) of S100A8-GST (p=0.01; paired t-test), S100A9- 
GST (p=0.05; paired t-test) and combined S100A8-GST and S100A9-GST (p= 0.02; 
paired t-test) recombinant proteins. The response of SUIT-2 cancer cell lines to low 
concentration f proteins did not exhibit a significant increase in growth.
Proliferation of Suit-2 cancer cell lines when treated with 
recombinent S100A8-GST and S100A9-GST proteins
Figure 2.40: MTT proliferation assay for SUIT-2 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GST (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05)
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MIA PaCa-2 cells demonstrated a significant increase in growth at 48 hours with high 
concentrations of S100A8-GST (p=0.01; paired t-test), S100A9-GST (p=0.05; paired t- 
test) and combined S100A8-GST and S100A9-GST (p=0.04; paired t-test) recombinant 
proteins (n=3, experiments conducted in quintet) (Figure 2.41). After 24h and 36h of 
treatment with SI00 proteins, MIA PaCa cancer cells showed an increase in proliferation 
however, this did not attain statistical significance.
Proliferation of MIA-PaCa-2 cancer cells when treated with 
recombinant S100A8-GST and S100A9-GST proteins
Figure 2.41: MTT proliferation assay for MIA PaCa-2 cells following 24h, 36h and 48h 
of incubation with recombinant S100A8-GST (denoted A8) or S100A9-GS1 (denoted 
A9) measuring the absolute absorbance. * denotes a significant result (p<0.05)
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The effects of S100A8-GST and S100A9-GST on Colorectal cancer cell 
proliferation
Recombinant S100A8-GST and S100A9-GST proteins induced proliferation of the 
colorectal cancer cell lines SW-837 and SW-480 alike. At concentrations of OApg/mL, 
neither S100A8-GST nor S100A9-GST significantly increased the proliferation of 
SW837 cells (n=2, experiments conducted in quintet) (Figure 2.42) relative to GST, 
however combined S100A8-GST and S100A9-GST protein was seen to induce a 
significant degree of proliferation at 24h and 36h respectively (p=0.03 and p=0.009 
respectively; paired t-test). When applied at 2|4.g/mL a significant increase in the 
proliferation of SW-837 cells was observed when the proteins were used singly or in 
combination after 24h, 36h and 48 hours of incubation (S100A8: p < 0.01, S100A9-GST: 
p< 0.01, S100A8-GST& S100A9-GST: p<0.01).
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Proliferation of SW-837 Cancer cell lines treated with recombinent S100A8- 
GST and S100A9-GST proteins
i
H 24hours
B 36hours
y 48hours
Figure 2.41: MTT proliferation assay for SW-837 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GST (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
The proliferative response of SW-480 (n=3, experiments conducted in quintet) (Figure 
2.42) cells did not show a significant increase in growth with S100A8-GST at low 
concentration (0.4pg/mL) however did show an increased proliferative response to 
S100A9-GST at 36h and 48h (p= 0.05 and p=0.01 respectively paired t-test). A 
significant increase however, in proliferation was observed with S100A8-GST (2pg/mL) 
at 24 and 36 hours (p<0.01; paired t-test). Similarly S100A9-GST at higher
245
concentrations (2fig/mL) demonstrated a significant increase in proliferation at 24h and 
36h but not at 48h (p= 0.01 and p=0.05 respectively; paired t-test). Combined S100A8- 
GST and S100A9-GST at both 0.4pg/mL and 2pg/mL produced a significant increase in 
proliferation of SW-480 at 24h and 36h (at 0.4pg/mL: p=0.05 and p=0.02 respectively; at 
2pg/mL: p=0.04 and p=0.04 respectively; paired t-test).
Proliferation of SW-480 cancer cell lines when treated with recombinant 
S100A8-GST and S100A9-GST proteins
Figure 2.42: MTT proliferation assay for SW480 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GST (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
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The effects of S100A8-GST and S100A9-GST on SMAD4 positive and 
negative colorectal clones proliferation
Differential response of S100A8-GST and S100A9-GST recombinant proteins in stable 
SMAD4 re-expressing clones of colorectal cancer cell lines of S W480 was also observed. 
The varied expression of SMAD4 in these cell lines has been shown in the motility 
section previously.
The SMAD4 negative subclone SWK3 (n=3, experiments conducted in quintet) (Figure 
2.43) demonstrated a significant increase in proliferation compared to GST controls when 
treated with high concentration (2pg/mL) of S100A9-GST recombinant protein only 
(p=0,05 paired t-test at 48 hours). This was not the case with S100A8-GST protein at 
both low and high concentration. Treatment with low concentration S100A9-GST on its 
own or combination with S100A8-GST was not undertaken for this cell line. Treatment 
with combined S100A8-GST and S100A9-GST at 2pg/mL induced a significant 
proliferative response at 48h (p^ 0.05; paired t-test) with the response being equal to that 
of S100A9-GST alone.
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Figure 2.43: MTT proliferation assay for SWK3 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GST (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
Interesting the SWD1 (Figure 2.44) (n=2 experiments conducted in quintet) and SWD14 
(Figure 2.45) (n=2 experiments conducted in quintet) subclones did not exhibit an 
increase in proliferative response to low (0.4p.g/mL) concentration of S100A8-GST, and 
in the case of SWD14 to S100A9-GST proteins. At a higher concentration (2pg/mL) 
S100A8-GST did not attain a statistically significant increase in proliferation for both cell 
lines either. Treatment with high concentration of S100A9-GST on its own or 
combination with S100A8-GST induced a significant increase in proliferation in both cell
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lines at 48h (SWD1 p=0.03; SWD14 p=0.006; paired t-test for S100A9-GST) and 
(SWD1 p=0.01; SWD14 p=0.05; paired t-test for S100A8-GST & S100A9-GST).
Proliferation of SWD1 cells treated with recombinant S100A8-GST and
S100A9-GST proteins
Figure 2.44: MTT proliferation assay for SWD1 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GSf (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
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Proliferation of SWD14 cells treated with recombinant 
S100A8-GST and S100A9-GST proteins
Figure 2.45: MTT proliferation assay for SWD14 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GST (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
The subclone SWD20 (n=3 experiments conducted in quintet) (Figure 2.46) which 
expressed the highest quantity of SMAD4, showed a positive proliferative response to 
recombinant S100A9-GST at both low and high concentration at 36h and 48h (p=0.01 
and p=0.03 respectively for 0.4pg/mL) (p=0.002 and p=0.05 respectively for (2pg/mL). 
S100A8-GST induced a significant increase in proliferation at 2|ig/mL at 48h (p= 0.05 
paired t-test). The combination of both proteins resulted in a significant increase in 
proliferation at both low (0.4pg/mL) and high concentration (2pg/mL) at 48 hours 
respectively (p<0.001 and p=0.04 respectively; paired t-test).
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Proliferation of SWD20 cells treated with recombinant S100A8- 
GST and S100A9-GST proteins
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Figure 2.46: MTT proliferation assay for SWD20 cells following 24h, 36h and 48h of 
incubation with recombinant S100A8-GST (denoted A8) or S100A9-GSf (denoted A9) 
measuring the absolute absorbance. * denotes a significant result (p<0.05).
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11.6 Discussion
The characterisation of S100A8- and S100A9-positive myeloid cells in the pancreatic 
cancer microenvironment as previously mentioned revealed a significant association 
between the numbers of S100A8/S100A9 expressing cells and the SMAD4 status of the 
tumour (Sheikh et ah, 2007). Moreover, in vitro experimentation using conditioned media 
from pancreatic cancer cell lines induced expression of these proteins in monocytic cell 
line HL-60. I was however not able to establish a conclusive differential protein 
expression pattern of S100A8 and S100A9 in HL-60 cells based on the SMAD4 status of 
the cancer cells from which the conditioned media was derived. The inflammatory 
chemoattractants S100A8 and S100A9, apart from serving as biomarkers of inflammatory 
disease conditions are now recognised to play an important role in the pathogenesis and 
progression of cancer (Ghavami et ah, 2009).
Using a mouse model of colon cancer, Kitamura et al (Kitamura et ah, 2007) reported 
that SMAD4-negative tumours recruited a specific type of myeloid cell, which promoted 
invasion through crosstalk with tumour cells. As previously mentioned Hiratsuka et al. 
showed that S100A8/A9 were powerful chemoattractants whose tumour induced presence 
in the lungs of tumour-bearing mice could stimulate the migration of Lewis Lung 
carcinoma cells and B16 melanoma cells to that organ. The ability of conditioned media 
from pancreatic cancer to induce S100A8 and S100A9 also indicated crosstalk channels 
existing in the pancreatic microenvironment. Therefore, I sought to determine the 
response of tumour cells to S100A8 and S100A9 in terms of their motility and
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proliferation. In this process, I also aimed to understand whether the SMAD4 status of the 
cancer affected growth or motility of the tumours when treated with recombinant S100A8 
and S100A9 proteins.
Both recombinant S100A8 and S100A9 proved to be highly chemotactic and proliferative 
for pancreatic cancer cell lines, regardless of whether the cells expressed SMAD4 or not. 
The pancreatic cancer cells showed a response in terms of growth and proliferation 
compared to the controls in all three cell lines with statistical significance being attained.
The colorectal cell lines SW-480 and SW-837 both underwent proliferation and 
chemotaxis in response to recombinant S100A8 and S100A9 proteins. Neomycin- 
resistant clonal derivatives of SW-480 cells, stably re-expressing SMAD4 (SWD20) at 
high levels and low level expressing transfectants (SWK3, SWD14, SWD1) all showed 
enhanced motility in response to S100A8 and S100A9 despite differing levels of 
SMAD4. Moreover, these cells all demonstrated significant cheomotaxis, the 
proliferation response of the SMAD4 clones SWD1, SWD14 and SWK3 was poor. 
Transient SMAD4 knockdown in PANC-1 was accompanied by an overall decrease in 
baseline motility however, compared to controls both proteins exerted chemotactic effects 
on the cells. Experiments using transient SMAD4 knockdown cells were only undertaken 
twice and therefore no substantial conclusions could be drawn. The possible mechanism 
by which these proteins exert their effects has been reported by Ghavami et al (Ghavami 
et al., 2008b) who demonstrated S100A8 and S100A9 proteins activated the multiligand 
receptor, RAGE, triggering the mitogen-activated protein kinase signalling pathway.
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My colleague Mr. Chin Ang who not only helped me with some aspects of this project 
took over the project after I left the department and conducted a series of further 
experiments to elucidate the effects of SMAD4 status had on S100A8-GST and S100A9- 
GST induced migration activity (Ang et al.s 2010). He revisited the transient siRNA- 
mediated depletion of SMAD4 in PANC-1 cells and also produced a transient 
knockdown of SWD20 (SMAD4 expressing subclone of SW-480) celts in a similar 
manner as described above. He successfully demonstrated that knockdown of SMAD4 in 
both cell lines resulted in an approximate 50% decrease in basal migration compared to 
respective controls, which was consistent with previous findings (Ang et ah, 2010). More 
importantly, he showed a significant reduction in motility and a loss of responsiveness to 
S100A8-GST, but not S100A9-GST when cells underwent a transient knockdown of 
SMAD4. He also demonstrated that SMAD4 re-expressing SW-480 subclones have a 
differential response to S100A8 and S100A9 proteins based on their levels of SMAD4 
expression. Interestingly, while the SMAD4-restored SWD20 cells showed increased 
proliferation in response to S100A8-GST and S100A9-GST, their SMAD4-negative 
clonal counterpart, SWK3 cells showed increased proliferation in response to S100A9- 
GST only. Both of these experiments suggested that SMAD4 was important in regulating 
the proliferative response to exogenous S100A8 (Ang et al., 2010). I was unable to 
produce similar results with the knockdown experiments as by Mr. Ang as primarily I 
undertook them towards the end of my research period and additionally these 
experiments were still in the phase of optimisation.
It can be postulated that myeloid cells (monocytes) expressing both S100A8 and S100A9 
are recruited to the tumour microenvironment in response to growth factors which are
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produced by the tumours cells and other stromal components alike. The production of 
S100A8/A9 may promote further recruitment of inflammatory cells as well as aiding 
cancer cell growth and invasion. A relationship between the phenotype of the tumour 
cells i.e. their SMAD4 status and S100A8 and S100A9 does exist as demonstrated by 
Ang et at (Ang et al., 2010). His work indicates that the crosstalk between SMAD4- 
negative cancer cells and myeloid cells occurs in a microenvironment that involves 
S100A9 to a greater extent than S100A8 and where the cancer cells respond better to 
S100A9 than S100A8. Either way experiments undertaken by Ang et al and myself 
indicate that crosstalk between the cancer cells and myeloid cells does occur with 
S100A8 and S100A9 being 2 proteins at the crossroads.
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CHAPTER 12
CONCLUSIONS
Pancreatic cancer is one of the most fatal solid organ malignancies, characterised by a 
dense desmoplastic stroma accounting for the bulky fibrotic nature of the tumour. Despite 
advances in surgical techniques and oncology, outcomes remain poor. Although a 
detailed understanding of the signature molecular events which occur in pancreatic cancer 
exists, the mechanisms linking these genetic changes to the aggressive nature of this 
disease remains a field of active research.
Recent years have seen the focus shift from the tumour cells as direct drivers of 
carcinogenesis to the wider tumour microenvironment. This complex ecosystem is 
composed of tumour cells, resident and infiltrating non-tumour cells (termed the 
‘stroma’) along with chemomediators (Joyce and Pollard, 2009; Marchesi et ah, 2012; 
Neesse et al., 2011; Shields et al., 2012b; Vincent et ah, 2011). A distinct molecular 
‘crosstalk’ between the host and its surrounding cells is the subject of study in a variety 
of cancer settings and plays an essential role in carcinogenesis, angiogenesis, 
invasion/metastasis and evasion of the host immune systems. Locally activated cellular 
and extracellular elements of the host microenvironment secrete molecules that can 
influence the malignant phenotype modifying the proliferative and invasive behaviour of 
the tumour, however these interactions are often than not complex and poorly understood.
Cells of myeloid linage are one such component of the dense stroma with monocytes and 
macrophages having a major role in all aspects of tumour biology and invasion, making 
them essential regulators in carcinogenesis (Coffelt et al., 2009; Ruffell et al., 2012) 
(Joyce and Pollard, 2009). S100A8 and S100A9, besides being upregulated in cancer
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cells have extensively been reported to be expressed in immature monocytes and cells of 
the myeloid lineage. Their role in tumour progression as regulators of the “pre-metastatic 
niche” has certainly been a breakthrough in better understanding of their function in 
carcinogenesis (Srikrishna, 2012). Moreover, these proteins have also been shown to 
carry a prognostic significance in a variety of cancers aiding cell motility through the 
multiligand receptor, RAGE signalling pathway.
My experimental work followed on from the discovery of S100A8 and S100A9 proteins 
in the stromal elements of microdissected pancreatic cancer samples using 2DE 
proteomic analysis. I was able to further validate this, demonstrating that ductal elements 
of pancreatic cancer did not express S100A8 and S100A9 proteins and it was stromal 
myeloid cells, that is stromal monocytes that exhibited high levels of expression of these 
proteins. Additionally, none of the other stromal cells demonstrated any expression of 
these proteins as seen in the co-immunoflorescence experiments. Immunohistochemical 
analysis of the TMA indicated varying numbers of cells expressing these proteins per 
tumour core with SMAD4 negative tumours having significantly fewer number of 
S100A8-postive cells in their stroma compared to S100A9-positive cells. Moreover, the 
ratio of S100A9/S100A8 positive cells was significantly higher in SMAD4 negative 
tumours compared to SMAD4 positive tumours (Sheikh et al., 2007). Thus, a strongly 
negative relationship between the expression of SMAD4 in tumours cells and the 
expression of S100A8 in stromal monocytes was established. This indicated channels of
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crosstalk between the pancreatic cancer cells and the stroma which was potentially 
influenced by the SMAD4 status of the tumour.
The presence of S100A8 in a subset of S100A9-positive pancreatic cancer stromal cells 
on immunoflorescence mirrored findings published by Zwadlo et al. that the presence of 
both SI00 proteins in monocytes is expressed at early stages of monocyte differentiation 
being down regulated during maturation to macrophages (Zwadlo et ah, 1988). The 
varying number of cells per tumour core expressing S100A8 and S100A9 indicated that 
the tumour cells may well be influencing this process with SMAD4 being a key regulator. 
Levels of expression of both of these proteins did not influence survival and no 
association to patient parameters was established other than their relation to the tumour 
phenotype.
In vitro interaction experiments between pancreatic cancer cell secretome and monocytes 
demonstrated induction of S100A8 and S100A9 proteins in both primary monocytes and 
monocytic cell lines indicating crosstalk between both cell types. The presence of VEGF- 
A and TGF-|3 soluble factors in the tumour secretome, suggested their potential role in 
inducing S100A8 and S100A9 expression as is the case in other cancer models in the 
literature. Immunohistochemical analysis of the pancreatic cancer TMA also 
demonstrated a strong presence of TGF-pU in both the tumour and stromal compartments. 
Importantly, only the presence of tumour nuclear TGF-pl expression significantly
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correlated to stromal S100A8 and S100A9 expression with no correlation seen between 
the SI00 proteins and stromal TGF-(31 expression. This suggested that the presence of 
TGF-pi in the cancer cells was one of the mediators effecting the expression of S100A8 
and S100A9 in monocytes both in cellular experiments and in the microenvironment. 
TGF-(31 overexpression was also seen to be associated with a poor 2-year survival that is 
consistent with the literature. In the face of TGF-(31 having no correlation to patient 
parameters i.e. perineural invasion, lymphovascular invasion and metastasis this is a 
significant finding warranting further validation in a larger cohort of patients. It can be 
concluded from my immunohistochemical and cellular experiments that monocytes 
expressing both S100A8 and S100A9 are recruited to the tumour microenvironment in 
response to growth factors such as TGF-pi produced by the tumours cells. Once recruited 
from the blood stream they initially express both S100A8 and S100A9 and as they 
mature, they lose S100A8 expression, leaving only S100A9 which is also subsequently 
lost as the cells matures further to form macrophages. The presence of CD68 
macrophages and the strong correlation they have to the number of S100A8- and 
S100A9-positive cells in the cancer stroma further consolidates this process and the role 
cells of myeloid linage have in the cancer microenvironment. I was also able to postulate 
that the rate of differentiation of monocytes once recruited to the microenvironment could 
well be influenced by the tumour SMAD4 expression (Sheikh et at., 2007). From my IHC 
data of the TMA it can be postulated that in SMAD4-negative tumours S100A8 
expression becomes very transient, leaving relatively greater numbers of cells expressing 
only S100A9; thought my experimental data did not support these findings, data from 
Ang et al. did support this hypothesis (Ang et aL> 2010). Likewise other tumour
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characteristics may influence the rate of maturation and expression of S100A8 and 
S100A9 in the pancreatic cancer microenvironment, these have yet to be evaluated.
The induction of S100A8 and S100A9 in monocytes from pancreatic cancer cell 
conditioned medium and its associations to the cancer phenotype on the IHC analysis 
indicated a crosstalk channel. Therefore, I sought to determine the response recombinant 
S100A8 and S100A9 proteins had on cancer cell motility and proliferation. In this 
process, I also aimed to understand whether the SMAD4 status of the cancer affected 
growth or motility of the tumours when treated with recombinant S100A8 and S100A9 
proteins. It can be concluded that both proteins proved to be highly chemotactic and 
proliferative for pancreatic and colorectal cell lines cancer cell lines, regardless of 
whether the cells expressed SMAD4 or not. Experiments with neomycin-resistant clonal 
derivatives of SW-480 cells, stably re-expressing SMAD4 and transient knockdown 
SMAD4 cellular experiments, all showed enhanced motility in response to S100A8 and 
S100A9 despite differing levels of SMAD4. I am unable to draw any substantial 
conclusions as to whether the SMAD4 status of the cancer cell effects its chemotactic or 
proliferative response to the SI00 proteins.
Future direction of work should me aimed at elucidating the effects SMAD4 status has on 
S100A8-GST and S100A9-GST induced migration activity. My colleague Mr C. Ang 
revisited the transient siRNA-mediated depletion of SMAD4 in PANC-1 cells
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experiments. He successfully demonstrated that knockdown of SMAD4 produced a 
significant reduction in motility and a loss of responsiveness to S100A8-GST, but not 
S100A9-GST when cells underwent a transient knockdown of SMAD4. He also 
demonstrated that SMAD4 re-expressing SW-480 subclones have a differential response 
to S100A8 and S100A9 proteins based on their levels of SMAD4 expression. SMAD4- 
restored SWD20 ceils showed increased proliferation in response to S100A8-GST and 
S100A9-GST, with their SMAD4-negative clonal counterpart, SWK3 cells showing 
increased proliferation in response to S100A9-GST only. Both of these experiments 
suggested that SMAD4 was important in regulating the proliferative response to 
exogenous S100A8 (Ang et al., 2010).
It can be concluded that monocytes expressing both S100A8 and S100A9 are recruited to 
the tumour microenvironment in response to growth factors such as TGF-[3 which are 
produced by the tumours cells and other stromal components. The production of 
S100A8/A9 may promote further recruitment of inflammatory cells but is influential in 
aiding cancer cell growth and invasion. A relationship between the phenotype of the 
tumour cells i.e. their SMAD4 status and S100A8 and S100A9 does exist as 
demonstrated by Ang et al (Ang et al., 2010). His work indicates that the crosstalk 
between SMAD4-negative cancer cells and myeloid cells occurs in a microenvironment 
that involves S100A9 to a greater extent than S100A8 and where the cancer cells respond 
better to S100A9 than S100A8. Either way experiments undertaken by Ang et al and 
myself indicate that crosstalk between the cancer cells and myeloid cells does occur with 
S100A8 and S100A9 being 2 proteins at the crossroads.
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This understanding of the relationship between cancer cells and S100A8/S100A9 proteins 
which is just one of the molecular interactions in the tumour microenvironment 
representing a small cog in a large machine. Certainly further studies to evaluate the 
mechanisms of S100A8/A9 signalling in the pancreatic and colorectal cancer tumour 
microenvironment will shed light on how these proteins influence the processes of 
tumour development and spread. Further cancer mouse model experiments using 
blocking antibodies to these SI00 proteins will provide the first steps for utilisation of 
these proteins as therapeutic targets.
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The expression of S100A8 in pancreatic cancer- 
associated monocytes is associated with the Smad4 
status of pancreatic cancer cells
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The cross-talk between tumour cells and the surrounding supporting host cells (stroma) is a key Received: December 1, 2006
regulator of cancer growth and progression. By undertaking 2-DE analysis of laser capture Revised: January 25,2007
microdissected malignant and stromal components of pancreatic tumours and benign ductal Accepted: February 24 2007 
elements, we have identified high levels of S100A8 and S100A9 in tumour-associated stroma but 
not in benign or malignant epithelia. Immunohistochemical analysis (n = 71 patients) revealed 
strong expression of both proteins in stromal myeloid cells, subsequently identified as CD14+/
CD68'monocytes/macrophages. Co-immunofluorescence revealed that S100A8 was expressed in 
a subset of S100A9-positive cells. Correlation of the expression of S100A8 and S100A9 to patient 
parameters revealed that the microenvironments of tumours which lacked expression of the 
tumour suppressor protein, Smad4, had significantly reduced numbers of S100A8-immuno- 
reactive (p = 0.023) but not S100A9-immunoreactive (p = 0.21) cells. The ratio of S100A8- to 
S100A9-positive cells within individual tumours was significantly lower in Smad4-negative 
tumours than in Smad4-positive tumours (p<0.003). Pancreatitic specimens also contained 
S100A8- and S100A9-expressing cells, although this was not observed in regions displaying 
extensive fibrosis. In conclusion, our study provides an extensive analysis of S100A8 and S100A9 
in pancreatic disease and highlights a potentially important relationship between pancreatic 
cancer cells and their surrounding microenvironment.
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1 Introduction
Pancreatic cancer is one of the most aggressive human can­
cers. Globally it is one of the leading causes of cancer-related 
deaths, accounting for over 200 000 deaths in the year 2000 
alone [1]. A characteristic genetic signature has been eluci-
# These authors contributed equally to this work.
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dated for pancreatic cancer and includes genetic alterations in 
K~ras, p53, pl6INK4a and Smad4 [2]. Surgical resection is still 
the only realistic form of curative intervention; however, only 
up to 9% of patients undergo a potentially curative procedure 
[3], as the disease is often at an advanced stage at the time of 
diagnosis. Given the currently dismal outlook for patients 
with pancreatic cancer, considerable effort is being directed 
towards further identifying cytogenetic characteristics and 
molecular mechanisms contributing to the disease.
The distinct molecular ‘cross-talk' between cancer cells 
and surrounding host cells is currently being examined in a 
number of settings [4]. Such signalling can result in mod­
ification of the microenvironment by the tumour cells 
themselves, in order to facilitate tumour invasion and pro­
gression. Host stromal cells may also influence tumour be­
haviour [5, 6] and stimulate tumour proliferation [7], In 
addition to influencing tumour behaviour; specific stromal 
components have also emerged as markers of poor survival 
in cancer patients [8, 9].
Pancreatic cancer shows a characteristically intense des­
moplastic stroma, which can account for up to 75% of the 
pancreatic tumour volume [10]. It is composed of a number of 
different host cell types, including fibroblasts, small endo­
thelial-lined vessels and a variety of inflammatory cells, which 
are both locally derived and recruited from the circulation. 
lacobuzio-Donahue et d. [11, 12] subdivided the pancreatic 
host stromal compartments into two distinct regions: juxta- 
tumoural stroma and panstroma. The term ‘juxtatumoural 
stroma' refers to stromal cells that are in direct contact with 
the tumour, while ‘panstroma’ refers to all stromal cells 
within the desmoplastic response to an infiltrating tumour. 
The pattern of gene expression in these stromal subcompait- 
ments was found to be distinct [12], potentially reflecting spe­
cific roles for each subcompartment. Whilst pancreatic cancer 
cells have been demonstrated to both modify [13] and be 
influenced by their surrounding microenvironment [5, 6], 
much remains to be elucidated about the interactions be­
tween this cancer type and its microenvironment.
We have previously employed proteomic-based studies to 
determine differential protein expression in pancreatic can­
cer [14]. In the present study, we employed laser capture 
microdissection and 2-DE to analyse protein expression in 
the stromal cells surrounding malignant pancreatic ductal 
cells. Two of the proteins we found to be preferentially 
expressed in host stromal cells compared to malignant or 
benign ductal cells are members of the S100 family of pro­
teins: S100A8 (calgranulin A, MRP8) and S100A9 (cal- 
granulin B, MRP 14).
These proteins have been implicated in a variety of 
inflammatory pathologies, where they have been specifically 
linked to monocytes and immature macrophages [15, 16]. 
They can exist as homodimers, although they form stable 
heterodimeric complexes [17] that are secreted at sites of 
inflammation [18]. They are thought to have a pro-inflam­
matory effect, involved in recruitment and migration of 
inflammatory cells [16,19, 20].
The SI 00 family of proteins appears to play a significant 
role in many cancers. We [14, 21-23] and several other 
groups [24—27] have previously reported the dysregulated 
expression of members of the S100 gene family of calcium­
binding proteins (e.g. S100A6, S100P, S100A4, S100A2 and 
S100A11) in pancreatic adenocarcinoma. In the current 
study, we characterised the expression of S100A8 and 
S100A9 in the panaeatic cancer microenvironment and in 
so doing, observed a significant association between the 
number of S100A8 positive cells and the Smad4 status of 
tumours.
The study was performed with ethical approval from 
Cheshire and Merseyside Health Authority (Hamilton 
House, 24 Pall Mall, Liverpool, L3 6AL, UK), LREC ref: 03/ 
02/316 A.
2 Materials and methods
2.1 Tissue preparation and laser capture 
microdissection
For the purposes of laser capture microdissection, frozen 
tissue was obtained and prepared as described previously 
[14]. Briefly, pancreatectomy specimens were obtained fol­
lowing surgery, with full ethical consent, examined by a spe­
cialist pathologist, cryofixed in liquid isopentane (-160°C) 
cooled by liquid nitrogen, and stored at -80°C. A histological 
diagnosis of pancreatic ductal adenocarcinoma was neces­
sary for inclusion in the study. For staining, 7-pm-thick fro­
zen sections were cut onto slides (that were pre-cleaned 
using detergent, washed with deionised water and oven- 
dried at 40°C) using a Bright OTF 5000 cryostat (chamber 
temperature -25°C). Sections were placed on dry ice or kept 
in the cryostat chamber prior to staining, Haematoxylin and 
eosin staining [14] was carried out only for monitoring of 
tissue sections. Methyl green staining of the sections used 
for laser capture microdissection was as follows: sections 
were fixed (using 70% ethanol for 1 min), washed in deion­
ised water for 15-30 s, stained with violet-free methyl green 
(2% w/v in deionised water) for 30 s, rinsed twice in deion­
ised water and dehydrated (70% ethanol for 30 s, 95% etha­
nol for 30 s, 2 x 100% ethanol for 30 s, xylene 2 x for 5 min). 
Complete protease inhibitor cocktail tablets (Roche) were 
added to the staining solutions (one tablet/80 mL solution). 
Following staining with methyl green, sections were air- 
dried and microdissected using an Arcturus PixCell II sys­
tem (Arcturus, Mountain View, CA, USA) with a 7.5-pm 
laser beam. Power and pulse duration were typically set at 
70 mW and 3-10 ms, respectively. An estimated 50 000 cells 
were laser captured using an average of 25 000 pulses (with 
the exception of proteins separated in Figs. IE and F, which 
were derived from an estimated 150 000 laser captured cells). 
In each case of stroma examined (n = 3), the stromal com­
partment was subdivided into two separate regions for 
microdissection, stromal cells adjacent to cancer cells denot­
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ed as juxtatumoural stroma, and all other stroma denoted 
panstroma. A total of four dissected benign and four dis­
sected malignant samples were analysed. In two cases, both 
the benign and malignant samples were form the same 
patient, and in one case the malignant and stromal sample 
were derived from the same patient.
2.2 Protein extraction and 2-D separation
Proteins were extracted from microdissected cells in lysis 
buffer (7 M urea, 2M thiourea, 4% CHAPS, 40 mM Tris 
base, 1% w/v DTT), Accurate protein quantification using 
conventional protein assays was rendered difficult due to the 
minute quantities of protein extracted from 50000 laser 
capture cells as well as the incompatibility of the lysis buffer 
with such assays. However, normalisation for the purposes 
of even gel loading was necessary and was undertaken as 
described in detail previously [14]. Briefly, sample protein 
concentrations were estimated relative to a reference sample 
lysate. Twofold dilution series, from undiluted to a l-in-16 
dilution of the test samples and reference sample, were pre­
pared in lysis buffer, mixed with two volumes of sample 
loading buffer (62.5 mM Tris-HCl, pH 6,8, 25% w/v glycerol, 
2% w/v SDS, 5% v/v 2-mercaptoethanol) containing a trace 
of bromophenol blue, heated at 95°C for 10 min and both 
test and reference samples subjected to 1-D SDS-PAGE on 
small format gels (10% separating and 4% stacking gels) at a 
constant voltage of 150 V. Gels were silver-stained, densito- 
metrically scanned and analysed using TotalLab software 
(Nonlinear Dynamics) to inform our estimation of relative 
protein amounts in the test samples compared to the refer­
ence sample.
2.3 Gel alignment for spot picking and protein 
identification
The separation of proteins from an estimated 50000 laser 
capture-procured cells yielded insufficient protein for identi­
fication by MS. Therefore, for the identification of S100A8 
and S100A9, alignment of gels was undertaken stepwise as 
follows: Silver-stained gels displaying proteins from 50 000 
laser capture-procured stromal cells were carefully aligned 
with silver-stained gels containing protein from an estimated 
150 000 laser capture-procured tumour cells. The latter were 
subsequently aligned with silver-stained gels containing 
protein from one complete undissected stroma-rich tumour 
tissue section and this gel was aligned with a CBB -stained 
gel containing protein from 30 complete, stroma-rich 
tumour tissue sections. In this way landmark reference pro­
tein spots were established, facilitating the location of pro­
tein spots of interest. Following spot picking, in-gel trypsin 
digestion was then performed and in the case of S100A9, a 
peptide mass fingerprint was obtained on a MALDI-TOF 
mass spectrometer (Voyager DE Pro, Applied Biosystems, 
Framingham, USA) and resultant mass lists searched 
against the NCBI database using MASCOT (Matrix Science),
with a peptide tolerance of 100 ppm. In the case of S100A8, 
LC-MS/MS analysis was necessary. The tryptic digest was 
delivered into a QSTAR® Pulsar i hybrid mass spectrometer 
(Applied Biosystems) by automated in-line RP-LC (integrated 
LCPackings System, 5 mm C18 p-precolumn cartridge and 
75 f.imx 15 cm CIS column, Dionex, Camberley, UK) via a 
nano-electrospray source head and a 10-pm id PicoTip (New 
Objective, Woburn, USA). A gradient from 5% ACN/0,05% 
TFA v/v to 48% ACN/0.05% TEA v/v in 60 min was applied 
at a demanded flow rate of 200 nL/min, and MS and MS/MS 
spectra were acquired automatically in positive ion mode 
using information-dependent acquisition (Analyst® soft­
ware, Applied Biosystems). Data were again submitted to 
MASCOT and the NCBI database was searched with the MS 
tolerance set to 1.2 Da and the MS/MS tolerance to 0.6 Da, 
with no modifications allowed.
2.4 Immunohistochemical staining
Immunohistochemical staining of three tissue microarrays 
(TMAs) was undertaken essentially as described previously 
[14]. The TMAs were as follows: (i) a pancreatic cancer (pan­
creatic ductal adenocarcinoma) microarray containing 
duplicate malignant specimens from 71 patients along with 
matched benign tissue from 53 patients (248 cores in total), 
and eight cores each of normal colonic, liver and kidney 
samples; (ii) a chronic pancreatitis tissue array containing 
cores representing 24 chronic pancreatitis specimens plus 24 
normal pancreas specimens, each arrayed in duplicate (96 
cores in total) with five cores each of normal colonic, Ever 
and kidney samples.
Five-micron-thick sections were deparaffinised in 
xylene and then rehydrated through alcohol to distilled 
water. Antigen was retrieved by pressure-cooking the slides 
in 10 mM EDTA (pH 7.0) for 3 rain. Immunohistochem­
ical staining was performed using an automatic staining 
system (Universal Staining System, DAKO). Slides were 
incubated for 1 h with polyclonal goat anti-human S100A8 
(0.1 pg/mL; Santa Cruz Biotechnology) or polyclonal rabbit 
anti-human S100A9 (0.2 pg/mL; Santa Cruz Biotechnol­
ogy), or an mAb raised against human Smad4 (clone B8; 
2.0 pg/mL, Santa Cruz Biotechnology), rinsed in PBS and 
the antibody localisation visualised by incubating sections 
with a HRP-conjugated secondary antibody for 30 min 
followed by diaminobenzidine (DAKO) for 10 min. Slides 
were counterstained with haematoxylin for 2 min, dehy­
drated with 100% ethanol and xylene and coverslips 
mounted with D.P.X. mountant (BDH). Negative controls 
were incubated with the labelled secondary antibodies 
only. Both TMAs were scored in a similar manner by spe­
cialist histopathologists. For S100A8 and S100A9, the 
numbers of positive cells per core were counted at a mag­
nification of 40 x . For Smad4, negative cases were defined 
as the complete absence of expression, as described pre­
viously [28].
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2.5 Immunofluorescence
Sections were de-waxed in xylene and rehydrated in graded 
ethanol to distilled water. Heat-mediated antigen retrieval 
was performed in a pressure cooker containing 10 mM/L 
EDTA (pH 7.4) in which sections were treated at full pres­
sure for 3 min. Manual staining was then undertaken in a 
flat-bed incubation tray. Primary antibodies (polyclonal goat 
anti-human S100A8 (0.1 pg/mf; Santa Cruz Biotechnology) 
or polyclonal rabbit anti-human S100A9 (0.2 pg/mL; Santa 
Cruz Biotechnology) or anti-CD14 (monocyte/macrophage 
marker; diluted 1:200), or anti-CD68 (mature macrophage 
marker; diluted 1:4000) or anti-smooth muscle actin (smooth 
muscle/myofibroblast marker; diluted 1:50) or anti-desmin 
(smooth muscle/myofibroblast marker; diluted 1:40) or anti- 
vimentin (diluted 1:200), or anti-CD20 (B lymphocyte mark­
er; diluted 1;4000) or anti-CD34 (endothelial marker; diluted 
1:50) or anti-CD38 (plasma cell marker; diluted 1:100) or 
anti-CD3 (T-cell marker; diluted 1:100) or anti-CD79A (B-cell 
marker; diluted 1:500) or anti-mast cell trypsin (mast cell 
marker; diluted 1:400) were applied singly or concurrently in 
pairs for 60 min, after which sections were washed in TBS 
and incubated for 60 min with a mixture of two fluorescently 
labelled secondary antibodies: e.g. FITC-labelled donkey anti­
goat IgG (30 pg/mL; Santa Cruz Biotechnology) and TRITC- 
labelled swine anti-rabbit Ig’s (25 pg/mL; DakoCytomation) 
for detection of S100A8 and S100A9, respectively. Sections 
were washed in TBS and mounted in aqueous mounting 
medium containing DAPI (Vector Laboratories, Peterbor­
ough, UK). Negative controls were performed using antibody 
diluent only in place of primary antibody.
2.6 Statistical analyses
All statistical analyses were performed using Statview ver­
sion 5.01 (SAS Institute). Results were considered significant 
for p-values <0.05. To evaluate the extent of S100A8 and 
S100A9 expression in pancreatic tumour-associated stroma, 
the number of positively stained cells in each TMA core was 
determined and the mean number of positive cells per 
duplicate patient core calculated. For the purpose of analysis, 
patients were categorised into two groups: those with 
S100A8-positive cell counts >median (high S100A8) and 
those with SlOOAS-positive cell counts <median (low 
S100A8). Groups were similarly established for high and low 
S100A9. Continuous variables were compared using the 
Mann-Whitney U or the Wilcoxon signed rank test. Asso­
ciations between the number of S100A8- or S100A9-positive 
inflammatory cells and each of the clinicopathologic param­
eters below were established by cross-tabulating data and 
applying Fisher’s two-sided exact test, (x2-test for tumour 
grade). Clinical data were available for gender, age at surgery, 
lymph node status, resection margin status, tumour size 
(<20mm versus >20mm), tumour grade, and presence of 
vascular and peri-neural invasion. To examine a correlation 
between S100A8- or S100A9-positive inflammatory cells and
patient survival time, life tables were constructed from sur­
vival data and Kaplan-Meier curves plotted. Comparisons 
between groups were performed using the log-rank test. 
Survival time was measured from date of initial surgery to 
date of death, counting death from any cause as the end 
point or the last date of information as the end point if no 
death was documented.
3 Results
3.1 Proteomic analysis of dissected pancreatic 
compartments revealed differences in the 
intensities of spots denoted X and Y
Using a 2-DE approach, we previously reported differential 
protein expression between laser capture-procured popula­
tions of benign and malignant pancreatic ductal epithelial 
cells [14]. Further proteomic analyses comparing similar 
quantities of microdissected tumour-associated stroma with 
benign or malignant ductal cells were performed. Specifical­
ly, comparisons of similarly loaded silver-stained gels pro­
duced with protein from approximately 50 000 laser capture- 
procured benign ductal epithelial cells (n = 3 patients), 
malignant cells (n = 3 patients), juxtatumoural stroma cells 
(n= 3 patients) and panstroma cells (n = 3 patients) was 
undertaken. An example of each gel type is shown in 
Figs. 1A-D. Analysis of all 12 2-D gels revealed two spots 
(labelled X and Y, Fig. 1) with higher intensities in gels con­
taining stromal-derived proteins compared to the gels con­
taining proteins from benign or malignant ductal cells. Spot 
X (denoted by squares in Fig. 1) was detected on both juxta­
tumoural and panstromal gels derived from all three patients 
(examples are shown in Figs. 1C and D). The spot intensities 
between juxtatumoural and panstromal gels for samples 
derived from the same patients were similar, indicating no 
detectable difference in the expression of this protein be­
tween juxtatumoural stroma and panstroma. In contrast, 
spot X was either undetectable (Figs. 1A and B) in benign 
(n = 2) and malignant cases (n = 2) or scarcely detectable in 
benign and malignant cases (n = 1 sample taken from same 
patient, not shown in the figure). Similarly, spot Y (denoted 
by circles in Fig. 1) was detected, with similar intensities on 
juxtatumoural and panstromal gels (see Figs. 1C and D), 
which were derived from two patients. Spot Y was undetect­
able in all benign (n = 3) and malignant (n - 3) cases exam­
ined. In one instance, juxtatumoural stroma, panstroma and 
malignant cells were derived from the same patient. In this 
case, both spots X and Y were detected on gels containing 
stroma-derived protein (juxtatumoural stroma and pan­
stroma), while neither protein spot was detected in the gel 
containing protein from malignant cells.
The gels produced with protein from approximately 
50000 laser capture-procured cells described above were 
compared with gels (Figs. IE and F) produced with protein 
from approximately 150 000 laser capture-procured benign
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Figure 1. Silver-stained gel im­
ages containing proteins extract­
ed from 50 000 laser capture-pro- 
cured benign (A), malignant (B), 
juxtatumoural (C) and panstro- 
mal (D) cells, as indicated. Panels 
E and F represent silver-stained 
gel images containing proteins 
extracted from approximately 
150000 laser capture-procured 
benign (E) or malignant cells (F). 
The juxtatumoural and panstro- 
mal cells used in panels C and D 
were patient-matched, as were 
the benign and malignant cells in 
panels E and F.
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and malignant cells which were derived from the same 
patient. While both the X and Y protein spots were detected 
on these gels, they were comparatively weakly stained de­
spite the increased protein load, compared to their appear­
ance on stromal gels.
3.2 S100A8 and S100A9 are overexpressed in 
tumour-associated stroma
Spots X and Y were not definitively identified from silver- 
stained gels containing protein from approximately 50000 
laser capture-procured cells, due to insufficient material. 
Therefore, such gels were aligned with bulk-loaded CBB- 
stained gels and proteins identified from the latter. Align­
ment of gels was undertaken stepwise, starting with silver- 
stained gels with low protein loads, and progressing to silver- 
stained gels containing protein from one undissected 
stroma-rich tumour tissue section and finally aligning with a 
CBB-stained gel containing protein from 30 undissected 
stroma-rich tumour tissue sections. This enabled landmark 
reference protein spots to be established, facilitating the 
location of the protein spots of interest, which were subse­
quently picked up from the bulk-loaded gel. Following LC- 
MS analysis, three peptides were detected for spot X 
(GNFHAVYR, ALNSIIDVYHK and carboxamidomethylated 
LLETECPQY1R), resulting in an overall MOWSE score of 
157 and a sequence coverage of 31%. The protein was iden­
tified as S100A8 or calgranulin A/MRP 8 (NCB1 accession 
number CAG28602). S100A8 is small (10.9 kDa) and basic 
(pj 9.19) due to an unusually high occurrence of lysine resi­
dues (12.9%), so that obtaining a higher sequence coverage 
using trypsin as the digestion reagent would be difficult. 
MALDI-MS led to the detection of four peptides for spot Y 
(DLQNFLK, LGHPDTLNQGEFK, N1ET1INTFHQYSVK, 
MHEGDEGPGHF1HKPGLGEGTP), resulting in an overall 
MOWSE score of 397 and a sequence coverage of 49%. This 
protein was identified as S100A9 or calgranulin B/MRP 14 
(NCBI accession number CAG47020), which is also small 
(13.2 kDa) and has a pf of 5.7. Since the gels from which 
spots were picked for identification contained both tumour 
and stromal proteins, the possibility that the proteins identi­
fied were not the same proteins as those present in spots X 
and Y on stromal gels loaded with laser capture-procured 
material could not formally be ruled out. Thus, validation of 
our proteomic findings was sought using an independent 
technique, described in the following sections.
3.3 Immunohistochemicai analysis of pancreatic 
cancer specimens confirmed high S100A8 and 
S100A9 expression in cells of tumour-associated 
stroma
Immunohistochemicai staining of a pancreatic cancer TMA 
for S100A8 resulted in no specific immunostaining of either 
benign or malignant epithelial cells (Figs. 2A-C). By con­
trast, strong S100A8 immunostaining was readily detected in
S100A8 S100A9
\ &
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Figure 2. Photomicrographs showing selected sections of 
benign and malignant tissue, as indicated, from a pancreatic 
cancer microarray, immunohistochemically stained for S100A8 
(left panel) and S100A9 (right panel). BD - benign duct, IF = 
inflammatory cell, S = stroma, T= tumour cell. Examples of can­
cer tissues with low (B, E) and high (C, F) numbers of positively 
stained inflammatory cells are shown.
the inflammatory cells of tumour stroma (Figs. 2B and C). 
Some tumours contained a limited number of S100A8-posi- 
tive inflammatory cells (Fig. 2B, see below for a detailed 
analysis), while others displayed a high density of S100A8- 
positive cells infiltrating the tumour (Fig. 2C). S100A9 dis­
played a very similar pattern of expression to that of S100A8 
(Figs. 2D-F). It was not detected in benign or malignant 
epithelial cells; however, distinct S100A9 immunostaining 
was evident in inflammatory cells in the stromal component 
of all tumours (71/71).
3.4 S100A8 is detectable in a subset of
S100A9-positive cells
Immunofluorescent double staining experiments on pan­
creatic cancer specimens showed co-localisation of S100A8 
or S100A9 with CD14, a monocyte/macrophage marker. 
Neither of the S100 proteins was co-expressed with CD68, a 
marker of mature macrophages (not shown). Moreover, cel­
lular markers of smooth muscle, myofibroblasts, lympho­
cytes, T- and B-cells, endothelial cells, mast cells and plasma 
cells also failed to co-localise with S100A9 (not shown).
To determine whether S100A8 and S100A9 were co­
expressed in the same cells, additional immunofluorescent 
double staining experiments were performed (n = 3 inde­
pendent pancreatic cancer cases). Serial sections were incu-
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bated separately or concurrendy with polyclonal goat anti- 
S100A8 and/or polyclonal rabbit anti-S100A9. In all cases, 
this was followed by the applicadon of two fluorescendy 
labelled secondary antibodies (i.e. the FITC-labelled donkey 
anti-goat IgG for the detection of the S100A8 antibody and 
the TRITC-labelled swine anti-rabbit Ig's for the detection of 
the anti-S100A9 antibody). This enabled the detection of any 
non-specific cross-reactivity of secondary antibodies. Under 
conditions of respective single labelling (Figs. 3A and B), 
S100A8 immunoreactive cells (green, Fig. 3A) and S100A9 
immunoreactive cells (red, Fig. 3B) were clearly visible and 
were confined to the stroma. Cross-reactivity between pri­
mary goat and secondary rabbit or primary rabbit and sec­
ondary goat antibodies was not detected (Figs. 3A and B, 
respectively). Tumour cells were unstained. Dual staining 
(Fig. 3C) revealed the presence of cells expressing both 
S100A8 and S100A9 (yellow). Under the conditions of dual 
staining, a number of cells showed expression of S100A9 
only (red). However, cells expressing S100A8 only were not 
detectable. An example of a tumour in which the majority of 
cells are co-labelled is also shown (Fig. 3D). Thus, S100A8 
was detected in a subset of S100A9-positive cells contained 
within the stromal compartment of pancreatic sample.
Figure 3. Pancreatic cancer sections were stained for (A) immuno­
fluorescence analysis with anti-Sl00A9-TRITC (red), (B) anti- 
S100A8-FITC (green), (C) co-stained with anti-S100A8-FITC and 
anti-S100A9-TRITC in a patient with a low S100A8-to-S100A9 
ratio, where A-C were serial sections from the same patient, (D) 
co-stained with anti-S100A8-FITC and anti-S100A9-TRITC in a 
patient with a high S100A8-to-S100A9 ratio.
3.5 Quantification of S100A8 and S100A9 staining 
and correlation with patient parameters
To evaluate the extent of S100A8 and S100A9 expression in 
pancreatic tumour-associated stroma, the number of posi­
tively stained cells in each tumour core of the immuno- 
stained cancer microarray was determined and the mean 
number of positive cells per duplicate patient core plotted 
(Fig. 4). Tumours contained significantly lower numbers of 
S100A8-positive cells than S100A9-positive cells, as evi­
denced by a median number of S100A8-positive cells of 15.0 
(inter-quartile range (IQR) 5.2-43.7) compared to a median 
number of 35 (IQR 20—74.5) of S100A9-positive cells 
(pCO.OOOl, Wilcoxon signed rank test). Overall, tumours 
contained 0.28- to 16-fold (median 2.2, IQR 1.48—4.5) 
greater numbers of S100A9-positive cells than S100A8- 
positive cells.
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Figure 4. Mean S100A8- and S100A9-positive cell counts in pan­
creatic cancer specimens from 71 patients shown as box plots. 
The p-value shown is for comparison of the median number of 
cells positive for S100A8 and S100A9 using the Wilcoxon signed 
rank test.
For the purposes of examining associations between the 
number of S100A8- or S100A9-immunopositive cells and 
other patient parameters, patients were categorised into two 
groups, i.e. those having positive cell numbers less < to the 
median or > than the median for the respective proteins. A 
strong positive correlation was observed between the num­
ber of S100A8- and S100A9-positive cells (Fisher’s exact test, 
p = 0.0001). For the parameters of gender, age at surgery, 
nodal metastases, tumour size and grade, data for 71 
patients were available. Resection margin status, vascular 
invasion and peri-neural invasion data were available for 63, 
65 and 68 patients, respectively. No associations were 
observed between the numbers of stromal associated 
S100A8- or S100A9-positive cells and these din- 
icopathologic parameters (Table 1). Survival data for all 71 
patients, three of whom were alive at the time of analysis, 
were available. Kaplan-Meier analysis indicated that the 
number of S100A8- or S100A9-positive cells did not corre­
late with patient survival (Log-rank p value, 0.72 and 0.49 for 
S100A8 and S100A9, respectively).
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Tablet. Pancreatic cancer: S100A8- and S100A9-positive cells and association with clinicopathologic parameters
Parameter All cases 
n = 71
(%)
Low
S100A8+ 
(<median) 
n = 36 (%)
High 
S100A8+ 
(>median) 
n = 35 (%)
Signif. Low
S100A9+ 
(<median) 
n = 39 (%)
High 
S100A9+ 
(>median) 
n = 32 <%)
Signif.
Gender
Male 43 (61) 25 (69) 18(51) nsal 23(59) 20 (63) nsal
Female 28 (39) 11 (31) 17 (49) 16(41) 12(37)
Age at surgery
<60 years 20 (28) 7(19) 13(37) nsal 7(18) 13(40) ns* a)
>60 years 51 (72) 29(81) 22 (63) 32(82) 19 (60)
Tumour size
<20 mm 22 (31) 13(36) 9(26) nsa) 13 (33) 9 (28) nsal
>20 mm 49 (69) 23 (64) 26 (74) 26 (67) 23(72)
Tumour grade
Poorly dif. 25 (35) 13(36) 12(34) 15(38) 10(31)
Moderate dif. 36(51) 15 (42) 21 (60) nsb) 17 (44) 19(59) nsb)
Well dif. 10(14) 8 (22) 2(6) 7 (18) 3 (10)
Nodal metastases
Present 57 (80) 28 (78) 29 (83) nsa) 37 (79) 26 (81) nsa|
Not present 14(20) 8 (22) 6(17) 8(21) 6(19)
Involved resection margin {n = 63)
Yes 42 (59) 22 (61) 20 (57) nsal 24 (67) 18(56) nsa)
No 21 (30) 9(25) 12(34) 10(26) 17 (34)
Not recorded (n = 8) 8(11) 5(14) 3(9) 5(13) 3 (10)
Vascular invasion (n = 65)
Present 54 (76) 28 (78) 26 (74) 32 (82) 22 (69)
Not present 11 (16) 5(14) 6(17) nsal 4(10) 7 (22) nsal
Not recorded (n = 6) 6(8) 3(8) 3(9) 3(8) 3(9)
Neural invasion (n = 68)
Present 65 (92) 33 (92) 32 (91) 37 (95) 28 (88)
Not present 3(4) 1 (3) 2(6) nsa) 0(0) 3(9) nsa)
Not recorded (n = 3) 3(4) 2(5) 1 (3) 2(5) 1 (3)
All values shown in parentheses are percentages
a) Fisher's two-sided exact test (significance set at p<0.05)
b) x2 test (significance set at p<0.05); ns = not significant
3.6 Loss of Smad4 expression is associated with 
reduced numbers of S100A8- but not 
S100A9-positive inflammatory cells
Smad4 expression data were available for 64 patients, of 
whom 29 patients (45%) were Smad4 negative. The number 
of S100A9-positive cells was independent of the Smad4 sta­
tus of tumours (Table 2: p = 0.21 Fisher’s exact test). By con­
trast, Smad4-negative tumours were associated with low 
numbers of SlOOAS-positive cells (p = 0,023, Table 2). When 
the mean number of S100A8-positive cells per tumour was 
examined relative to Smad4 status (Fig. 5A), Smad4-negative 
tumours had significantly fewer SlOOAS-positive cells (me­
dian 8, IQR 3.0-20) compared to Smad4-positive tumours 
(median 20.5, IQR 9-49; p = 0.01, Mann-Whitney LT-test).
Such a relationship was not established for S100A9-positive 
cells and Smad4 status (Fig. 5B). The median number of 
SlOOA9-positive cells in Smad4-negative tumours was 28 
(IQR 18.7-60), compared to a median of 40 (IQR 23.5-98.2) 
in Smad4-positive tumours (p = 0.21, Mann-Whitney U-test). 
To examine the relationship between S100A8- and S100A9- 
immunoreactive cells within each individual patient tumour, 
the ratio of S100A8- to S100A9-positive cells was assessed for 
each tumour (Table 2). A striking difference between Smad4- 
positive and Smad4-negative tumours was observed 
(Fig. 5C). A median S100A8;S100A9 ratio of 0.60 (IQR 
0.325-0.825) in Smad4-positive tumours was observed com­
pared with a significantly lower median S100A8:S100A9 
ratio of 0.316 (IQR 0.15-0.466) in Smad4-negative tumours 
(p<0.003, Mann-Whitney 17-test). Thus, a strong positive
© 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
Proteomics 2007, 7,1929-1940 Biomedicine 1937
B
p < 0.003
Figure 5. The mean numbers of S100A8- (A) or S100A9-positive cells (B) or the ratio of S100A8:S100A9 (C) per patient were plotted for 
Smad4-negative and Smad4-positive tumours. The p-value shown is for comparison (using the Mann-Whitney U-test) of the median 
number of S100A8- or S100A9-positive cells for Smad4-negative and Smad4-positive tumours. Outliers (with >250 Sl00A9-positive cells) 
are not shown, but were included in the analyses.
Table 2. Smad4 expression and association with S100A8- and S100A9-positive cells counts
Smad4 expression All
cases
Low
S100A8+
cells
High
S100A8’
cells
Signif. Low
S100A9*
cells
High
S100A9+
cells
Signif. Median Signif.
number of 
cells S100A87 
S100A9*
Pancreatic cancer (n = 64) n = 71 n -36 n = 35 n = 39 n -32
Positive 35 19 10 0.023al 18 19 0.21 0.60 0.003bl
Negative 29 12 23 16 11 0.316
Not recorded 7 5 2 5 2
a) Fisher's two-sided exact test (significance set at p<0.05)
b) Mann Whitney test (significance set at p<0.05)
relationship between the loss expression of Smad4 in 
tumours cells and the lack of expression of S100A8 in stro­
mal inflammatory cells was established.
3.7 S100A8- and S100A9-positive inflammatory cells 
are detectable in tissue affected by chronic 
pancreatitis
To examine whether S100A8 and S100A9 are expressed in 
tissue affected by chronic pancreatitis, a pancreatitis tissue 
array was immunostained for the detection of both proteins. 
Normal tissue contained few S100A8- (Fig. 6A) or S100A9- 
positive cells (Fig. 6E). By contrast, in tissue affected by 
chronic pancreatitis, inflammatory cells positive for S100A8 
(Figs. 6B and C) and S100A9 (Figs. 6F and G) were readily 
detected. A median S100A8:S100A9 ratio of 0.723 (IQR 
0.508-1.08) was observed (n = 23 cases). The exception was 
extensive fibrotic elements of chronic pancreatitis tissue 
which contained few cells positive for either S100A8 or 
S100A9 (Figs. 6D and H, respectively). Benign ductal cells 
were negative for both proteins, as before.
4 Discussion
In this study, we have uncovered a relationship between the 
phenotype of monocytes/macrophages in the microenviron­
ment of pancreatic cells and the Smad4 status of the corre­
sponding tumour cells. Our study highhghts the complex 
interaction between tumour cells and the surrounding host 
tissue.
We initially identified S100A8 and S100A9 as predomi­
nantly stromal proteins through comparison of laser capture- 
procured pancreatic stromal cell protein and benign or 
malignant epithelial cell protein. Two recent proteomics 
studies, both performed with undissected bulk pancreatic 
tissue [29, 30], reported high levels of S100A8 and S100A9, 
respectively, in bulk pancreatic cancer tissue compared to 
bulk normal pancreas tissue. Our study is consistent with 
these reports, although it pinpoints the high-level expression 
of these proteins to the tumour-associated stroma. While 
proteomic analysis of microdissected material provides valu­
able information, its labour-intensive nature, combined with 
the restriction to readily dissectible specimens, limited its 
use to a small number of cases. Therefore, an independent
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Figure 6. Photomicrographs showing selected sections of nor­
mal (A and E) and pancreatitic tissue (B-D, F-H), from a micro- 
array of chronic pancreatitis tissue, immunohistochemically 
stained for S100A8 (left) and S100A9 (right). BD = benign duct, IF 
= inflammatory cell. Panels D and H show fibrotic areas labelled 
with S100A8 and S100A9, respectively.
approach, namely, immunohistochemistry, enabling rapid 
analysis of larger numbers of samples was subsequently 
adopted. Our immunohistochemical analysis confirmed the 
presence of high levels of both S100A8 and S100A9 in spe­
cific cells of stroma compared to either benign or malignant 
epithelial elements. Of note, neither the proteomic nor the 
immunohistochemical approach indicated a significant dif­
ference in the expression of S100A8 or S100A9 between jux- 
tatumoural stroma and panstroma.
The cells strongly positive for S100A8 or S100A9 were 
identified as monocytes/immature macrophages (i.e. 
CD14+/CD68 ), while strongly positive neutrophils were also 
observed in blood vessels around the tumour (not shown). 
This is consistent with the reported abundant expression of 
these proteins in cells of the myeloid lineage, [15] namely, 
granulocytes, monocytes, and immature macrophages. 
Specifically, expression has been documented to be restricted 
to the early stages of monocyte differentiation and not 
observed in resting mature tissue macrophages [16, 31, 32].
The precise function of S100A8 and S100A9 in the pan­
creatic cancer tumour microenvironment is unclear, al­
though their expression and secretion are likely to contribute 
to the host inflammatory response to the tumour. These 
proteins have been impUcated in a variety of chronic inflam­
matory conditions such as cystic fibrosis, rheumatoid arthri­
tis, tuberculosis and transplant rejection [15, 16]. They form 
stable heterodimeric complexes (also known as calprotectin) 
at sites of inflammation [16, 17] and are highly chemotactic, 
contributing to host inflammatory responses such as leuko­
cyte trafficking, adhesion and migration [16, 19, 20]. They 
also promote phagocyte migration by enhancing the poly­
merisation of microtubules [33, 34], and S100A8/S100A9 
heterodimers are believed to recruit further monocytes to 
sites of inflammation [35]. The results of a recent study [36] 
suggest that the expression of S100A8/S100A9 was induced 
in the lungs of mice by the presence of distant primary 
tumours in the same animals. This in turn attracted myeloid 
cells to the lungs and ultimately supported the invasion of 
tumour cells to this site. The study showed that factors such 
as vascular endothelial growth factor-A as well as transform­
ing growth factor-beta (TGF-(3) induced the expression of 
S100A8 and S100A9. The study supports a role for these 
proteins in the pre-metastatic phase of cancer dissemination.
While no significant associations were observed between 
the number of S100A8 or S100A9 positive cells in the pan­
creatic tumour environment and clinical parameters of dis­
ease, a major finding from our TMA analysis was that the 
number of SlOOAS-positive inflammatory cells in the stroma 
was linked to the Smad4 status of tumour cells. Smad4 is an 
intracellular mediator of TGF-P signalling [37]. Loss of 
Smad4 expression is observed in around 50% of pancreatic 
cancers [38] and is a relatively late event in pancreatic cancer 
development, which presumably allows tumour cells to 
escape the growth suppressive and pro-apoptotic effects of 
TGF-P [39, 40]. While the exact consequences of Smad4 loss 
on pancreatic cancer are unknown, its loss from pancreatic 
cancer cells appears primarily to affect the interaction be­
tween cancer cells and the tumour microenvironment rather 
than affecting the growth of the cancer cells themselves. 
Schwarte-Waldhoff et al. [41] showed that restoration of 
Smad4 in pancreatic cancer cells suppressed tumour forma­
tion in vivo, by inhibiting angiogenesis in the tumour 
microenvironment. An independent study confirmed the 
reduction in angiogenesis following re-expression of Smad4, 
and also reported reduced invasion [42]. A recent study has 
shown that knock-down of Smad4 rendered cancer cells 
resistant to TGF-P-induced cell cycle arrest and migration 
but not to TGF-P-induced epithelial-mesenchymal transition 
[43], indicating that loss of Smad4 appeared to abolish TGF- 
P-mediated tumour suppressive functions, while maintain­
ing some TGF-P-mediated tumour-promoting functions [44], 
Pancreatic cancer cells have been shown to overexpress TGF- 
P [37], which, in turn, is likely to affect the tumour micro­
environment [13] influencing the composition of the extra­
cellular matrix. Although it is unclear how the Smad4 status
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of the cancer influences S100A8 expression, a murine model 
of wound healing shows that TGF-(3 negatively regulates the 
expression of S100A8 in fibroblasts [45]. Future studies will 
be required to unravel the relationship between the Smad4 
status of tumour cells and the expression of S100A8 in the 
tumour monocytes. Interestingly, we did not observe a sta­
tistically significant link between S100A9-positive cell num­
bers and Smad4 tumour status. Thus the overall number of 
monocytes/immature macrophages present in the environ­
ment of tumours appeared to be independent of the Smad4 
status. The expression of S100A8 and S100A9 is believed to 
change as monocytes, recruited from the blood stream to 
sites of inflammation, differentiate to mature macrophages 
[46]. They initially express both S100A8 and S100A9 and as 
they mature, S100A8 expression ceases, leaving only 
S100A9, which is also subsequently lost as the cell matures 
further [46]. Our co-immunofluorescence data are consistent 
with the presence of S100A8 in a subset of S100A9-positive 
pancreatic cancer stromal cells. Evidence has been provided 
for the presence of S100A8-S100A9 heterodimeric com­
plexes during the early stages of monocyte/macrophage 
maturation and their expression has been shown to correlate 
with the intensity of the inflammatory process [32]. It is thus 
possible that the process of maturation of monocytes to 
macrophages in the pancreatic cancer tumour micro­
environment is influenced by the Smad4 status of tumour 
cells.
Finally, our study has important implications for the 
potential use of S100A8 and S100A9 as markers of pancrea­
tic cancer. The overexpression of S100A8 and S100A9 in cer­
tain cancer types has focussed much recent interest on then- 
use as tumour markers. S100A9 expression has been report­
ed in immunohistochemical studies of hepatocellular carci­
nomas, pulmonary adenocarcinomas and invasive ductal 
carcinomas of the breast [47-49]. Expression of both S100A8 
and S100A9 has been observed by immunohistochemical 
studies in invasive squamous cell carcinoma of the uterine 
cervix and in prostate cancer [50, 51]. In the case of the latter 
[51], S100A9 levels were significantly elevated in serum from 
prostate cancer patients compared to healthy controls and 
patients with benign prostatic hyperplasia. Moreover, both 
proteins were detected in the cystic fluid and serum of 
patients with ovarian carcinomas [52]. The predominant 
detection of these proteins as part of the inflammatory re­
sponse in pancreatic cancer rather than in tumour cells 
themselves means that their specificity for detecting cancer 
would necessitate the exclusion of other sources of inflam­
mation. The S100A8/S100A9 complex has proven to be a 
useful diagnostic marker of inflammation in a variety of 
conditions, especially in non-infectious inflammatory dis­
eases such as arthritis and chronic inflammatory lung and 
bowel disease [16, 18]. It has also been shown to predict the 
severity of glomerulonephritis [32]. We observed S100A8- 
and S100A9-positive inflammatory cells in tissues affected by 
chronic pancreatitis. Whether higher concentrations of 
S100A8 or S100A9 proteins will be found in blood/serum of
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patients with pancreatic cancer compared to patients with 
pancreatitis or healthy controls is a question that needs to be 
addressed directly. What seems clear, however, is that for 
either of these proteins to be useful positive markers of pan­
creatic cancer, other possible sources of inflammation, 
including pancreatitis, need to be excluded.
In conclusion, we have demonstrated overexpression of 
S100A9 and S100A8 in monocytes/immature macrophages 
in the stroma surrounding malignant pancreatic tumour 
cells. Furthermore, in a subset of these cells, the two proteins 
are co-expressed, and this relationship appears to be influ­
enced by the Smad4 status of the corresponding tumour 
cells, providing evidence of tumour-host communication. 
Clearly, functional studies into the role of S100A8 and 
S100A9 in pancreatic cancer are required, but this study 
provides further novel evidence of the complex interaction 
between cancer and surrounding host cells.
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Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and 
attenuated response to S100A8 in colorectal and pancreatic cancer cells
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S100A8 and its dimerization partner S100A9 are emerging as 
important chemokines in cancer. We previously reported that 
Smad4-negative pancreatic tumors contain fewer stromal 
SlOOAS-positive monocytes than their Smad4-positive counter­
parts. Here, we studied S100A8/A9-expressing cells in colorectal 
tumors relating their presence to clinicopathological parameters 
and Smad4 status. Two-dimensional gel electrophoresis (h = 12) 
revealed variation in the levels of S100A8 protein in colorectal 
cancer tumors, whereas immunohistochemical analysis (« = 313) 
showed variation in the numbers of stromal SlOOAS-positive and 
S100A9-positive cells. Loss of Smad4 expression was observed in 
42/304 (14%) colorectal tumors and was associated with reduced 
numbers of SlOOAS-positive (jP = 0.03) hut not S100A9-positive 
stromal cells (P = 0.26). High S100A9 cell counts were associated 
with large tumor sizes OP = 0.0006) and poor differentiation 
grade (P = 0.036). However, neither S10QA8 nor S100A9 cell 
counts predicted poor survival, except for patients with Smad4- 
negative tumors (P — 0.02). To address the impact of environ­
mental S100A8/A9 chemokines on tumor cells, we examined the 
effects of exogenously added S100A8 and S100A9 proteins on 
cellular migration and proliferation of colorectal and pancreatic 
cancer cells. S100A8 and S100A9 enhanced migration and pro­
liferation in Smad4-positive and Smad4-negative cancer ceils. 
However, transient depletion of Smad4 resulted in loss of respon­
siveness to exogenous S100A8, but not S100A9. S100A8 and 
S100A9 activated Smad4 signaling as evidenced by phosphoryla­
tion of Smad2/3; blockade of the receptor for the advanced gly- 
cation end products inhibited this response. In conclusion, Smad4 
loss alters the tumor’s interaction with stromal myeloid cells and 
the tumor cells’ response to the stromal chemokine, S100A8.
Introduction
The complex interaction between tumor cells and surrounding non- 
malignant stromal host cells is increasingly understood to be a vital
Abbreviations: MTS, (3-(4,5-dLmethylthiazol-2-yl)-5-(3-caiboxymethoxy- 
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium); RAGE, receptor for the advanced 
glycation end products; siRNA, small interfering Ribonucleic acid.
'These authors contributed equally to this work.
regulator of cancer growth and progression (1). Bone marrow-derived 
myeloid cells are an important component of the tumor microenvi­
ronment. Several bone marrow-derived myeloid cells, such as macro­
phages, Tie-2 expressing monocytes, neutrophils and mast cells have 
been shown to contribute to tumor angiogenesis (2). They have also 
been implicated in processes of tumor invasion and metastasis [for 
review see Joyce et ah (3)]. The presence of S100A8- and S100A9- 
positive myeloid cells in the pancreatic cancer microenvironment was 
previously characterized, revealing an association between the num­
bers of SlOOAS-expressing cells and the expression in tumor cells of 
the tumor suppressor protein Smad4 (4). The Smad4 gene is mutated 
at a high frequency in pancreatic and colon cancer and to a lesser 
extent in a variety of other cancers (5). The microenvironment of 
pancreatic tumors, which lacked expression of Smad4, was found to 
have significantly fewer SlOOAS-expressing cells compared with the 
microenvironment of Smad4-positive tumors (4). This finding sug­
gested a phenotypic difference in the myeloid-derived infiltrate 
related to the Smad4 status of these tumors.
S100A8 (calgranulin A, MRP8) and S100A9 (calgranulin B, 
MRP 14) are low-molecular weight members of the S100 family of 
calcium-binding proteins, which are abundantly expressed in cells 
of the myeloid lineage, including monocytes and neutrophils and 
early-differentiation states of macrophages (6,7). They are secreted 
inflammatory chemoattractants that mediate further recruitment of 
inflammatory cells to sites of tissue damage (8) and have been impli­
cated in a variety of chronic inflammatory conditions such as cystic 
fibrosis, rheumatoid arthritis, tuberculosis and transplant rejection 
(9,10). Recent attention has focused on the involvement of S100A8/ 
A9 in cancer (11). These inflammatory proteins have been reported to 
promote tumorigenesis (12) and cause cancer metastasis by stimulating 
the migration of monocytes and tumor cells to metastatic sites (13,14).
In this study, stromal S100A8 and S100A9-expressing myeloid 
cells in colorectal tumors were thoroughly examined. The relationship 
between these myeloid cells and the Smad4 status of the colorectal 
cancers was determined as was the effect of exogenous S100A8 and 
S100A9 on Smad4-positive and Smad4-negative colorectal and pan­
creatic cancer cells.
Materials and methods
Two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 
protein identification and immunodetection
Proteins were extracted from frozen colectomy specimens, separated by two- 
dimensional electrophoresis and S100A8 identified as described previously 
(4,15). Colorectal cancer tissue microarrays were obtained from the Liverpool 
Tissue Bank, University of Liverpool and contained duplicate or triplicate 
cores from 313 independent specimens of adenocarcinoma. Fourteen cores 
of normal colon and 10 cores each of normal kidney, liver and testis were 
included as control tissue, Immunohistochemistry was undertaken as described 
previously (16) using polyclonal goat anti-S100A8, polyclonal rabbit anti- 
S100A9 or monoclonal anti-Smad4 (CIone-B8; Santa Cruz Biotechnology, 
Heidelberg, Germany) primary antibodies. S100A8 and S100A9 antibodies 
detect single bands in stimulated HL60 monocytic cells (supplementary 
Figure 1A is available at Carcinogenesis Online). Co-immunofluorescence 
was performed on duplicate formalin-fixed colorectal tumor sections 
using the following primary antibodies: a monoclonal mouse anti-S100A8 
and polyclonal rabbit anti-S100A9 (Santa Cruz), monoclonal mouse anti- 
CD68 (Dako, Ely, Cambridgeshire, UK) and monoclonal mouse anti-CD14 
(Novocastra, Newcastle, UK). Microarrays were scored by a specialist his- 
topathologist (author B.A.) and an independent evaluator. The intensity of 
Smad4 staining (using a 0-3 scale) was recorded and a score of <0.5 (mean 
score of at least two cores per tumor) was classified as Smad4 negative. The 
number of stromal cells positive for S100A8 and S100A9 cells was counted 
(using x40 magnification) for each tumor core and the mean number per 
tumor obtained by averaging the number of positive cells across all the tumor 
cores scored for that patient.
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Generation of recombinant S100A8 and S100A9 pmteins 
pGEX4T-l plasmids encoding S100A8-GST and S100A9-GST (13) were 
kindly provided by Y.Maru, Tokyo Women’s Medical University School of 
Medicine, Japan. Proteins were expressed in Escherichia coli following 
induction with isopropyl-b-o-thiogalactopyranoside (VWR international, 
Lutterworth, Leicestershire, UK) and purified with glutathione sepharose 
beads (GE Healthcare, Amersham, Buckinghamshire, UK). The quantity of 
recombinant S100A8-GST and S100A9-GST was determined by performing 
one-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
against serial dilutions of a reference standard of bovine serum albumin (1-15 pg/ 
lane) followed by densitometric evaluation of the Coomassie-stained gels (GS- 
800 scanner; Bio-Rad, Bath, UK) using QuandlyOne software (Bio-Rad). All 
experiments using fusion proteins were performed with at least two independent 
batches of each protein.
Cell lines and western blotting
The rectal cell line SW837 was purchased from tire European Collection of 
Cell Cultures in March 2008. The colonic cell line SW480 and the pancreatic 
adenocarcinoma cell line Panc-1 were obtained from American Type Culture 
Collection in 1999. Neomycin-resistant clonal derivatives of Smad4-deficient 
SW480 cells, stably reexpressing Smad4 (SWD20) and a negative control 
transfectant (SWK3), described previously (17,18) were maintained in medium 
containing geneticin (0.2 mg/ml;Gibco, Paisley, UK). All cell lines were last 
authenticated in October 2009 using short tandem repeat profiling against the 
international reference standard for cell line.
Western blot analysis was performed as described previously (16) using mouse 
anti-Smad4 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA), 
anti-phospho-Smad2, anti-phospho-Smad3, anti-phospho-Smad 1/5/8 antibodies 
(Cell Signaling Technology, Massachusetts, MA) and mouse anti-P-actin 
monoclonal antibody (Sigma-Aldrich, Gillingham, Dorset, UK).
in vitro cell migration assay
Cells were plated (5 x 104 for SW837/SW480/SWD20/SWK3 and 5 x 103for 
Panc-1) in medium containing 1% fetal bovine serum for Boyden Chamber 
assays, conducted over 18 h, as described previously (16). Recombinant proteins, 
S100A8-GST, S100A9-GST or GST in medium containing 1% fetal bovine 
seium were added to the lower transwell chambers. Migrated cells were stained 
and counted (16), ?i = 2 inserts per treatment, and the average number of 
migrated cells were calculated. Experiments were performed at least three times.
Cell proliferation assay
Cells (3 x 103/200 pi medium, supplemented with 1% fetal bovine serum) 
were plated in wells of 96-well plates and recombinant S100A8-GST, S100A9- 
GST or GST added. Proliferation was assessed at 24, 48 and 72 h using the 
EZ4U non-radioactive cell proliferation assay (Biomedica, Vienna, Austria) 
according to the manufacturer’s instructions. Absorbance readings at 450 nm 
were taken at 4 h following incubation with the 3-(4,5-dimethylthiazol-2-yl)- 
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagents. 
Experiments were performed at least three times and five wells utilized for each 
treatment.
Cellular phospho-Smad expression and blocking of receptor of advanced 
glycation end products with specific blocking antibody 
Cells were cultured for 48 h in serum-free medium supplemented with bovine 
serum albumin (10 pg/ml; Sigma-Aldrich) and human insulin (5 pg/ml; 
Sigma-Aldrich) and then treated with S100A8-GST, S100A9-GST, GST or 
transforming growth factor-p (10 ng/ml; PeproTech EC Ltd, London, UK) 
for 1 h, followed by cell collection for western blotting as described above. 
For receptor of advanced glycation end products (RAGE) blocking, cells 
were treated with RAGE-blocking antibody (40 or 80 pg/ml; R&D Systems, 
Abingdon, UK) for 1 h before the addition of recombinant proteins.
Transient Smad4 knockdown
Small interfering Ribonucleic acid (siRNA) experiments were performed as 
described previously (16). Smad4-targeting siRNAs, GUGUGCAGUUG- 
GAAUGUAA (Smad4 siRNA 1) and GUACAGAGUUACUACUUAG (Smad4 
siRNA2) were purchased from Dharmacon (Chicago, IL). Two non-targeting 
control siRNAs were used, control 1 (siControl non-targeting siRNA 1 from 
Dharmacon) and control 2 (GGACGCAUCCUUCUUAA, a gift from M.Boyd, 
University of Liverpool, UK). Smad4 levels diminished between 48 and 72 h 
post-transfection with Smad4-targeting siRNAs and remained low out to 120 h 
(data not shown).
Cellular immunofluorescence
Cells were fixed with 4% formaldehyde for 15 min at room temperature and 
permeabilized with 0.1% Triton X-100 for 10 min. Phospho-Smad2/3 was 
detected with anti-phospho-Smad2/3 antibody (Cell Signaling Technology)
and visualized with a fluorescein isothiocyanate-conjugated goat anti-rabbit IgG 
secondary antibody (Jackson ImmunoResearch Laboratories West Grove, PA). 
Actin filaments were labeled with phalloidin (Invitrogen, Renfrew, UK).
Statistical analysis
Comparisons between two groups were made using nonparametric continuity 
corrected chi-square test or chi-squared test, when more than two groups were 
analyzed. Continuous variables were compared using the Mann-Whitney 
[/-test or the Wilcoxon signed-rank test. To evaluate the effect of stromal 
S100A8 or S100A9 cells on patient survival, life tables were constructed 
and Kaplan-Meier curves plotted. Overall survival was measured from date 
of initial surgery to date of death, counting death from any cause as the end 
point or the last date of information as the end point if no event was docu­
mented. To analyze data from ’motility’ or ‘proliferation’ experiments, con­
tinuous variables were compared using the Student’s /-test and were expressed 
as mean. All analyses were performed using Statview Version 5.01 (SAS 
Institute Cary, North Carolina). A P-value of <0.05 was considered significant.
Results
Variable S100A8 and S100A9 levels in colorectal cancer 
microenvironments
Two-dimensional gels displaying proteins extracted from 12 individual 
undissected colorectal tumors revealed variation (Figure 1A-C) in the 
intensity of a spot (arrowed in Figure 1A and B) that was suspected, on 
the basis of its gel location, to contain S100A8. Protein recovered from 
this spot was trypsin digested and analyzed by Liquid Chromatography- 
Mass Spectrometry/Mass Spectrometry (Figure ID). This resulted in 
the detection of five peptides, providing sequence coverage of 37.6% 
and confirmed the identification of SI0CA8 (National Centre for 
Biotechnology Information accession no. CAG28602). To establish 
the cellular- basis for the variability of S100A8, immunohistochemistry 
of formalin-fixed colorectal adenocarcinomas was undertaken, for tire 
detection of S100A8 and its dimerization partner S100A9. This revealed 
the expression of both proteins in cells scattered throughout the tumor 
stroma [Figure 2A(i-iv)]. While S100A9 expression was not detected 
in cancer cells, a very low intensity of cytoplasmic S1OOA8 staining was 
observed in tumor cells of virtually all cases and was not subjected to 
analysis. Co-immunofluorescence indicated extensive colocalization of 
S100A8 and S100A9 in stromal cells [Figure 2B(i)]. Furthermore, co 
localization of S100A8 or S100A9 was observed in some cells with the 
monocyte marker CD 14 [Figure 2B(ii and iii), respectively] but not the 
macrophage marker CD68 [Figure 2B (iv and v), respectively).
The number of SlOOAS-positive or S100A9-positive cells in each 
of 313 patient tumors (mean of at least two Tissue Microarray cores 
per tumor case) was determined. Numbers ranged from 0 (4.5% of 
cases) to 288 and from 0 (0.65% of cases) to 882 for S100A8 and 
S100A9, respectively. The median number of stromal S100A8- 
expressing cells was 23 [Inter-quartile range (IQR) 6-70], whereas 
the median number of stromal S100A9-expressing cells was 65 (IQR 
27-126) with 284/308 (92%) tumors showing more S100A9 
than SlOOAS-expressing cells in the stroma. Although tumors gener­
ally contained fewer SlOOAS-positive than S100A9-positive cells 
{P < 0.0001, Wilcoxon signed-rank test), there was a strong positive 
relationship between S100A8 and S100A9 counts (n = 302 indepen­
dent tumor cases; R2 = 0.76, P < 0.0001). This is entirely consistent 
with our observation that S100A8 colocalized with S100A9. The 
median S100A9:S100A8 ratio was 2.2 (IQR 1.3M.4). To examine 
whether a relationship existed between the numbers of stromal 
SlOOAS-positive or S100A9-positive cells and the Smad4 tumor 
status, the expression of Smad4 protein was determined by immuno­
histochemistry [Figure 2A (v and vi)]. Forty-two of 304 patients 
(14%) were categorized as Smad4 negative based on mean cytoplas­
mic intensity scores of <0.5. The remaining 262 of 304 patients 
(86%) were categorized as Smad4 positive. Loss of Smad4 expression 
in primary colorectal tumor cells was associated with a significantly 
lower median count of SlOOAS-positive stromal cells (14, IQR 5-37) 
compared with a median S 100A8-positive cell count of 25 (IQR 6-76) 
in the Smad4-positive group [Figure 2C (i)], P = 0.03, Mann- 
Whitney (7-test). A similar relationship was not observed between
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Fig. 1. (A) Colloidal Coomassie Blue-stained two-dimensional gel image of a colorectal cancer lysate, with the SlOOAS-containing spot arrowed. (B) Insets from 
12 independent colorectal tumor gels showing different intensities in the S100A8 protein spot. (C) Normalized S100A8 levels (S100A8 spot intensity/total spots 
intensity). (D) Mass Spectrometry/Mass Spectrometry spectrum of the peptide ALNSIIDVYHK from S100A8.
tumor cell Smad4 expression and S100A9-positive stromal mono­
cytes [Figure 2C (ii)], P = 0.26).
Relationship between S100A8/A9-positive stromal cells and 
clinicopathological characteristics
To examine for associations between stromal SlOOAS-positive cells 
and patient clinicopathological parameters, patients were catego­
rized as having mean SlOOAS-positive cell counts that were low 
(< median of 23) or high (>23). Similarly, for S100A9, patients 
were categorized as having low (< median of 65) or high (>65) 
cell counts. The degree of stromal S100A8/A9-positive infiltration 
showed no correlation with the parameters of age at surgery, gen­
der, site of tumor, depth of tumor invasion or nodal metastases 
(Table I). However, high cell S100A8 and S100A9 counts were
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Fig. 2. Colorectal cancer tissue illustrating a low [A(i and Hi)], and a high jA(ii and iv)] infiltrate of S100A8- and Sl(X)A9-positive cells, respectively; the absence 
and presence, respectively, of Smad4 staining [A(v and vi)]; colocalization of S100A9 and S100A8 [B(i>], S100A8 or S100A9 and CD 14 [B(ii and iii)]; lack of 
colocalization of S100A8 or S100A9 and CD68 [B (iv and v)]. The mean numbers of S100A8-positive [C(i)] or S100A9-positive cells [C(ii>] per tumor were 
plotted for Smad4-negative and Smad4-positive tumors.
associated with larger tumor size (P = 0.01 and 0.0006, 
respectively). These proteins are co-expressed to a high degree. 
Nevertheless, we wished to determine whether either protein was 
independently associated with tumor size. We therefore performed 
logistic regression analyses. Both high S100A8 and high S100A9 
cell counts were associated with large tumor size on univariate
analysis (P = 0.01 and 0.0007, respectively; supplementary Table 1 
is available at Carcinogenesis Online). However, on multivariate 
analysis, only high S100A9 cell counts remained independently 
associated with large tumor sizes (P = 0.02). High S100A9 cell 
counts were also associated with poor differentiation grade 
(P = 0.036).
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Table I. Clinicopathological characteristics and correlation with S100A8 and S100A9 expression
All cases. S100A8-positive cells. P value3 S100A9-positive cells. P value”
n = 313 (%)
§C*~iIIc n = 306
Low < 23 cells (%), High > 23 cells (%), Low < 65 cells (%), High > 65 cells (%),
n = 156 n = 153 n = 159 n = 147
Age 70 (IQR 62-76 years)
Young (<median) 155 (49) 75 (48) 80 (52) 0.459 75 (47) 78 (53) 0.303
Old (>median)
Gender
158 (51) 81 (52) 73 (48) 84 (53) 69 (47)
Male 188 (60) 93 (60) 92 (60) 0.926 97 (61) 85 (58) 0.570
Female
Site of tumor
125 (40) 63 (40) 61 (40) 62 (39) 62 (42)
Colon 188 (60) 89 (57) 96 (63) 0.307 94 (59) 90 (61) 0.707
Rectum
Size 50 (IQR 38-60 mm)
125 (40) 67 (43) 57 (47) 65 (41) 57 (39)
Small-medium (<60 mm) 214 (69) 116(74) 94 (61) 0.014 123 (77) 87 (59) 0.0006
Large (>60 mm) 
Differentiation grade
99(31) 40 (26) 59 (39) 36 (23) 60(41)
Well 5(2) 2(1) 2(1) 0.819 2(1) 3(2) 0.036
Moderate 283 (90) 140 (90) 140 (92) 150 (94) 127 (86)
Poor 21 (7) 12(8) 9(6) 5(4) 15(11)
U ncategorized/DN A 
Excision margin
4(1) 2(1) 2(1) 2(1) 2(1)
Clear 270 (86) 130 (83) 138 (90) 0.055 134 (84) 130 (88) 0.199
Involved 39(13) 25 (16) 12(8) 24(15) 14 (10)
Uncategorized/DNA
T-stage
4(1) 1 (1) 3(2) 1 (1) 3(2)
T1 13(4) 8(5) 5(3) 0.766 8(5) 5(3) 0.356
T2 47(15) 22(14) 25 (16) 21 (13) 24(16)
T3 206 (66) 104 (67) 101 (66) 110(69) 92 (63)
T4 44(14) 19(12) 22 (15) 18 (12) 25 (17)
U ncategorized/DNA 
N-stage
3(1) 3(2) 0 2(1) 1 (1)
NO 177 (56) 82 (53) 93 (61) 0.446 90 (57) 82 (56) 0.332
N1 71 (23) 38 (24) 32 (21) 40 (25) 30 (20)
N2 62 (20) 33 (21) 28 (18) 27 (17) 34 (23)
Uncategorized/DNA 3(1) 3(2) 0 2(1) 1 (1)
AJCC/UICC stage groupings
I 39(13) 22(14) 17(11) 0.319 21 (13) 17(12) 0.860
II 136 (43) 60 (38) 74 (48) 68 (43) 65 (44)
III 132 (42) 70 (45) 60 (39) 66(41) 63 (43)
Uncategorized/DNA
Chemoradiotherapy
6(2) 4(3) 2(2) 4(3) 2(1)
Neoadjuvant only 35(11) 21 (13) 14(9) 0.630 19(12) 15(10) 0.724
Adjuvant only 77 (25) 37 (24) 40 (26) 37 (23) 40 (27)
Neoadjuvant and adjuvant 12(4) 6(4) 5(3) 6(4) 4(3)
No chemoradiotherapy 188(60) 92 (59) 93 (61) 97 (61) 87 (59)
DNA 1 (0.3) 0(0) 1 (1) 0(0) 1 (1)
AJCC/UICC, American Joint Committee on Cancer/Intemational Union Against Cancer; DNA, data not available. 
“Chi-squared test.
Neither S100A8-positive nor S100A9-positive stromal cell counts 
were associated with patient survival [Figure 3A (i and ii)]. However, 
for the smaller cohort of patients exhibiting loss of Smad4 expression, 
high S100A8 or S100A9 cell counts predicted poor 3 year survival 
[Figure 3B (i and ii)]. The number of Smad4-negative tumor patients 
in the study was too small to determine whether either of the proteins 
was independently associated with poor outcome. No survival dif­
ference was observed for either high S100A8 or S100A9 counts at 
60 months in this Smad4-negative cohort. For patients with Smad4- 
positive tumors, neither S100A8-positive nor S100A9-positive counts 
predicted overall short- or long-term survival [Figure 3C (i and ii)].
The effects of Smad4 status on SI00A8- and S100A9-induced 
migration activity
S100A8 and S100A9 are secreted chemokines, which could affect 
tumor cells in their vicinity. We next investigated their chemoattrac- 
tive functions on tumor cells in vitro. The addition of purified 
S100A8-GST and S100A9-GST fusion proteins (see supplementary
Figure IB, available at Carcinogenesis Online) at concentrations of 
either 0.4 or 2 pg/ml significantly increased the migration activity of 
the rectal cancer cell line SW837, the colon cancer cell line SW480 
and the pancreatic cancer cell line Panc-1 (Figure 4A) (P < 0.001) 
compared with the addition of purified GST control protein. The 
addition of both S100A8-GST and S100A9-GST proteins simulta­
neously did not significantly increase the response over proteins 
added individually (see supplementary Figure S2, available at Carci­
nogenesis Online) and may be due to failure of the recombinant 
proteins to interact correctly.
Both Panc-1 and SW837 cells express Smad4 (see inset Figure 4A). 
To determine whether the Smad4 status of cells influenced their re­
sponse to S100A8 or S100A9, we depleted Smad4 in these cell lines 
and examined their migration activity in response to S100A8 and 
S100A9. An ~50% decrease in basal migration in Panc-1 cells com­
pared with control siRNA-treated cells was observed (Figure 4B), 
consistent with previously published data (19). Smad4 knockdown 
totally suppressed migration responses toward S100A8. In contrast, 
S100A9-treated cells retained an ~2-fold increase in migration after
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A(i) ------  Low SI OOAS (<median) A(ii) ------- LowS100A9 (<median)
— High SI OOAS (>medwn) •i* High S1OOA9 (>median)
S100A9:Smad4-negative group, n = 39S100A8:Smad4-negative group, n = 38
n-24
n-22n = 14
p = 0.02p = 0.02
36 48 60 72 84 96
Time (months)Time (months)
Life table
C(i) C(ii)
S100A9:Smad4-positne group, n = 252
n= 123
n= 129
Tmne (months)
S100A8:Smad4-positive group, n = 255
n= 131
p = 0.37 n= 124
Life table
Fig. 3. Kaplan-Meier graphical analysis showing (A) no survival difference based on S100A8 [A(i)] or S100A9 [A(ii)] cell counts in all patients, (B) a survival 
difference in patients with Smad4-negative tumors based on S100A8 [B(i)] or S100A9 [B(ii)] cells counts and (C) no survival difference in patients with Smad4- 
positive tumors based on S100A8 [C(i)] or S100A9 [C(ii)] cell counts.
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Fig. 4. Migration activities of indicated cell lines treated with S100A8-GST (A8-GST), S100A9-GST (A9-GST), GST at concentrations of 0.4 or 2.0 |ig/ml, in 
medium containing 1% fetal bovine serum (FBS) (A) or Smad4-depleted Panc-1 cells (B) or clonal derivative of SW480 cells that stably reexpresses Smad4 
(SWD20) and its Smad4-negative control (SWK3) (C) or Smad4-depleted SWD20 (D). **P < 0.001, *P < 0.05. The Smad4 status of cells is shown as insets on 
western blots.
1547
D
ow
nloaded from http://carcin.oxfordjoum
als.org/ by guest on N
ovem
ber 24, 2012
C.W.Ang et al.
Smad4 knockdown. Smad4 knockdown caused an almost total loss of 
basal and chemokine-induced migration of the less motile SW837 
cells (supplementary Figure 3 is available at Carcinogenesis Online).
SW480 cells do not express Smad4 (see inset Figure 4A). 
Neomycin-resistant clonal derivatives of SW480 cells, stably reex­
pressing Smad4 (SWD20) and negative control transfectants 
(SWK3) (17,18) were used to determine whether restoration of Smad4 
would alter responsiveness to S100A8 or S100A9. We found that both 
the Smad4-negative and Smad4-positive subclones had enhanced mi­
gration following incubation with S100A8-GST or S100A9-GST 
(Figure 4C). However, transient siRNA-mediated depletion of Smad4 
from SWD20 cells resulted in a reduction in motility and a loss of 
responsiveness to S100A8-GST, but not S100A9-GST (Figure 4D). 
This was similar to the result obtained with Panc-1 cells (Figure 4B).
The effects of Smad4 status on SJ00A8- and S100A9-induced 
proliferation
Similarly, we sought to examine the effects of S100A8 and S100A9 
on tumor cell proliferation and explore whether Smad4 status was 
important in this context. Incubation of SW837 and SW480 cells with 
2 pg/ml of S100A8-GST or S100A9-GST resulted in modest, though 
statistically significant increases in MTS readings (Figure 5A). No 
increase was observed using 0.4 pg/ml recombinant proteins (data not 
shown) and Panel cells did not show an increased MTS response at all 
(supplementary Figure 4A, available at Carcinogenesis Online). In 
the case of SW837 cells, the simultaneous addition of S100A8-GST 
and S100A9-GST proteins at 2 pg/ml significantly improved the re­
sponse over proteins added individually (see supplementary Figure 4B, 
available at Carcinogenesis Online), although this effect was not 
observed with SW480 or Panc-1 cells (supplementary' Figure 4C and 
D is available at Carcinogenesis Online).
The Smad4-negative SW480 subclone, SWK3 showed enhanced 
proliferation in response to 2 pg/ml S100A9-GST (Figure 5B), 
whereas the Smad4 reexpressing subclone, SWD20, responded to 
both S100A8-GST and S100A9-GST, although the response to 
SI00A9-GST was greater (Figure 5B). Following depletion of 
Smad4 from SWD20 cells, responsiveness to S100A8-GST was 
lost (Figure 5C). S100A9-GST continued to induce proliferation, 
although the extent of proliferation reached was not as great as that 
observed in control siRNA-treated cells (Figure 5C). Depletion of 
Smad4 from Panc-1 cells gave a similar result (supplementary 
Figure 5 is available at Carcinogenesis Online) although the increase 
in MTS readings in response to S100A9 was very small.
The effects of exogenous S100A8 and S100A9 on Smad4 signaling and 
RAGE
Our results indicated that the effects of exogenous S100A8 and 
S100A9 were influenced to an extent by tire presence of Smad4 in 
tumor cells. To examine whether these proteins could signal via 
Smad4, cells were incubated for 1 h with 2 pg/ml of S100A8-GST 
or S100A9-GST and the activation of members of the Smad pathway 
examined. Both recombinant SI00 proteins alone, but not GST, in­
duced increased levels of phospho-Smad2, phospho-Smad3, but not 
phospho-Smad 1/5/8 in Panc-1 cells [Figure 5D (i)]. Furthermore, 
phospho-Smad2/3 was shown to accumulate in the nucleus following 
incubation with S100A8-GSTor S100A9-GST, but not GST (supple­
mentary Figure 6 is available at Carcinogenesis Online). Similar re­
sults were obtained with SWD20 cells (data not shown). S100A8/A9 
heterodimers are known to stimulate cells through binding to the 
cellular receptor RAGE (20,21), although it is unclear whether the 
individual proteins are ligands for this receptor. RAGE expression was 
observed in the cell lines used in this study [Figure 5D (ii)]. To de­
termine whether S100A8 and S100A9 were activating the Smad path­
way through RAGE, we used a RAGE-blocking antibody at two 
concentrations, 40 and 80 pg/ml. When Panc-1 cells were pretreated 
with the RAGE-blocking antibody, a dose-dependent reduction of 
phopho-Smad2 and phospho-Smad3 levels was observed in response 
to S100A8-GST or S100A9-GST stimulation [Figure 5D (iii)].
Discussion
The inflammatory chemoattractants, S100A8 and S100A9, apart from 
serving as markers of phagocytes (intracellular S100A8/A9) or as 
biomarkers of inflammatory disease conditions (secreted extracellular 
S100A8/A9), are now recognized to play important roles themselves 
in the pathogenesis of inflammatory disorders and more recently in 
cancer (11). The presence of S100A8- and S100A9-positive cells has 
been reported previously in smaller studies of colorectal cancer 
(12,22). Here, we provide a comprehensive analysis, in which we 
quantified the numbers of S100A8/A9 cells infiltrating the environ­
ment of colorectal tumors. We also noted expression of S100A8/A9 
proteins in neutrophils localized in the tumor vasculature, although 
this cell type was not studied further. S100A8 and S100A9 proteins 
were largely co-expressed in the same cells, and the majority of 
tumors (92%) contained more S100A9-positive cells than S100A8- 
positive cells, which may reflect the differentiation state of the mye­
loid cells expressing these proteins (23). There was overlap in the 
expression of S100A8 and S100A9 and the monocyte/macrophage 
marker CD14, although the S100A8/A9-positive cell population did 
not express the mature macrophage marker CD68, indicating that 
the S100A8/A9 population may be at an early stage of monocyte/ 
macrophage maturation.
Relatively little is known about tumor-associated monocytes in 
colorectal cancer, although CD68'1 tumor-associated macrophages have 
been analyzed in detail. High infiltrates of CD681 tumor-associated 
macrophages in colorectal tumors were shown to correlate with absence 
of vascular- and lymph node invasion (24) and improved survival 
(25,26). No evidence was found for an association between the numbers 
of S 100A8/A9-positive cells and either depth of tumor invasion or nodal 
metastases. High S100A9 infiltrate, however, was associated with poor 
differentiation grade and correlated strongly with larger tumor size. In 
contrast to tire reported links between high CD68+ infiltrate and im­
proved outcome, when the entire cohort of ~300 patients was examined 
as a whole, no association was found between S100A8/A9 levels and 
survival. Nonetheless, the short-term survival of patients with Smad4- 
negative tumors and high A8/A9 infiltrate was significantly poorer than 
Smad4-negative patients with low A8/A9 infiltrate. This suggests that 
Smad4-negative tumors have a shorter time to recurrence or metastases 
in the presence of high stromal S100A8- or S100A9-expressing mono­
cytes. Mutations or inactivation of Smad4 in colorectal carcinoma 
coincide with progression to metastatic disease; the highest percentages 
of inactivation (>30%) are observed in patients with distant organ 
metastasis (27). In our study, only non-metastatic tumors with stages 
I-m disease were included, which accounts for the lower frequency of 
Smad4 loss (14%) in our cohort.
One of the main aims of our study was to detennine if the extent of 
the S100A8/A9-positive infiltrate was influenced by the Smad4 status 
of the colorectal tumors under examination. The motivation to exam­
ine this stemmed from the previous observation that Smad4-negative 
pancreatic tumors contained fewer S 100A8-positive stromal cells than 
Smad4-negative pancreatic tumors (4). Furthermore, using a mouse 
model of colon cancer, Kitamura et al. (28) reported that Smad4- 
negative tumors recruited a specific type of myeloid cell, which pro­
moted invasion through cross talk with tumor cells. We obseived 
a distinctive reduction in the numbers of SlOOAS-positive, but not 
S100A9-positive stromal cells in Smad4-negative colorectal tumors, 
resulting in a change in the relative levels of S100A8 to S100A9. The 
S100A8/A9 myeloid cell population that we have studied does not 
appear to be identical to that observed in the mouse study of Kitamura 
et al. (28) because the mice cells lacked expression of CD14. How­
ever, our observation that the loss of Smad4 is accompanied by 
a change to the phenotype of the myeloid infiltrate is consistent with 
that of Kitamura et al. and provides important evidence in human 
colorectal cancer that the phenotype of the myeloid infiltrate is influ­
enced by the Smad4 status of the tumor.
Hxratsuka et al. (13) showed that S100A8/A9 were powerful che­
moattractants whose tumor-induced presence in the lungs of tumor­
bearing mice could stimulate tire migration of Lewis Lung carcinoma
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Fig. 5. MTS readings of indicated cells in response to S100A8-GST (A8-GST), SI00A9-GST (A9-GST) or GST at a concentration of 2.0 pg/ml (A) or SW480 
derivatives (B) or Smad4-depleted SWD20 (C). 'P < 0.01, ¥P < 0.05. Western detection of phospho-Smad2, phospho-Smad3 and phospho-Smad 1/5/8 
levels (D(i)] following treatment of Panc-1 cells with 2 pg/ml of S100A8-GST (A8-GST), S100A9-GST (A9-GST) or GST. Transforming growth factor (TGF-P) 
(10 ng/ml) and 10% fetal bovine serum (FBS) were the positive control for phospho-Smad2/3 and phospho-Smad I/5/8 activation, respectively. Western detection 
of RAGE expression [D(ii)]. Western detection and densitometric representation of the levels of phospho-Smad2 and phospho-Smad3, which were reduced in 
Panc-1 cells pretreated with RAGE-blocking antibody (R) (40 and 80 pg/ml) before the addition of 0.4 or 2 pg/ml of S100A8-GST or S100A9-GST [D(iii)].
cells and B16 melanoma cells to that organ, where they formed sec­
ondary tumors. We sought to determine whether the response of tumor 
cells to S100A8/A9 was potentially influenced by their Smad4 status.
Both S100A8 and S100A9 were highly chemotactic for rectal, colon 
and pancreatic cancer cell lines, regardless of whether the cells ex­
pressed Smad4 or not. In Smad4-expressing cells, such as Panc-1 cells
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or tlie SWD20 cells, where Smad4 expression has been stably re­
stored, transient depletion of Smad4 expression was accompanied 
by a loss of responsiveness to SlOOAS-induced migration activity 
but not that of S100A9, suggesting that S100A8 elicits its response 
through a Smad4-dependent pathway. Transient Smad4 depletion, 
such as we undertook in our siRNA experiments, may not allow 
sufficient time for cells to adapt and to allow S100A8 to signal in 
a Smad4-independent manner. Our observation of increased levels of 
phosphor-Smad2 and phospho-Smad3 in response to cell treatment 
with S100A8 and S100A9 provide supporting evidence that these 
proteins can activate the Smad4 signaling pathway.
S 100A8/A9-induced proliferation of the cancer cell lines studied was 
also observed, although at concentrations higher that those required to 
induce migration activity. S100A8/A9 may contribute to apoptosis (11), 
however, the apoptotic role of these proteins was not investigated in this 
study. Ghavami et al. (21) reported that S100A8 and S100A9 proteins 
promoted growth of human breast cancer and neuroblastoma cells and 
confirmed that these proteins activate the multiligand receptor, RAGE, 
triggering the mitogen-activated protein kinase signaling pathway. The 
mitogenic effects of S100A8/A9, coupled with our observation that 
high levels of A8/A9 infiltrate were associated with larger tumors sug­
gest that the proteins may contribute to the growth of these tumors. 
Interestingly, while the Smad4-restored SWD20 cells showed increased 
proliferation in response to S100A8-GST and S100A9-GST, their 
Smad4-negative clonal counterpart, SWK3 cells showed increased pro­
liferation in response to S100A9-GST only, suggesting that Smad4 is 
important in regulating the proliferative response to exogenous 
S100A8. Transient Smad4 knockdown in SWD20 and Panc-1 was 
accompanied by a loss of response to S100A8-GST. Thus, although 
the measured proliferation effects of S100A8/A9 were not as marked as 
their chemotactic effects, the dependence on Smad4 for S100A8 sig­
naling was a recurrent theme. Our RAGE-blocking experiments pro­
vide evidence that S100A8 and S100A9 activation of the Smad4 
pathway occurs at least in part through RAGE. The ability of Advanced 
Glycation Endproducts to activate transforming growth factor-p 
signaling via RAGE and mitogen-activated protein kinases has been 
established by Li et al. (29).
Monocytes, once recruited from blood initially express both S100A8 
and S100A9 and as they mature, they lose S100A8 expression, leaving 
only S100A9, which is also subsequendy lost as the cell matures further 
(30). We postulate that myeloid cells (such as monocytes) expressing 
both S100A8 and S100A9 are recruited to the tumor microenvironment 
of Smad4-positive tumors, where they secrete S100A8/A9 that may 
promote further recruitment of inflammatory cells as well as cancer 
cell growth and invasion. In the case of Smad4-negative tumors, our 
data suggest that the myeloid cells recruited express S100A9, but ex­
hibit lower S100A8 expression. Alternatively, the myeloid cells re­
cruited are similar- in the case of Smad4-positive and Smad4-negative 
tumors, however, the rate of differentiation, once recruited to the envi­
ronment of Smad4-negative tumors is different, sucli that S100A8 ex­
pression becomes very transient, leaving relatively greater numbers of 
cells expressing only S100A9. Either way, our experiments indicate 
that the cross talk between Smad4-negative cancer cells and myeloid 
cells occurs in an environment that involves S100A9 to a greater extent 
than S100A8 and where the cancer cells respond better to S100A9 than 
S100A8. Further research into S100A8/A9 signaling in the tumor mi- 
croenvironment will shed light on how these proteins may influence the 
processes of tumor development/spread and will provide opportunities 
for targeted intervention.
Supplementary material
Supplementary Figures 1-6 and Table 1 can be found at http://carcin 
.oxfordjournals.org/
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